

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number
WO 01/62797 A2

(51) International Patent Classification⁷: **C07K 14/72**,
C12N 15/63, 15/11, C07K 1/14, C12Q 1/68, G01N 33/53,
C07K 16/28, A61K 38/17, 39/395

(21) International Application Number: PCT/US01/05676

(22) International Filing Date: 23 February 2001 (23.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/184,305	23 February 2000 (23.02.2000)	US
60/184,304	23 February 2000 (23.02.2000)	US
60/184,303	23 February 2000 (23.02.2000)	US
60/184,397	23 February 2000 (23.02.2000)	US
60/184,247	23 February 2000 (23.02.2000)	US
60/186,457	2 March 2000 (02.03.2000)	US
60/186,810	3 March 2000 (03.03.2000)	US
60/188,064	9 March 2000 (09.03.2000)	US
60/188,880	13 March 2000 (13.03.2000)	US
60/194,344	3 April 2000 (03.04.2000)	US
60/213,861	23 June 2000 (23.06.2000)	US
60/217,370	11 July 2000 (11.07.2000)	US
60/217,369	11 July 2000 (11.07.2000)	US
60/218,337	14 July 2000 (14.07.2000)	US
60/218,492	20 July 2000 (20.07.2000)	US

(71) Applicant (for all designated States except US): **PHARMACIA & UPJOHN COMPANY** [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **VOGELI, Gabriel** [US/US]; 3005 First Avenue, Seattle, WA 98121 (US). **WOOD, Linda, S.** [US/US]; 10193 Fox Hollow, Portage, MI 49024 (US). **PARODI, Luis, A.** [SE/SE]; Grevgafan-24, S-115 43 Stockholm (SE). **LIND, Peter** [SE/SE]; Borjegatan 31 C, S-751 29 Uppsala (SE).

(74) Agents: **DELUCA, Mark** et al.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/62797 A2

(54) Title: NOVEL G PROTEIN-COUPLED RECEPTORS

(57) Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-x; constructs and recombinant host cells incorporating the genes; the nGPCR-x polypeptides encoded by the gene; antibodies to the nGPCR-x polypeptides; and methods of making and using all of the foregoing.

NOVEL G PROTEIN-COUPLED RECEPTORS

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to Application Serial Numbers 60/184,305 filed February 23, 2000, 60/184,304 filed February 23, 2000, 60/184,303 filed February 23, 2000, 5 60/184,397 filed February 23, 2000, 60/184,247 filed February 23, 2000, 60/188,880 filed March 13, 2000, 60/217,369 filed July 11, 2000, 60/217,370 filed July 11, 2000, 60/219,492 filed July 20, 2000, 60/186,810 filed March 3, 2000, 60/188,064 filed March 9, 2000, 60/186,457 filed March 2, 2000, 60/213,861 filed June 23, 2000, 60/194,344 filed April 3, 2000, and 60/218,337 filed July 14, 2000, each of which is incorporated herein by reference in its 10 entirety.

FIELD OF THE INVENTION

The present invention relates generally to the fields of genetics and cellular and molecular biology. More particularly, the invention relates to novel G protein coupled receptors, to polynucleotides that encode such novel receptors, to reagents such as antibodies, probes, 15 primers and kits comprising such antibodies, probes, primers related to the same, and to methods which use the novel G protein coupled receptors, polynucleotides or reagents.

BACKGROUND OF THE INVENTION

The G protein-coupled receptors (GPCRs) form a vast superfamily of cell surface receptors which are characterized by an amino-terminal extracellular domain, a carboxyl- 20 terminal intracellular domain, and a serpentine structure that passes through the cell membrane seven times. Hence, such receptors are sometimes also referred to as seven transmembrane (7TM) receptors. These seven transmembrane domains define three extracellular loops and three intracellular loops, in addition to the amino- and carboxy- terminal domains. The extracellular portions of the receptor have a role in recognizing and binding one or more extracellular binding 25 partners (*e.g.*, ligands), whereas the intracellular portions have a role in recognizing and communicating with downstream molecules in the signal transduction cascade.

The G protein-coupled receptors bind a variety of ligands including calcium ions, hormones, chemokines, neuropeptides, neurotransmitters, nucleotides, lipids, odorants, and even photons, and are important in the normal (and sometimes the aberrant) function of many cell 30 types. (See generally Strosberg, *Eur. J. Biochem.* 196:1-10 (1991) and Bohm *et al.*, *Biochem J.* 322:1-18 (1997)). When a specific ligand binds to its corresponding receptor, the ligand typically stimulates the receptor to activate a specific heterotrimeric guanine-nucleotide-binding regulatory protein (G-protein) that is coupled to the intracellular portion of the receptor. The G protein in turn transmits a signal to an effector molecule within the cell, by either stimulating or

inhibiting the activity of that effector molecule. These effector molecules include adenylate cyclase, phospholipases and ion channels. Adenylate cyclase and phospholipases are enzymes that are involved in the production of the second messenger molecules cAMP, inositol triphosphate and diacylglycerol. It is through this sequence of events that an extracellular ligand
5 stimuli exerts intracellular changes through a G protein-coupled receptor. Each such receptor has its own characteristic primary structure, expression pattern, ligand-binding profile, and intracellular effector system.

Because of the vital role of G protein-coupled receptors in the communication between cells and their environment, such receptors are attractive targets for therapeutic intervention, for
10 example by activating or antagonizing such receptors. For receptors having a known ligand, the identification of agonists or antagonists may be sought specifically to enhance or inhibit the action of the ligand. Some G protein-coupled receptors have roles in disease pathogenesis (*e.g.*, certain chemokine receptors that act as HIV co-receptors may have a role in AIDS pathogenesis), and are attractive targets for therapeutic intervention even in the absence of
15 knowledge of the natural ligand of the receptor. Other receptors are attractive targets for therapeutic intervention by virtue of their expression pattern in tissues or cell types that are themselves attractive targets for therapeutic intervention. Examples of this latter category of receptors include receptors expressed in immune cells, which can be targeted to either inhibit autoimmune responses or to enhance immune responses to fight pathogens or cancer; and
20 receptors expressed in the brain or other neural organs and tissues, which are likely targets in the treatment of mental disorder, depression, schizophrenia, bipolar disease, or other neurological disorders. This latter category of receptor is also useful as a marker for identifying and/or purifying (*e.g.*, via fluorescence-activated cell sorting) cellular subtypes that express the receptor. Unfortunately, only a limited number of G protein receptors from the central nervous
25 system (CNS) are known. Thus, a need exists for G protein-coupled receptors that have been identified and show promise as targets for therapeutic intervention in a variety of animals, including humans.

SUMMARY OF THE INVENTION

The present invention relates to an isolated nucleic acid molecule that comprises a
30 nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to sequences selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120, or a fragment thereof. In some embodiments, the nucleic acid molecule encodes at least a portion of SEQ ID NO:111 to SEQ ID NO:120. In some embodiments, the nucleic acid molecule comprises a sequence that encodes a polypeptide comprising a sequence selected from the group

consisting of SEQ ID NO:61 to SEQ ID NO:120, or a fragment thereof. In some embodiments, the nucleic acid molecule comprises a sequence homologous to a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, or a fragment thereof. In some embodiments, the nucleic acid molecule comprises a sequence selected from the group
5 consisting of SEQ ID NO:1 to SEQ ID NO:60, or fragments thereof.

According to some embodiments, the present invention provides vectors which comprise the nucleic acid molecule of the invention. In some embodiments, the vector is an expression vector.

According to some embodiments, the present invention provides host cells which
10 comprise the vectors of the invention. In some embodiments, the host cells comprise expression vectors.

The present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence complementary to at least a portion of a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, said portion comprising at least 10 nucleotides.

15 The present invention provides a method of producing a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120, or a homolog or fragment thereof. The method comprising the steps of introducing a recombinant expression vector that includes a nucleotide sequence that encodes the polypeptide into a compatible host cell, growing the host cell under conditions for expression of the polypeptide
20 and recovering the polypeptide.

The present invention provides an isolated antibody which binds to an epitope on a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120, or a homolog or fragment thereof.

25 The present invention provides an method of inducing an immune response in a mammal against a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120, or a homolog or fragment thereof. The method comprises administering to a mammal an amount of the polypeptide sufficient to induce said immune response.

30 The present invention provides a method for identifying a compound which binds nGPCR-x. The method comprises the steps of contacting nGPCR-x with a compound and determining whether the compound binds nGPCR-x.

The present invention provides a method for identifying a compound which binds a nucleic acid molecule encoding nGPCR-x. The method comprises the steps of contacting said

nucleic acid molecule encoding nGPCR-x with a compound and determining whether said compound binds said nucleic acid molecule.

The present invention provides a method for identifying a compound which modulates the activity of nGPCR-x. The method comprises the steps of contacting nGPCR-x with a
5 compound and determining whether nGPCR-x activity has been modulated.

The present invention provides a method of identifying an animal homolog of nGPCR-x. The method comprises the steps screening a nucleic acid database of the animal with a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, or a portion thereof and determining whether a portion of said library or database is homologous to said sequence
10 selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, or portion thereof.

The present invention provides a method of identifying an animal homolog of nGPCR-x. The methods comprises the steps screening a nucleic acid library of the animal with a nucleic acid molecule having a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, or a portion thereof and determining whether a portion of said library or database is
15 homologous to said sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, or a portion thereof.

Another aspect of the present invention relates to methods of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor. The methods comprise the steps of assaying nucleic acid of a human subject to determine a presence or an
20 absence of a mutation altering an amino acid sequence, expression, or biological activity of at least one nGPCR that is expressed in the brain. The nGPCR comprise an amino acid sequence selected from the group consisting of SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120, and allelic variants thereof. A diagnosis of the disorder or predisposition is made from the presence or absence of the mutation. The presence of a mutation altering the amino acid
25 sequence, expression, or biological activity of the nGPCR in the nucleic acid correlates with an increased risk of developing the disorder.

The present invention further relates to methods of screening for a hereditary mental disorder genotype related to nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 in a human patient. The methods comprise the steps of providing a biological sample comprising nucleic acid from the
30 patient, in which the nucleic acid includes sequences corresponding to alleles of nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70. The presence of one or more mutations in the nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 allele is detected indicative of a hereditary mental disorder genotype.

The present invention provides kits for screening a human subject to diagnose mental disorder or a genetic predisposition therefor. The kits include an oligonucleotide useful as a

probe for identifying polymorphisms in a human nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 gene. The oligonucleotide comprises 6-50 nucleotides in a sequence that is identical or complementary to a sequence of a wild type human nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 gene sequence or nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 coding sequence, except for one
5 sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide substitution. The kit also includes a media packaged with the oligonucleotide. The media contains information for identifying polymorphisms that correlate with mental disorder or a genetic predisposition therefor; the polymorphisms being identifiable using the oligonucleotide as a probe.

10 The present invention further relates to methods of identifying nGPCR allelic variants that correlates with mental disorders. The methods comprise the steps of providing biological samples that comprise nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny, and detecting in the nucleic acid the presence of one or more mutations in an nGPCR that is expressed in the brain. The nGPCR comprises an
15 amino acid sequence selected from the group consisting of SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120, and allelic variants thereof. The nucleic acid includes sequences corresponding to the gene or genes encoding nGPCR. The one or more mutations detected indicate an allelic variant that correlates with a mental disorder.

The present invention further relates to purified polynucleotides comprising nucleotide
20 sequences encoding alleles of nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 from a human with mental disorder. The polynucleotide hybridizes to the complement of SEQ ID Numbers 1, 2, 8, 31, 34, 36, 37, 39, 40, and 51-60 under the following hybridization conditions: (a) hybridization for 16 hours at 42C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and (b) washing 2 times for 30 minutes at 60C in a wash solution
25 comprising 0.1x SSC and 1% SDS. The polynucleotide that encodes nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 amino acid sequence of the human differs from SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120 by at least one residue.

The present invention also provides methods for identifying a modulator of biological activity of nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 comprising the steps of contacting a cell
30 that expresses nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 in the presence and in the absence of a putative modulator compound and measuring nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 biological activity in the cell. The decreased or increased nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 biological activity in the presence versus absence of the putative modulator is indicative of a modulator of biological activity.

The present invention further provides methods to identify compounds useful for the treatment of mental disorders. The methods comprise the steps of contacting a composition comprising nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 with a compound suspected of binding nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70. The binding between nGPCR-42, 46, 48, 49, 51,
5 52, 61, 63, or 70 and the compound suspected of binding nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 is detected. Compounds identified as binding nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 are candidate compounds useful for the treatment of mental disorder. Compounds identified as binding nGPCR-42, 46, 48, 49, 51, 52, 61, 63, 70, or other nGPCRs can be further tested in other assays including, but not limited to, *in vivo* models, in order to confirm or quantitate their
10 activity.

The present invention further provides methods for identifying a compound useful as a modulator of binding between nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 and a binding partner of nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70. The methods comprise the steps of contacting the binding partner and a composition comprising nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 in
15 the presence and in the absence of a putative modulator compound and detecting binding between the binding partner and nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70. Decreased or increased binding between the binding partner and nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 in the presence of the putative modulator, as compared to binding in the absence of the putative modulator is indicative a modulator compound useful for the treatment of a related disease or
20 disorder. Compounds identified as modulating binding between nGPCR-42, 46, 48, 49, 51, 52, 61, 63, 70, or other nGPCRs and an nGPCR-x binding partner can be further tested in other assays including, but not limited to, *in vivo* models, in order to confirm or quantitate their activity as modulators.

Another aspect of the present invention relates to methods of purifying a G protein from
25 a sample containing a G protein. The methods comprise the steps of contacting the sample with an nGPCR for a time sufficient to allow the G protein to form a complex with the nGPCR, isolating the complex from remaining components of the sample, maintaining the complex under conditions which result in dissociation of the G protein from the nGPCR, and isolating said G protein from the nGPCR.

Another aspect of the present invention relates to methods of identifying a compound
30 that binds to or modulates nGPCR-51. The methods comprise contacting a composition comprising nGPCR-51 and Peptide A with a test compound, or a plurality of test compounds, and determining whether the test compound or compounds compete with Peptide A for binding to nGPCR-51.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Definitions

Various definitions are made throughout this document. Most words have the meaning that would be attributed to those words by one skilled in the art. Words specifically defined
5 either below or elsewhere in this document have the meaning provided in the context of the present invention as a whole and as are typically understood by those skilled in the art.

“Synthesized” as used herein and understood in the art, refers to polynucleotides produced by purely chemical, as opposed to enzymatic, methods. “Wholly” synthesized DNA sequences are therefore produced entirely by chemical means, and “partially” synthesized DNAs
10 embrace those wherein only portions of the resulting DNA were produced by chemical means.

By the term “region” is meant a physically contiguous portion of the primary structure of a biomolecule. In the case of proteins, a region is defined by a contiguous portion of the amino acid sequence of that protein.

The term “domain” is herein defined as referring to a structural part of a biomolecule
15 that contributes to a known or suspected function of the biomolecule. Domains may be co-extensive with regions or portions thereof; domains may also incorporate a portion of a biomolecule that is distinct from a particular region, in addition to all or part of that region. Examples of GPCR protein domains include, but are not limited to, the extracellular (*i.e.*, N-terminal), transmembrane and cytoplasmic (*i.e.*, C-terminal) domains, which are co-extensive
20 with like-named regions of GPCRs; each of the seven transmembrane segments of a GPCR; and each of the loop segments (both extracellular and intracellular loops) connecting adjacent transmembrane segments.

As used herein, the term “activity” refers to a variety of measurable indicia suggesting or revealing binding, either direct or indirect; affecting a response, *i.e.* having a measurable affect
25 in response to some exposure or stimulus, including, for example, the affinity of a compound for directly binding a polypeptide or polynucleotide of the invention, or, for example, measurement of amounts of upstream or downstream proteins or other similar functions after some stimulus or event.

Unless indicated otherwise, as used herein, the abbreviation in lower case (gpcr) refers to
30 a gene, cDNA, RNA or nucleic acid sequence, while the upper case version (GPCR) refers to a protein, polypeptide, peptide, oligopeptide, or amino acid sequence. The term “nGPCR-x” refers to any of the nGPCRs taught herein, while specific reference to a nGPCR (for example nGPCR-63) refers only to that specific nGPCR.

As used herein, the term "antibody" is meant to refer to complete, intact antibodies, and Fab, Fab', F(ab)2, and other fragments thereof. Complete, intact antibodies include monoclonal antibodies such as murine monoclonal antibodies, chimeric antibodies and humanized antibodies.

5 As used herein, the term "binding" means the physical or chemical interaction between two proteins or compounds or associated proteins or compounds or combinations thereof. Binding includes ionic, non-ionic, Hydrogen bonds, Van der Waals, hydrophobic interactions, etc. The physical interaction, the binding, can be either direct or indirect, indirect being through or due to the effects of another protein or compound. Direct binding refers to interactions that do
10 not take place through or due to the effect of another protein or compound but instead are without other substantial chemical intermediates. Binding may be detected in many different manners. As a non-limiting example, the physical binding interaction between a nGPCR-x of the invention and a compound can be detected using a labeled compound. Alternatively, functional evidence of binding can be detected using, for example, a cell transfected with and expressing a
15 nGPCR-x of the invention. Binding of the transfected cell to a ligand of the nGPCR that was transfected into the cell provides functional evidence of binding. Other methods of detecting binding are well-known to those of skill in the art.

As used herein, the term "compound" means any identifiable chemical or molecule, including, but not limited to, small molecule, peptide, protein, sugar, nucleotide, or nucleic acid,
20 and such compound can be natural or synthetic.

As used herein, the term "complementary" refers to Watson-Crick basepairing between nucleotide units of a nucleic acid molecule.

As used herein, the term "contacting" means bringing together, either directly or indirectly, a compound into physical proximity to a polypeptide or polynucleotide of the
25 invention. The polypeptide or polynucleotide can be in any number of buffers, salts, solutions etc. Contacting includes, for example, placing the compound into a beaker, microtiter plate, cell culture flask, or a microarray, such as a gene chip, or the like, which contains the nucleic acid molecule, or polypeptide encoding the nGPCR or fragment thereof.

As used herein, the phrase "homologous nucleotide sequence," or "homologous amino
30 acid sequence," or variations thereof, refers to sequences characterized by a homology, at the nucleotide level or amino acid level, of at least the specified percentage. Homologous nucleotide sequences include those sequences coding for isoforms of proteins. Such isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. Homologous

nucleotide sequences include nucleotide sequences encoding for a protein of a species other than humans, including, but not limited to, mammals. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the nucleotide sequence encoding other known GPCRs. Homologous amino acid sequences include those amino acid sequences which contain conservative amino acid substitutions and which polypeptides have the same binding and/or activity. A homologous amino acid sequence does not, however, include the amino acid sequence encoding other known GPCRs. Percent homology can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison WI), using the default settings, which uses the algorithm of Smith and Waterman (*Adv. Appl. Math.*, 1981, 2, 482-489, which is incorporated herein by reference in its entirety).

As used herein, the term "isolated" nucleic acid molecule refers to a nucleic acid molecule (DNA or RNA) that has been removed from its native environment. Examples of isolated nucleic acid molecules include, but are not limited to, recombinant DNA molecules contained in a vector, recombinant DNA molecules maintained in a heterologous host cell, partially or substantially purified nucleic acid molecules, and synthetic DNA or RNA molecules.

As used herein, the terms "modulates" or "modifies" means an increase or decrease in the amount, quality, or effect of a particular activity or protein.

As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues which has a sufficient number of bases to be used in a polymerase chain reaction (PCR). This short sequence is based on (or designed from) a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 50 nucleotides, preferably about 15 to 30 nucleotides. They are chemically synthesized and may be used as probes.

As used herein, the term "probe" refers to nucleic acid sequences of variable length, preferably between at least about 10 and as many as about 6,000 nucleotides, depending on use. They are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are usually obtained from a natural or recombinant source, are highly specific and much slower to hybridize than oligomers. They may be single- or double-stranded and carefully designed to have specificity in PCR, hybridization membrane-based, or ELISA-like technologies.

The term "preventing" refers to decreasing the probability that an organism contracts or develops an abnormal condition.

The term "treating" refers to having a therapeutic effect and at least partially alleviating or abrogating an abnormal condition in the organism.

5 The term "therapeutic effect" refers to the inhibition or activation factors causing or contributing to the abnormal condition. A therapeutic effect relieves to some extent one or more of the symptoms of the abnormal condition. In reference to the treatment of abnormal conditions, a therapeutic effect can refer to one or more of the following: (a) an increase in the proliferation, growth, and/or differentiation of cells; (b) inhibition (*i.e.*, slowing or stopping) of
10 cell death; (c) inhibition of degeneration; (d) relieving to some extent one or more of the symptoms associated with the abnormal condition; and (e) enhancing the function of the affected population of cells. Compounds demonstrating efficacy against abnormal conditions can be identified as described herein.

15 The term "abnormal condition" refers to a function in the cells or tissues of an organism that deviates from their normal functions in that organism. An abnormal condition can relate to cell proliferation, cell differentiation, cell signaling, or cell survival. An abnormal condition may also include obesity, diabetic complications such as retinal degeneration, and irregularities in glucose uptake and metabolism, and fatty acid uptake and metabolism.

20 Abnormal cell proliferative conditions include cancers such as fibrotic and mesangial disorders, abnormal angiogenesis and vasculogenesis, wound healing, psoriasis, diabetes mellitus, and inflammation.

 Abnormal differentiation conditions include, but are not limited to, neurodegenerative disorders, slow wound healing rates, and slow tissue grafting healing rates. Abnormal cell signaling conditions include, but are not limited to, psychiatric disorders involving excess
25 neurotransmitter activity.

 Abnormal cell survival conditions may also relate to conditions in which programmed cell death (apoptosis) pathways are activated or abrogated. A number of protein kinases are associated with the apoptosis pathways. Aberrations in the function of any one of the protein kinases could lead to cell immortality or premature cell death.

30 The term "administering" relates to a method of incorporating a compound into cells or tissues of an organism. The abnormal condition can be prevented or treated when the cells or tissues of the organism exist within the organism or outside of the organism. Cells existing outside the organism can be maintained or grown in cell culture dishes. For cells harbored within the organism, many techniques exist in the art to administer compounds, including (but

not limited to) oral, parenteral, dermal, injection, and aerosol applications. For cells outside of the organism, multiple techniques exist in the art to administer the compounds, including (but not limited to) cell microinjection techniques, transformation techniques and carrier techniques.

The abnormal condition can also be prevented or treated by administering a compound to
5 a group of cells having an aberration in a signal transduction pathway to an organism. The effect of administering a compound on organism function can then be monitored. The organism is preferably a mouse, rat, rabbit, guinea pig or goat, more preferably a monkey or ape, and most preferably a human.

By "amplification" it is meant increased numbers of DNA or RNA in a cell compared
10 with normal cells. "Amplification" as it refers to RNA can be the detectable presence of RNA in cells, since in some normal cells there is no basal expression of RNA. In other normal cells, a basal level of expression exists, therefore in these cases amplification is the detection of at least 1 to 2-fold, and preferably more, compared to the basal level.

As used herein, the phrase "stringent hybridization conditions" or "stringent conditions"
15 refers to conditions under which a probe, primer, or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the
20 temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present in excess, at T_m , 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH
25 7.0 to 8.3 and the temperature is at least about 30C for short probes, primers or oligonucleotides (e.g. 10 to 50 nucleotides) and at least about 60C for longer probes, primers or oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

The amino acid sequences are presented in the amino to carboxy direction, from left to
30 right. The amino and carboxy groups are not presented in the sequence. The nucleotide sequences are presented by single strand only, in the 5' to 3' direction, from left to right. Nucleotides and amino acids are represented in the manner recommended by the IUPAC-IUB Biochemical Nomenclature Commission or (for amino acids) by three letters code.

Polynucleotides

The present invention provides purified and isolated polynucleotides (*e.g.*, DNA sequences and RNA transcripts, both sense and complementary antisense strands, both single- and double-stranded, including splice variants thereof) that encode unknown G protein-coupled receptors heretofore termed novel GPCRs, or nGPCRs. These genes are described herein and designated herein collectively as nGPCR-x (where x is 42, 44, 45, 46, 47, 48, 49, 50, 51, 52, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2024, 2025, 2026, 2027, 2028, 2029, and 2030). That is, these genes are described herein and designated herein as nGPCR-42, nGPCR-44, etc. Table 1 below identifies the novel gene sequence nGPCR-x designation, the SEQ ID NO: of the gene sequence, the SEQ ID NO: of the polypeptide encoded thereby, and the U.S. Provisional Application in which the gene sequence has been disclosed.

Table 1

nGPCR	Nucleotide Sequence (SEQ ID NO:)	Amino acid Sequence (SEQ ID NO:)	Originally filed in:
0042	31	91	D
0042	54	114	I
0044	32	92	D
0045	33	93	D
0046	34	94	D
0046	55	115	J
0047	35	95	D
0048	36	96	D
0048	56	116	K
0049	37	97	D
0049	59	119	N
0050	38	98	D
0051	39	99	D
0051	57	117	L
0052	40	100	D
0052	58	118	M
0061	1	61	A
0061	60	120	O
0063	2	62	A
0063	53	113	H
0063	51	111	F
0064	3	63	A
0065	4	64	A
0066	5	65	A
0067	6	66	A
0068	7	67	A
0069	10	70	A
0070	8	68	A
0070	52	112	G
0071	9	69	A
0072	43	103	E
2001	21	81	C
2002	22	82	C
2003	23	83	C
2004	24	84	C
2005	25	85	C
2006	26	86	C
2007	27	87	C
2008	28	88	C

2009	29	89	C
2010	30	90	C
2011	11	71	B
2012	12	72	B
2013	13	73	B
2014	14	74	B
2015	15	75	B
2016	16	76	B
2017	17	77	B
2018	18	78	B
2019	19	79	B
2020	20	80	B
2021	41	101	E
2022	42	102	E
2024	44	104	E
2025	45	105	E
2026	46	106	E
2027	47	107	E
2028	48	108	E
2029	49	109	E
2030	50	110	E

Legend

A= Ser. No. 60/184,305
C= Ser. No. 60/184,303
E= Ser. No. 60/184,247
G= Ser. No. 60/217,369
I= Ser. No. 60/186,810
K= Ser. No. 60/186,457
M= Ser. No. 60/194,344
O= Ser. No. 60/217,370

B= Ser. No. 60/184,304
D= Ser. No. 60/184,397
F= Ser. No. 60/188,880
H= Ser. No. 60/219,492
J= Ser. No. 60/188,064
L= Ser. No. 60/213,861
N= Ser. No. 60/218,337

When a specific nGPCR is identified (for example nGPCR-63), it is understood that only that specific nGPCR is being referred to.

As described in Example 5 below, the genes encoding nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 have been detected in brain tissue indicating that these nGPCR proteins are neuroreceptors.

The invention provides purified and isolated polynucleotides (*e.g.*, cDNA, genomic DNA, synthetic DNA, RNA, or combinations thereof, whether single- or double-stranded) that comprise a nucleotide sequence encoding the amino acid sequence of the polypeptides of the invention. Such polynucleotides are useful for recombinantly expressing the receptor and also for detecting expression of the receptor in cells (*e.g.*, using Northern hybridization and *in situ* hybridization assays). Such polynucleotides also are useful in the design of antisense and other molecules for the suppression of the expression of nGPCR-x in a cultured cell, a tissue, or an animal; for therapeutic purposes; or to provide a model for diseases or conditions characterized by aberrant nGPCR-x expression. Specifically excluded from the definition of polynucleotides of the invention are entire isolated, non-recombinant native chromosomes of host cells. A preferred polynucleotide has a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, which correspond to naturally occurring nGPCR-x sequences. It will be appreciated that numerous other polynucleotide sequences exist that also encode nGPCR-x

having the sequence selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120, due to the well-known degeneracy of the universal genetic code.

The invention also provides a purified and isolated polynucleotide comprising a nucleotide sequence that encodes a mammalian polypeptide, wherein the polynucleotide
5 hybridizes to a polynucleotide having the sequence set forth in sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, or the non-coding strand complementary thereto, under the following hybridization conditions: (a) hybridization for 16 hours at 42C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate; and (b) washing 2 times for 30 minutes each at 60C in a wash solution comprising 0.1% SSC,
10 1% SDS. Polynucleotides that encode a human allelic variant are highly preferred.

The present invention relates to molecules which comprise the gene sequences that encode the nGPCRs; constructs and recombinant host cells incorporating the gene sequences; the novel GPCR polypeptides encoded by the gene sequences; antibodies to the polypeptides and homologs; kits employing the polynucleotides and polypeptides, and methods of making
15 and using all of the foregoing. In addition, the present invention relates to homologs of the gene sequences and of the polypeptides and methods of making and using the same.

Genomic DNA of the invention comprises the protein-coding region for a polypeptide of the invention and is also intended to include allelic variants thereof. It is widely understood that, for many genes, genomic DNA is transcribed into RNA transcripts that undergo one or more
20 splicing events wherein intron (*i.e.*, non-coding regions) of the transcripts are removed, or "spliced out." RNA transcripts that can be spliced by alternative mechanisms, and therefore be subject to removal of different RNA sequences but still encode a nGPCR-x polypeptide, are referred to in the art as splice variants which are embraced by the invention. Splice variants comprehended by the invention therefore are encoded by the same original genomic DNA
25 sequences but arise from distinct mRNA transcripts. Allelic variants are modified forms of a wild-type gene sequence, the modification resulting from recombination during chromosomal segregation or exposure to conditions which give rise to genetic mutation. Allelic variants, like wild type genes, are naturally occurring sequences (as opposed to non-naturally occurring variants that arise from *in vitro* manipulation).

The invention also comprehends cDNA that is obtained through reverse transcription of
30 an RNA polynucleotide encoding nGPCR-x (conventionally followed by second strand synthesis of a complementary strand to provide a double-stranded DNA).

Preferred DNA sequences encoding human nGPCR-x polypeptides are selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60. A preferred DNA of the invention

comprises a double stranded molecule along with the complementary molecule (the “non-coding strand” or “complement”) having a sequence unambiguously deducible from the coding strand according to Watson-Crick base-pairing rules for DNA. Also preferred are other polynucleotides encoding the nGPCR-x polypeptide selected from the group consisting of SEQ ID NO:61 to
5 SEQ ID NO:120, which differ in sequence from the polynucleotides selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, by virtue of the well-known degeneracy of the universal nuclear genetic code.

The invention further embraces other species, preferably mammalian, homologs of the human nGPCR-x DNA. Species homologs, sometimes referred to as “orthologs,” in general,
10 share at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homology with human DNA of the invention. Generally, percent sequence “homology” with respect to polynucleotides of the invention may be calculated as the percentage of nucleotide bases in the candidate sequence that are identical to nucleotides in the nGPCR-x
15 sequence set forth in sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.

Polynucleotides of the invention permit identification and isolation of polynucleotides encoding related nGPCR-x polypeptides, such as human allelic variants and species homologs,
20 by well-known techniques including Southern and/or Northern hybridization, and polymerase chain reaction (PCR). Examples of related polynucleotides include human and non-human genomic sequences, including allelic variants, as well as polynucleotides encoding polypeptides homologous to nGPCR-x and structurally related polypeptides sharing one or more biological, immunological, and/or physical properties of nGPCR-x. Non-human species genes encoding
25 proteins homologous to nGPCR-x can also be identified by Southern and/or PCR analysis and are useful in animal models for nGPCR-x disorders. Knowledge of the sequence of a human nGPCR-x DNA also makes possible through use of Southern hybridization or polymerase chain reaction (PCR) the identification of genomic DNA sequences encoding nGPCR-x expression control regulatory sequences such as promoters, operators, enhancers, repressors, and the like.
30 Polynucleotides of the invention are also useful in hybridization assays to detect the capacity of cells to express nGPCR-x. Polynucleotides of the invention may also provide a basis for diagnostic methods useful for identifying a genetic alteration(s) in a nGPCR-x locus that underlies a disease state or states, which information is useful both for diagnosis and for selection of therapeutic strategies.

According to the present invention, the nGPCR-x nucleotide sequences disclosed herein may be used to identify homologs of the nGPCR-x, in other animals, including but not limited to humans and other mammals, and invertebrates. Any of the nucleotide sequences disclosed herein, or any portion thereof, can be used, for example, as probes to screen databases or nucleic acid libraries, such as, for example, genomic or cDNA libraries, to identify homologs, using screening procedures well known to those skilled in the art. Accordingly, homologs having at least 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, and most preferably at least 100% homology with nGPCR-x sequences can be identified.

The disclosure herein of full-length polynucleotides encoding nGPCR-x polypeptides makes readily available to the worker of ordinary skill in the art every possible fragment of the full-length polynucleotide.

One preferred embodiment of the present invention provides an isolated nucleic acid molecule comprising a sequence homologous sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, and fragments thereof. Another preferred embodiment provides an isolated nucleic acid molecule comprising a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, and fragments thereof.

As used in the present invention, fragments of nGPCR-x-encoding polynucleotides comprise at least 10, and preferably at least 12, 14, 16, 18, 20, 25, 50, or 75 consecutive nucleotides of a polynucleotide encoding nGPCR-x. Preferably, fragment polynucleotides of the invention comprise sequences unique to the nGPCR-x-encoding polynucleotide sequence, and therefore hybridize under highly stringent or moderately stringent conditions only (*i.e.*, "specifically") to polynucleotides encoding nGPCR-x (or fragments thereof). Polynucleotide fragments of genomic sequences of the invention comprise not only sequences unique to the coding region, but also include fragments of the full-length sequence derived from introns, regulatory regions, and/or other non-translated sequences. Sequences unique to polynucleotides of the invention are recognizable through sequence comparison to other known polynucleotides, and can be identified through use of alignment programs routinely utilized in the art, *e.g.*, those made available in public sequence databases. Such sequences also are recognizable from Southern hybridization analyses to determine the number of fragments of genomic DNA to which a polynucleotide will hybridize. Polynucleotides of the invention can be labeled in a manner that permits their detection, including radioactive, fluorescent, and enzymatic labeling.

Fragment polynucleotides are particularly useful as probes for detection of full-length or fragments of nGPCR-x polynucleotides. One or more polynucleotides can be included in kits

that are used to detect the presence of a polynucleotide encoding nGPCR-x, or used to detect variations in a polynucleotide sequence encoding nGPCR-x.

The invention also embraces DNAs encoding nGPCR-x polypeptides that hybridize under moderately stringent or high stringency conditions to the non-coding strand, or
5 complement, of the polynucleotides set forth in sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60.

Exemplary highly stringent hybridization conditions are as follows: hybridization at 42C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% Dextran sulfate, and washing twice for 30 minutes at 60C in a wash solution comprising 0.1 X SSC and
10 1% SDS. It is understood in the art that conditions of equivalent stringency can be achieved through variation of temperature and buffer, or salt concentration as described Ausubel *et al.* (Eds.), *Protocols in Molecular Biology*, John Wiley & Sons (1994), pp. 6.0.3 to 6.4.10.

Modifications in hybridization conditions can be empirically determined or precisely calculated based on the length and the percentage of guanosine/cytosine (GC) base pairing of the probe.

15 The hybridization conditions can be calculated as described in Sambrook, *et al.*, (Eds.), *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (1989), pp. 9.47 to 9.51.

With the knowledge of the nucleotide sequence information disclosed in the present invention, one skilled in the art can identify and obtain nucleotide sequences which encode
20 nGPCR-x from different sources (*i.e.*, different tissues or different organisms) through a variety of means well known to the skilled artisan and as disclosed by, for example, Sambrook *et al.*, "Molecular cloning: a laboratory manual", Second Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989), which is incorporated herein by reference in its entirety.

For example, DNA that encodes nGPCR-x may be obtained by screening of mRNA,
25 cDNA, or genomic DNA with oligonucleotide probes generated from the nGPCR-x gene sequence information provided herein. Probes may be labeled with a detectable group, such as a fluorescent group, a radioactive atom or a chemiluminescent group in accordance with procedures known to the skilled artisan and used in conventional hybridization assays, as described by, for example, Sambrook *et al.*

30 A nucleic acid molecule comprising any of the nGPCR-x nucleotide sequences described above can alternatively be synthesized by use of the polymerase chain reaction (PCR) procedure, with the PCR oligonucleotide primers produced from the nucleotide sequences provided herein. See U.S. Patent Numbers 4,683,195 to Mullis *et al.* and 4,683,202 to Mullis. The PCR reaction provides a method for selectively increasing the concentration of a particular

nucleic acid sequence even when that sequence has not been previously purified and is present only in a single copy in a particular sample. The method can be used to amplify either single- or double-stranded DNA. The essence of the method involves the use of two oligonucleotide probes to serve as primers for the template-dependent, polymerase mediated replication of a desired nucleic acid molecule.

A wide variety of alternative cloning and *in vitro* amplification methodologies are well known to those skilled in the art. Examples of these techniques are found in, for example, Berger *et al.*, *Guide to Molecular Cloning Techniques*, Methods in Enzymology 152, Academic Press, Inc., San Diego, CA (Berger), which is incorporated herein by reference in its entirety.

Automated sequencing methods can be used to obtain or verify the nucleotide sequence of nGPCR-x. The nGPCR-x nucleotide sequences of the present invention are believed to be 100% accurate. However, as is known in the art, nucleotide sequence obtained by automated methods may contain some errors. Nucleotide sequences determined by automation are typically at least about 90%, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of a given nucleic acid molecule. The actual sequence may be more precisely determined using manual sequencing methods, which are well known in the art. An error in a sequence which results in an insertion or deletion of one or more nucleotides may result in a frame shift in translation such that the predicted amino acid sequence will differ from that which would be predicted from the actual nucleotide sequence of the nucleic acid molecule, starting at the point of the mutation.

The nucleic acid molecules of the present invention, and fragments derived therefrom, are useful for screening for restriction fragment length polymorphism (RFLP) associated with certain disorders, as well as for genetic mapping.

The polynucleotide sequence information provided by the invention makes possible large-scale expression of the encoded polypeptide by techniques well known and routinely practiced in the art.

Vectors

Another aspect of the present invention is directed to vectors, or recombinant expression vectors, comprising any of the nucleic acid molecules described above. Vectors are used herein either to amplify DNA or RNA encoding nGPCR-x and/or to express DNA which encodes nGPCR-x. Preferred vectors include, but are not limited to, plasmids, phages, cosmids, episomes, viral particles or viruses, and integratable DNA fragments (*i.e.*, fragments integratable into the host genome by homologous recombination). Preferred viral particles include, but are not limited to, adenoviruses, baculoviruses, parvoviruses, herpesviruses, poxviruses, adeno-

associated viruses, Semliki Forest viruses, vaccinia viruses, and retroviruses. Preferred expression vectors include, but are not limited to, pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech). Other expression vectors include, but are not limited to, pSPORT™ vectors, pGEM™ vectors (Promega), pPROEXvectors™ (LTI, Bethesda, MD), Bluescript™ vectors (Stratagene),
5 pQE™ vectors (Qiagen), pSE420™ (Invitrogen), and pYES2™(Invitrogen).

Expression constructs preferably comprise GPCR-x-encoding polynucleotides operatively linked to an endogenous or exogenous expression control DNA sequence and a transcription terminator. Expression control DNA sequences include promoters, enhancers, operators, and regulatory element binding sites generally, and are typically selected based on the
10 expression systems in which the expression construct is to be utilized. Preferred promoter and enhancer sequences are generally selected for the ability to increase gene expression, while operator sequences are generally selected for the ability to regulate gene expression. Expression constructs of the invention may also include sequences encoding one or more selectable markers that permit identification of host cells bearing the construct. Expression constructs may also
15 include sequences that facilitate, and preferably promote, homologous recombination in a host cell. Preferred constructs of the invention also include sequences necessary for replication in a host cell.

Expression constructs are preferably utilized for production of an encoded protein, but may also be utilized simply to amplify a nGPCR-x-encoding polynucleotide sequence. In
20 preferred embodiments, the vector is an expression vector wherein the polynucleotide of the invention is operatively linked to a polynucleotide comprising an expression control sequence. Autonomously replicating recombinant expression constructs such as plasmid and viral DNA vectors incorporating polynucleotides of the invention are also provided. Preferred expression vectors are replicable DNA constructs in which a DNA sequence encoding nGPCR-x is
25 operably linked or connected to suitable control sequences capable of effecting the expression of the nGPCR-x in a suitable host. DNA regions are operably linked or connected when they are functionally related to each other. For example, a promoter is operably linked or connected to a coding sequence if it controls the transcription of the sequence. Amplification vectors do not require expression control domains, but rather need only the ability to replicate in a host, usually
30 conferred by an origin of replication, and a selection gene to facilitate recognition of transformants. The need for control sequences in the expression vector will vary depending upon the host selected and the transformation method chosen. Generally, control sequences include a transcriptional promoter, an optional operator sequence to control transcription, a

sequence encoding suitable mRNA ribosomal binding and sequences which control the termination of transcription and translation.

Preferred vectors preferably contain a promoter that is recognized by the host organism. The promoter sequences of the present invention may be prokaryotic, eukaryotic or viral.

5 Examples of suitable prokaryotic sequences include the P_R and P_L promoters of bacteriophage lambda (The bacteriophage Lambda, Hershey, A. D., Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1973), which is incorporated herein by reference in its entirety; Lambda II, Hendrix, R. W., Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1980), which is incorporated herein by reference in its entirety); the *trp*, *recA*, heat shock, and *lacZ* promoters of
10 *E. coli* and the SV40 early promoter (Benoist *et al. Nature*, 1981, 290, 304-310, which is incorporated herein by reference in its entirety). Additional promoters include, but are not limited to, mouse mammary tumor virus, long terminal repeat of human immunodeficiency virus, maloney virus, cytomegalovirus immediate early promoter, Epstein Barr virus, Rous sarcoma virus, human actin, human myosin, human hemoglobin, human muscle creatine, and
15 human metallothionein.

Additional regulatory sequences can also be included in preferred vectors. Preferred examples of suitable regulatory sequences are represented by the Shine-Dalgarno of the replicase gene of the phage MS-2 and of the gene *cII* of bacteriophage lambda. The Shine-Dalgarno sequence may be directly followed by DNA encoding nGPCR-x and result in the
20 expression of the mature nGPCR-x protein.

Moreover, suitable expression vectors can include an appropriate marker that allows the screening of the transformed host cells. The transformation of the selected host is carried out using any one of the various techniques well known to the expert in the art and described in Sambrook *et al., supra*.

25 An origin of replication can also be provided either by construction of the vector to include an exogenous origin or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter may be sufficient. Alternatively, rather than using vectors which contain viral origins of replication, one skilled in the art can transform mammalian cells by the method of co-transformation with a
30 selectable marker and nGPCR-x DNA. An example of a suitable marker is dihydrofolate reductase (DHFR) or thymidine kinase (*see*, U.S. Patent No. 4,399,216).

Nucleotide sequences encoding GPCR-x may be recombined with vector DNA in accordance with conventional techniques, including blunt-ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends

as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases. Techniques for such manipulation are disclosed by Sambrook et al., *supra* and are well known in the art. Methods for construction of mammalian expression vectors are disclosed in, for example, Okayama et al., *Mol. Cell. Biol.*, **1983**, *3*, 280, Cosman et al., *Mol.*
5 *Immunol.*, **1986**, *23*, 935, Cosman et al., *Nature*, **1984**, *312*, 768, EP-A-0367566, and WO 91/18982, each of which is incorporated herein by reference in its entirety.

Host cells

According to another aspect of the invention, host cells are provided, including prokaryotic and eukaryotic cells, comprising a polynucleotide of the invention (or vector of the
10 invention) in a manner that permits expression of the encoded nGPCR-x polypeptide. Polynucleotides of the invention may be introduced into the host cell as part of a circular plasmid, or as linear DNA comprising an isolated protein coding region or a viral vector. Methods for introducing DNA into the host cell that are well known and routinely practiced in the art include transformation, transfection, electroporation, nuclear injection, or fusion with
15 carriers such as liposomes, micelles, ghost cells, and protoplasts. Expression systems of the invention include bacterial, yeast, fungal, plant, insect, invertebrate, vertebrate, and mammalian cells systems.

The invention provides host cells that are transformed or transfected (stably or transiently) with polynucleotides of the invention or vectors of the invention. As stated above,
20 such host cells are useful for amplifying the polynucleotides and also for expressing the nGPCR-x polypeptide or fragment thereof encoded by the polynucleotide.

In still another related embodiment, the invention provides a method for producing a nGPCR-x polypeptide (or fragment thereof) comprising the steps of growing a host cell of the invention in a nutrient medium and isolating the polypeptide or variant thereof from the cell or
25 the medium. Because nGPCR-x is a seven transmembrane receptor, it will be appreciated that, for some applications, such as certain activity assays, the preferable isolation may involve isolation of cell membranes containing the polypeptide embedded therein, whereas for other applications a more complete isolation may be preferable.

According to some aspects of the present invention, transformed host cells having an
30 expression vector comprising any of the nucleic acid molecules described above are provided. Expression of the nucleotide sequence occurs when the expression vector is introduced into an appropriate host cell. Suitable host cells for expression of the polypeptides of the invention include, but are not limited to, prokaryotes, yeast, and eukaryotes. If a prokaryotic expression vector is employed, then the appropriate host cell would be any prokaryotic cell capable of

expressing the cloned sequences. Suitable prokaryotic cells include, but are not limited to, bacteria of the genera *Escherichia*, *Bacillus*, *Salmonella*, *Pseudomonas*, *Streptomyces*, and *Staphylococcus*.

If an eukaryotic expression vector is employed, then the appropriate host cell would be any eukaryotic cell capable of expressing the cloned sequence. Preferably, eukaryotic cells are cells of higher eukaryotes. Suitable eukaryotic cells include, but are not limited to, non-human mammalian tissue culture cells and human tissue culture cells. Preferred host cells include, but are not limited to, insect cells, HeLa cells, Chinese hamster ovary cells (CHO cells), African green monkey kidney cells (COS cells), human 293 cells, and murine 3T3 fibroblasts. Propagation of such cells in cell culture has become a routine procedure (*see*, Tissue Culture, Academic Press, Kruse and Patterson, eds. (1973), which is incorporated herein by reference in its entirety).

In addition, a yeast host may be employed as a host cell. Preferred yeast cells include, but are not limited to, the genera *Saccharomyces*, *Pichia*, and *Kluveromyces*. Preferred yeast hosts are *S. cerevisiae* and *P. pastoris*. Preferred yeast vectors can contain an origin of replication sequence from a 2T yeast plasmid, an autonomously replication sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Shuttle vectors for replication in both yeast and *E. coli* are also included herein.

Alternatively, insect cells may be used as host cells. In a preferred embodiment, the polypeptides of the invention are expressed using a baculovirus expression system (*see*, Luckow *et al.*, *Bio/Technology*, 1988, 6, 47, Baculovirus Expression Vectors: A Laboratory Manual, O'Rielly *et al.* (Eds.), W.H. Freeman and Company, New York, 1992, and U.S. Patent No. 4,879,236, each of which is incorporated herein by reference in its entirety). In addition, the MAXBAC™ complete baculovirus expression system (Invitrogen) can, for example, be used for production in insect cells.

Host cells of the invention are a valuable source of immunogen for development of antibodies specifically immunoreactive with nGPCR-x. Host cells of the invention are also useful in methods for the large-scale production of nGPCR-x polypeptides wherein the cells are grown in a suitable culture medium and the desired polypeptide products are isolated from the cells, or from the medium in which the cells are grown, by purification methods known in the art, *e.g.*, conventional chromatographic methods including immunoaffinity chromatography, receptor affinity chromatography, hydrophobic interaction chromatography, lectin affinity chromatography, size exclusion filtration, cation or anion exchange chromatography, high

pressure liquid chromatography (HPLC), reverse phase HPLC, and the like. Still other methods of purification include those methods wherein the desired protein is expressed and purified as a fusion protein having a specific tag, label, or chelating moiety that is recognized by a specific binding partner or agent. The purified protein can be cleaved to yield the desired protein, or can
5 be left as an intact fusion protein. Cleavage of the fusion component may produce a form of the desired protein having additional amino acid residues as a result of the cleavage process.

Knowledge of nGPCR-x DNA sequences allows for modification of cells to permit, or increase, expression of endogenous nGPCR-x. Cells can be modified (*e.g.*, by homologous recombination) to provide increased expression by replacing, in whole or in part, the naturally
10 occurring nGPCR-x promoter with all or part of a heterologous promoter so that the cells express nGPCR-x at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to endogenous nGPCR-x encoding sequences. (See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. WO 91/09955.) It is also contemplated that, in addition
15 to heterologous promoter DNA, amplifiable marker DNA (*e.g.*, *ada*, *dhfr*, and the multifunctional CAD gene which encodes carbamoyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the nGPCR-x coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the nGPCR-x coding
20 sequences in the cells.

Knock-outs

The DNA sequence information provided by the present invention also makes possible the development (*e.g.*, by homologous recombination or "knock-out" strategies; see Capecchi, *Science* 244:1288-1292 (1989), which is incorporated herein by reference in its entirety) of
25 animals that fail to express functional nGPCR-x or that express a variant of nGPCR-x. Such animals (especially small laboratory animals such as rats, rabbits, and mice) are useful as models for studying the *in vivo* activities of nGPCR-x and modulators of nGPCR-x.

Antisense

Also made available by the invention are anti-sense polynucleotides that recognize and
30 hybridize to polynucleotides encoding nGPCR-x. Full-length and fragment anti-sense polynucleotides are provided. Fragment antisense molecules of the invention include (i) those that specifically recognize and hybridize to nGPCR-x RNA (as determined by sequence comparison of DNA encoding nGPCR-x to DNA encoding other known molecules). Identification of sequences unique to nGPCR-x encoding polynucleotides can be deduced

through use of any publicly available sequence database, and/or through use of commercially available sequence comparison programs. After identification of the desired sequences, isolation through restriction digestion or amplification using any of the various polymerase chain reaction techniques well known in the art can be performed. Anti-sense polynucleotides are particularly relevant to regulating expression of nGPCR-x by those cells expressing nGPCR-x mRNA.

Antisense nucleic acids (preferably 10 to 30 base-pair oligonucleotides) capable of specifically binding to nGPCR-x expression control sequences or nGPCR-x RNA are introduced into cells (*e.g.*, by a viral vector or colloidal dispersion system such as a liposome). The antisense nucleic acid binds to the nGPCR-x target nucleotide sequence in the cell and prevents transcription and/or translation of the target sequence. Phosphorothioate and methylphosphonate antisense oligonucleotides are specifically contemplated for therapeutic use by the invention. The antisense oligonucleotides may be further modified by adding poly-L-lysine, transferrin polylysine, or cholesterol moieties at their 5' end. Suppression of nGPCR-x expression at either the transcriptional or translational level is useful to generate cellular or animal models for diseases/conditions characterized by aberrant nGPCR-x expression.

Antisense oligonucleotides, or fragments of sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, or sequences complementary or homologous thereto, derived from the nucleotide sequences of the present invention encoding nGPCR-x are useful as diagnostic tools for probing gene expression in various tissues. For example, tissue can be probed *in situ* with oligonucleotide probes carrying detectable groups by conventional autoradiography techniques to investigate native expression of this enzyme or pathological conditions relating thereto. Antisense oligonucleotides are preferably directed to regulatory regions of sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, or mRNA corresponding thereto, including, but not limited to, the initiation codon, TATA box, enhancer sequences, and the like.

Transcription factors

The nGPCR-x sequences taught in the present invention facilitate the design of novel transcription factors for modulating nGPCR-x expression in native cells and animals, and cells transformed or transfected with nGPCR-x polynucleotides. For example, the Cys₂-His₂ zinc finger proteins, which bind DNA via their zinc finger domains, have been shown to be amenable to structural changes that lead to the recognition of different target sequences. These artificial zinc finger proteins recognize specific target sites with high affinity and low dissociation constants, and are able to act as gene switches to modulate gene expression. Knowledge of the particular nGPCR-x target sequence of the present invention facilitates the engineering of zinc

finger proteins specific for the target sequence using known methods such as a combination of structure-based modeling and screening of phage display libraries (Segal *et al.*, *Proc. Natl. Acad. Sci. USA* 96:2758-2763 (1999); Liu *et al.*, *Proc. Natl. Acad. Sci. USA* 94:5525-5530 (1997); Greisman *et al.*, *Science* 275:657-661 (1997); Choo *et al.*, *J. Mol. Biol.* 273:525-532 (1997)). Each zinc finger domain usually recognizes three or more base pairs. Since a
5 recognition sequence of 18 base pairs is generally sufficient in length to render it unique in any known genome, a zinc finger protein consisting of 6 tandem repeats of zinc fingers would be expected to ensure specificity for a particular sequence (Segal *et al.*). The artificial zinc finger repeats, designed based on nGPCR-x sequences, are fused to activation or repression domains to
10 promote or suppress nGPCR-x expression (Liu *et al.*). Alternatively, the zinc finger domains can be fused to the TATA box-binding factor (TBP) with varying lengths of linker region between the zinc finger peptide and the TBP to create either transcriptional activators or repressors (Kim *et al.*, *Proc. Natl. Acad. Sci. USA* 94:3616-3620 (1997). Such proteins and polynucleotides that encode them, have utility for modulating nGPCR-x expression *in vivo* in both native cells,
15 animals and humans; and/or cells transfected with nGPCR-x-encoding sequences. The novel transcription factor can be delivered to the target cells by transfecting constructs that express the transcription factor (gene therapy), or by introducing the protein. Engineered zinc finger proteins can also be designed to bind RNA sequences for use in therapeutics as alternatives to antisense or catalytic RNA methods (McColl *et al.*, *Proc. Natl. Acad. Sci. USA* 96:9521-9526
20 (1997); Wu *et al.*, *Proc. Natl. Acad. Sci. USA* 92:344-348 (1995)). The present invention contemplates methods of designing such transcription factors based on the gene sequence of the invention, as well as customized zinc finger proteins, that are useful to modulate nGPCR-x expression in cells (native or transformed) whose genetic complement includes these sequences.

Polypeptides

25 The invention also provides purified and isolated mammalian nGPCR-x polypeptides encoded by a polynucleotide of the invention. Presently preferred is a human nGPCR-x polypeptide comprising the amino acid sequence set out in sequences selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120, or fragments thereof comprising an epitope specific to the polypeptide. By "epitope specific to" is meant a portion of the nGPCR receptor
30 that is recognizable by an antibody that is specific for the nGPCR, as defined in detail below.

Although the sequences provided are particular human sequences, the invention is intended to include within its scope other human allelic variants; non-human mammalian forms of nGPCR-x, and other vertebrate forms of nGPCR-x.

It will be appreciated that extracellular epitopes are particularly useful for generating and screening for antibodies and other binding compounds that bind to receptors such as nGPCR-x. Thus, in another preferred embodiment, the invention provides a purified and isolated polypeptide comprising at least one extracellular domain (*e.g.*, the N-terminal extracellular domain or one of the three extracellular loops) of nGPCR-x. Purified and isolated polypeptides comprising the N-terminal extracellular domain of nGPCR-x are highly preferred. Also preferred is a purified and isolated polypeptide comprising a nGPCR-x fragment selected from the group consisting of the N-terminal extracellular domain of nGPCR-x, transmembrane domains of nGPCR-x, an extracellular loop connecting transmembrane domains of nGPCR-x, an intracellular loop connecting transmembrane domains of nGPCR-x, the C-terminal cytoplasmic region of nGPCR-x, and fusions thereof. Such fragments may be continuous portions of the native receptor. However, it will also be appreciated that knowledge of the nGPCR-x gene and protein sequences as provided herein permits recombining of various domains that are not contiguous in the native protein. Using a FORTRAN computer program called "tmrest.all" (Parodi *et al.*, *Comput. Appl. Biosci.* 5:527-535 (1994)), nGPCR-x was shown to contain transmembrane-spanning domains.

The invention also embraces polypeptides that have at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55% or at least 50% identity and/or homology to the preferred polypeptide of the invention. Percent amino acid sequence "identity" with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the nGPCR-x sequence after aligning both sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Percent sequence "homology" with respect to the preferred polypeptide of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the nGPCR-x sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and also considering any conservative substitutions as part of the sequence identity.

In one aspect, percent homology is calculated as the percentage of amino acid residues in the smaller of two sequences which align with identical amino acid residue in the sequence being compared, when four gaps in a length of 100 amino acids may be introduced to maximize alignment (Dayhoff, in *Atlas of Protein Sequence and Structure*, Vol. 5, p. 124, National

Biochemical Research Foundation, Washington, D.C. (1972), incorporated herein by reference in its entirety).

Polypeptides of the invention may be isolated from natural cell sources or may be chemically synthesized, but are preferably produced by recombinant procedures involving host cells of the invention. Use of mammalian host cells is expected to provide for such post-translational modifications (*e.g.*, glycosylation, truncation, lipidation, and phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention. Glycosylated and non-glycosylated forms of nGPCR-x polypeptides are embraced by the invention.

The invention also embraces variant (or analog) nGPCR-x polypeptides. In one example, insertion variants are provided wherein one or more amino acid residues supplement a nGPCR-x amino acid sequence. Insertions may be located at either or both termini of the protein, or may be positioned within internal regions of the nGPCR-x amino acid sequence. Insertional variants with additional residues at either or both termini can include, for example, fusion proteins and proteins including amino acid tags or labels.

Insertion variants include nGPCR-x polypeptides wherein one or more amino acid residues are added to a nGPCR-x acid sequence or to a biologically active fragment thereof.

Variant products of the invention also include mature nGPCR-x products, *i.e.*, nGPCR-x products wherein leader or signal sequences are removed, with additional amino terminal residues. The additional amino terminal residues may be derived from another protein, or may include one or more residues that are not identifiable as being derived from specific proteins. nGPCR-x products with an additional methionine residue at position -1 (Met⁻¹-nGPCR-x) are contemplated, as are variants with additional methionine and lysine residues at positions -2 and -1 (Met⁻²-Lys⁻¹-nGPCR-x). Variants of nGPCR-x with additional Met, Met-Lys, Lys residues (or one or more basic residues in general) are particularly useful for enhanced recombinant protein production in bacterial host cells.

The invention also embraces nGPCR-x variants having additional amino acid residues that result from use of specific expression systems. For example, use of commercially available vectors that express a desired polypeptide as part of a glutathione-S-transferase (GST) fusion product provides the desired polypeptide having an additional glycine residue at position -1 after cleavage of the GST component from the desired polypeptide. Variants that result from expression in other vector systems are also contemplated.

Insertional variants also include fusion proteins wherein the amino terminus and/or the carboxy terminus of nGPCR-x is/are fused to another polypeptide.

In another aspect, the invention provides deletion variants wherein one or more amino acid residues in a nGPCR-x polypeptide are removed. Deletions can be effected at one or both termini of the nGPCR-x polypeptide, or with removal of one or more non-terminal amino acid residues of nGPCR-x. Deletion variants, therefore, include all fragments of a nGPCR-x polypeptide.

The invention also embraces polypeptide fragments of sequences selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120, wherein the fragments maintain biological (e.g., ligand binding and/or intracellular signaling) immunological properties of a nGPCR-x polypeptide.

In one preferred embodiment of the invention, an isolated nucleic acid molecule comprises a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to sequences selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120, and fragments thereof, wherein the nucleic acid molecule encoding at least a portion of nGPCR-x. In a more preferred embodiment, the isolated nucleic acid molecule comprises a sequence that encodes a polypeptide comprising sequences selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120, and fragments thereof.

As used in the present invention, polypeptide fragments comprise at least 5, 10, 15, 20, 25, 30, 35, or 40 consecutive amino acids of sequences selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120. Preferred polypeptide fragments display antigenic properties unique to, or specific for, human nGPCR-x and its allelic and species homologs. Fragments of the invention having the desired biological and immunological properties can be prepared by any of the methods well known and routinely practiced in the art.

In still another aspect, the invention provides substitution variants of nGPCR-x polypeptides. Substitution variants include those polypeptides wherein one or more amino acid residues of a nGPCR-x polypeptide are removed and replaced with alternative residues. In one aspect, the substitutions are conservative in nature; however, the invention embraces substitutions that are also non-conservative. Conservative substitutions for this purpose may be defined as set out in Tables 2, 3, or 4 below.

Variant polypeptides include those wherein conservative substitutions have been introduced by modification of polynucleotides encoding polypeptides of the invention. Amino acids can be classified according to physical properties and contribution to secondary and tertiary protein structure. A conservative substitution is recognized in the art as a substitution of one amino acid for another amino acid that has similar properties. Exemplary conservative

substitutions are set out in Table 2 (from WO 97/09433, page 10, published March 13, 1997 (PCT/GB96/02197, filed 9/6/96), immediately below.

Table 2

Conservative Substitutions I

<u>SIDE CHAIN CHARACTERISTIC</u>	<u>AMINO ACID</u>
Aliphatic	
Non-polar	G A P I L V
Polar - uncharged	C S T M N Q
Polar - charged	D E K R
Aromatic	H F W Y
Other	N Q D E

Alternatively, conservative amino acids can be grouped as described in Lehninger, (*Biochemistry*, Second Edition; Worth Publishers, Inc. NY, NY (1975), pp.71-77) as set out in Table 3, below.

Table 3

Conservative Substitutions II

<u>SIDE CHAIN CHARACTERISTIC</u>	<u>AMINO ACID</u>
Non-polar (hydrophobic)	
A. Aliphatic:	A L I V P
B. Aromatic:	F W
C. Sulfur-containing:	M
D. Borderline:	G
Uncharged-polar	
A. Hydroxyl:	S T Y
B. Amides:	N Q
C. Sulfhydryl:	C
D. Borderline:	G
Positively Charged (Basic):	K R H
Negatively Charged (Acidic):	D E

As still another alternative, exemplary conservative substitutions are set out in Table 4, below.

Table 4

Conservative Substitutions III

Original Residue	Exemplary Substitution
Ala (A)	Val, Leu, Ile

Arg (R)	Lys, Gln, Asn
Asn (N)	Gln, His, Lys, Arg
Asp (D)	Glu
Cys (C)	Ser
Gln (Q)	Asn
Glu (E)	Asp
His (H)	Asn, Gln, Lys, Arg
Ile (I)	Leu, Val, Met, Ala, Phe,
Leu (L)	Ile, Val, Met, Ala, Phe
Lys (K)	Arg, Gln, Asn
Met (M)	Leu, Phe, Ile
Phe (F)	Leu, Val, Ile, Ala
Pro (P)	Gly
Ser (S)	Thr
Thr (T)	Ser
Trp (W)	Tyr
Tyr (Y)	Trp, Phe, Thr, Ser
Val (V)	Ile, Leu, Met, Phe, Ala

It should be understood that the definition of polypeptides of the invention is intended to include polypeptides bearing modifications other than insertion, deletion, or substitution of amino acid residues. By way of example, the modifications may be covalent in nature, and include for example, chemical bonding with polymers, lipids, other organic, and inorganic
5 moieties. Such derivatives may be prepared to increase circulating half-life of a polypeptide, or may be designed to improve the targeting capacity of the polypeptide for desired cells, tissues, or organs. Similarly, the invention further embraces nGPCR-x polypeptides that have been covalently modified to include one or more water-soluble polymer attachments such as polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol. Variants that display
10 ligand binding properties of native nGPCR-x and are expressed at higher levels, as well as variants that provide for constitutively active receptors, are particularly useful in assays of the invention; the variants are also useful in providing cellular, tissue and animal models of diseases/conditions characterized by aberrant nGPCR-x activity.

In a related embodiment, the present invention provides compositions comprising
15 purified polypeptides of the invention. Preferred compositions comprise, in addition to the polypeptide of the invention, a pharmaceutically acceptable (*i.e.*, sterile and non-toxic) liquid, semisolid, or solid diluent that serves as a pharmaceutical vehicle, excipient, or medium. Any diluent known in the art may be used. Exemplary diluents include, but are not limited to, water, saline solutions, polyoxyethylene sorbitan monolaurate, magnesium stearate, methyl- and

propylhydroxybenzoate, talc, alginates, starches, lactose, sucrose, dextrose, sorbitol, mannitol, glycerol, calcium phosphate, mineral oil, and cocoa butter.

Variants that display ligand binding properties of native nGPCR-x and are expressed at higher levels, as well as variants that provide for constitutively active receptors, are particularly useful in assays of the invention; the variants are also useful in assays of the invention and in providing cellular, tissue and animal models of diseases/conditions characterized by aberrant nGPCR-x activity.

The G protein-coupled receptor functions through a specific heterotrimeric guanine-nucleotide-binding regulatory protein (G-protein) coupled to the intracellular portion of the G protein-coupled receptor molecule. Accordingly, the G protein-coupled receptor has a specific affinity to G protein. G proteins specifically bind to guanine nucleotides. Isolation of G proteins provides a means to isolate guanine nucleotides. G Proteins may be isolated using commercially available anti-G protein antibodies or isolated G protein-coupled receptors. Similarly, G proteins may be detected in a sample isolated using commercially available detectable anti-G protein antibodies or isolated G protein-coupled receptors.

According to the present invention, the isolated n-GPCR-x proteins of the present invention are useful to isolate and purify G proteins from samples such as cell lysates. Example 14 below sets forth an example of isolation of G proteins using isolated n-GPCR-x proteins. Such methodology may be used in place of the use of commercially available anti-G protein antibodies which are used to isolate G proteins. Moreover, G proteins may be detected using n-GPCR-x proteins in place of commercially available detectable anti-G protein antibodies. Since n-GPCR-x proteins specifically bind to G proteins, they can be employed in any specific use where G protein specific affinity is required such as those uses where commercially available anti-G protein antibodies are employed.

Antibodies

Also comprehended by the present invention are antibodies (*e.g.*, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, bifunctional/bispecific antibodies, humanized antibodies, human antibodies, and complementary determining region (CDR)-grafted antibodies, including compounds which include CDR sequences which specifically recognize a polypeptide of the invention) specific for nGPCR-x or fragments thereof. Preferred antibodies of the invention are human antibodies that are produced and identified according to methods described in WO93/11236, published June 20, 1993, which is incorporated herein by reference in its entirety. Antibody fragments, including Fab, Fab', F(ab')₂, and F_v, are also provided by the invention. The term "specific for," when used to

describe antibodies of the invention, indicates that the variable regions of the antibodies of the invention recognize and bind nGPCR-x polypeptides exclusively (*i.e.*, are able to distinguish nGPCR-x polypeptides from other known GPCR polypeptides by virtue of measurable differences in binding affinity, despite the possible existence of localized sequence identity, homology, or similarity between nGPCR-x and such polypeptides). It will be understood that specific antibodies may also interact with other proteins (for example, *S. aureus* protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and, in particular, in the constant region of the molecule. Screening assays to determine binding specificity of an antibody of the invention are well known and routinely practiced in the art. For a comprehensive discussion of such assays, see Harlow *et al.* (Eds.), *Antibodies A Laboratory Manual*; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988), Chapter 6. Antibodies that recognize and bind fragments of the nGPCR-x polypeptides of the invention are also contemplated, provided that the antibodies are specific for nGPCR-x polypeptides. Antibodies of the invention can be produced using any method well known and routinely practiced in the art.

The invention provides an antibody that is specific for the nGPCR-x of the invention. Antibody specificity is described in greater detail below. However, it should be emphasized that antibodies that can be generated from polypeptides that have previously been described in the literature and that are capable of fortuitously cross-reacting with nGPCR-x (*e.g.*, due to the fortuitous existence of a similar epitope in both polypeptides) are considered "cross-reactive" antibodies. Such cross-reactive antibodies are not antibodies that are "specific" for nGPCR-x. The determination of whether an antibody is specific for nGPCR-x or is cross-reactive with another known receptor is made using any of several assays, such as Western blotting assays, that are well known in the art. For identifying cells that express nGPCR-x and also for modulating nGPCR-x-ligand binding activity, antibodies that specifically bind to an extracellular epitope of the nGPCR-x are preferred.

In one preferred variation, the invention provides monoclonal antibodies. Hybridomas that produce such antibodies also are intended as aspects of the invention. In yet another variation, the invention provides a humanized antibody. Humanized antibodies are useful for *in vivo* therapeutic indications.

In another variation, the invention provides a cell-free composition comprising polyclonal antibodies, wherein at least one of the antibodies is an antibody of the invention specific for nGPCR-x. Antisera isolated from an animal is an exemplary composition, as is a

composition comprising an antibody fraction of an antisera that has been resuspended in water or in another diluent, excipient, or carrier.

In still another related embodiment, the invention provides an anti-idiotypic antibody specific for an antibody that is specific for nGPCR-x.

5 It is well known that antibodies contain relatively small antigen binding domains that can be isolated chemically or by recombinant techniques. Such domains are useful nGPCR-x binding molecules themselves, and also may be reintroduced into human antibodies, or fused to toxins or other polypeptides. Thus, in still another embodiment, the invention provides a polypeptide comprising a fragment of a nGPCR-x-specific antibody, wherein the fragment and
10 the polypeptide bind to the nGPCR-x. By way of non-limiting example, the invention provides polypeptides that are single chain antibodies and CDR-grafted antibodies.

Non-human antibodies may be humanized by any of the methods known in the art. In one method, the non-human CDRs are inserted into a human antibody or consensus antibody framework sequence. Further changes can then be introduced into the antibody framework to
15 modulate affinity or immunogenicity.

Antibodies of the invention are useful for, *e.g.*, therapeutic purposes (by modulating activity of nGPCR-x), diagnostic purposes to detect or quantitate nGPCR-x, and purification of nGPCR-x. Kits comprising an antibody of the invention for any of the purposes described herein are also comprehended. In general, a kit of the invention also includes a control antigen for
20 which the antibody is immunospecific.

Compositions

Mutations in the nGPCR-x gene that result in loss of normal function of the nGPCR-x gene product underlie nGPCR-x-related human disease states. The invention comprehends gene therapy to restore nGPCR-x activity to treat those disease states. Delivery of a functional
25 nGPCR-x gene to appropriate cells is effected *ex vivo*, *in situ*, or *in vivo* by use of vectors, and more particularly viral vectors (*e.g.*, adenovirus, adeno-associated virus, or a retrovirus), or *ex vivo* by use of physical DNA transfer methods (*e.g.*, liposomes or chemical treatments). See, for example, Anderson, *Nature*, supplement to vol. 392, no. 6679, pp.25-20 (1998). For additional reviews of gene therapy technology see Friedmann, *Science*, 244: 1275-1281 (1989); Verma, *Scientific American*: 68-84 (1990); and Miller, *Nature*, 357: 455-460 (1992). Alternatively, it is
30 contemplated that in other human disease states, preventing the expression of, or inhibiting the activity of, nGPCR-x will be useful in treating disease states. It is contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of nGPCR-x.

Another aspect of the present invention is directed to compositions, including pharmaceutical compositions, comprising any of the nucleic acid molecules or recombinant expression vectors described above and an acceptable carrier or diluent. Preferably, the carrier or diluent is pharmaceutically acceptable. Suitable carriers are described in the most recent
5 edition of *Remington's Pharmaceutical Sciences*, A. Osol, a standard reference text in this field, which is incorporated herein by reference in its entirety. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles such as fixed oils may also be used. The formulations are sterilized by commonly used techniques.

10 Also within the scope of the invention are compositions comprising polypeptides, polynucleotides, or antibodies of the invention that have been formulated with, *e.g.*, a pharmaceutically acceptable carrier.

The invention also provides methods of using antibodies of the invention. For example, the invention provides a method for modulating ligand binding of a nGPCR-x comprising the
15 step of contacting the nGPCR-x with an antibody specific for the nGPCR-x, under conditions wherein the antibody binds the receptor.

GPCRs that may be expressed in the brain, such as nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70, provide an indication that aberrant nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 signaling activity may correlate with one or more neurological or psychological disorders. The
20 invention also provides a method for treating a neurological or psychiatric disorder comprising the step of administering to a mammal in need of such treatment an amount of an antibody-like polypeptide of the invention that is sufficient to modulate ligand binding to a nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 in neurons of the mammal. nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 may also be expressed in other tissues, including but not limited to, peripheral blood
25 lymphocytes, pancreas, ovary, uterus, testis, salivary gland, thyroid gland, kidney, adrenal gland, liver, bone marrow, prostate, fetal liver, colon, muscle, and fetal brain, and may be found in many other tissues. Within the brain, nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 mRNA transcripts may be found in many tissues, including, but not limited to, frontal lobe, hypothalamus, pons, cerebellum, caudate nucleus, and medulla. Tissues and brain regions where
30 specific nGPCRs of the present invention are expressed are identified in the Examples below.

Kits

The present invention is also directed to kits, including pharmaceutical kits. The kits can comprise any of the nucleic acid molecules described above, any of the polypeptides described above, or any antibody which binds to a polypeptide of the invention as described above, as well

as a negative control. The kit preferably comprises additional components, such as, for example, instructions, solid support, reagents helpful for quantification, and the like.

In another aspect, the invention features methods for detection of a polypeptide in a sample as a diagnostic tool for diseases or disorders, wherein the method comprises the steps of:

- 5 (a) contacting the sample with a nucleic acid probe which hybridizes under hybridization assay conditions to a nucleic acid target region of a polypeptide having sequences selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120, said probe comprising the nucleic acid sequence encoding the polypeptide, fragments thereof, and the complements of the sequences and fragments; and (b) detecting the presence or amount of the probe:target region hybrid as an
10 indication of the disease.

In preferred embodiments of the invention, the disease is selected from the group consisting of thyroid disorders (*e.g.* thyreotoxicosis, myxoedema); renal failure; inflammatory conditions (*e.g.*, Crohn's disease); diseases related to cell differentiation and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (*e.g.*, pain
15 including migraine; stroke; psychotic and neurological disorders, including anxiety, mental disorder, manic depression, anxiety, generalized anxiety disorder, post-traumatic-stress disorder, depression, bipolar disorder, delirium, dementia, severe mental retardation; dyskinesias, such as Huntington's disease or Tourette's Syndrome; attention disorders including attention deficit disorder (ADD) and attention deficit-hyperactivity disorder (ADHD), and degenerative
20 disorders such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, *etc.*); infections, such as viral infections caused by HIV-1 or HIV-2; metabolic and cardiovascular diseases and disorders (*e.g.*, type 2 diabetes, impaired glucose tolerance, dyslipidemia, obesity, anorexia, hypotension, hypertension, thrombosis, myocardial infarction, cardiomyopathies, atherosclerosis, *etc.*); proliferative diseases and cancers (*e.g.*,
25 different cancers such as breast, colon, lung, *etc.*, and hyperproliferative disorders such as psoriasis, prostate hyperplasia, *etc.*); hormonal disorders (*e.g.*, male/female hormonal replacement, polycystic ovarian syndrome, alopecia, *etc.*); and sexual dysfunction, among others.

As described above and in Example 5 below, the genes encoding nGPCR-42, 46, 48, 49,
30 51, 52, 61, 63, and 70 have been detected in brain tissue indicating that these n-GPCR-x proteins are neuroreceptors. Kits may be designed to detect either expression of polynucleotides encoding these proteins or the proteins themselves in order to identify tissue as being neurological. For example, oligonucleotide hybridization kits can be provided which include a container having an oligonucleotide probe specific for the n-GPCR-x-specific DNA and

optionally, containers with positive and negative controls and/or instructions. Similarly, PCR kits can be provided which include a container having primers specific for the n-GPCR-x-specific sequences, DNA and optionally, containers with size markers, positive and negative controls and/or instructions.

5 Hybridization conditions should be such that hybridization occurs only with the genes in the presence of other nucleic acid molecules. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having 1 or 2 mismatches out of 20 contiguous nucleotides. Such conditions are defined supra.

10 The diseases for which detection of genes in a sample could be diagnostic include diseases in which nucleic acid (DNA and/or RNA) is amplified in comparison to normal cells. By "amplification" is meant increased numbers of DNA or RNA in a cell compared with normal cells.

 The diseases that could be diagnosed by detection of nucleic acid in a sample preferably
15 include central nervous system and metabolic diseases. The test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids. The samples used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid extracts of cells are well known in the art and can
20 be readily adapted in order to obtain a sample that is compatible with the method utilized.

 Alternatively, immunoassay kits can be provided which have containers container having antibodies specific for the n-GPCR-x-protein and optionally, containers with positive and negative controls and/or instructions.

 Kits may also be provided useful in the identification of GPCR binding partners such as
25 natural ligands or modulators (agonists or antagonists). Substances useful for treatment of disorders or diseases preferably show positive results in one or more *in vitro* assays for an activity corresponding to treatment of the disease or disorder in question. Substances that modulate the activity of the polypeptides preferably include, but are not limited to, antisense oligonucleotides, agonists and antagonists, and inhibitors of protein kinases.

30 **Methods of inducing immune response**

 Another aspect of the present invention is directed to methods of inducing an immune response in a mammal against a polypeptide of the invention by administering to the mammal an amount of the polypeptide sufficient to induce an immune response. The amount will be

dependent on the animal species, size of the animal, and the like but can be determined by those skilled in the art.

Methods of identifying ligands

The invention also provides assays to identify compounds that bind nGPCR-x. One such
5 assay comprises the steps of: (a) contacting a composition comprising a nGPCR-x with a
compound suspected of binding nGPCR-x; and (b) measuring binding between the compound
and nGPCR-x. In one variation, the composition comprises a cell expressing nGPCR-x on its
surface. In another variation, isolated nGPCR-x or cell membranes comprising nGPCR-x are
employed. The binding may be measured directly, *e.g.*, by using a labeled compound, or may be
10 measured indirectly by several techniques, including measuring intracellular signaling of
nGPCR-x induced by the compound (or measuring changes in the level of nGPCR-x signaling).
Following steps (a) and (b), compounds identified as binding nGPCR-x can be further tested in
other assays including, but not limited to, *in vivo* models, in order to confirm or quantitate
binding to nGPCR-x.

15 Specific binding molecules, including natural ligands and synthetic compounds, can be
identified or developed using isolated or recombinant nGPCR-x products, nGPCR-x variants, or
preferably, cells expressing such products. Binding partners are useful for purifying nGPCR-x
products and detection or quantification of nGPCR-x products in fluid and tissue samples using
known immunological procedures. Binding molecules are also manifestly useful in modulating
20 (*i.e.*, blocking, inhibiting or stimulating) biological activities of nGPCR-x, especially those
activities involved in signal transduction.

The DNA and amino acid sequence information provided by the present invention also
makes possible identification of binding partner compounds with which a nGPCR-x polypeptide
or polynucleotide will interact. Methods to identify binding partner compounds include solution
25 assays, *in vitro* assays wherein nGPCR-x polypeptides are immobilized, and cell-based assays.
Identification of binding partner compounds of nGPCR-x polypeptides provides candidates for
therapeutic or prophylactic intervention in pathologies associated with nGPCR-x normal and
aberrant biological activity.

The invention includes several assay systems for identifying nGPCR-x binding partners.
30 In solution assays, methods of the invention comprise the steps of (a) contacting a nGPCR-x
polypeptide with one or more candidate binding partner compounds and (b) identifying the
compounds that bind to the nGPCR-x polypeptide. Identification of the compounds that bind
the nGPCR-x polypeptide can be achieved by isolating the nGPCR-x polypeptide/binding
partner complex, and separating the binding partner compound from the nGPCR-x polypeptide.

An additional step of characterizing the physical, biological, and/or biochemical properties of the binding partner compound is also comprehended in another embodiment of the invention, wherein compounds identified as binding nGPCR-x can be further tested in other assays including, but not limited to, *in vivo* models, in order to confirm or quantitate binding to
5 nGPCR-x. In one aspect, the nGPCR-x polypeptide/binding partner complex is isolated using an antibody immunospecific for either the nGPCR-x polypeptide or the candidate binding partner compound.

In still other embodiments, either the nGPCR-x polypeptide or the candidate binding partner compound comprises a label or tag that facilitates its isolation, and methods of the
10 invention to identify binding partner compounds include a step of isolating the nGPCR-x polypeptide/binding partner complex through interaction with the label or tag. An exemplary tag of this type is a poly-histidine sequence, generally around six histidine residues, that permits isolation of a compound so labeled using nickel chelation. Other labels and tags, such as the FLAG® tag (Eastman Kodak, Rochester, NY), well known and routinely used in the art, are
15 embraced by the invention.

In one variation of an *in vitro* assay, the invention provides a method comprising the steps of (a) contacting an immobilized nGPCR-x polypeptide with a candidate binding partner compound and (b) detecting binding of the candidate compound to the nGPCR-x polypeptide. In an alternative embodiment, the candidate binding partner compound is immobilized and binding
20 of nGPCR-x is detected. Immobilization is accomplished using any of the methods well known in the art, including covalent bonding to a support, a bead, or a chromatographic resin, as well as non-covalent, high affinity interactions such as antibody binding, or use of streptavidin/biotin binding wherein the immobilized compound includes a biotin moiety. Detection of binding can be accomplished (i) using a radioactive label on the compound that is not immobilized, (ii) using
25 of a fluorescent label on the non-immobilized compound, (iii) using an antibody immunospecific for the non-immobilized compound, (iv) using a label on the non-immobilized compound that excites a fluorescent support to which the immobilized compound is attached, as well as other techniques well known and routinely practiced in the art.

The invention also provides cell-based assays to identify binding partner compounds of a
30 nGPCR-x polypeptide. In one embodiment, the invention provides a method comprising the steps of contacting a nGPCR-x polypeptide expressed on the surface of a cell with a candidate binding partner compound and detecting binding of the candidate binding partner compound to the nGPCR-x polypeptide. In a preferred embodiment, the detection comprises detecting a calcium flux or other physiological event in the cell caused by the binding of the molecule.

Another aspect of the present invention is directed to methods of identifying compounds that bind to either nGPCR-x or nucleic acid molecules encoding nGPCR-x, comprising contacting nGPCR-x, or a nucleic acid molecule encoding the same, with a compound, and determining whether the compound binds nGPCR-x or a nucleic acid molecule encoding the same. Binding can be determined by binding assays which are well known to the skilled artisan, including, but not limited to, gel-shift assays, Western blots, radiolabeled competition assay, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross linking, interaction trap/two-hybrid analysis, southwestern analysis, ELISA, and the like, which are described in, for example, *Current Protocols in Molecular Biology*, 1999, John Wiley & Sons, NY, which is incorporated herein by reference in its entirety. The compounds to be screened include (which may include compounds which are suspected to bind nGPCR-x, or a nucleic acid molecule encoding the same), but are not limited to, extracellular, intracellular, biologic or chemical origin. The methods of the invention also embrace ligands, especially neuropeptides, that are attached to a label, such as a radiolabel (*e.g.*, ^{125}I , ^{35}S , ^{32}P , ^{33}P , ^3H), a fluorescence label, a chemiluminescent label, an enzymic label and an immunogenic label. Modulators falling within the scope of the invention include, but are not limited to, non-peptide molecules such as non-peptide mimetics, non-peptide allosteric effectors, and peptides. The nGPCR-x polypeptide or polynucleotide employed in such a test may either be free in solution, attached to a solid support, borne on a cell surface or located intracellularly or associated with a portion of a cell. One skilled in the art can, for example, measure the formation of complexes between nGPCR-x and the compound being tested. Alternatively, one skilled in the art can examine the diminution in complex formation between nGPCR-x and its substrate caused by the compound being tested.

In another embodiment of the invention, high throughput screening for compounds having suitable binding affinity to nGPCR-x is employed. Briefly, large numbers of different test compounds are synthesized on a solid substrate. The peptide test compounds are contacted with nGPCR-x and washed. Bound nGPCR-x is then detected by methods well known in the art. Purified polypeptides of the invention can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the protein and immobilize it on the solid support.

Generally, an expressed nGPCR-x can be used for HTS binding assays in conjunction with its defined ligand, in this case the corresponding neuropeptide that activates it. The identified peptide is labeled with a suitable radioisotope, including, but not limited to, ^{125}I , ^3H , ^{35}S or ^{32}P , by methods that are well known to those skilled in the art. Alternatively, the peptides

may be labeled by well-known methods with a suitable fluorescent derivative (Baindur *et al.*, *Drug Dev. Res.*, **1994**, *33*, 373-398; Rogers, *Drug Discovery Today*, **1997**, *2*, 156-160).

Radioactive ligand specifically bound to the receptor in membrane preparations made from the cell line expressing the recombinant protein can be detected in HTS assays in one of several
5 standard ways, including filtration of the receptor-ligand complex to separate bound ligand from unbound ligand (Williams, *Med. Res. Rev.*, **1991**, *11*, 147-184; Sweetnam *et al.*, *J. Natural Products*, **1993**, *56*, 441-455). Alternative methods include a scintillation proximity assay (SPA) or a FlashPlate format in which such separation is unnecessary (Nakayama, *Cur. Opinion Drug Disc. Dev.*, **1998**, *1*, 85-91 Bossé *et al.*, *J. Biomolecular Screening*, **1998**, *3*, 285-292.). Binding
10 of fluorescent ligands can be detected in various ways, including fluorescence energy transfer (FRET), direct spectrophotofluorometric analysis of bound ligand, or fluorescence polarization (Rogers, *Drug Discovery Today*, **1997**, *2*, 156-160; Hill, *Cur. Opinion Drug Disc. Dev.*, **1998**, *1*, 92-97).

Other assays may be used to identify specific ligands of a nGPCR-x receptor, including
15 assays that identify ligands of the target protein through measuring direct binding of test ligands to the target protein, as well as assays that identify ligands of target proteins through affinity ultrafiltration with ion spray mass spectroscopy/HPLC methods or other physical and analytical methods. Alternatively, such binding interactions are evaluated indirectly using the yeast two-hybrid system described in Fields *et al.*, *Nature*, 340:245-246 (1989), and Fields *et al.*, *Trends in*
20 *Genetics*, 10:286-292 (1994), both of which are incorporated herein by reference in its entirety. The two-hybrid system is a genetic assay for detecting interactions between two proteins or polypeptides. It can be used to identify proteins that bind to a known protein of interest, or to delineate domains or residues critical for an interaction. Variations on this methodology have been developed to clone genes that encode DNA binding proteins, to identify peptides that bind
25 to a protein, and to screen for drugs. The two-hybrid system exploits the ability of a pair of interacting proteins to bring a transcription activation domain into close proximity with a DNA binding domain that binds to an upstream activation sequence (UAS) of a reporter gene, and is generally performed in yeast. The assay requires the construction of two hybrid genes encoding (1) a DNA-binding domain that is fused to a first protein and (2) an activation domain fused to a
30 second protein. The DNA-binding domain targets the first hybrid protein to the UAS of the reporter gene; however, because most proteins lack an activation domain, this DNA-binding hybrid protein does not activate transcription of the reporter gene. The second hybrid protein, which contains the activation domain, cannot by itself activate expression of the reporter gene because it does not bind the UAS. However, when both hybrid proteins are present, the

noncovalent interaction of the first and second proteins tethers the activation domain to the UAS, activating transcription of the reporter gene. For example, when the first protein is a GPCR gene product, or fragment thereof, that is known to interact with another protein or nucleic acid, this assay can be used to detect agents that interfere with the binding interaction.

- 5 Expression of the reporter gene is monitored as different test agents are added to the system. The presence of an inhibitory agent results in lack of a reporter signal.

The yeast two-hybrid assay can also be used to identify proteins that bind to the gene product. In an assay to identify proteins that bind to a nGPCR-x receptor, or fragment thereof, a fusion polynucleotide encoding both a nGPCR-x receptor (or fragment) and a UAS binding domain (*i.e.*, a first protein) may be used. In addition, a large number of hybrid genes each encoding a different second protein fused to an activation domain are produced and screened in the assay. Typically, the second protein is encoded by one or more members of a total cDNA or genomic DNA fusion library, with each second protein-coding region being fused to the activation domain. This system is applicable to a wide variety of proteins, and it is not even necessary to know the identity or function of the second binding protein. The system is highly sensitive and can detect interactions not revealed by other methods; even transient interactions may trigger transcription to produce a stable mRNA that can be repeatedly translated to yield the reporter protein.

Other assays may be used to search for agents that bind to the target protein. One such screening method to identify direct binding of test ligands to a target protein is described in U.S. Patent No. 5,585,277, incorporated herein by reference in its entirety. This method relies on the principle that proteins generally exist as a mixture of folded and unfolded states, and continually alternate between the two states. When a test ligand binds to the folded form of a target protein (*i.e.*, when the test ligand is a ligand of the target protein), the target protein molecule bound by the ligand remains in its folded state. Thus, the folded target protein is present to a greater extent in the presence of a test ligand which binds the target protein, than in the absence of a ligand. Binding of the ligand to the target protein can be determined by any method that distinguishes between the folded and unfolded states of the target protein. The function of the target protein need not be known in order for this assay to be performed. Virtually any agent can be assessed by this method as a test ligand, including, but not limited to, metals, polypeptides, proteins, lipids, polysaccharides, polynucleotides and small organic molecules.

Another method for identifying ligands of a target protein is described in Wieboldt *et al.*, *Anal. Chem.*, 69:1683-1691 (1997), incorporated herein by reference in its entirety. This technique screens combinatorial libraries of 20-30 agents at a time in solution phase for binding

to the target protein. Agents that bind to the target protein are separated from other library components by simple membrane washing. The specifically selected molecules that are retained on the filter are subsequently liberated from the target protein and analyzed by HPLC and pneumatically assisted electrospray (ion spray) ionization mass spectroscopy. This procedure
5 selects library components with the greatest affinity for the target protein, and is particularly useful for small molecule libraries.

Determining whether a test compound binds to nGPCR-51 can also be accomplished by measuring the intrinsic fluorescence of nGPCR-51 and determining whether the intrinsic fluorescence is modulated in the presence of the test compound. Preferably, the intrinsic
10 fluorescence of nGPCR-51 is measured as a function of the tryptophan residue(s) of nGPCR-51. Preferably, fluorescence of nGPCR-51 is measured and compared to the fluorescence intensity of nGPCR-51 in the presence of the test compound, wherein a decrease in fluorescence intensity indicates binding of the test compound to nGPCR-51. Preferred methodology is set forth in "Principles of Fluorescence Spectroscopy" by Joseph R. Lakowicz, New York, Plenum Press,
15 1983 (ISBN 0306412853) and "Spectrophotometry And Spectrofluorometry" by C.L. Bashford and D.A. Harris Oxford, Washington DC, IRL Press, 1987 (ISBN 0947946691), each of which is incorporated herein by reference in its entirety.

Other embodiments of the invention comprise using competitive screening assays in which neutralizing antibodies capable of binding a polypeptide of the invention specifically
20 compete with a test compound for binding to the polypeptide. In this manner, the antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants with nGPCR-x. Radiolabeled competitive binding studies are described in A.H. Lin *et al.* *Antimicrobial Agents and Chemotherapy*, 1997, vol. 41, no. 10. pp. 2127-2131, the disclosure of which is incorporated herein by reference in its entirety.

Another aspect of the present invention relates to methods of identifying a compound
25 that binds to or modulates nGPCR-51. The methods comprise contacting a composition comprising nGPCR-51 and Peptide A with a test compound, or a plurality of test compounds, and determining whether the test compound competes with Peptide A for binding to nGPCR-51. A decrease in the amount of the complex between Peptide A, or a protein homologous thereto,
30 and nGPCR-51 in the presence of a test compound or compounds confirms that the compound or compounds binds to nGPCR-51. In some embodiments, the affinity or displacement of Peptide A is measured, wherein a low affinity indicates that the test compound interacts with nGPCR-51. In these methods, the composition that comprises nGPCR-51 and Peptide A can be cells. Compounds identified as binding to nGPCR-51 are also expected to modulate nGPCR-51

activity. Binding of a test compound to nGPCR-51 can be determined by any of the binding assays described above.

As described above and in Example 5 below, the genes encoding nGPCR-42, 46, 48, 49, 51, 52, 61, 63, and 70 have been detected in brain tissue indicating that these n-GPCR-x proteins are neuroreceptors. Accordingly, natural binding partners of these molecules include neurotransmitters.

Identification of modulating agents

The invention also provides methods for identifying a modulator of binding between a nGPCR-x and a nGPCR-x binding partner, comprising the steps of: (a) contacting a nGPCR-x binding partner and a composition comprising a nGPCR-x in the presence and in the absence of a putative modulator compound; (b) detecting binding between the binding partner and the nGPCR-x; and (c) identifying a putative modulator compound or a modulator compound in view of decreased or increased binding between the binding partner and the nGPCR-x in the presence of the putative modulator, as compared to binding in the absence of the putative modulator. Following steps (a) and (b), compounds identified as modulating binding between nGPCR-x and an nGPCR-x binding partner can be further tested in other assays including, but not limited to, *in vivo* models, in order to confirm or quantitate modulation of binding to nGPCR-x.

nGPCR-x binding partners that stimulate nGPCR-x activity are useful as agonists in disease states or conditions characterized by insufficient nGPCR-x signaling (*e.g.*, as a result of insufficient activity of a nGPCR-x ligand). nGPCR-x binding partners that block ligand-mediated nGPCR-x signaling are useful as nGPCR-x antagonists to treat disease states or conditions characterized by excessive nGPCR-x signaling. In addition nGPCR-x modulators in general, as well as nGPCR-x polynucleotides and polypeptides, are useful in diagnostic assays for such diseases or conditions.

In another aspect, the invention provides methods for treating a disease or abnormal condition by administering to a patient in need of such treatment a substance that modulates the activity or expression of a polypeptide having sequences selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120.

Agents that modulate (*i.e.*, increase, decrease, or block) nGPCR-x activity or expression may be identified by incubating a putative modulator with a cell containing a nGPCR-x polypeptide or polynucleotide and determining the effect of the putative modulator on nGPCR-x activity or expression. The selectivity of a compound that modulates the activity of nGPCR-x can be evaluated by comparing its effects on nGPCR-x to its effect on other GPCR compounds. Following identification of compounds that modulate nGPCR-x activity or expression, such

compounds can be further tested in other assays including, but not limited to, *in vivo* models, in order to confirm or quantitate their activity. Selective modulators may include, for example, antibodies and other proteins, peptides, or organic molecules that specifically bind to a nGPCR-x polypeptide or a nGPCR-x-encoding nucleic acid. Modulators of nGPCR-x activity will be

5 therapeutically useful in treatment of diseases and physiological conditions in which normal or aberrant nGPCR-x activity is involved. nGPCR-x polynucleotides, polypeptides, and modulators may be used in the treatment of such diseases and conditions as infections, such as viral infections caused by HIV-1 or HIV-2; pain; cancers; metabolic and cardiovascular diseases and disorders (*e.g.*, type 2 diabetes, impaired glucose tolerance, dyslipidemia, obesity, anorexia,

10 hypotension, hypertension, thrombosis, myocardial infarction, cardiomyopathies, atherosclerosis, *etc.*); Parkinson's disease; and psychotic and neurological disorders, including anxiety, mental disorder, manic depression, schizophrenia, migraine, major depression, attention disorders including ADD and ADHD, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Tourette's Syndrome, among others. nGPCR-x

15 polynucleotides and polypeptides, as well as nGPCR-x modulators, may also be used in diagnostic assays for such diseases or conditions.

Methods of the invention to identify modulators include variations on any of the methods described above to identify binding partner compounds, the variations including techniques wherein a binding partner compound has been identified and the binding assay is carried out in

20 the presence and absence of a candidate modulator. A modulator is identified in those instances where binding between the nGPCR-x polypeptide and the binding partner compound changes in the presence of the candidate modulator compared to binding in the absence of the candidate modulator compound. A modulator that increases binding between the nGPCR-x polypeptide and the binding partner compound is described as an enhancer or activator, and a modulator that

25 decreases binding between the nGPCR-x polypeptide and the binding partner compound is described as an inhibitor. Following identification of modulators, such compounds can be further tested in other assays including, but not limited to, *in vivo* models, in order to confirm or quantitate their activity as modulators.

The invention also comprehends high-throughput screening (HTS) assays to identify

30 compounds that interact with or inhibit biological activity (*i.e.*, affect enzymatic activity, binding activity, *etc.*) of a nGPCR-x polypeptide. HTS assays permit screening of large numbers of compounds in an efficient manner. Cell-based HTS systems are contemplated to investigate nGPCR-x receptor-ligand interaction. HTS assays are designed to identify "hits" or "lead compounds" having the desired property, from which modifications can be designed to improve

the desired property. Chemical modification of the "hit" or "lead compound" is often based on an identifiable structure/activity relationship between the "hit" and the nGPCR-x polypeptide.

Another aspect of the present invention is directed to methods of identifying compounds which modulate (*i.e.*, increase or decrease) activity of nGPCR-x comprising contacting nGPCR-x with a compound, and determining whether the compound modifies activity of nGPCR-x. The activity in the presence of the test compared is measured to the activity in the absence of the test compound. Where the activity of the sample containing the test compound is higher than the activity in the sample lacking the test compound, the compound will have increased activity. Similarly, where the activity of the sample containing the test compound is lower than the activity in the sample lacking the test compound, the compound will have inhibited activity. Following identification of compounds that modulate an activity of nGPCR-x, such compounds can be further tested in other assays including, but not limited to, *in vivo* models, in order to confirm or quantitate their activity.

The present invention is particularly useful for screening compounds by using nGPCR-x in any of a variety of drug screening techniques. The compounds to be screened include (which may include compounds which are suspected to modulate nGPCR-x activity), but are not limited to, extracellular, intracellular, biologic or chemical origin. The nGPCR-x polypeptide employed in such a test may be in any form, preferably, free in solution, attached to a solid support, borne on a cell surface or located intracellularly. One skilled in the art can, for example, measure the formation of complexes between nGPCR-x and the compound being tested. Alternatively, one skilled in the art can examine the diminution in complex formation between nGPCR-x and its substrate caused by the compound being tested.

The activity of nGPCR-x polypeptides of the invention can be determined by, for example, examining the ability to bind or be activated by chemically synthesized peptide ligands. Alternatively, the activity of nGPCR-x polypeptides can be assayed by examining their ability to bind calcium ions, hormones, chemokines, neuropeptides, neurotransmitters, nucleotides, lipids, odorants, and photons. Alternatively, the activity of the nGPCR-x polypeptides can be determined by examining the activity of effector molecules including, but not limited to, adenylate cyclase, phospholipases and ion channels. Thus, modulators of nGPCR-x polypeptide activity may alter a GPCR receptor function, such as a binding property of a receptor or an activity such as G protein-mediated signal transduction or membrane localization. In various embodiments of the method, the assay may take the form of an ion flux assay, a yeast growth assay, a non-hydrolyzable GTP assay such as a [³⁵S]-GTP γS assay, a cAMP assay, an inositol triphosphate assay, a diacylglycerol assay, an Aequorin assay, a

Luciferase assay, a FLIPR assay for intracellular Ca^{2+} concentration, a mitogenesis assay, a MAP Kinase activity assay, an arachidonic acid release assay (e.g., using [^3H]-arachidonic acid), and an assay for extracellular acidification rates, as well as other binding or function-based assays of nGPCR-x activity that are generally known in the art. In several of these

5 embodiments, the invention comprehends the inclusion of any of the G proteins known in the art, such as G_{16} , G_{15} , or chimeric $\text{G}_{q\delta 5}$, $\text{G}_{q\delta 5}$, $\text{G}_{q\delta 5}$, G_{q25} , and the like. nGPCR-x activity can be determined by methodologies that are used to assay for FaRP activity, which is well known to those skilled in the art. Biological activities of nGPCR-x receptors according to the invention include, but are not limited to, the binding of a natural or an unnatural ligand, as well as any one

10 of the functional activities of GPCRs known in the art. Non-limiting examples of GPCR activities include transmembrane signaling of various forms, which may involve G protein association and/or the exertion of an influence over G protein binding of various guanidylate nucleotides; another exemplary activity of GPCRs is the binding of accessory proteins or polypeptides that differ from known G proteins.

15 The modulators of the invention exhibit a variety of chemical structures, which can be generally grouped into non-peptide mimetics of natural GPCR receptor ligands, peptide and non-peptide allosteric effectors of GPCR receptors, and peptides that may function as activators or inhibitors (competitive, uncompetitive and non-competitive) (e.g., antibody products) of GPCR receptors. The invention does not restrict the sources for suitable modulators, which may

20 be obtained from natural sources such as plant, animal or mineral extracts, or non-natural sources such as small molecule libraries, including the products of combinatorial chemical approaches to library construction, and peptide libraries. Examples of peptide modulators of GPCR receptors exhibit the following primary structures: GLGPRPLRFamide, GNSFLRFamide, GGPQGPLRFamide, GPSGPLRFamide, PDVDHVFLRFamide, and pyro-

25 EDVDHVFLRFamide.

Other assays can be used to examine enzymatic activity including, but not limited to, photometric, radiometric, HPLC, electrochemical, and the like, which are described in, for example, *Enzyme Assays: A Practical Approach*, eds. R. Eisinger and M. J. Danson, 1992, Oxford University Press, which is incorporated herein by reference in its entirety.

30 The use of cDNAs encoding GPCRs in drug discovery programs is well-known; assays capable of testing thousands of unknown compounds per day in high-throughput screens (HTSs) are thoroughly documented. The literature is replete with examples of the use of radiolabelled ligands in HTS binding assays for drug discovery (see Williams, *Medicinal Research Reviews*, 1991, 11, 147-184.; Sweetnam, *et al.*, *J. Natural Products*, 1993, 56, 441-455 for review).

Recombinant receptors are preferred for binding assay HTS because they allow for better specificity (higher relative purity), provide the ability to generate large amounts of receptor material, and can be used in a broad variety of formats (see Hodgson, *Bio/Technology*, 1992, 10, 973-980; each of which is incorporated herein by reference in its entirety).

5 A variety of heterologous systems is available for functional expression of recombinant receptors that are well known to those skilled in the art. Such systems include bacteria (Strosberg, *et al.*, *Trends in Pharmacological Sciences*, 1992, 13, 95-98), yeast (Pausch, *Trends in Biotechnology*, 1997, 15, 487-494), several kinds of insect cells (Vanden Broeck, *Int. Rev. Cytology*, 1996, 164, 189-268), amphibian cells (Jayawickreme *et al.*, *Current Opinion in Biotechnology*, 1997, 8, 629-634) and several mammalian cell lines (CHO, HEK293, COS, etc.; see Gerhardt, *et al.*, *Eur. J. Pharmacology*, 1997, 334, 1-23). These examples do not preclude the use of other possible cell expression systems, including cell lines obtained from nematodes (PCT application WO 98/37177).

15 In preferred embodiments of the invention, methods of screening for compounds that modulate nGPCR-x activity comprise contacting test compounds with nGPCR-x and assaying for the presence of a complex between the compound and nGPCR-x. In such assays, the ligand is typically labeled. After suitable incubation, free ligand is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular compound to bind to nGPCR-x.

20 It is well known that activation of heterologous receptors expressed in recombinant systems results in a variety of biological responses, which are mediated by G proteins expressed in the host cells. Occupation of a GPCR by an agonist results in exchange of bound GDP for GTP at a binding site on the G_α subunit; one can use a radioactive, non-hydrolyzable derivative of GTP, $GTP\gamma[^{35}S]$, to measure binding of an agonist to the receptor (Sim *et al.*, *Neuroreport*, 1996, 7, 729-733). One can also use this binding to measure the ability of antagonists to bind to the receptor by decreasing binding of $GTP\gamma[^{35}S]$ in the presence of a known agonist. One could therefore construct a HTS based on $GTP\gamma[^{35}S]$ binding, though this is not the preferred method.

The G proteins required for functional expression of heterologous GPCRs can be native constituents of the host cell or can be introduced through well-known recombinant technology. 30 The G proteins can be intact or chimeric. Often, a nearly universally competent G protein (e.g., $G_{\alpha 16}$) is used to couple any given receptor to a detectable response pathway. G protein activation results in the stimulation or inhibition of other native proteins, events that can be linked to a measurable response.

Examples of such biological responses include, but are not limited to, the following: the ability to survive in the absence of a limiting nutrient in specifically engineered yeast cells (Pausch, *Trends in Biotechnology*, 1997, 15, 487-494); changes in intracellular Ca^{2+} concentration as measured by fluorescent dyes (Murphy, *et al.*, *Cur. Opinion Drug Disc. Dev.*, 5 1998, 1, 192-199). Fluorescence changes can also be used to monitor ligand-induced changes in membrane potential or intracellular pH; an automated system suitable for HTS has been described for these purposes (Schroeder, *et al.*, *J. Biomolecular Screening*, 1996, 1, 75-80). Melanophores prepared from *Xenopus laevis* show a ligand-dependent change in pigment organization in response to heterologous GPCR activation; this response is adaptable to HTS 10 formats (Jayawickreme *et al.*, *Cur. Opinion Biotechnology*, 1997, 8, 629-634). Assays are also available for the measurement of common second messengers, including cAMP, phosphoinositides and arachidonic acid, but these are not generally preferred for HTS.

Preferred methods of HTS employing these receptors include permanently transfected CHO cells, in which agonists and antagonists can be identified by the ability to specifically alter 15 the binding of $\text{GTP}\gamma[^{35}\text{S}]$ in membranes prepared from these cells. In another embodiment of the invention, permanently transfected CHO cells could be used for the preparation of membranes which contain significant amounts of the recombinant receptor proteins; these membrane preparations would then be used in receptor binding assays, employing the radiolabelled ligand specific for the particular receptor. Alternatively, a functional assay, such as fluorescent 20 monitoring of ligand-induced changes in internal Ca^{2+} concentration or membrane potential in permanently transfected CHO cells containing each of these receptors individually or in combination would be preferred for HTS. Equally preferred would be an alternative type of mammalian cell, such as HEK293 or COS cells, in similar formats. More preferred would be permanently transfected insect cell lines, such as *Drosophila* S2 cells. Even more preferred 25 would be recombinant yeast cells expressing the *Drosophila melanogaster* receptors in HTS formats well known to those skilled in the art (*e.g.*, Pausch, *Trends in Biotechnology*, 1997, 15, 487-494).

The invention contemplates a multitude of assays to screen and identify inhibitors of ligand binding to nGPCR-x receptors. In one example, the nGPCR-x receptor is immobilized 30 and interaction with a binding partner is assessed in the presence and absence of a candidate modulator such as an inhibitor compound. In another example, interaction between the nGPCR-x receptor and its binding partner is assessed in a solution assay, both in the presence and absence of a candidate inhibitor compound. In either assay, an inhibitor is identified as a compound that decreases binding between the nGPCR-x receptor and its binding partner.

Following identification of compounds that inhibit ligand binding to nGPCR-x receptors, such compounds can be further tested in other assays including, but not limited to, *in vivo* models, in order to confirm or quantitate their activity. Another contemplated assay involves a variation of the dihybrid assay wherein an inhibitor of protein/protein interactions is identified by detection
5 of a positive signal in a transformed or transfected host cell, as described in PCT publication number WO 95/20652, published August 3, 1995.

Candidate modulators contemplated by the invention include compounds selected from libraries of either potential activators or potential inhibitors. There are a number of different libraries used for the identification of small molecule modulators, including: (1) chemical
10 libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules. Chemical libraries consist of random chemical structures, some of which are analogs of known compounds or analogs of compounds that have been identified as "hits" or "leads" in other drug discovery screens, some of which are derived from natural products, and some of which arise from non-directed synthetic organic chemistry.
15 Natural product libraries are collections of microorganisms, animals, plants, or marine organisms which are used to create mixtures for screening by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of plants or marine organisms. Natural product libraries include polyketides, non-ribosomal peptides, and variants (non-naturally occurring) thereof. For a review, see *Science* 282:63-68 (1998). Combinatorial
20 libraries are composed of large numbers of peptides, oligonucleotides, or organic compounds as a mixture. These libraries are relatively easy to prepare by traditional automated synthesis methods, PCR, cloning, or proprietary synthetic methods. Of particular interest are non-peptide combinatorial libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of
25 combinatorial chemistry and libraries created therefrom, see Myers, *Curr. Opin. Biotechnol.* 8:701-707 (1997). Identification of modulators through use of the various libraries described herein permits modification of the candidate "hit" (or "lead") to optimize the capacity of the "hit" to modulate activity.

Still other candidate inhibitors contemplated by the invention can be designed and
30 include soluble forms of binding partners, as well as such binding partners as chimeric, or fusion, proteins. A "binding partner" as used herein broadly encompasses non-peptide modulators, as well as such peptide modulators as neuropeptides other than natural ligands, antibodies, antibody fragments, and modified compounds comprising antibody domains that are immunospecific for the expression product of the identified nGPCR-x gene.

The polypeptides of the invention are employed as a research tool for identification, characterization and purification of interacting, regulatory proteins. Appropriate labels are incorporated into the polypeptides of the invention by various methods known in the art and the polypeptides are used to capture interacting molecules. For example, molecules are incubated with the labeled polypeptides, washed to remove unbound polypeptides, and the polypeptide complex is quantified. Data obtained using different concentrations of polypeptide are used to calculate values for the number, affinity, and association of polypeptide with the protein complex.

Labeled polypeptides are also useful as reagents for the purification of molecules with which the polypeptide interacts including, but not limited to, inhibitors. In one embodiment of affinity purification, a polypeptide is covalently coupled to a chromatography column. Cells and their membranes are extracted, and various cellular subcomponents are passed over the column. Molecules bind to the column by virtue of their affinity to the polypeptide. The polypeptide-complex is recovered from the column, dissociated and the recovered molecule is subjected to protein sequencing. This amino acid sequence is then used to identify the captured molecule or to design degenerate oligonucleotides for cloning the corresponding gene from an appropriate cDNA library.

Alternatively, compounds may be identified which exhibit similar properties to the ligand for the nGPCR-x of the invention, but which are smaller and exhibit a longer half time than the endogenous ligand in a human or animal body. When an organic compound is designed, a molecule according to the invention is used as a "lead" compound. The design of mimetics to known pharmaceutically active compounds is a well-known approach in the development of pharmaceuticals based on such "lead" compounds. Mimetic design, synthesis and testing are generally used to avoid randomly screening a large number of molecules for a target property. Furthermore, structural data deriving from the analysis of the deduced amino acid sequences encoded by the DNAs of the present invention are useful to design new drugs, more specific and therefore with a higher pharmacological potency.

Comparison of the protein sequence of the present invention with the sequences present in all the available databases showed a significant homology with the transmembrane portion of G protein coupled receptors. Accordingly, computer modeling can be used to develop a putative tertiary structure of the proteins of the invention based on the available information of the transmembrane domain of other proteins. Thus, novel ligands based on the predicted structure of nGPCR-x can be designed.

In a particular embodiment, the novel molecules identified by the screening methods according to the invention are low molecular weight organic molecules, in which case a composition or pharmaceutical composition can be prepared thereof for oral intake, such as in tablets. The compositions, or pharmaceutical compositions, comprising the nucleic acid
5 molecules, vectors, polypeptides, antibodies and compounds identified by the screening methods described herein, can be prepared for any route of administration including, but not limited to, oral, intravenous, cutaneous, subcutaneous, nasal, intramuscular or intraperitoneal. The nature of the carrier or other ingredients will depend on the specific route of administration and particular embodiment of the invention to be administered. Examples of techniques and protocols that are
10 useful in this context are, *inter alia*, found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A (ed.), 1980, which is incorporated herein by reference in its entirety.

The dosage of these low molecular weight compounds will depend on the disease state or condition to be treated and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. For treating human or animals,
15 between approximately 0.5 mg/kg of body weight to 500 mg/kg of body weight of the compound can be administered. Therapy is typically administered at lower dosages and is continued until the desired therapeutic outcome is observed.

The present compounds and methods, including nucleic acid molecules, polypeptides, antibodies, compounds identified by the screening methods described herein, have a variety of
20 pharmaceutical applications and may be used, for example, to treat or prevent unregulated cellular growth, such as cancer cell and tumor growth. In a particular embodiment, the present molecules are used in gene therapy. For a review of gene therapy procedures, see *e.g.* Anderson, *Science*, 1992, 256, 808-813, which is incorporated herein by reference in its entirety.

The present invention also encompasses a method of agonizing (stimulating) or
25 antagonizing a nGPCR-x natural binding partner associated activity in a mammal comprising administering to said mammal an agonist or antagonist to one of the above disclosed polypeptides in an amount sufficient to effect said agonism or antagonism. One embodiment of the present invention, then, is a method of treating diseases in a mammal with an agonist or antagonist of the protein of the present invention comprises administering the agonist or
30 antagonist to a mammal in an amount sufficient to agonize or antagonize nGPCR-x-associated functions.

In an effort to discover novel treatments for diseases, biomedical researchers and chemists have designed, synthesized, and tested molecules that modulate the function of G

protein coupled receptors. Some small organic molecules form a class of compounds that modulate the function of G protein coupled receptors.

Exemplary diseases and conditions amenable to treatment based on the present invention include, but are not limited to, thyroid disorders (*e.g.* thyrotoxicosis, myxoedema); renal failure; inflammatory conditions (*e.g.*, Crohn's disease); diseases related to cell differentiation and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (*e.g.*, pain including migraine; stroke; psychotic and neurological disorders, including anxiety, mental disorder, manic depression, anxiety, generalized anxiety disorder, post-traumatic-stress disorder, Schizophrenia, depression, bipolar disorder, delirium, dementia, severe mental retardation; dyskinesias, such as Huntington's disease or Tourette's Syndrome; attention disorders including ADD and ADHD, and degenerative disorders such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, *etc.*); infections, such as viral infections caused by HIV-1 or HIV-2; metabolic and cardiovascular diseases and disorders (*e.g.*, type 2 diabetes, impaired glucose tolerance, dyslipidemia, obesity, anorexia, hypotension, hypertension, thrombosis, myocardial infarction, cardiomyopathies, atherosclerosis, *etc.*); proliferative diseases and cancers (*e.g.*, different cancers such as breast, colon, lung, *etc.*, and hyperproliferative disorders such as psoriasis, prostate hyperplasia, *etc.*); hormonal disorders (*e.g.*, male/female hormonal replacement, polycystic ovarian syndrome, alopecia, *etc.*); sexual dysfunction, among others.

Methods of determining the dosages of compounds to be administered to a patient and modes of administering compounds to an organism are disclosed in U.S. Application Serial No. 08/702,282, filed August 23, 1996 and International patent publication number WO 96/22976, published August 1 1996, both of which are incorporated herein by reference in their entirety, including any drawings, figures or tables. Those skilled in the art will appreciate that such descriptions are applicable to the present invention and can be easily adapted to it.

The proper dosage depends on various factors such as the type of disease being treated, the particular composition being used and the size and physiological condition of the patient, including such factors as, for example, weight, age, sex, disease state, *etc.* Therapeutically effective doses for the compounds described herein can be estimated initially from cell culture and animal models. For example, a dose can be formulated in animal models to achieve a circulating concentration range that initially takes into account the IC_{50} as determined in cell culture assays. The animal model data can be used to more accurately determine useful doses in humans.

Plasma half-life and biodistribution of the drug and metabolites in the plasma, tumors and major organs can also be determined to facilitate the selection of drugs most appropriate to inhibit a disorder. Such measurements can be carried out. For example, HPLC analysis can be performed on the plasma of animals treated with the drug and the location of radiolabeled compounds can be determined using detection methods such as X-ray, CAT scan and MRI. Compounds that show potent inhibitory activity in the screening assays, but have poor pharmacokinetic characteristics, can be optimized by altering the chemical structure and retesting. In this regard, compounds displaying good pharmacokinetic characteristics can be used as a model.

Toxicity studies can also be carried out by measuring the blood cell composition. For example, toxicity studies can be carried out in a suitable animal model as follows: 1) the compound is administered to mice (an untreated control mouse should also be used); 2) blood samples are periodically obtained via the tail vein from one mouse in each treatment group; and 3) the samples are analyzed for red and white blood cell counts, blood cell composition and the percent of lymphocytes versus polymorphonuclear cells. A comparison of results for each dosing regime with the controls indicates if toxicity is present.

At the termination of each toxicity study, further studies can be carried out by sacrificing the animals (preferably, in accordance with the American Veterinary Medical Association guidelines Report of the American Veterinary Medical Assoc. Panel on Euthanasia, Journal of American Veterinary Medical Assoc., 202:229-249, 1993). Representative animals from each treatment group can then be examined by gross necropsy for immediate evidence of metastasis, unusual illness or toxicity. Gross abnormalities in tissue are noted and tissues are examined histologically. Compounds causing a reduction in body weight or blood components are less preferred, as are compounds having an adverse effect on major organs. In general, the greater the adverse effect the less preferred the compound.

For the treatment of many diseases, the expected daily dose of a hydrophobic pharmaceutical agent is between 1 to 500 mg/day, preferably 1 to 250 mg/day, and most preferably 1 to 50 mg/day. Drugs can be delivered less frequently provided plasma levels of the active moiety are sufficient to maintain therapeutic effectiveness. Plasma levels should reflect the potency of the drug. Generally, the more potent the compound the lower the plasma levels necessary to achieve efficacy.

nGPCR-42, 46, 48, 49, 51, 52, 61, 63, and 70 mRNA transcripts may found in many tissues, including, but not limited to, brain, peripheral blood lymphocytes, pancreas, ovary, uterus, testis, salivary gland, kidney, adrenal gland, liver, bone marrow, prostate, fetal liver, colon, muscle, and fetal brain, and may be found in many other tissues. Within the brain,

nGPCR-42, 46, 48, 49, 51, 52, 61, 63, and 70 mRNA transcripts may be found in many tissues, including, but not limited to, frontal lobe, hypothalamus, pons, cerebellum, caudate nucleus, and medulla. Tissues and brain regions where specific nGPCR mRNA transcripts are expressed are identified in the Examples, below.

5 Sequences selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60 will, as detailed above, enable screening the endogenous neurotransmitters/hormones/ligands which activate, agonize, or antagonize nGPCR-x and for compounds with potential utility in treating disorders including, but not limited to, thyroid disorders (*e.g.* thyreotoxicosis, myxoedema); renal failure; inflammatory conditions (*e.g.*, Crohn's disease); diseases related to cell
10 differentiation and homeostasis; rheumatoid arthritis; autoimmune disorders; movement disorders; CNS disorders (*e.g.*, pain including migraine; stroke; psychotic and neurological disorders, including anxiety, mental disorder, manic depression, anxiety, generalized anxiety disorder, post-traumatic-stress disorder, Schizophrenia, depression, bipolar disorder, delirium, dementia, severe mental retardation; dyskinesias, such as Huntington's disease or Tourette's
15 Syndrome; attention disorders including ADD and ADHD, and degenerative disorders such as Parkinson's, Alzheimer's; movement disorders, including ataxias, supranuclear palsy, *etc.*); infections, such as viral infections caused by HIV-1 or HIV-2; metabolic and cardiovascular diseases and disorders (*e.g.*, type 2 diabetes, impaired glucose tolerance, dyslipidemia, obesity, anorexia, hypotension, hypertension, thrombosis, myocardial infarction, cardiomyopathies,
20 atherosclerosis, *etc.*); proliferative diseases and cancers (*e.g.*, different cancers such as breast, colon, lung, *etc.*, and hyperproliferative disorders such as psoriasis, prostate hyperplasia, *etc.*); hormonal disorders (*e.g.*, male/female hormonal replacement, polycystic ovarian syndrome, alopecia, *etc.*); sexual dysfunction, among others.

 For example, nGPCR-x may be useful in the treatment of respiratory ailments such as
25 asthma, where T cells are implicated by the disease. Contraction of airway smooth muscle is stimulated by thrombin. Cicala *et al* (1999) Br J Pharmacol 126:478-484. Additionally, in bronchiolitis obliterans, it has been noted that activation of thrombin receptors may be deleterious. Hauck *et al.* (1999) Am J Physiol 277:L22-L29. Furthermore, mast cells have also been shown to have thrombin receptors. Cirino *et al* (1996) J Exp Med 183:821-827. nGPCR-x
30 may also be useful in remodeling of airway structures in chronic pulmonary inflammation via stimulation of fibroblast procollagen synthesis. See, *e.g.*, Chambers *et al.* (1998) Biochem J 333:121-127; Trejo *et al.* (1996) J Biol Chem 271:21536-21541.

 In another example, increased release of sCD40L and expression of CD40L by T cells after activation of thrombin receptors suggests that nGPCR-x may be useful in the treatment of

unstable angina due to the role of T cells and inflammation. See Aukrust *et al.* (1999) *Circulation* 100:614-620.

A further example is the treatment of inflammatory diseases, such as psoriasis, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and thyroiditis. Due to the tissue expression profile of nGPCR-x, inhibition of thrombin receptors may be beneficial for these diseases. See, *e.g.*, Morris *et al.* (1996) *Ann Rheum Dis* 55:841-843. In addition to T cells, NK cells and monocytes are also critical cell types which contribute to the pathogenesis of these diseases. See, *e.g.*, Naldini & Carney (1996) *Cell Immunol* 172:35-42; Hoffman & Cooper (1995) *Blood Cells Mol Dis* 21:156-167; Colotta *et al.* (1994) *Am J Pathol* 144:975-985.

Expression of nGPCR-x in bone marrow and spleen may suggest that it may play a role in the proliferation of hematopoietic progenitor cells. See DiCuccio *et al.* (1996) *Exp Hematol* 24:914-918.

As another example, nGPCR-x may be useful in the treatment of acute and/or traumatic brain injury. Astrocytes have been demonstrated to express thrombin receptors. Activation of thrombin receptors may be involved in astrogliosis following brain injury. Therefore, inhibition of receptor activity may be beneficial for limiting neuroinflammation. Scar formation mediated by astrocytes may also be limited by inhibiting thrombin receptors. See, *e.g.*, Pindon *et al.* (1998) *Eur J Biochem* 255:766-774; Ubl & Reiser. (1997) *Glia* 21:361-369; Grabham & Cunningham (1995) *J Neurochem* 64:583-591.

nGPCR-x receptor activation may mediate neuronal and astrocyte apoptosis and prevention of neurite outgrowth. Inhibition would be beneficial in both chronic and acute brain injury. See, *e.g.*, Donovan *et al.* (1997) *J Neurosci* 17:5316-5326; Turgeon *et al.* (1998) *J Neurosci* 18:6882-6891; Smith-Swintosky *et al.* (1997) *J Neurochem* 69:1890-1896; Gill *et al.* (1998) *Brain Res* 797:321-327; Suidan *et al.* (1996) *Semin Thromb Hemost* 22:125-133.

The attached Sequence Listing contains the sequences of the polynucleotides and polypeptides of the invention and is incorporated herein by reference in its entirety.

As described above and in Example 5 below, the genes encoding nGPCR-42, 46, 48, 49, 51, 52, 61, 63, and 70 have been detected in brain tissue indicating that these n-GPCR-x proteins are neuroreceptors. The identification of modulators such as agonists and antagonists is therefore useful for the identification of compounds useful to treat neurological diseases and psychiatric disorders. Such neurological diseases and disorders, including but are not limited to, mental disorder, affective disorders, ADHD/ADD, and neural disorders such as Alzheimer's disease, Parkinson's disease, migraine, schizophrenia, and senile dementia as well as depression, anxiety, bipolar disease, epilepsy, neuritis, neurasthenia, neuropathy, neuroses, and the like.

Methods of Screening Human Subjects

Thus in yet another embodiment, the invention provides genetic screening procedures that entail analyzing a person's genome -- in particular their alleles for GPCRs of the invention - - to determine whether the individual possesses a genetic characteristic found in other individuals that are considered to be afflicted with, or at risk for, developing a mental disorder or disease of the brain that is suspected of having a hereditary component. For example, in one embodiment, the invention provides a method for determining a potential for developing a disorder affecting the brain in a human subject comprising the steps of analyzing the coding sequence of one or more GPCR genes from the human subject; and determining development potential for the disorder in said human subject from the analyzing step.

More particularly, the invention provides a method of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor, comprising the steps of: (a) assaying nucleic acid of a human subject to determine a presence or an absence of a mutation altering the amino acid sequence, expression, or biological activity of at least one seven transmembrane receptor that is expressed in the brain, wherein the seven transmembrane receptor comprises an amino acid sequence selected from the group consisting of SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120, or an allelic variant thereof, and wherein the nucleic acid corresponds to the gene encoding the seven transmembrane receptor; and (b) diagnosing the disorder or predisposition from the presence or absence of said mutation, wherein the presence of a mutation altering the amino acid sequence, expression, or biological activity of allele in the nucleic acid correlates with an increased risk of developing the disorder. In preferred variations, the seven transmembrane receptor is nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 comprising an amino acid sequence set forth in SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120, or an allelic variant thereof, and the disease is mental disorder.

By "human subject" is meant any human being, human embryo, or human fetus. It will be apparent that methods of the present invention will be of particular interest to individuals that have themselves been diagnosed with a disorder affecting the brain or have relatives that have been diagnosed with a disorder affecting the brain.

By "screening for an increased risk" is meant determination of whether a genetic variation exists in the human subject that correlates with a greater likelihood of developing a disorder affecting the brain than exists for the human population as a whole, or for a relevant racial or ethnic human sub-population to which the individual belongs. Both positive and negative determinations (i.e., determinations that a genetic predisposition marker is present or is absent) are intended to fall within the scope of screening methods of the invention. In preferred

embodiments, the presence of a mutation altering the sequence or expression of at least one nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 seven transmembrane receptor allele in the nucleic acid is correlated with an increased risk of developing mental disorder, whereas the absence of such a mutation is reported as a negative determination.

5 The "assaying" step of the invention may involve any techniques available for analyzing nucleic acid to determine its characteristics, including but not limited to well-known techniques such as single-strand conformation polymorphism analysis (SSCP) (Orita *et al.*, *Proc Natl. Acad. Sci. USA*, 86: 2766-2770 (1989)); heteroduplex analysis (White *et al.*, *Genomics*, 12: 301-306 (1992)); denaturing gradient gel electrophoresis analysis (Fischer *et al.*, *Proc. Natl. Acad. Sci. USA*, 80: 1579-1583 (1983); and Riesner *et al.*, *Electrophoresis*, 10: 377-389 (1989)); DNA sequencing; RNase cleavage (Myers *et al.*, *Science*, 230: 1242-1246 (1985)); chemical cleavage of mismatch techniques (Rowley *et al.*, *Genomics*, 30: 574-582 (1995); and Roberts *et al.*, *Nucl. Acids Res.*, 25: 3377-3378 (1997)); restriction fragment length polymorphism analysis; single nucleotide primer extension analysis (Shumaker *et al.*, *Hum. Mutat.*, 7: 346-354 (1996); and
10 Pastinen *et al.*, *Genome Res.*, 7: 606-614 (1997)); 5' nuclease assays (Pease *et al.*, *Proc. Natl. Acad. Sci. USA*, 91:5022-5026 (1994)); DNA Microchip analysis (Ramsay, G., *Nature Biotechnology*, 16: 40-48 (1999); and Chee *et al.*, U.S. Patent No. 5,837,832); and ligase chain reaction (Whiteley *et al.*, U.S. Patent No. 5,521,065). (See generally, Schafer and Hawkins, *Nature Biotechnology*, 16: 33-39 (1998).) All of the foregoing documents are hereby
15 incorporated herein by reference in their entirety.
20

Thus, in one preferred embodiment involving screening nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 sequences, for example, the assaying step comprises at least one procedure selected from the group consisting of: (a) determining a nucleotide sequence of at least one codon of at least one nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 allele of the human subject; (b)
25 performing a hybridization assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences; (c) performing a polynucleotide migration assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences; and (d) performing a restriction endonuclease digestion to determine whether nucleic
30 acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences.

In a highly preferred embodiment, the assaying involves sequencing of nucleic acid to determine nucleotide sequence thereof, using any available sequencing technique. (See, *e.g.*, Sanger *et al.*, *Proc. Natl. Acad. Sci. (USA)*, 74: 5463-5467 (1977) (dideoxy chain termination

method); Mirzabekov, *TIBTECH*, 12: 27-32 (1994) (sequencing by hybridization); Drmanac *et al.*, *Nature Biotechnology*, 16: 54-58 (1998); U.S. Patent No. 5,202,231; and *Science*, 260: 1649-1652 (1993) (sequencing by hybridization); Kieletzawa *et al.*, *Science*, 258: 1787-1791 (1992) (sequencing by primer walking); (Douglas *et al.*, *Biotechniques*, 14: 824-828 (1993) (Direct sequencing of PCR products); and Akane *et al.*, *Biotechniques* 16: 238-241 (1994); Maxam and Gilbert, *Meth. Enzymol.*, 65: 499-560 (1977) (chemical termination sequencing), all incorporated herein by reference in its entirety). The analysis may entail sequencing of the entire nGPCR gene genomic DNA sequence, or portions thereof; or sequencing of the entire seven transmembrane receptor coding sequence or portions thereof. In some circumstances, the analysis may involve a determination of whether an individual possesses a particular allelic variant, in which case sequencing of only a small portion of nucleic acid -- enough to determine the sequence of a particular codon characterizing the allelic variant -- is sufficient. This approach is appropriate, for example, when assaying to determine whether one family member inherited the same allelic variant that has been previously characterized for another family member, or, more generally, whether a person's genome contains an allelic variant that has been previously characterized and correlated with a mental disorder having a heritable component.

In another highly preferred embodiment, the assaying step comprises performing a hybridization assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences. In a preferred embodiment, the hybridization involves a determination of whether nucleic acid derived from the human subject will hybridize with one or more oligonucleotides, wherein the oligonucleotides have nucleotide sequences that correspond identically to a portion of the GPCR gene sequence taught herein, such as the nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 coding sequence set forth in SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120, or that correspond identically except for one mismatch. The hybridization conditions are selected to differentiate between perfect sequence complementarity and imperfect matches differing by one or more bases. Such hybridization experiments thereby can provide single nucleotide polymorphism sequence information about the nucleic acid from the human subject, by virtue of knowing the sequences of the oligonucleotides used in the experiments.

Several of the techniques outlined above involve an analysis wherein one performs a polynucleotide migration assay, *e.g.*, on a polyacrylamide electrophoresis gel (or in a capillary electrophoresis system), under denaturing or non-denaturing conditions. Nucleic acid derived from the human subject is subjected to gel electrophoresis, usually adjacent to (or co-loaded with) one or more reference nucleic acids, such as reference GPCR-encoding sequences having

a coding sequence identical to all or a portion of SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120 (or identical except for one known polymorphism). The nucleic acid from the human subject and the reference sequence(s) are subjected to similar chemical or enzymatic treatments and then electrophoresed under conditions whereby the polynucleotides will show a differential migration pattern, unless they contain identical sequences. (See generally Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, New York: John Wiley & Sons, Inc. (1987-1999); and Sambrook *et al.*, (eds.), *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press (1989), both incorporated herein by reference in their entirety).

In the context of assaying, the term "nucleic acid of a human subject" is intended to include nucleic acid obtained directly from the human subject (*e.g.*, DNA or RNA obtained from a biological sample such as a blood, tissue, or other cell or fluid sample); and also nucleic acid derived from nucleic acid obtained directly from the human subject. By way of non-limiting examples, well known procedures exist for creating cDNA that is complementary to RNA derived from a biological sample from a human subject, and for amplifying (*e.g.*, via polymerase chain reaction (PCR)) DNA or RNA derived from a biological sample obtained from a human subject. Any such derived polynucleotide which retains relevant nucleotide sequence information of the human subject's own DNA/RNA is intended to fall within the definition of "nucleic acid of a human subject" for the purposes of the present invention.

In the context of assaying, the term "mutation" includes addition, deletion, and/or substitution of one or more nucleotides in the GPCR gene sequence (*e.g.*, as compared to the seven transmembrane receptor-encoding sequences set forth of SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120 and other polymorphisms that occur in introns (where introns exist) and that are identifiable via sequencing, restriction fragment length polymorphism, or other techniques. The various activity examples provided herein permit determination of whether a mutation modulates activity of the relevant receptor in the presence or absence of various test substances.

In a related embodiment, the invention provides methods of screening a person's genotype with respect to GPCRs of the invention, and correlating such genotypes with diagnoses for disease or with predisposition for disease (for genetic counseling). For example, the invention provides a method of screening for an nGPCR-63 hereditary mental disorder genotype in a human patient, comprising the steps of: (a) providing a biological sample comprising nucleic acid from the patient, the nucleic acid including sequences corresponding to said patient's nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 alleles; (b) analyzing the nucleic acid

for the presence of a mutation or mutations; (c) determining an nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 genotype from the analyzing step; and (d) correlating the presence of a mutation in an nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 allele with a hereditary mental disorder.

genotype. In a preferred embodiment, the biological sample is a cell sample containing human cells that contain genomic DNA of the human subject. The analyzing can be performed analogously to the assaying described in preceding paragraphs. For example, the analyzing comprises sequencing a portion of the nucleic acid (e.g., DNA or RNA), the portion comprising at least one codon of the nGPCR-63 alleles.

Although more time consuming and expensive than methods involving nucleic acid analysis, the invention also may be practiced by assaying protein of a human subject to determine the presence or absence of an amino acid sequence variation in GPCR protein from the human subject. Such protein analyses may be performed, e.g., by fragmenting GPCR protein via chemical or enzymatic methods and sequencing the resultant peptides; or by Western analyses using an antibody having specificity for a particular allelic variant of the GPCR.

The invention also provides materials that are useful for performing methods of the invention. For example, the present invention provides oligonucleotides useful as probes in the many analyzing techniques described above. In general, such oligonucleotide probes comprise 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides that have a sequence that is identical, or exactly complementary, to a portion of a human GPCR gene sequence taught herein (or allelic variant thereof), or that is identical or exactly complementary except for one nucleotide substitution. In a preferred embodiment, the oligonucleotides have a sequence that corresponds in the foregoing manner to a human GPCR coding sequence taught herein, and in particular, the coding sequences set forth in SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120. In one variation, an oligonucleotide probe of the invention is purified and isolated. In another variation, the oligonucleotide probe is labeled, e.g., with a radioisotope, chromophore, or fluorophore. In yet another variation, the probe is covalently attached to a solid support. (See generally Ausubel *et al.* and Sambrook *et al.*, *supra*.)

In a related embodiment, the invention provides kits comprising reagents that are useful for practicing methods of the invention. For example, the invention provides a kit for screening a human subject to diagnose a mental disorder or a genetic predisposition therefor, comprising, in association: (a) an oligonucleotide useful as a probe for identifying polymorphisms in a human nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 seven transmembrane receptor gene, the oligonucleotide comprising 6-50 nucleotides that have a sequence that is identical or exactly

complementary to a portion of a human nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 gene sequence or nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 coding sequence, except for one sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide substitution; and (b) a media packaged with the oligonucleotide

5 containing information identifying polymorphisms identifiable with the probe that correlate with mental disorder or a genetic predisposition therefor. Exemplary information-containing media include printed paper package inserts or packaging labels; and magnetic and optical storage media that are readable by computers or machines used by practitioners who perform genetic screening and counseling services. The practitioner uses the information provided in the media

10 to correlate the results of the analysis with the oligonucleotide with a diagnosis. In a preferred variation, the oligonucleotide is labeled.

In still another embodiment, the invention provides methods of identifying those allelic variants of GPCRs of the invention that correlate with mental disorders. For example, the invention provides a method of identifying a seven transmembrane allelic variant that correlates

15 with a mental disorder, comprising steps of: (a) providing a biological sample comprising nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny; (b) analyzing the nucleic acid for the presence of a mutation or mutations in at least one seven transmembrane receptor that is expressed in the brain, wherein the at least one seven transmembrane receptor comprises an amino acid sequence selected from

20 the group consisting of SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120 or an allelic variant thereof, and wherein the nucleic acid includes sequence corresponding to the gene or genes encoding the at least one seven transmembrane receptor; (c) determining a genotype for the patient for the at least one seven transmembrane receptor from said analyzing step; and (d) identifying an allelic variant that correlates with the mental disorder from the determining step.

25 To expedite this process, it may be desirable to perform linkage studies in the patients (and possibly their families) to correlate chromosomal markers with disease states. The chromosomal localization data provided herein facilitates identifying an involved GPCR with a chromosomal marker.

The foregoing method can be performed to correlate GPCRs of the invention to a

30 number of disorders having hereditary components that are causative or that predispose persons to the disorder. For example, in one preferred variation, the disorder is a mental disorder, and the at least one seven transmembrane receptor comprises nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 having an amino acid sequence set forth in SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120 or an allelic variant thereof.

Also contemplated as part of the invention are polynucleotides that comprise the allelic variant sequences identified by such methods, and polypeptides encoded by the allelic variant sequences, and oligonucleotide and oligopeptide fragments thereof that embody the mutations that have been identified. Such materials are useful in *in vitro* cell-free and cell-based assays for identifying lead compounds and therapeutics for treatment of the disorders. For example, the variants are used in activity assays, binding assays, and assays to screen for activity modulators described herein. In one preferred embodiment, the invention provides a purified and isolated polynucleotide comprising a nucleotide sequence encoding a nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 receptor allelic variant identified according to the methods described above; and an oligonucleotide that comprises the sequences that differentiate the allelic variant from the nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 sequences set forth in SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120. The invention also provides a vector comprising the polynucleotide (preferably an expression vector); and a host cell transformed or transfected with the polynucleotide or vector. The invention also provides an isolated cell line that is expressing the allelic variant GPCR polypeptide; purified cell membranes from such cells; purified polypeptide; and synthetic peptides that embody the allelic variation amino acid sequence. In one particular embodiment, the invention provides a purified polynucleotide comprising a nucleotide sequence encoding a nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 seven transmembrane receptor protein of a human that is affected with a mental disorder; wherein said polynucleotide hybridizes to the complement of SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120 under the following hybridization conditions: (a) hybridization for 16 hours at 42C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and (b) washing 2 times for 30 minutes at 60C in a wash solution comprising 0.1x SSC and 1% SDS; and wherein the polynucleotide encodes a nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 amino acid sequence that differs from SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120 by at least one residue.

An exemplary assay for using the allelic variants is a method for identifying a modulator of nGPCR-x biological activity, comprising the steps of: (a) contacting a cell expressing the allelic variant in the presence and in the absence of a putative modulator compound; (b) measuring nGPCR-x biological activity in the cell; and (c) identifying a putative modulator compound in view of decreased or increased nGPCR-x biological activity in the presence versus absence of the putative modulator.

Additional features of the invention will be apparent from the following Examples. Examples 1-6, 12, 14, and 15 are actual, while the remaining Examples are prophetic.

Additional features and variations of the invention will be apparent to those skilled in the art from the entirety of this application, including the detailed description, and all such features are intended as aspects of the invention. Likewise, features of the invention described herein can be re-combined into additional embodiments that also are intended as aspects of the invention, 5 irrespective of whether the combination of features is specifically mentioned above as an aspect or embodiment of the invention. Also, only such limitations which are described herein as critical to the invention should be viewed as such; variations of the invention lacking limitations which have not been described herein as critical are intended as aspects of the invention.

EXAMPLES

10 **Example 1: Identification of nGPCR-x**

A. Database search

The Celera database was searched using known GPCR receptors as query sequences to find patterns suggestive of novel G protein-coupled receptors. Positive hits were further analyzed with the GCG program BLAST to determine which ones were the most likely 15 candidates to encode G protein-coupled receptors, using the standard (default) alignment produced by BLAST as a guide.

Briefly, the BLAST algorithm, which stands for Basic Local Alignment Search Tool is suitable for determining sequence similarity (Altschul *et al.*, J. Mol. Biol., 1990, 215, 403-410, which is incorporated herein by reference in its entirety). Software for performing BLAST 20 analyses is publicly available through the National Center for Biotechnology Information through the world wide web of the Internet (ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood 25 word score threshold (Altschul *et al.*, *supra*). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension for the word hits in each direction are halted when: 1) the cumulative alignment score falls off by the quantity X from its maximum achieved value; 2) the cumulative score goes to 30 zero or below, due to the accumulation of one or more negative-scoring residue alignments; or 3) the end of either sequence is reached. The Blast algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The Blast program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff *et al.*, Proc. Natl. Acad. Sci. USA, 1992,

89, 10915-10919, which is incorporated herein by reference in its entirety) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm (Karlin *et al.*, Proc. Natl. Acad. Sci. USA, 1993, 90, 5873-5787, which is incorporated herein by reference in its entirety) and Gapped BLAST perform a
5 statistical analysis of the similarity between two sequences. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a GPCR gene or cDNA if the
10 smallest sum probability in comparison of the test nucleic acid to a GPCR nucleic acid is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

Homology searches are performed with the program BLAST version 2.08. A collection of about 200 to about 350 query amino acid sequences derived from GPCRs was used to search the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.01
15 were collected from each BLAST search. The amino acid sequences have been edited to remove regions in the sequence that produce non-significant alignments with proteins that are not related to GPCRs.

Multiple query sequences may have a significant alignment to the same genomic region, although each alignment may not cover exactly the same DNA region. A procedure is used to
20 determine the region of maximum common overlap between the alignments from several query sequences. This region is called the consensus DNA region. The procedure for determining this consensus involves the automatic parsing of the BLAST output files using the program MSPcrunch to produce a tabular report. From this tabular report the start and end of each alignment in the genomic DNA is extracted. This information is used by a PERL script to derive
25 the maximum common overlap. These regions are reported in the form of a unique sequence identifier, a start and the end position in the sequence. The sequences defined by these regions were extracted from the original genomic sequence file using the program fetchdb.

The consensus regions are assembled into a non-redundant set by using the program phrap. After assembly with phrap a set of contigs and singletons were defined as candidate DNA
30 regions coding for nGPCRs. These sequences were then submitted for further sequence analysis.

Further sequence analysis involves the removal of sequences previously isolated and removal of sequences that are related to olfactory GPCRs.

nGPCR-70

Homology searches were performed with the program BLAST version 2.08. A collection of 286 query amino acid sequences derived from GPCRs was used to search the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.1 were collected from each BLAST search. The amino acid sequences were edited to remove regions in the sequence that produce non-significant alignments with proteins that are not related to GPCRs.

The consensus regions were assembled into a non-redundant set by using the program "GelStart". After assembly with GelStart, a set of contigs and singletons were defined as candidate DNA regions coding for nGPCR-70. Further sequence analysis involved the removal of sequences previously isolated and removal of sequences that are related to olfactory GPCRs. The transmembrane regions for the sequences that remained were determined using a FORTRAN computer program called "tmrest.all" (Parodi *et al.*, Comput. Appl. Biosci. 5:527-535(1994)). Transmembrane regions within the amino acid sequences were visually inspected with an outliner (MaxThink) and the Celera sequences with promising transmembrane regions were kept. In a last step, the blast results were compared against SWPLUS and the transmembrane regions of the sequences and promising Celera sequences for full length cloning were selected. The sequence of nGPCR-70s is shown above in Table 5.

nGPCR-63

Homology searches were performed with the program BLAST version 2.08. A collection of 286 query amino acid sequences derived from GPCRs was used to search the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.1 were collected from each BLAST search. The amino acid sequences were edited to remove regions in the sequence that produce non-significant alignments with proteins that are not related to GPCRs.

The consensus regions were assembled into a non-redundant set by using the program "GelStart". After assembly with "GelStart" a set of contigs and singletons were defined as candidate DNA regions coding for nGPCR-63. Further sequence analysis involved the removal of sequences previously isolated and removal of sequences that are related to olfactory GPCRs. The transmembrane regions for the sequences that remained were determined using a FORTRAN computer program called "tmrest.all" (Parodi *et al.*, Comput. Appl. Biosci. 5:527-535(1994)). Transmembrane regions within the amino acid sequences were visually inspected with an outliner (MaxThink) and the Celera sequences with promising transmembrane regions were kept. In a last step, the blast results were compared against SWPLUS and the

transmembrane regions of the sequences and promising Celera sequences for full length cloning were selected. The sequence of nGPCR-63 is shown above in Table 5.

nGPCR-42

Homology searches were performed with the program BLAST version 2.08. A collection
5 of 340 query amino acid sequences derived from GPCRs was used to search the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.01 were collected from each BLAST search. The amino acid sequences have been edited to remove regions in the sequence that produce non-significant alignments with proteins that are not related to GPCRs.

The consensus regions were assembled into a non-redundant set by using the program
10 phrap. After assembly with phrap a set of contigs and singletons were defined as candidate DNA regions coding for nGPCR-42. These sequences were then submitted for further sequence analysis. Further sequence analysis involves the removal of sequences previously isolated and removal of sequences that are related to olfactory GPCRs. The transmembrane regions for the sequences that remained were determined using a FORTRAN computer program called
15 "tmrest.all" (Parodi *et al.*, Comput. Appl. Biosci. 5:527-535(1994)). Only sequences that contained transmembrane regions in a pattern found in GPCRs were retained. These nGPCR-42s are shown above in Table 5.

nGPCR-46

Homology searches are performed with the program BLAST version 2.08. A collection
20 of 340 query amino acid sequences derived from GPCRs was used to search the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.01 were collected from each BLAST search. The amino acid sequences have been edited to remove regions in the sequence that produce non-significant alignments with proteins that are not related to GPCRs.

The consensus regions are assembled into a non-redundant set by using the program
25 phrap. After assembly with phrap a set of contigs and singletons were defined as candidate DNA regions coding for nGPCR-46. These sequences were then submitted for further sequence analysis. Further sequence analysis involves the removal of sequences previously isolated and removal of sequences that are related to olfactory GPCRs. The transmembrane regions for the sequences that remained were determined using a FORTRAN computer program called
30 "tmrest.all" (Parodi *et al.*, Comput. Appl. Biosci. 5:527-535(1994)). Only sequences that contained transmembrane regions in a pattern found in GPCRs were retained. These nGPCR-46s are shown above in Table 5.

nGPCR-48

Homology searches are performed with the program BLAST version 2.08. A collection of 340 query amino acid sequences derived from GPCRs was used to search the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.01 were collected from each BLAST search. The amino acid sequences have been edited to remove regions in the
5 sequence that produce non-significant alignments with proteins that are not related to GPCRs.

The consensus regions are assembled into a non-redundant set by using the program phrap. After assembly with phrap a set of contigs and singletons were defined as candidate DNA regions coding for nGPCR-48. These sequences were then submitted for further sequence analysis. Further sequence analysis involves the removal of sequences previously isolated and
10 removal of sequences that are related to olfactory GPCRs. The transmembrane regions for the sequences that remained were determined using a FORTRAN computer program called "tmtrest.all" (Parodi *et al.*, Comput. Appl. Biosci. 5:527-535(1994)). Only sequences that contained transmembrane regions in a pattern found in GPCRs were retained. These nGPCR-48s are shown above in Table 5.

15 *nGPCR-49*

Homology searches were performed with the program BLAST version 2.08. A collection of 286 query amino acid sequences derived from GPCRs was used to search the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.1 were collected from each BLAST search. The amino acid sequences were edited to remove regions
20 in the sequence that produce non-significant alignments with proteins that are not related to GPCRs.

The consensus regions were assembled into a non-redundant set by using the program "GelStart". After assembly with GelStart a set of contigs and singletons were defined as candidate DNA regions coding for nGPCR-49. Further sequence analysis involved the removal
25 of sequences previously isolated and removal of sequences that are related to olfactory GPCRs. The transmembrane regions for the sequences that remained were determined using a FORTRAN computer program called "tmtrest.all" (Parodi *et al.*, Comput. Appl. Biosci. 5:527-535(1994)). Transmembrane regions within the amino acid sequences were visually inspected with an outliner (MaxThink) and the Celera sequences with promising transmembrane regions
30 were kept. In a last step, the blast results were compared against SWPLUS and the transmembrane regions of the sequences and promising Celera sequences for full length cloning were selected. The sequence of nGPCR-49 is shown above in Table 5.

nGPCR-61

Homology searches were performed with the program BLAST version 2.08. A collection of 286 query amino acid sequences derived from GPCRs was used to search the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.1 were collected from each BLAST search. The amino acid sequences were edited to remove regions in the sequence that produce non-significant alignments with proteins that are not related to GPCRs.

The consensus regions were assembled into a non-redundant set by using the program phrap. After assembly with phrap a set of contigs and singletons were defined as candidate DNA regions coding for nGPCR-61. Further sequence analysis involved the removal of sequences previously isolated and removal of sequences that are related to olfactory GPCRs. The transmembrane regions for the sequences that remained were determined using a FORTRAN computer program called "tmrest.all" (Parodi *et al.*, Comput. Appl. Biosci. 5:527-535(1994)). Transmembrane regions within the amino acid sequences were visually inspected with an outliner (MaxThink) and the Celera sequences with promising transmembrane regions were kept. In a last step, the blast results were compared against SWPLUS and the transmembrane regions of the sequences and promising Celera sequences for full length cloning were selected. The sequence of nGPCR-61 is shown above in Table 5.

nGPCR-51

Homology searches were performed with the program BLAST version 2.08. A collection of 340 query amino acid sequences derived from GPCRs was used to search the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.01 were collected from each BLAST search. The amino acid sequences were edited to remove regions in the sequence that produce non-significant alignments with proteins that are not related to GPCRs.

The consensus regions were assembled into a non-redundant set by using the program phrap. After assembly with phrap a set of contigs and singletons were defined as candidate DNA regions coding for nGPCR-51. These sequences were then submitted for further sequence analysis. Further sequence analysis involved the removal of sequences previously isolated and removal of sequences that are related to olfactory GPCRs. The transmembrane regions for the sequences that remained were determined using a FORTRAN computer program called "tmrest.all" (Parodi *et al.*, Comput. Appl. Biosci. 5:527-535(1994)). Only sequences that contained transmembrane regions in a pattern found in GPCRs were retained. The sequence of nGPCR-51s is shown above in Table 5.

nGPCR-52

Homology searches are performed with the program BLAST version 2.08. A collection of 340 query amino acid sequences derived from GPCRs was used to search the genomic DNA sequence using TBLASTN and alignments with an E-value lower than 0.01 were collected from each BLAST search. The amino acid sequences have been edited to remove regions in the sequence that produce non-significant alignments with proteins that are not related to GPCRs.

The consensus regions are assembled into a non-redundant set by using the program phrap. After assembly with phrap a set of contigs and singletons were defined as candidate DNA regions coding for nGPCR-52. These sequences were then submitted for further sequence analysis. Further sequence analysis involves the removal of sequences previously isolated and removal of sequences that are related to olfactory GPCRs. The transmembrane regions for the sequences that remained were determined using a FORTRAN computer program called "tmrest.all" (Parodi *et al.*, Comput. Appl. Biosci. 5:527-535(1994)). Only sequences that contained transmembrane regions in a pattern found in GPCRs were retained. These nGPCR-52s are shown above in Table 5.

nGPCR-x cDNAs were sequenced directly using an ABI377 fluorescence-based sequencer (Perkin-Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI PRISMTM Ready Dye-Deoxy Terminator kit with Taq FSTM polymerase. Each ABI cycle sequencing reaction contained about 0.5 µg of plasmid DNA. Cycle-sequencing was performed using an initial denaturation at 98C for 1 minute, followed by 50 cycles using the following parameters: 98C for 30 seconds, annealing at 50C for 30 seconds, and extension at 60C for 4 minutes. Temperature cycles and times were controlled by a Perkin-Elmer 9600 thermocycler. Extension products were purified using CentriflexTM gel filtration cartridges (Advanced Genetic Technologies Corp., Gaithersburg, MD). Each reaction product was loaded by pipette onto the column, which is then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B tabletop centrifuge) at 1500 x g for 4 minutes at room temperature. Column-purified samples were dried under vacuum for about 40 minutes and then dissolved in 5 µl of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples were then heated to 90C for three minutes and loaded into the gel sample wells for sequence analysis using the ABI377 sequencer. Sequence analysis was performed by importing ABI377 files into the Sequencer program (Gene Codes, Ann Arbor, MI). Generally, sequence reads of 700 bp were obtained. Potential sequencing errors were minimized by obtaining sequence information from both DNA strands and by re-sequencing difficult areas using primers annealing at different locations until all sequencing ambiguities were removed.

The following Table 5 contains the sequences of the polynucleotides and polypeptides of the invention. Start and stop codons within the polynucleotide sequence are identified by boldface type. The transmembrane domains within the polypeptide sequence are identified by underlining.

5

Table 5

The following DNA sequence nGPCR-Seq61 <SEQ ID NO. 1> was identified in *H. sapiens*:

CCTATGCTACAATCGGCAGATGGGAACTAGGAGCCATGATCTCTCAGATTGCAGGTCTCATTG
GAACCACATTTATTGGATTTTCCTTTTCTAGTAGTACTAACATCATACTACTCTTTTGTAAAGCCA
TCTGAGAAAAATAAGAACCTGTACGTCCATTATGGAGAAAGATTGACTTACAGTTCTGTGAA
AAGACATCTTTTGGTCATCCAGATTCTACTAATAGTTTGCTTCCTTCCTTATAGTATTTTAAAC
CCATTTTATATGTTCTACACCAAAGAGATAACTGTCAGCAATTGAATTATTTAATAGAAACAA
AAAACATTCTCACCTGTCTTGCTTCGGCCAGAAGTAGCACAGACCCCATATATTTCTTTTATT
AGACAAAACATTCAAGAAGACACTATATAATCTCTTTACAAAGTCTAATTCAGCACATATGCA
ATCATATGGTTGACTTTTGAATGGAAAACCCCAACAATATTAAGAAAAGCATTTCATGTGACTTT
ATTAGGGACACTAAACTACATCATTAACATGTCACAG

The following amino acid sequence <SEQ ID NO. 61> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 1:

YATIGRWE LGAMISQIAG LIGTTFIGFS FLVVLTSYYS FVSHLRKIRT CTSIMEKDLT
YSSVKRHLLV IQILLIVCFL PYSIFKPIFY VLHQRDNCQQ LNYLIETKNI LTCLASARSS
TDPIIFLLLD KTFKKTLYNL FTKSNSAHMQ SYG*LLNGKP HNIKKSIHVT LLGTLNLIIN MSQ

The following DNA sequence nGPCR-Seq63 <SEQ ID NO. 2> was identified in *H. sapiens*:

CAGTGAGCCG AGATGGTGCC ATTGCACTCT AGCCTGGGGC AACAGAGCCG ACTCCATCT
CCAAAAA AAGGCCATTC TGAGGATCAA GGCACCACTA GCAACAGGGA GCCCATGGG
TCTCAGACCC TCTCCCCACA TCTCCTGGTCCCTGCCCCCA CCTGGCGTAC AGGGACCAGC
CCCACGGAAG GCTCTTGAGG CCAGGTAACC ATGGGGAGGG GAGGAATGGG GACACCTTCC
TCCTGAGTGT CTTAGGGAAG AGAAGCTTAG GTCAGGTGGC TGAGGGTGA AATGAGAGAG
GGGTCTCCTC CTGGAGGGTC TCACCATTC CTTGGTCACC CACCCAACCTC TCATCTCCCC
TGATGTGGGG AGGAGCAGGG GGCATGGATT CCTGAGCCCC AGACTCAACT GTTGTGGTTT
ACAGGGGCAT CAGGAGAGAG AGCGAGCAGA ACACACTCCT GCAGCATCCC CTGGCCCCC
GCCCATGAT GGAGCCAGA GAAGCTGGAC AGCAGTGGG GGCCGCCAAC GGCGCCAGG
AGGATGTGGC CTTCAACCTC ATCATCCTGT CCTCACCAG GGGGCTCGGC CTCGGTGGG
TGCTGGGGAA TGGGGCAGTC CTCTGGCTGC TCAGCTCAA TGTCTACAGA AACCCTTCG
CCATCTACCT CCTGGACGTG GCCTGCGCG ATCTCATCTT CCTTGGCTGC CACATGGTGG
CCATCGTCCC CGACTTGCTG CAAGGCCGGC TGGACTTCCC GGGCTTCGTG CAGACCAGCC
TGGCAACGCT GCGCTTCTT TGCTACATCG TGGCCTGAG TCTCCTGGCG GCCGTCAGCG
TGGAGCAGTG CTTGGCCGCC CTCTTCCAG CTTGGTACTC GTGCCGCCG CCACGCCACC
TGACCACCTG TGTGTGCGCC CTCACCTGGG CCCTCTGCCT GCTGCTGCAC CTGCTGCTCA
GCGGCGCCTG CACCCAGTTC TTCGGGGAGC CCAGCCGCCA CTTGTGCCGG ACGCTGTGGC
TGGTGGCAGC GGTGCTGCTG GCTCTGCTGT GTTGACCAT GTGTGGGGCC AGCCTTATGC
TGCTGCTGCG GGTGGAGCGA GGCCCCCAGC GGCCCCCACC CCGGGGCTTC CCTGGGCTCA
TCCTCCTCAC CGTCTCCTC TTCCTCTTCT GCGGCCTGCC CTTCGGCATC TACTGGCTGT
CCCGGAACCT GCTCTGGTAC ATCCCCCACT ACTTCTACCA CTTAGCTTC CTCATGGCCG
CCGTGCACTG CGCGGCCAAG CCCGTCGTCT ACTTCTGCCT GGGCAGTGCC CAGGGCCGCA
GGCTGCCCC CTGGCTGGTC CTCCAGCGAG CGCTGGGAGA CGAGGCTGAG CTGGGGGCCG
TCAGGGAGAC TCCCCGCCG GGCCTGGTGG ACATAGCAGC CTGAGCCCTG GGGCCCCGA
CCCCAGCTGC AGCCCCGTG AGGCAAGAGG GTGACGTGGG GAAGGTGGTG GGGTCAGAGG
CTGGGGCCAG CCGGACCTGG AGGAGGCCTT GGTGGGTGAC CCGGTCATGT GCTGTCAAAG
TTGTGACCTT TGGTCTGGAG CATGAGGCTC CCCTGGGAGG CAGCTGAAAA GG

The following amino acid sequence <SEQ ID NO. 62> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 2:

VSRDGA IAL*PGATEP DSISKKKRPF *GSRHH*QQG APWVSDPLPT SPGPCPHLAY
 RDQPHGRLLR PGNHGEGRNG DTFLLSVLGK RSLGQVAEGG NERGVSWSRV SPFPWSPTQL
 SSPLMWGGAG GMDS*APDST VVVYRGIRRE SEQNTLLQHP LAPRPMMEPR EAGQHVGAAN
 GAQEDVAFNL ILSLTEGLG LGGLLNGAV LWLLSSNVYR NPFAIYLLDV ACADLIFLGC
 HMVAIVPDL QGRLDFFPGFV QTSLATLRF CYIVGLSLLA AVSVEQCLAA LFPAWYSCRR
 PRHLTTCVCA LTWALCLLLH LLLSGACTQF FGEP SRHL CR TLWLVA AVL L ALLCCTMCGA
 SLMLLRVER GPQRPPRGF PGLILLTVLL FLFCGLPFGI YWLSRNLLWY IPHYFYHFSF
 LMAAVHCAAK PVVYFCLGSA QGRRPLRLV LQRALGDEAE LGAVRETSRR GLVDIAA*AL
 GPPTAAAPV RQEGDVGKVV GSEAGASRTW RRPWWVTRSC AVKVVTGLG HEAPLGGSWK

The following DNA sequence nGPCR-Seq64 <SEQ ID NO. 3> was identified in *H. sapiens*:

AAAATTGCTC TTCCTCCTGA GCTTGACAC AATGATTGAG TTCAAGATGA AGAAGATGGA
 GCAGGGCACC AGGTAGACGG TGAAGCAGTG GATCCAGATG AGGACGTGAT GCACAGAGGT
 GCTGATGTAG TCTTCAGTCC AGATGTTGGG CCACCAGTAA TAGGGGATGC TGGTCAGGAA
 GCAGGTGATG TAAACACTTA CAATGACTTT CCGGGTGCGG GCTGGGTATG AGACCGTGTG
 GTACTTGAGC GGGTGGCAGA CAGCGATATA CCTGTCAATG GTTAACGGTA CAGTAATCCA
 TATGGAGGTG TGGATGGATG AGAATTCCAG CACTTCTATG ATCTTGTCGG GGACCTGAGG
 CATCTGCATG TTCAAGATGA AATCTTCCAA CAGGAAGTCC ACAAACACTA TGAAAAAGAG
 GACCAAGATG TCGGCAGCAG CGAGTGCCAA GAGATAGTTG TAGGAGGACT TCTGTCTTCT
 TGCCACCAGC TGGGAGAGGA TGATCACTGT CAAGATATTT GCTGTGGAGA GAAGAAAAAC
 TGGTTAGCT CTGAAGCAAA GATGACTTCG TTGGCTCCTA TGGGGGCCCT AGGCATATGT
 TTATTTTGCA CTCCCATGGA AGTGAAAATG ATGAATCAA TGCTTTTGAG GGACAACCTC
 AGCATTACAA ATAGCACCTC ATACAATTAG TGGATACTAT TTAAAGTTA TGCTTATATT
 CTAACACAAC CATGAGAGGT GGTGCCTCCA TTCTCCTCAT CTTAGAAGTG AAAGTGGGGC
 TCTGAGAGCC TCACACAGCC ATGAGAGGTG GTGCCGCCAT TCTCCTCACA CAACCATGAG
 TGGTGTGTC GCCATTCTCC TCACACAACA ATGAGAGGTG GTGCCACCAT TCTTCTCACA
 CAACCGTGAG AGGCGATGCT GCCATTATCC

The following amino acid sequence <SEQ ID NO. 63> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 3:

G* WQHRLSRLCE KNGGTTSHCC VRRMAATPLM VV*GEWRHHL SWLCEALRAP
 VSLLR*GEWR HHLSWLC*NI SITLK*YPLI V*GAICNAEV VPQKH*FNHF HFHGS AK*TY
 A*GPHRSQRS HLCFRAKPVF LLSTANILTV ILSQLVARR QKSSYNYLLA LAAADILVLF
 FIVEVDFLE DFILNMQMPQ VPDKHEVLE FSSIHTSIWI TVPLTIDRYI AVCHPLKYHT
 VSYPARTRKV IVSVYITCFL TSIPYWWPN IWTEYISTS VHHVLIWIHC FTVYLVPCSI
 FFILNSIIVY KLRRKSNFDN GSIASHGCVR

The following DNA sequence nGPCR-Seq65 <SEQ ID NO. 4> was identified in *H. sapiens*:

GGCCCGCTCCACGCTGTGTAGTGTACTTTTCATTTTCAATAAATCACTTCATTCTCCTT
 TGCTTTGTTTGTGCGTTTGTCCAATTCCTTTGTTCAAGACGCCAAGAACCTGGACAGCCT
 CCACCATTAGAATAACAAGAGCAGTTTCTGTACATGTACATATGGGGGTGGGTGGATCT
 CGCTACGCCCTTCCAGGACAGCGGTTTGTGGAATGCTTTTCTGAACTCGTGGCAGA
 ATGAGTACGGAAGAGGGCTGATAGCCGAATTCAGCCAGTGGAGCCAGAAGCGTGTCTCAT
 AGAGAAAGTGCTGGACATGTGACCCGTGGCAGGCAGCTCCGATGATCACGAGCAGTGTAG
 GGAGCCCAGCACAGGACAAATGCACACACCATGACGTCAAGCGACGTGGACGCTCATTTG
 TCCCGGGAGACGCCGTGCTGGGGAGGCTCGGCTGTCTGCTGCCATTGCAGGCGTTCTCGC
 TGCCCTGTAGCGGGTCTTCTGCGTAGGATTATCAAGTCCACCTGCAGAGGTGA

The following amino acid sequence <SEQ ID NO. 64> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 4:

HLCRWT**SY AEDPLQSEN ACNGSRQPSL PSTASPGTNE RPRRLTSWC HLSCAGLPTL
 LVIGAACHG SHVQHFLYET RFWLHWNLSA ISPLPYSFCH EFQKSIPSNR CVLERLSEIH
 PPPYVHVTET ALVFLMVEAV QVLGVLNKL DKTHKQSKEG MK*FIENEST LHSVAG

The following DNA sequence nGPCR-Seq66 <SEQ ID NO. 5> was identified in *H. sapiens*:

TACTTTTACCCAAAAC TATTATGTTTCATTATTAGAGTTTCCTAGAAAAATACCTAAGGAG
 TTAATGGTTTCATATCTTTTGCTCTATTATGAAGAAGAAAAATGTTTACAAATATTTTC
 ATTATTGGAGCATTTTTTGTGTTAGTGAAATTATCAAACTAGGATTGATTCTATTCT
 GTTACTTTTGTATAATCTTTATCCTTTTCTCTTAATTTCTGTATTTTGGATGCCTAAC
 TTAGAATACATTACCAAAGTTACCTTTTCAATTTAGTCTCTCAATACAAGATGATTAAAA
 CATTTATGGTTACCTTTTTTAATTTTTTGTCTATGCAAATTTATAAAAGGGCAAAGTCTT
 TGTGCTCTAATAATACCTGCTTTCTCATGTTTACATGTTCTACGATTTATTTTGTTTT
 ATAATGTAATTTTCGTTTACCTAATTGTGCACATAGTGAATAATAGATTATAATGAAGAA
 AACTTGGATTAAAAATCTATTGTTAAAAAGGTTTTTCAGGCAATAATAATCATTGGATTT
 TTCTGATGTATTTAAAAAGATATGTTTATTTTGTAGCAACTCGTGTGC

The following amino acid sequence <SEQ ID NO. 65> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 5:

YFYPKLLCSL LEFPRKIPKE LMVSYLLLYY EEEKCFNIF IIGAFFVVSE IIKTRIDFYS
VYFCYNLYPF LLISVFWMPN LEYITKVTF SLSIQDDLK HLWLPFLIFL LCKFIKGQSL
CALIPAFSC FTCSTIYFVF IM*FSFT*LC T**IIDYNEE NLD*NLLLR FRQ**IGF F*CIKRYVY
F*ATRV

The following DNA sequence nGPCR-Seq67 <SEQ ID NO. 6> was identified in *H. sapiens*:

GGCTACTTGT TATGGAAAAG TTATGATTGG TGTAAGACTG TACAGGTTGC TTCTGGCACT
 TGAAGAAAGC CTTGAGCGTG GCGGCTGCCA TGGTGCGGAA CCGCTTGCTG ATGAAGCAGT
 AGAGGAAGAA GTTGATGGCT GTGTTAGAA GGGCTAGCAT GTTGGCAATG TCGGACATGA
 TGTGTACCAG CCAGCGGTTT TGGATGGGCG CCCCATAGAG GTGGTAAAGA ATCATGATGA
 TGCGGGGGGG CCAAAGTGTG GCAAAGATGG AGGTAATGGT GAACAAGATG GCGGTGGTCT
 TCCCCGTGGA GTAGCCACGG AGACGAAAAT TGCTCTTCCT CCTGAGCTTG TACACAATGA
 TTGAGTTCAA GATGAAGAAC ATGGAGCAGG GCACCAAGTA GACGGTGAAG CAGTGGATCC
 AGATGAGGAC GTGATGCACA GAGGTGCTGA TGTAATCTTC AGTCCAGATG TTGGGCCACC
 AGTAATAGGG GATGCTGGTC AGGAAGCAGG TGATGTAAAC ACTTACAATG ACTTCCGGG
 TGCGGGCTGG GTATGAGACC GTGTGGTACT TGAGCGGGTG GCAGACAGCG ATATACCTGT
 CAATGGTTAA CGGTACAGTA ATCCATATGG AGGTGTGGAT GGATGAGAAT TCCAGCACTT
 CTATGATCTT GTCGGGGACC TGAGGCATCT GCATGTTCAA GATGAAATCT TCCAACAGGA
 AGTCCACAAA CACTATGAAA AAGAGGACCA AGATGTCGGC AGCAGCGAGT GCCAAGAGAT
 AGTTGTAGGA GGAATCTGT CTCTTGCCA CCAGCTGGGA GAGGATGATC ACTGTCAAGA
 TATTTGCTGT GGAGAGAAGA AAAC

The following amino acid sequence <SEQ ID NO. 66> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 6:

FLL STANILTVII LSQVARRQK SSYNYLLALA AADILVLFVI VFVDFLLEDF ILNMQMPQVP
DKIIEVLEFS SIHTSIWITV PLTIDRYIAV CHPLKYHTVS YPARTRKVIV SVYITCFILTS
IPYYWWPNIW TEDYISTSVH HVLIIWHCFV VYLVPCSMFF ILNSIIVYKL RRKSNFRLRG
YSTGKTTAIL FTITSIFATL WAPRIIMILY HLYGAPIQNR WLVIHMSDIA NMLALLNTAI
NFFLYCFISK RFRTMAAATL KAFFKCKQKP VQFYTNHNS ITSS

The following DNA sequence nGPCR-Seq68 <SEQ ID NO. 7> was identified in *H. sapiens*:

GACACCTGCC AACATGTTCA TTATCAACCT CGCGGTCAGC GACTTCCTCA TGTCCTTCAC
 CCAGGCCCCCT GTCTTCTTCA CCAGTAGCCT CTATAAGCAG TGGCTCTTTG GGGAGACAGG
 TAGATGCTGG GGCTCCCTTT TGCTGGAGGG AGGAGGAGGG TTTTGACCTG GGGATGCCCT
 CAATGGAGGG TGGCCCAAAG GAGGTGATTT GCTGCTTCTG GGCAGAGAGT GGGTAGCTGC
 CCTCAGTCTGTGAGTAAGC AAGAAGGGAA GATGCAGTGT TGGTCTTAAG GCCTCTGCCA
 GCCTTGGCCA GATGTGGCAG GTGGAGGGGG TGGAGTGGCG TCAGTCTTGC TCTTCTGTG
 AGGTGAAGGC CAGAGCAGAG TCTACCCTGT CCCCAGACCC TCCTCCCCAG GACTCAGAGC
 AGGGGCTGTG CCCACAGGCT GCGAGTTCTA TGCTTCTGT GGAGCTCTCT TTGGCATTTT
 CTCCATGATC ACCCTGACGG CCATCGCCCT GGACCGCTAC CTGGTAATCA CACGCCCGCT
 GGCCACCTTT GGTGTGGCGT CCAAGAGGCG TGCGGCATTT GTCCTGCTGG GCGTTTGGCT
 CTATGCCCTG GCCTGGAGTC TGCCACCCTT CTTGCGCTGG AGTAAGTGGG CTGCTGGAAC

TGGAAGGGG GCAGATGGGC TGGGAGGGGC ACATTCAAGG GTAAGTAGGT GACTTGGGT
CAGCCAGCTG GCGGGAGCAG GGTGCCCAGG AGCTACCTGA GCCTCAGGTG AGATGGACAT
TCAGGGGGAC ATGACTGGCA GCAAGGGAAA CTGACACTGC CCA

The following amino acid sequence <SEQ ID NO. 67> is a predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 7:

TPANMF IINLAVSDFL MSFTQAPVFF TSSLYKQWLF GETGRCWGS LLEGGGGF*P
GDALNGGWPK GGDLLLLGRE WVAALSPVSK QEGKMQCWS* GLCQPWPDVA GGGGGVRSVL
LFL*GEGQSR VYPVPRPSSP GLRAGAVPTG CEFYAFCGAL FGISSMITLT AIALDRYLVI
TRPLATFGVA SKRRAAFVLL GVWLYALAWS LPFFGWSKW AAGTGRGADG LGGAHSRVS
WTWVSQLAGA GCPGAT*ASG EMDIQGDMTG SKGN*HCPHL

The following DNA sequence nGPCR-Seq70 <SEQ ID NO. 8> was identified in *H. sapiens*:

TTCTCCCCTTGACGGGTGACTAACTCTGCCTGCGTGTTCCTTTTGTCCACCAGCATAGGCA
CTGAGTGCGGTCTGTGCACCCCTTTGCCACCCACCGGTGCCGGCACTGAGCCTGCAACCT
GTCTACGCCCCTCTGGCTGTTGCCATGACGTCCACCTGCACCAACAGCAGCGCGAGAGT
AACAGCAGCCACACGTGCATGCCCCTCTCCAAAATGCCCATCAGCCTGGCCACGGCATC
ATCCGCTCAACCGTGCTGGTTATCTTCCTCGCCGCTCTTTCGTGCGCAACATAGTGCTG
GCGCTAGTGTTGCAGCGCAAGCCGCGAGCTGCTGCAGGTGACCAACCGTTTATCTTTAAC
CTCCTCGTCACCGACCTGCTGCAGATTTCGCTCGTGGCCCCCTGGGTGGTGGCCACCTCT
GTGCCTCTCTTCTGGCCCCCTCAACAGCCACTTCTGCACGGCCCTGGTTAGCCTCACCAC
CTGTTGCGCTTCGCCAGCGTCAACACCATTGTCGTGGTGTCACTGGATCGCTACTTGTCC
ATCATCCACCTCTCTTCTACCCGTCCAAGATGACCCAGCGCCGCGGGTACCTGCTCCTC
TATGGCACCTGGATTGTGG

The following amino acid sequence <SEQ ID NO. 68> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 8:

FSP*RVNTSA CVFLLSPA*A LSAVCAPLCH PPVPALS LQP VSRPLAVAMT STCTNSTRES
NSSHTCMPLS KMPISLAHGI IRSTVLVIFL AASFVGNIVL ALVLQRKPQL LQVTNRIFN
LLVTDLLQIS LVAPWV VATS VPLFWPLNSH FCTALVSLTH LFAFASVNTI VVVSVDRLS
IHPLFYPSK MTQRRGYLLL YGTWIV

The following DNA sequence nGPCR-Seq71 <SEQ ID NO. 9> was identified in *H. sapiens*:

AGGACAACGATGGTCACTGATTTGGTGACCTTCGACAGTCTCCGGGCGCTGGCTCCGGTC
GGGCGTCTCCGGCTACCGCGGCCCTCCTTTGGTCCCCGCGCGCGCGGTCCGGCGATG
AAGCGCACCAGCAGCAGGTAGCACAAGATAATGATGCCAGCGGCAGCACGAAGCCCAGC
AGCACCTTCTGCGAGTGGTAGAGGCCAGCCAGAACTGCCTGTCGCGGCCAGCAACTTG
TCCGGGAAACGCACCGAGGCACAGCTCCTCGCCCATCACCTTGACCGTGGTGGAGAAAATG
GCACTGGGCAGCGAGGCCAGCGCGGCCAAAGCCAGATCCACACACACAGCGCCTTGCC
GAGAAGCAGCAGCTGTCCCCAGGCTCCGGCCGCGAGTGCCTCCGCGCGGTGTCTCGG
GTCCCGGTGGCTCTTCAGAGCCGAGGCCACCGAATGGTAGCGCGTCACTCATGGCAGT
GAGGAAGAACACGCTGGCGTACATGTTTCATGGGACGTACCATGGACACGATCTTACACA
TGGCCTTGCC

The following amino acid sequence <SEQ ID NO. 69> is a predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 9:

QGHV*D RVHGDVP*TC TPACSSSLP* V*RATIRWPR L*RATGTRGH GRGDCCGRSL
GDSCCFSAKA LCVWIWALAA LASLPSAIFS TTVKVMGEEL CLVRFDPKLL GRDRQFWLGL
YHSQVLLGF VLPLGIIILC YLLLVRFIAD RRAAGTKGGA AVAGGRPTGA SARRLSKVTK
SVTIVV

The following DNA sequence nGPCR-Seq69 <SEQ ID NO. 10> was identified in *H. sapiens*:

CTGGAAAGGG TGCTGGTGGC GCGCCGCGAC GCCGCGGCGC GACTGCCTGC CTGGTACTCA
ACCTCTTCTG CGCGGACCTG CTCTTCATCA GCGCTATCCC TCTGGTGCTG GCCGTGCGCT
GGACTGAGGC CTGGCTGCTG GGCCCCGTTG CCTGCCACCT GCTCTTCTAC GTGATGACCC

TGAGCGGCAG CGTCACCATC CTCACGCTGG CCGCGGTCAG CCTGGAGCGC ATGGTGTGCA
TCGTGCACCT GCAGCGCGGC GTGCGGGGTC CTGGGCGGCG GGCGCGGGCA GTGCTGCTGG
CGCTCATCTG GGGCTATTCG GCGGTCGCGG CTCTGCCTCT CTGCGTCTTC TTCCGAGTCG
TCCCACAACG GCTCCCCGGC GCCGACCAGG TGAGCGCCCC TCTGTGTGTG CCGGGCAGGT
GTCCCTGCGCA GGCTGGGAAG CGGGGCCCCG ACGGAAGCTG GGATGAGGAT GATCAAGAAC
AACAAAGACC ATTTATTGCA CTAAATCGTT GTGCCAAATC TTGTGCCCAT GGCTGTGAAG
TTTAATCTCT TAAATCTCAC TACAACGCTG TGCACACGCC CTCCTAAATG ATGTAAGTGG
AGTCCCCCAA ATTCTTGCAA AATGCAATGA CTGTTGCGAG GTTAATTAAC GAGTAGTTTA
GGAGCGAGAC GGAACCTTGG GGGTGCAGGG TGGCCAAACA CTTGTATTG AATCATGATT
CCTCGCCAGG TGCTACAATA CTGTTATTAT CACACCCATT TCACAGATGA GAACCAGAGG
CACACCGAAG TGTATAATAA CTTGCCCAAG GTATTTTATC CGTAATTCGA GGAGGAGATG
GGCTCCTTCC AGAAGTTTAC CCGTAATTCA AGGAGGAGTT GGGCTCCTGT CCAGGGTTGG
GTTATGGTCC TGCTTTGAAA GCGCGCGGAC AGGCATGTGA GACCCGGGGA CCCAGATGC
AATGCTGTCT TTAGGGGACT TGTGACAGAA TTCCCTTCCG GGGTCTTCAG TTTTTCAGC
TGCAAAACGG AAGGATTACA CTAGACCTTC GAGGTGTCCT GGGCGCCTGA AATGTGCAGA
TTACAGAGGC TGGACCGACG AGCT

The following amino acid sequence <SEQ ID NO. 70> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 10:

KKGAG GAPRRRGATA CLVLNLFCA^D LLFISAIPLV LAVRWTEAWL LGPVACHLLF
YVMTLSGSVT ILTLAAVSLE RMVCIVHLQR GVRGPGRRAR AVLLALIWGY SAVAALPLCV
FFRVVPQRLP GADQVSAPLC VPGRCPAQAG KRGPDGSWDE DDQEQQ*PFI ALNRCAKSCA
HGCEV*SLKS HYNAVHTPS* MM*VESPKFL QNAMTVARLI NE*FRSETEL WGRVAKHFV
LNHDSSPGAT ILLSHPFHR *EPEAHRSV* *LAQSILSVI RGGDGLLPEV YP*FKBELGS
CPGLGYGPAL KARGQACETR GPQMCCCL*G TCDRIPFRGL QFFQLQNGRI TDLRGLVLA
*NVQITEAGP TS

The following DNA sequence nGPCR-Seq2011 <SEQ ID NO. 11> was identified in *H. sapiens*:

TTAATCCCTGGAAGTCCACGAACAATGAATCCATTTTCATGCATCTTGTGGAACACCTCT
GCCGAACTTTTAAACAAATCCTGGAATAAAGAGTTTGCTTATCAAACTGCCAGTGTGGTA
GATACAGTCATCTCCCTTCCATGATTGGGATTATCTGTTCAACAGGGCTGGTTGGCAAC
ATCCTCATTGTATTCACTATAATAAGGTAAGGAATGGCTCCTTTTTTTTTTTTCTCCTC
CATACTTTAGGAACTACAGTCAAAGCTCCCTAAATGAGTCCTTTCCCTGTAGCATTTT
GCTTAATGAAATGCAATTTTGGAATATTTGCTTAAGATAATTAATGAAGATTCTACAGA
TATTTTCGTCATGCATTAGGTAACATCTCAGTTGCAATCTCAACATGCTAAGACCTAGG
CCAATGCTTACTGCTGGGTCACTGAGTTTTAGGGAAATGACTCTCACTCTCAGTCTTAG
CTGCATATTAGAATCATCTGGGGAGCTTTAAAACTCCTGATATGCAGTTTACCCCCAGA
CCCATTAACTCAGAATCTCTAAGGGTAGGGCCCGGGTAAGATTTAAACTG

The following amino acid sequence <SEQ ID NO. 71> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 11:

LIPGSPRTMN PFHASCWNTS AELLNKS^WNK BFA^YQTASVV DTVILPSMIG IICSTGLVGN
ILIVFTIIR* GMAPFFFFSF HTLGNYSQSS LNESFPL*HF A**NAILEIF A*DN**RFYR
YFRHALGNIS VANLNMLRPR PMLTAGSVSF *GND^SHSQS* LHRIIWGAL KTPDMQFHPR
PINSESLRVG PG*DLKL

The following DNA sequence nGPCR-Seq2012 <SEQ ID NO. 12> was identified in *H. sapiens*:

GGGTGACAGGA^ACTCTGGAAGGTGATAGTTTTCCAGGTGAAGAAGGGACAGTAGGTTTCC
CTGCTTTACTGCTATCTCCCTATGGCCTTCGGTCAGGCCTGAACTGTGATGAGAGTCTCT
GCCCCTGCTCTTTGGGATTCCTCAAATATCCTCCCTTCATTGTTCCCTGAATTATCTAGA
TCAATACAAACCAATCCCTCCTGCTTAAACTTTTAATTGCTTACAGGGGAAAGTGCA
GACTCCTTAGCTGGCGCACAAGCCTTTTGCACCTGGCACACATAGAGCTTTCTAGGGCTA
TCTCCTGCCATTCTCTAGCCTGTCTCCTTCTGCTCTGGGTCTCCAGAACTGCCCATGAAT
TCCCTCACATGCCTTTCT

The following amino acid sequence <SEQ ID NO. 72> is the predicted amino acid sequence derived from

the DNA sequence of SEQ ID NO. 12:

VTGTLEGDS FPGEETVGF PALLSPYGL RSGLNCDSESL CPCSLGFLKY PPFIVP*II*
INTNQSLCL KLLIAYRGKC RLLSWRTSLL HLAHIELSRA ISCHSLACLL LLWVSRTAHE
FPHMPF

The following DNA sequence nGPCR-Seq2013 <SEQ ID NO. 13> was identified in *H. sapiens*:

CCTATGCTTTCTATAGCTCATGGACCAAGCCATTTCTCCAACATCATAATTTTCTCTTA
TCATCCCTTTCTTGCAATTATTCTCCAGATGAAAAAGTTCAAATGCCTCCTCCCTATTT
TCAGCTGAGAAGGTGAGATGCCCCGTGCCTGGATTTCAGGCTCCTGCCTGCTTGGCAGAC
CACTGTGACCGTGACGACTAAGTCCACTCTTCCCAGCCAGCATCCCCTGCTCTCCCCAG
GCCAACTTCTTTGTGTTCTATTCTATCTCCTTGCCTGGAAGTACTCAGACCCCTCT
GTCTTTCTGCCTCTTGCCCAATCTTCCAGGCTCTAGTTTGTGGCTTTCTGCCTCCAAAA
ATGATTTTAAGCATTTGTGAGTCTTTCTCTCCACAGAACTCCAGACTCTTTGAAAATGCC
GTAGTTCGTAAATTACTTCCAATATTTAAGAAGTGCTTATCATGCTCCCTGCGGGTTCA
TGCTCTTTGGTATTGATTTTCCT

The following amino acid sequence <SEQ ID NO. 73> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 13:

YAFI*L MDQAISPTS* FFLIIPFLAL FSR*KKFKCL LPIFS*EGEM PVPGFPGSCL LGRPL*PCTT
KSTLPSQHPL LSPGQLLCVL FPIISLPELL RPLCLSASCP IFQALVCWLS ASKNDFKHL*
VFLSTELQTL *KCRSS*ITS NI*EVLIMLP CGFMLFGIDF

The following DNA sequence nGPCR-Seq2014 <SEQ ID NO. 14> was identified in *H. sapiens*:

CAAATGAGGTGGATGCACCTAGAAGGAAGGGTAGAACAAATATTCGTTGATGATATACAA
TGTGTCAGATACAGAGATACACAGACTAGGGCTGTGGGAATCTCAGATTTTAATTTGTCA
ACAGTGTGTTTTGATTTTTTTGTTTTGTATATTTGCCTCCCCAATTAATTTACAGGCTT
AATCATCTTTACAAGACATTATTTAAAGAGAAAGCGAACTTACTGAAGTTTTATGCTTC
CCTGATTGTGATGAGCTGGTTGATTCTAGCTCTAGTTTCAATGTTCTGAAAAACTGAA
GTACTTCCACCTGGTGGCACTTAGTGAACATTGCAGAACCGAGTAATAGGTTATTCGTT
GGGTTTCTCGAACAAATCTGAGTTATAGCTAGGAACTCTCAACTAACAATTTATGAGAAC
CTTCTGTACACATGTGAATTTACATATTTATTCCTTTGCAGTTGAAGGATGGGATGTAT
GCAAAGGAGAAATGAAGTCTACTACAGTAATGGAAAGAAGTGATAGAAGATGAAACTCCAA
AATGCCTATCTGCTACTTGAGTGGAAGTCACTAGAAATATATCAAATGCAGAGAGAAACAT
GTGACTAGGCTCTAGTCAACAATTGTCATCAAATACTTGCTGAATATATAACACATTTT
AGGGAGCTGTG

The following amino acid sequence <SEQ ID NO. 74> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 14:

K*GGCT* KEG*NKYSLM IYNVSDTEIH RLGLWESQIL ICQQCVLIFL FCIFASPINF TGLIIFTRHY
FKEKANLLKF YASLIVMSWL ILALVSMFWK ILKYFHLVAL SEHCRT**V IPLGFSNKSE
L*LGTLN*QF MRTFCYTCEF TYLFLCS*RM GCMQRRMNST TVMERSDRR* NSKMPCICYS
GTH*NISNAE RNM*LGSSQT IVIKYLLNI* HILGSC

The following DNA sequence nGPCR-Seq2015 <SEQ ID NO. 15> was identified in *H. sapiens*:

AAAAAATACATTCTGTATGGAAGACTAAATATTAAGAAAAAACAGTTATCCATATG
TTGTTTCATAGCTTTAAGTATCCTAGTCTAAATCCAAAGGGACTTTTTTGGGGACTCAA
AAAAAATTTCTAAAGTTGATCCAGAAGAGTAAAGAGACTAATATAGTCAAAATAATAT
TTGAAAAGGTTAAATAATTATGGGAAAACATGCTTAGCAAAAATATAAACAAACAAACAT
TCAAACAGACAAAAACCTATGAAAAACCAAAACCTATTTAAAACTAAATTTCTAAATG
AGAACTAACATACAAATCAAGAATCAGCATAGATAGCTAAGAAGCAAATTATAGCATATA
AACTAATTCAATTTATTATAAAG

The following amino acid sequence <SEQ ID NO. 75> is the predicted amino acid sequence derived from

the DNA sequence of SEQ ID NO. 15:

FI IN*ISLYAI CFLAIYADS* FVC*FSFRI* FLNRFVLFHR VFVCLKFCLF IFLLSMFSHN
YLTFNSNILT ILVSLFWIN FRIFFFESPK KSLWILD*DT *SYETTYG*L FFSLIFSLPY RNVVF

The following DNA sequence nGPCR-Seq2016 <SEQ ID NO. 16> was identified in *H. sapiens*:

CTAGGCTGCTCCTGTGTGGTTATAATGAATCTCATCAGCTACAATCATTTCCTCCAAAAAGG
ACAGAAAGTGAATCTGTCTTATAAAGATGGTTTCAAAGCCAACTACAGATATCATAGAA
AAAAAAAAAAAAACAGTGGCAGATAAGACCTTTCATCTTTTCTTATCCCATGGGCTTTT
CTGCCTCCAGATTTCTTGCACATCAAGGGGGTTCTGTGCAAAATCAGTGGGCTGGCCCT
CTGCCACCCCTGGGCTAAGCTGTGGTTGCCATGGCTACGAAGACAAGAATGACCCCTGGT
TTTATAGAGCCCTGGGTCCTTGCTCACAGGCCTTTTCAGTTGATATTTCTTTCATCTTC
TTCAGAACCCCATGTGGCAGGTGCAACAAGGAGTTCACCAATGCTCCGGCCAAAGTGAGT
AATGAGGGACACATGCACGACCAGGCAGAGCAGCCCTGAAGAAGTGGTTTGTGAGGGTGT
GGAGGAAGGGCTTGCTTCCACACTCTGCACTTCTGGGTCTAAGGCACTAATCACACCTG
GCTCAGGCATCATTCTCAGCCTCATGCTACTTTTGTCCAGGGACAGAACAGAGGTGCCA
GCACTCAAGGGAATCCTGCACCACAACAGGCAGGGGACCATCATGACTGCTGAAATAGGC
AGCAGGAGTCCGAACATATGGCATAAAAATGTACAGCAACACCACAGGGGGGAACCCCTG
GGGGGAAGTAGGGGCATGGTGA

The following amino acid sequence <SEQ ID NO. 76> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 16:

RLLLCG YNESHQLQSF PKKDRK*ICL IKMVFKANYR YHRKKKKNSG R*DLSSFSYP
MGFSASRFP CTSRGFCANQW AWPSAHPGLS CGCHGYEDKN DPWFYRALGP
LLTGFLS*YF FHLLQNPMWQ VQQGVHQCSG QSE**GTHAR PGRAALKKWF
VRVWRKGLLP HSALLGPKAL ITPGSGHLS LMLLSRDRT RGASTQGNPA
PQQAGDHHDC *NRQSESELW HKNVTATPQG GTPGGK*GHG

The following DNA sequence nGPCR-Seq2017 <SEQ ID NO. 17> was identified in *H. sapiens*:

ATTATCTCCATTATGCTCTATCAGTTTCTTTATAGAATATGATTACTACTTAGTGATAAA
GCTTCCTTTGCTAAGATTTTCAGCCTACGAACCATGATCCAAACCCTACTTCTAAACATA
TAAACATGCTTTACAAGTATCCTATATATGGAAAAGTCCTTGGAATTATTTGGGTAATTA
ACCTGGTATTACATGTGTTATTTCTGATCTACTATTGCAAATTGACA

The following amino acid sequence <SEQ ID NO. 77> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 17:

SIC NSRSGNNTCN TRLITQIIPR FPYIGYL*S MFICFRSRVW IMVRRLKS*Q RKLYH*VVII
FYKETDRA*W FPYIGYLA MFICF

The following DNA sequence nGPCR-Seq2018 <SEQ ID NO. 18> was identified in *H. sapiens*:

TCTTGATTTACACAAAAAACCATAACTAACTAAAAATAGAAAACCTTTTAATTATCTGTATT
GTTGTATAAAATGTTTTATATATTAGGAATCTAAAAATTTGTTTTTGTCTTTTATCCTCT
GTCATAGGAAGAAGACATCATGTCTCTGTTTACTGTAACCATTAAATAAAGGCTAATAACA
GACAGTACATGATGATACTTTTAACTAGGGCAAACAAAAGTAATATTTTAAACAATGAGGT
TTGGTCTTTGCTATCTATACCTCATGTCTAATTTTCCCTACAATGTAAATGTCATTCTC
CTCTCTACCCATTTGTAAGGGTCTCAGTTTTCTGCTCTTGCATGACTTATTTTAAAGGGT
CACAATAAGGCCAGGTAATTCATATTTTAAAAATTCATTTAGAATAATTACATCTAAAA
ATTCACAAGAAAGACAATTTCAATATAAAATAATAAATTACTAATATTGGAATTTCAAGC
ATTAGTCATGGCAAAAAAGAGATAATTTGTAGCAGAATATTTAATGGCAACTTTCTTAT
TCTATCACTTATTGTGTTCTATTTGTTATGACCAAGAAATTACTCTATATCCACTACAA
TTCATAAAACAGGCATGGAAGAAGTCTTTTTTCTTGGTGCTCATGTCTAAGAAGATGA
ACCTCAGAAGTATGTCATTTTCAATACTATGTTCTGAACAGACAGCACACATTATTTT
GAATGGACACCAAATCTCAAACATATATAGA

LIYTKNHN*L K*KTFNYLYC CIKCFY*ES KNLFFAFILC HRKKTSCLC L*PLIKANNR
QYMMILLTRA NKSNI LTMRF GLCYLYLSMN FPNVNVIPP LYPFVRVSF CSCMTYFKGS
Q*GQVIHLK IPFRITSKN SQERQFYKI INY*YWNFKH *SWQKRDNL* QNILMATFLF
YHLLCSICYD QRNYSISTTI HKTGMEEVFF FLVLMSKKMN LRSMSEFFNTM F*TDSTHYF*
MDTKSOTYI

GTCCTAATAATCTTCAATGAATTTTAACTAATTTTCAGGGATAACAAAGCACTTCAGATT
GAAGTCAATTCATGTACTACTATTTACTCAGGAACTTTAAATTTTCTATCATACATATG
CTGTTGCTGGGTTTCTTATTTGTAAAAAGATATTCATTCCCTACTGTGTTACCCCTTG
TTAGCAAAGTTGGTTTAGAGTGACATAGCCTGATGAAACCCATAAAACAGCCATAAAATTG
CTCTTATATGGGATAAAACAATATTTGAACACTATATTTCTTAAAAATATAATCTTATAT
TGGGTGGTTAGAAGTGATCTTCACATCGTGTGTGTGTGTGTGTGTGTGTGTGTAATATAT
AATATGAAAGACTTTTAAAAGTAACTTTAAAAATACATATTTTATATACATATTTTCAT
ACATATTTACATACATTTTCTGTTTTCATTCATCTAGGTTTACATTAGACTATGTCCTT
AGTTTGTAGTGTTAAAAACTATAAAAAGAGAATAAAGTTACAGCAGAAATTAATTGCCAAGGA
TATGACAGTTCGAGCACTACAGTAAAAAATGAGACACAGGTTTATAAAAAACATTTAAATT
CTGAATTTTTGCTTTCTTAGGTTTCTCTGTCAGTAATAGATAATTGTTAGTATGAAA

FILTH YY*QRNLRKQ KFRI*MFL*T CVSFFTIVLE LSPWQLILL *LYSLFIVLT LKLRT*SNVN
LDELKTENVC KYV*KYVYKN MYF*SYF*KS FIFYITHHT HTHTM*RSLL TTQYKHFLR
NIVFKYCFIP YKSNLWLFYG FHQAMSL*TN FANKG*TQ*G MKYLLTNKKP SNSMYVIGKI
KSS*VNSIHE LTSI*SALLS LKIS*NSLKI IR

TTTCTAAATCTTTGTTACATTCTTCTTTACTCTGAGGGGTTTTAGTCATCTGCTAGTAAA
CTAGTTAGTCCTTTCCGTCAGCTGGGTAAAAAGCTATAAATGGTTTTCAACTCTATGCAG
CTCCCTTGGGTTGCTCATTTGATCTGAGCCAGGTTTGAAGTTGGGCCATTGAGAATGATC
TGTCCTCATGATGTAGGGGGTGACTCCAGCCAATTCTTAATATTGCTGGAATTAATTAAC
TTTGATTCCCTCTAACTGAAAGAGGGCATTTTACTCTACCGTGTATTATTAATAACCTTAT
AACTTGATTTTTTTGATTTTGTTCCTTGCTCAGTGAGTACTTAAAATATCCCTGCCGAT
ATAGTAATTTGTTCCCTGTTTAATATGGCTTTTTCCCTTTGTTTACTCTGGACTCAAGTCT
TTGTAGCTTGTTTTTCTAAGTCAGCTCAAAAGTTGCTGGTCATTGGATTTGGCAGCCTTT
TCAAGCTTTACCCACCAAGATCTACAGG

SK SLHSSLL*G VLVIC**TS* SFPSAG*KAINGFQLYAAPL GCSFDLSQV* SWAIENDLSS
*CRG*LQPIL NIAGIN*L*F L*LKEGILLY RVLLNTL*LD FFDVFLSE YLKYPCRYSN
LFPV*YGFFL CLLWTQVFVA CFSKSAQKLL VIGFGSLFKL YPPESYR

CCCGGCCCAAGTCTCCACATCTTGTAAAGTGGGGAGATAAAACCTATCTAAGGGGGATATTA
TGAGGAGCAGGAGAGAAGGCATGTCATTCTCCTAATTAATTGGCATTCACTAAAGAGTTA
TGTGATTATTAAATACATAATAAAATATAAAAAATATAAGGTGCTCTAGTTATATAATCAT
GAGGTCCTGAGGATGGTGATGACTGCACTTCAGTGGACTACCTTATGAGGGACTGACTGTC
AAGAAGCTCTGTGCATGTGTGCTTGTGTGTGTGTCATCTGTGTATTATATATATACATATA
CGGTATATAAATAGGCATTTTATTATATAAGAAAATGATGCACAGTAAAAATGCATAA
ATATTATTGAGCATGTTTGTATAAACGAGTGAACAAAGAGACATTTGGGATGCAAGACCA

GTGGTATAATCTGCCCAAACACAAGCCCCGTTTACTGTTGCTAATGCACAAAGAGAGGG
CTGGCAGACATGGCCTGCATGCTCTGTACACCTGCCCATCTGCACCACACTCCCCCATGG
TCTTGCTGTTGTTGCTGTGTTGGGCTCATCCCGCCTCTCACA

The following amino acid sequence <SEQ ID NO. 81> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 21:

CERRDEPNTA TTARPWGSVV QMGRCTEHAG HVCQPSLCAL ATVKRGLCLG RLYHWSCIPN
VSLFTRLYKH AQ*YLCIFTV TSFSYIHKVP IYIPYMYIYN TQMHTHKHTC TELLDSQSLI
LCIFTV TSFSYIHKVP IYIP R*STEVQSSP SSDLMII*LE HLIFLYFIMY LIIT*LFSEC QLIRRMTCLL
SCSS*YPP*I GFISPLTRCG DWAG

The following DNA sequence nGPCR-Seq2002 <SEQ ID NO. 22> was identified in *H. sapiens*:

AGGCAGAGATTATGTGAGACTTTGCATGATAGGGGTCTGTGCATTCTTGCGCATTTCCTTA
GCTCTGTGTGAGCAATATTTAAGTAGTCATTACATAAAATCTATTGAACCTATACAAAGA
AGTGAACACACTGTGATGAGTTGGCTCCTACCAAGTAAGGCCTGGGGCTGGTCTCTTTAT
GGTTCCCCAGCACACATCTTAAATAGTTCCTTTGTGGATAAACTCTCTTTGAATTATTC
TATTTTGAGTGTGCCATCTGATTCCTGTAGGACTCTGACTTTAAAAAGGTAGAGCATTG
CTCTCAT

The following amino acid sequence <SEQ ID NO. 82> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 22:

RQRLCETLHD RGLCILAHFL ALCEQYLSSH YIKSIEPIQR SEHTVMSWLL
PSKAWGLVLY GSPAHLK*F LCG*TLFELF YFECAL*FLL GL*L*KGRAL LS

The following DNA sequence nGPCR-Seq2003 <SEQ ID NO. 23> was identified in *H. sapiens*:

CAAATGGATTAATTTACATATGGATGAACATGATCTGTTGCTCTCCAGGTCCCAAAGGAT
ACATAAGAAGAAAAATTTAGTGATGTTACTGGATGATGTCTTTTAAGACAACACAATACA
ATATCTGAGTATGTACCCCTTACGACATAGAGAAGGGATTTTCAAAATA'TTTAACTTAAA
TAGATTCATAAAAAGAAATCACCTTCCAACCACTGTTCCCTTGTCTCTGGTCAATTAGGGT
CATAATATTGTTTTTATTGATTACAAAAGGTAAGAATGTACACTGTATAAATGAATAAAA
TAATATAGATTACTAGATAAGCAGATAAATAAATACAAAAGCACAAAAATACAAAAGCAA
ATGACCACTCAACTCACTTCCACCCACTTCAAGGAAAACACAGTTCCTTATCATAGTTA
CTATTAGAAGTCTTTCCTGTCTTCATTTTCTACAAGCATGCAGAAATATATATGTGGAC
ACATTTGTGCCAGAATTCCTTTTTTCTGACACTCACTTTTTCTCCTACTCCACAATA
TGTCAGGACAAATTTCTACAAGATATAGCAAATGGAGTAACATAGAAATAGAGCAAAACAT
GAAAACCTCAAACTCATTAGTGGATGATGTTTT

The following amino acid sequence <SEQ ID NO. 83> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 23:

KWINLHMDE HDLLLSRSQR IHKKKNLVML LDDVF*DNTI QYLSMYPYDI EKGFSKYFNL
NRFTKRNHLP TTVPLWSIR VILFSLY YK R*ECTLYK*I NNIDY*ISR* INTKAQKYKS
K*PLNSLPPT SRKTQFLYHS YY*KSFLSSF SYKHAIEIYMW THLCQNSFFS DTHFFPPTPQ
YVRTIFYKI* QME*HRIEQN MKTSNSLVDD V

The following DNA sequence nGPCR-Seq2004 <SEQ ID NO. 24> was identified in *H. sapiens*:

GGGAAGGCTCTTCTAAGAAACCACGCCACACACAAATTAGTAAATTCGACAAAACAGGA
AACAAACAAAAATTTTGTGTTAAAAAGTAACACTAAATCAAAATGAAAAGATAAAAGGCAA
ACACAAAATTGACAAGGATGCTTGCAACTGTGTAAGTAAAGGGCTATTTTCTGAA
TATATTTCTCTATTCTATAATTACTTTCTTAAATATATTTTAAAAACTTCTGTAAGTAAG
TATAGAAATGACAAATGATAAGAACAGTTATCAGAAAATGAAATACAAATGATTCAAAACA
TGAAAAGATGCTCGAGCTCAGTCTATAATAATAGACCCTTAAAAGTATAATGAAATATCT
TTTTTTAAACCCCTATCTGATTAGCAAAGACCAGCAAGTTGGAAAAACAGAGGGCTTTTT
CAAAGATCAAGCTTGTGAGCCAACTAAAGGATTCTGTGCTTCAAGAATTACACTGTTT

AGAGTTTGGACTTTTGGAAAAAATGTACATGTCTATGAAATAAATTGGCCTTTTAAAAA
 AGAGTTTGCAGCAATGCTGAAAGTAGTGGCCAAAAGCATGATCAAGAGATAGGATATTCA
 TCTAATCTCAAACCATCTCCCTACAAGCTATTTATCAATTACAAAGTGAAAAATACTAAC
 TGCACAGTGGTGAA

The following amino acid sequence <SEQ ID NO. 84> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 24:

SPLC S*YFSLCN** IACREMV*D* MNILSLDHAF GHYFQHCKL FFKRPIYFID MYIFFKSKL
 *TV*FLKAQN PLVWLTSLIF EKALCFNLL VFANQIGV*K KIFHYTFKGL LL*TELEHLF
 MFESFVFHFL ITVLIICLFH TYLQKFLKYI KESNYRIEKY IQENSPLSVT QVASILVNFV
 FAFYLFILI* CYF*HKIFCC FLFCRIY*FV CGRGFLEEPS

The following DNA sequence nGPCR-Seq2005 <SEQ ID NO. 25> was identified in *H. sapiens*:

ACAAAAGTCACTCCTCTGCTCAAAATCTTTGCACGGTTTCCTGCTGTACTTGGAATACAA
 CCCCAGTCCCTTTCCTAGGGCACTAGCCTTGATTGGCCTTGATCACTGCTCCTGCCAC
 CTCATACTCCTTGTCAATTTGGCCATTATAGTCCAACAACATCCACTCATCCGCTTTCTCG
 CAGGCCCTGGAATATTCTAAGCACTTTCCCATCTCAGGGGTGTTGTGAATGCTGTTTCTC
 TACCTGCTCTCATCTCCCACTCTTTATCACTAAGTTCTCACATACACATGTTTGATCT
 CAAGCTGTGTGTGTTTACTTGTTTGTATTTGAAGCACTATGCTGAGCCATAGTGGAATC
 TGAGGTAAAAGGAAAAATAAGTAATATTGACTCTGAGTTTATGTAATATTTTGATTTTTT
 CCCATGAAGGAATTTTGCATTAATTTTTATTTTAAAAATATTGTATTAAAAATTTTATTTA
 TCTTGATTACTGAGTATTTTGGTGTCCCCTTAAAAATTCTCACCAAAGGACAAGTGCCTCG
 CTCACCTCACCTTTTCCAGTACTGGTCATTGGTCTGTCCCACCAAAGTGTAAAGTAAAC

The following amino acid sequence <SEQ ID NO. 85> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 25:

QKSLCSKSL HGFLLYLEYN PKSFPRALAL YWP*SLLLPT SYHLSFGHYS PTTSTHPLSR
 RPWNILSTFP SQGVVNAVSS TCSHPPILYQ LSSHIHMF DL KLCVFTCLLF EALC*AIVES
 EVKGKISNID SEFM*YFDFP P*RNFAIFI LKILY*NFIY LDY*VFWCPL KILTKGQVPR
 SPHPFSSTGH WSVPPNCK*

The following DNA sequence nGPCR-Seq2006 <SEQ ID NO. 26> was identified in *H. sapiens*:

CCGAGGGCTTTCCCTGTGAGAATCAGTTTCAAATATGAGGTTGATTTTATTTTCCCCGGT
 TGCAATTAACTGAAAAAATATTTCAAAGCTGTATAATTAAAGGCCGCATTTTATTAGG
 GTTTAAAAATAGTCGCTATGAAATTTGCTCCTGCCATTGGTAATTACAACGTACATCTTAA
 TATCCCCCTGCTTGCCAGCCCCGAGATAACAGCGCTGTGTGTGCTGCATTTGGCTTTGCA
 GAGAAGGTAAAATCCTTATCTTATCTCCATCTGCACACAACAACAGCCTCTCTTCCAAT
 TCAACCCTAATCTTCTTAGTAAATAATACTGATATTTTACCATAACAAAATGGAGCTG
 GTGCCAGATTCTCACTGATAACACCTCTCGTTTACACACCATCTCTGTCAAAAATCGGCC
 CGATTTTTCTTAATCTCTTTAACTTATCAAAAAAATACTTTTTACATTTGGCCATAGTA
 AGTTCTTTTCTACCAAATAATAATATTATAAATAAATCCCTTTGCCTACAGCTGACTCAT
 TGAAAAGATACTCAGCCTCCTCATTTTCTTCATGAATGGAAATTGTTCTGCTCTTCAATT
 TTCCTCCCAAGTTTGGGGGTCCACACCAAGGGAATTGTTCCAGGCAGGCCCTGAGCCAT
 CTTTGTATCTTGCAGGGGGTCATCTTGGTCCAGGATGTGCATGCTTCTC

The following amino acid sequence <SEQ ID NO. 86> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 26:

EKH AHPGPR*PPA RYKDGSGPAW EQFPWCGPPN LGGKLKSR TI SIHEENEEAE YLFNESA VGK
 GIYL*YYYL V EKNLLWPNVK SIFFDKLRL RKIGPIL TEN GV*TRGVISE NLAPAPFCYG
 EKYQYYLLRR LGLNWKRGWL LCADGDKIRI LPSLSQMQH TQRCYL GAGK QGDIKMYVVI
 TNGRSKFHSD YFKP**NAGL *LYSFEIFFS VNCNRGK*NQ PHI*N*FSQG KPS

The following DNA sequence nGPCR-Seq2007 <SEQ ID NO. 27> was identified in *H. sapiens*:

AGTATAAAATCTGGGAGAAAAATCCATCAAATTATAAAATAGAACTAATAATGCTTTTCAT

GGGTAAGCAATGAAACAAACCAAGGTAAACCAGCGTTTTAAAGATTGATATTTCTTTAA
 GAAGAGAATGGAAAATAAATTTAAATATACATTTTATATTGATTATCATGAAGTTTTCT
 AGTTTCTTACCTGAAGTTTCTGGAGGAACTTAACAGCACTCATTTGACATTAGGAAGA
 AGCCGAATGTAAATAAATCCTAGGTGGATAAGCATAATATAATGAGTAATATGATCTTAA
 ATGGAAAAAAGATTATGTAAAGTTGTTTATACTCTTAACATTTTCCACCCACTACACTGT
 GAAGCAGATTAACCTTTTGTCAAAGGTGTAACCTTCT

The following amino acid sequence <SEQ ID NO. 87> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 27:

EGY TFDKRLICFT V*WVENVKSI NNFT*SFFHL RSYYSLYYAY PPRIYLHSAS S*QMSAVKV
 PPGNFR*ETR KTS*SI*NV YFNLFSLFL KKYQSLKRWF TFGLFHCLPM KALLVLFYNL
 MDFSPRFYT

The following DNA sequence nGPCR-Seq2008 <SEQ ID NO. 28> was identified in *H. sapiens*:

CTTTGAAGGATGAAGAGAAGTTACCAAGTGAACGTGGAGGAAAAGCAGTCCAGGCAGAA
 GGAACAGCTGCTGAAAAGGTGAGGTGCCCAAACCAGAAAGGCATGTGAGGGAATTCATGG
 GCAGTTCTGGAGAACCAGAGCAGAAGGAGACAGGCTAGAGAATGGCAGGAGATAGCCCTA
 GAAAGCTCTATGTGTGCCAGGTGCAAAAGGCTTGTGCGCCAGCTAAGGAGTCTGCACTTT
 CCCCTGTAAGCAATTAAGTTTAAAGCAGAGGAGGGATTGGTTTGTATTGATCTAGATA
 ATTCAGGGAACAATGAAGGGAGGATATTTGAGGAATCCCAAAGAGCAGGGGCAGAGACTC
 TCATCACAGTTTCAAGCCTGACCGAAGGCCATAGGGAGATAGCAGTAAAGCAGGGAAACCT
 ACTGTCCCTTCTTACCTGGAAAACCTATCACCTTCCAGAGTTCCTGTCAACCCCAAGTGAA
 GGCAACCACTGTCTCTTCTGTTACCTAACACGTGGTACAAACAGCTACCATAGCATG

The following amino acid sequence <SEQ ID NO. 88> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 28:

MLW*LF VPRVR*QKRQ WLPSLGVTGT LEGDSFPGEE GTVGFPALL SPYGLRSGLN
 CDESLCPCSL GFLKYPPFIV P*II*INTNQ SLLCLKLLIA YRGKCRLLSW RTSLLHLAHI
 ELSRAISCHS LACLLLLWFS RTAHEFPMP FWFGHLTFSA AVPSAWTAF PRSLGELLFI LQ

The following DNA sequence nGPCR-Seq2009 <SEQ ID NO. 29> was identified in *H. sapiens*:

TATAAGGTAGTTGTGTAGCTTTAAGACTAAGACCTCTACACCTGGAAATTGGTATACCTT
 TTCAATAAAGCATCAGATAGTAAAGTTTTGTGGGCCATATGTCTCTGCTGCAACTACTCA
 GCTCTGCCATTGTGCAAAAGCAGCCACAGATAATATGTAAATGAATGAAGTTGGCTGTTT
 TCACAAAAACAGGCGGCTGTTAGGATTGGCTTGCTGACTCTTAACCTGGATTCTCACTT
 CTGAAAGCATGGTCTAGGAGACCAGCAGCATCAGCATTACCTGTGAACCTGTTAGAGATA
 CAGAATGTTGAGCCCCCTTCTACTGATTGCTCTAGAGTCTAAACCATGTTTCTCAAAC
 TTCAGCATACATAGGACTCACCTGGGGATCTTGTGAAAGTACAGACTCTGAGATAGCAGG
 GCTGAACACCATACTAGCCTTGGGGAGGCAATGTTATGACCTGGTCAGTGTTCCTTGGGG
 AGTCCGCAATCTATTAGGAGAGACTGCTATATAACAAATAATTCAATACAGACTAGTA
 AATGCTATAACGGAGGTATCTTCAGCAGAGGAGCACCA

The following amino acid sequence <SEQ ID NO. 89> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 29:

YKVVV*L*D* DLYTWKLVYF FNKASDSKVL WAICLCCNYS ALPLCKSSHR *YVNE*TWLF
 SQKQAAVRIW LADS*LGFS LKAWSRRPAA SALPVNLEI QNVEPLILI ALESKP CFSN
 FSIHRTHLGI L*KYRL*DSR AEHHTSLGEA ML*PGQCSLG SPQSIRDCY INK*FQYRLV
 NAITEVSSAE EH

The following DNA sequence nGPCR-Seq2010 <SEQ ID NO. 30> was identified in *H. sapiens*:

ATTTTCATGTTGATGGCAATCATCCAAGAGAGAGCAGGCCATGTCACGCAATAATAGAAC
 AAGGAGAAATGCACACTTTTCTTTTCCATGTCTCTGCTTGCATTACATTTGCTAATACC
 ACTTTAGCCAGATAAATTAACACAGCGCAGCACATAGTCAAAAAAATAGAAGACCAGAAG

TTACAGAACAACCTGACATGGTTTAGAAAAGCAATTAAGACCATCAGTGAAATCAGTCTAC
 CACAAAAGGTAATTCATTTGTTTCAACGCTGTTGAAAAGACTTATCTTCCAAGACAGGA
 AATGGTTCTCCACTGAAGGGTGAAGACATTTCAATTTTCAGTCATTTGGGGAAGAGTTGG
 ATCTCCAACGAGTAACTTTTCATGCAAGGACAAGAATTTAGTAGTGAAATAGAGGTTATTC
 GTTTTTTTACCATAAAATAATTAATAATCTTGGAGGCAGTTTCCTCATAGCAGTTATTAT
 GGCAGTTGTGTTTCATTTACAGGAAAACTGAGAAACTCTAAGATGTTTTTGGGAAAAAAA
 GTATTTTGAAGCTTGCAGGTGTTAACTTCCACAATAGATATACTCTTC

The following amino acid sequence <SEQ ID NO. 90> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 30:

R VYLLWKLTLA SFQNTFFSQK HLRVSQFSCK *TQLP**LL* GNCLQDY*LF YGKKTNNLYF
 TTKFLSLHES YSLEIQLFPK *LKIEMSSPF SGEPFPVLED KSFQQRCEQM NYLLW*TDFT
 DGLNCFSPKPC QLFNFWSSI FLTMCCEAVLI YLAKVVLANV MQAETWKKKS VHFSLFYYCV
 TWPALSWMIA INMK

The following DNA sequence nGPCR-Seq42 <SEQ ID NO. 31> was identified in *H. sapiens*:

CGCACAGCGC GCAGGTCCTC ACCAGAGCTC TGGTGGCCAC CTCTGTCCCG CCATGCTGCT
 CACCGACAGT GGCCAGGGCC CACAGCACCA AGAGGCTTGG GCCACAAAGT
 AAAGGGTCGC GGAGCCTCGC CGGCCGCCAT GTGGAGCTGC AGCTGGTTCA ACGGCACAGG
 GCTGGTGGAG GAGCTGCCTG CCTGCCAGGA CTGCGAGCTG GGGCTGTCAC TGTGTGCTG
 GCTGGGCCTG GTGGTGGGCG TGCCAGTGGG CCTGTGCTAC AACGCCCTGC TGGTGTGGC
 CAACCTACAC AGCAAGGCCA GCATGACCAT GCCGGACGTG TACTTTGTCA ACATGGCAGT
 GGCAGGCCTG GTGCTCAGCG CCCTGGCCCC TGTGCACCTG CTCGGCCCCC CGAGCTCCCC
 GTGGGCGCTG TGGAGTGTGG GCGGCGAAGT CCACGTGGCA CTGCAGATCC CCTCAATGT
 GTCCTCACTG GTGGCCATGT ACTCCACCGC CCTGTGAGC CTCGACCACT ACATCGAGCG
 TGCATGCGCG CGGACCTACATGGCCAGCGT GTACAACACG CGGCACGTGT GCGGCTTCGT
 GTGGGGTGGC GCGTGTCTGA CCAGCTTCTC CTCGCTGCTC TTCTACATCT GCAGCCATGT
 GTCCACCCGC GCGCTAGAGT GCGCCAAGAT GCAGAACGCA GAAGCTGCCG ACGCCACGCT
 GGTGTTTCATC GGCTACGTGG TGCCAGCACT GGCCACCCTC TACGCGCTGG TGCTACTCTC
 CCGCGTCCGC AGGGAGGACA CGCCCCTGGA CCGGGACACG GGCCGGCTGG AGCCCTCGGC
 ACACAGGCTG CTGGTGGCCA CCGTGTGCAC GCAGTTTGGG CTCTGGACGC CACACTATCT
 GATCCTGCTG GGGCACACGG GCATCATCTC GCGAGGGAAG CCCGTGGACG CACACTACCT
 GGGGCTACTG CACTTTGTGA AGGATTTCTC CAAACTCCTG GCCTTCTCCA GCAGCTTTGT
 GACACCACTT CTCTACCGCT ACATGAACCA GAGCTTCCCC AGCAAGCTCC AACGGCTGAT
 GAAAAAGCTG CCCTGCGGGG ACCGGCAGT CTCCCCGGAC CACATGGGGG TGCAGCAGGT
 GCTGGCGTAG GCGGCCAGC CCTCCTGGGG AGACGTGACT CTGGTGGACG CAGAGCACTT
 AGTTACCCTG GACGCTCCCC ACATCCTTCC AGAAGGAGAC GAGCTGCTGG AAGAGAAGCA
 GGAGGGGTGT TTTTCTTGAA GTTTCCTTTT TCCACAAAT GCCACTCTTG GGCCAAGGCT
 GTGGTCCCCG TGGCTGGCAT CTGGCTTGAG TCTCCCCGAG GCCTGTGCGT CTCCCAAACA
 CGCAGCTCAA GGTCCACATC CGCAAAAGCC TCCTCGCCTT CAGCCTCTC AGCATTCACT
 TTGTCAATGA AGTGATGAAA GCTTAGAGCC AGTATTTATA CTTGTGGTT AAAATACTTG
 ATTCCCCCTT GTTTGTTTAA CAAAAACAGA TGTTTCCTAG AAAAATGACA AATAGTAAAA
 TGAACAAAAC CCTACGAAAG AATGGCAACA GCCAGGGTGG CCGGGCCCTG CCAGTGGGCG
 GCGTGTGCTA GCAAGGCCCTG CCGGGTGTGC CGCAGTCACC ACAGGGTTCT GAGAACATTT
 CACAGAAGTG CCTGAGACGC GGAGACATGG CTGGTGTTAA ATGAGACTAT TCAATAGCAG
 TGACGCGCTC TCCTCAGCCA

The following amino acid sequence <SEQ ID NO. 91> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 31:

MWSC SWFNGTGLVE ELPACQDLQL GLSLLSLLGL VVGVPVGLCY NALLVLNLH
 SKASMTMPDV YFVNMAVAGL VLSALAPVHL LGPPSSRWAL WSVGGEVHVA LQIPFNVSSL
 VAMYSTALLS LDHYIERALP RTYMASVYNT RHVCGFVWGG ALLTSFSSLL FYICSHVSTR
 ALECAKMQNA EAADATLVFI GYVVPALATL YALVLLSRVR REDTPLDRDT GRLEPSAHLR
 LVATVCTQFG LWTPHYLL L GHTGIISRGK PVDAYHLGLL HFVKDFSKLL AFSSSFVTPL
 LYRYMNQSF P SKLQRLMKKL PCGDRHCSPD HMGVQVLA

The following DNA sequence nGPCR-Seq44 <SEQ ID NO. 32> was identified in *H. sapiens*:

CCACAAGACAGTGCCATTTAGTGGCAGCCCTAGGATAAAGATGATACTGTAGGCCAGGGA
 GAGGTAGACTTGCTTGTAATCTCTGAGAACTGGCAGAGACCTTGTTCTGTGATGTATT
 CATGTCCACCTTCTCCATGTCCCGGGAGGCTCCCTCCAGGAGCAGAGCTCCACGACGGCT
 CCCGCTTCTGCTTCCCCTGGAAGGAAGCAAAATGGACAGCATAACATCATGACCTCAGCA
 TGGCATCAGCCTCTGCCCCAACCCGGCATTCAACTTTGTCCCCCAAAGTCTAGTCAGAGG
 CCTTGTTTAAAAGAGACCAACCCAGGAAATAGAGTATTCAACAAGGGCCAAATAATCT
 TCCAAAGCTGGGCGTCTAGACTTACCAGGTCCAAAGGGTTGGCCTTACATGGACTTGTAT
 GCTGTCTACTCTAGGCTGGGTGTGATAGAAATGGTGGTGGGATGACACTGTCATTTAAA
 CAGGGTACTCAGAACCTCCAGCTCTGTGTCTCCTCTGCTAGAAATCCATTGCATAGAGTC
 AGAAAATCTCC

The following amino acid sequence <SEQ ID NO. 92> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 32:

TRLWGTLNA GLQRLMPC* GHDVMLSILL PSRGSRSRGR RGALLLEGAS
 RDMEKVDMNT SQEQGLCQFS EKYKQVYLSL AYSIIIFILGL PLNGTVLW

The following DNA sequence nGPCR-Seq45 <SEQ ID NO. 33> was identified in *H. sapiens*:

CATCCTAAGCTCGGGCACACAAAGTCCCAGAGGCACACAGATTCAGTGGCTTGGGGATAG
 CATATTCAACTCTTGGGCCCCTAACTCAAAATCCCCAACACCCTCAGTCACCTGTGGC
 TCCAGTCTGTGTTTGGTTTTCACAGATCACAAGGCATCAAGGAAGAGGCTCACGGTAA
 GCCTGGCCTACCGGAGAGGCCACCATCCGCGTGTCCAGCAGGACTTCCGGCTCTTCC
 GCACCCTCTTCCTTCTAATGGTCTCCTTCTTCATCATGTGGAGCCCCATCATATTACCA
 TCCTCCTAATCCTGATCCAGAACTCAAGCAAGACCTGGTCATCTGGCCGTCCCTCTTCT
 TCTGGGTGGTGGGCTTCACATTTGCTAATTCAGCCCTAAACCCCATCCTCTACAACATGACACT
 GT

The following amino acid sequence <SEQ ID NO. 93> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 33:

S*ARAHK VPEAHRFSGL GIAYNSWAP NSKSPTTLISH LWLQSCFGFP QITKASRKRL
 TVSLAYSESH QIRVSQDQFR LFRTLFLLMV SFFIMWSPII ITILLILIQN FKQDLVIWPS
LEFWVVGFTF ANSALNPILY NMTL

The following DNA sequence nGPCR-Seq46 <SEQ ID NO. 34> was identified in *H. sapiens*:

GCTGGGAAGTGCTCCTGGTGCAGCCGGCGGTAGATGGCGGAGGGGCACGGTGAGCAGCAAG
 GCCAGTGTCCAGGCTGCCCCACAGGCCACCTGCACCCCGCAGCCCGCTGAACCGTATAC
 CACCAGGCAGGCCGAGAGCCAGGAAGCAGAGGTGCGCACTGAGAGCTGCCAGGAGCAGG
 ACGCTGGCATAATGGTGCAGCAGGATGATGGAGGGCAGCGCCGACAGCCCACTGCACCA
 TACGGTCAGTGGCCTCCACGGGCAATGGGCACTGCCAGGATGGGCAGAGACAAACAGCAC
 AGCAAATCCGCCACGGCCAGGTGGAGCAACCAGGTGGCACCCACCCTCCGGCGGGCCACC
 TTCCAGCCACCCAGGCCACCATGGCATTGCCCGGCACCCCAACAGGAAGATGGCGGCA
 TACAGTGGGAGCGGGGCCACGCGCAGCGGGTCGATGGCCAGGCAGGCGCCATCCAGGCAG
 TCCACAGGGCGGTCCGAGAGGTGCGTGTAAATCCCCATACTCGTAGCTGACAGAATCG

The following amino acid sequence <SEQ ID NO. 94> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 34:

DSVSYE YGDYSDLSR PVDCLDGACL AIDPLRVAPL PLYAAIFLVG VPGNAMVAWV
 AGKVARRRVG ATWLLHLAVA DLCLLSLPI LAVPIARGGH *PYGAVGCRA LPSIILLTMY
ASVLLLAALS ADLCFLALGPAWWYTVQRAC GVQVACGAAW TLALLTVPS AIYRRLHQEH FP

The following DNA sequence nGPCR-Seq47 <SEQ ID NO. 35> was identified in *H. sapiens*:

GGCTCCACTGGCCTTTCGGCAAGGGGCTCTGCAGGCTGACGGCGTTTGTGCTCTACACCG
 ACACCTACGGGGGGTCTACCTCATGGCCTGTGTGAGCGTGGACCATACCCAGCTGTGGT
 CTGTGCCCACTGGGGCCCGTGCTCCGCACGGCTGGCCGCGCCAGGCTGGTCTGCGTGGC

CATCTGGACCTTGGTGCTGCTGCAGACGATGCCCTTGCTCTTGATGCCCATGACCAAGCC
 GCTGGTGGGCAAGCTGGCCTGCATGGAGTACAGCAGCATGGAGTCAGTCCTCGGGGCTGC
 CCCTCATGGTCCTGGTGGCCTTTGCCATTGGCTTCTGTGGGCCAGTGGGGATCATCTGT
 CCTGCTATATGAAGATCACCTGGAAGCTGTGCAGCACAGCTGGGAGAACCCAGTGACCAG
 CGGAAAAGGACACCACCGGCGGGCAGCCCGGGAGGACCCAGTGACCAGCAGGAAAGGAC
 GCCACCGGCGGGGACGCCAGGAGGACCCAGTGACCAGCGGGAAAGGACACCACCG

The following amino acid sequence <SEQ ID NO. 95> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 35:

AP LAFRQALQA DGVCALHRHLR GVYLMACVS VDHYPVVCA HWGPCLRTAG
 RARLVCVAIW TLVLLQTMPL LLMPMTKPLV GKLACMEYSS MESVLGAAPH GPGGLCHWLL
 WASGDHPVLLYEDHLEAVQH SWENPVTSGK GHHRGSPGG PSDQQERTPP AGQPRRTQ*P
 AGKDTT

The following DNA sequence nGPCR-Seq48 <SEQ ID NO. 36> was identified in *H. sapiens*:

GAGGCAGGCT GCAGGGAAAGT AAGGAGGAGG CATGGCACCT TCTCATCGGG CATCACAGGT
 GGGGTTTTGC CCCACCCCTG AACGCCTCT GTGGCGCCTT CCACCCACCT GTAGGCCAG
 AAGGATGTCG GTCTGTACC GTCCCCAGG GAACGAGACA CTGCTGAGCT GGAAGACTTC
 GCGGGCCACA GGCACAGCCT TCCTGCTGT GCGGGCGCTG CTGGGGCTGC CTGGCAACGG
 CTTCTGTGTG TGGAGCTTGG CCGGCTGGCG GCCTGCACGG GGGCGACCGC TGGCGGCCAC
 GCTTGTGCTG CACCTGGCGC TGGCCGACG CGCGGTGCTG CTGCTACGC CGCTCTTGT
 GGCCTTCTG ACCCGGCAGG CCTGGCCGCT GGGCCAGGCG GGCTGCAAGG CGGTGTACTA
 CGTGTGCGCG CTCAGCATGT ACGCCAGCGT GCTGCTACC GGCCTGCTCA GCCTGCAGCG
 CTGCCTCGCA GTCACCCGCC CCTTCTTGGC GCCTCGGCTG CGCAGCCCGG CCCTGGCCCC
 CCGCTGCTG CTGGCGGTCT GGCTGGCCGC CCGTGTGCTC GCCGTCCCG CCGCCGTCTA
 CCGCCACCTG TGGAGGGACC GCGTATGCCA GCTGTGCCAC CCGTCGCCGG TCCACGCCGC
 CGCCACCTG AGCCTGGAGA CTCTGACCG TTTCTGTCTT CCTTTCGGG TGATGCTCGG
 CTGTACAGC GTGACGCTGG CACGGCTGCG GGGCGCCCG TGGGGTCCG GGCAGCACGG
 GGCAGGGGTG GGCCGGCTGG TGAGCGCCAT CGTGCTTGCC TTCGGCTTGC TCTGGGCCCC
 CTACCACGCA GTCAACCTT TGCAGGCGGT CGCAGCGCTG GCTCCACCGG AAGGGGCCTT
 GGCGAAGCTG GGCGGAGCCG GCCAGGCGGC GCGAGCGGGA ACTACGGCCT TGGCCTTCTT
 CAGTTCTAGC GTCAACCCCG TGCTCTACGT CTTACCGCT GGAGATCTGC TGCCCCGGGC
 AGGTCCCCGT TTCCTACGC GGCTCTTCA AGGCTCTGGG GAGGCCCGAG GGGGCGGCCG
 CTCTAGGGA GGGACCATGG AGTCCGAAC TACCCCTCAG CTGAAAGTGG TGGGGCAGGG
 CCGCGGCAAT GGAGACCCGG GGGGTGGGAT GGAGAAGGAC GGTCCGGAAT GGACCTTTG
 ACAGCAGACC CTACAACCTG CTGCCCTTC CTGCTTTC CCACCCCCACCCACCTCC
 AGAGGTCAGT GTTCTGGGAC ATTTGGGGAC CTTCTTTGA CTAGAGTTG GATCTGGCTG
 GGTAGGATTA CTATACACTT GGGGCAGGCC CAGGCTCCTC CAACTGAGG GATTATGAGG
 GTGGTGATGG TCCCTGTAA GGAATATTGT GTGCTTGCAA GTTGGCATGT ACCCATGTGC
 CAGCATTGCT

The following amino acid sequence <SEQ ID NO. 96> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 36:

MS VCYPGNET LLSWKTSRAT GTAFLLLAAL LGLPGNGFVV WSLAGWRPAR GRPLAATLVL
 HLAALADGAVL LLTPLFVAF TRQAWPLGQA GCKAVYYVCA LSMYASVLLT GLLSLQRCLA
 VTRPFLAPRL RSPALARRLL LAVWLAALL AVPAAYRHL WRDRVCQLCH PSPVHAAHL
 SLETLTAFVL PFGLMLGCYS VTLARLRGAR WSGRHRGARV GRLVSAIVLA FGLWAPYHA
 VNLLQAVAAL APPEALAKL GGAGQAARAG TTAFFSS VNPVLYVFTA GDLLPRAGPR
 FLTRLFEGSG EARGGGRSRE GTMELRTTPQ LKVVQGGRNGDPGGGMEKD GPEWDL

The following DNA sequence nGPCR-Seq49 <SEQ ID NO. 37> was identified in *H. sapiens*:

CCAGCCGTCCAGGCGACGCGGGCCAGCACCAGGAACCAGGTGACGCTGGCCACGTGGTAG
 CGCGGGCAGACCAGGGGGCAGCGCTGTTGCGCAGCAGGCCGAGGCGTTGGCGGGCAGC
 GGCACGGCCGCGCAGGGTCCGCGGTCCACACAGGGCGCAGAGGACGGCCGAGGCGTGTCTG
 GGCCGGCAGCCCTGGTAGCAGGCGGGGAAGAGGTGCGAGAGGCAGCGCTCCACGCTGAAG
 GCCGCCAGCAGCCAGAGCCCCACCGGAACCACAGGAAGGTGAGCACGAAGTAGAGTGTG

TCCTGGGCGCCAGGGCAGCCTGAGCCACGGAGAAGCCACACGGCAGGAGAGGAACAGG
AAGTCGGCGGCGGCCAGGTGCAGCAGGTAGATGGAGAAGGGGCCCTTCTTGATGCGGAAG
CCGAGGTTCCAGAGCACCAGCCGTTACCTACCGGTCCCCGAGGCCACGATCAGCGTC
AGGTAGAAGACCACACTGTGGAAGGTTCTCCAGAGGCCGAACAGCCAAACATCCTGGCC
GGCTCAGAGGGTGCTGGCGAGGGACCTGCAAGATGGAGACAGACATGGTCCTCAGGAGTC
TTTTGTGCCCCCGCTGGGGGCACAGGGAGTGGCAT

The following amino acid sequence <SEQ ID NO. 97> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 37:

MPLPVPP AGAQKTPEDH VCLHLAGPSP APSEPARMFG LFGLWRTFDS VVFYLLIVG
LGGPVGNGLV L WNLGFRIKK GPFYIYLLHL AAADFLFLSC RVGFSVAQAA LGAQDTLYFV
LTLFWFAVGL WLLAAFSV ER CLSDLFPACY QGCRPRHASA VLCALVWTPT LPAVPLPA NA
CGLLRNSACP LVCPRYHVAS VTWFLVLARV AWT

The following DNA sequence nGPCR-Seq50 <SEQ ID NO. 38> was identified in *H. sapiens*:

ATGTCTACAGAAACCCCTTCGCCATCTACCTCCTGGTACGTGGCCTGCAGCAGGATCTCA
TCTTCCTTGGCTGCCACATGGTGGCCATCGTCCCCGACTTGCTGCAAGGCCGGCTGGACT
TCCCGGGCTTCGTGCAGACCAGCCTGGCAACGCTGCGCTTCTTCTGCTACATCGTGGGCC
TGAGTCTCCTGGCGGCCGTCAGCGTGGAGCAGTGCCTGGCCGCCCTCTTCCCAGCCTGGT
ACTCGTGGCGCCGCCACGCCACCTGACCACCTGTGTGTGCGCCCTCACCTGGGCCCTTT
GCCTGCTGCTGCACCTGCTGCTCAGCAGCGCCTGCACCCAGTTCTTCGGGGAGCCAGCC
GCCACTTGTGCCGACGCTGTGGCTGGTGGCAGCGGTGCTGCTGGCTCTGCTGTGTTGCA
CCATGTGTGGGGCCAGCCTTATGCTGCTGCTGCGGGTGGAGCGAGGCCCCAGCGGCCCC
CACCCCGGGCTTCCCTGGGCTCATCCTTCCTCACCGTCTCTCTTCTCTTCTGCGGC
CTGCCCTTCGGCATCTACTGGCTG

The following amino acid sequence <SEQ ID NO. 98> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 38:

VYRNP FAIYLLVRGL QQDLIFLGCH MVAIVPDLQ GRLDPPGFVQ TSLATLRFEC
YIVGLSLLAA VSVEQCLAA FPAWYSCRPP RHLTTCVCL TWALCLLLHL LLSSACTQFF
GEPSRHLCRT LWLVAAVLLA LLCCTMCGAS LMLLLRVERG PQRPPPRGFP GLILPHRPPL
PLLRPALRHL LA

The following DNA sequence nGPCR-Seq51 <SEQ ID NO. 39> was identified in *H. sapiens*:

AAGGTTCTAGGAACACATTGCCCATATTTCTATGGTTGTTTATACCCTGTCTATCTGA
ATGTTTCCTCTGCAGCTGCAATCCCAGTGTACCAAAACAGAGAAGTGATGAAGTTGACAA
AGATGGTGTCTGGTGTGGTGGTGTCTTTATCCTGAGTGTGCCCCCTTATCATGTGATAC
AACTGGTGAACCTACAGATGGAACAGCCACACTGGCCTTCTATGTGGGTTATTACCTCT
CCATCTGTCTCAGCTATGCCAGCAGCAGCATTAACCCCTTCTCTACATCCTGCTGAGTG
GAAATTTCCAGAAACGTCTGCCTCAAATCCAAAGAAGAGCGACTGAGAAGGAAATCAACA
ATATGGGAAACACTCTGAAATCACACTTTTAGGAAAGTACATGGATCACCATGAGTCTAG
ACATGATTGTCTATCTTACTGGTATTATTAGAAAGGGCAGGTGTACCGATATGTTTATGC
CCATTCTTCTTGTGTAAGTGTGACTCTTAGCAGCATGGAAGAGAAGTGTAACCATGCAAA
TACAATGAGCTTAATATGCTAACTTTAGCAAGATGTAAAATGTTGATCTATATTGTGGGT
AGGGAATGGGATAGTCTGAGATACCCAGGCTTCATGATGGTGTATATTATTCAGCATAT
TATAAAGTAGTCACTAATG

The following amino acid sequence <SEQ ID NO. 99> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 39:

GSNTLPH NFYGLYPVY LNVSSAAAP VYQNVEMKL TKMVLVLVVV FILSAAPYHV
IQLVNLQMEQ PTLAFYVGY LSLCLSYASS SINFLYILL SGNFQKRLPQ IORRATEKEI
NNMGNLTKSH F*ESTWITMS LDMIVYLTGI IRKGRCTDMF MPILLVYL*L LAAWKRSVTM
QIQ*A*YANF SKM*NVDLYC G*GMG*SEIP RLHDGVVYFS IL*TSH*

The following DNA sequence nGPCR-Seq52 <SEQ ID NO. 40> was identified in *H. sapiens*:

CAATTTTCTATTGCCTCTCTGGCCTGTGCTGACTTCTTGGTAGGTGTGACTGTGATGCTT
TTCAGCATGGTCAGGACGGTGGAGAGCTGCTGGTATTTTGGAGCCAAATTTTGTACTCTT
CACAGTTGCTGTGATGTGGCATTCTTGTACTCTTCTGTCTCCACTTGTGCTTCATCTGC
ATCGACAGGTACATTGTGGTTACTGATCCCCTGGTCTATGCTACCAAGTTCACCGTGTCT
GTGTCGGGAATTTGCATCAGCGTGTCTGGATTCTGCCTCTCACGTACAGCGGTGCTGTG
TTCTACACAGGTGTCAATGATGATGGGCTGGAGGAATTAGTAAGTGCTCTCAACTGCGTA
GGTGGCTGTCAAATTATTGTAAGTCAAGGCTGGGTGTGATAGATTTTCTGTATTCTTC
ATACCTACCCTTGTTATGATAATCTTTACAGTAAGATTTTCTTATAGCTAAACAACAA
GCTATAAAAATTGAACTACTAGTAGCAAAGTAGAATCATCCTCAGAGAGTTATAAAATCAG
AG

The following amino acid sequence <SEQ ID NO. 100> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 40:

QFSIASLACA DFLVGVTVM LFSMVRTVESC WYFGAKFCTL HSCCDVAF CYSSVLHLCFIC
IDRYIVTDP LVYATKFTVS VSGICISVSW ILPLTY SGAV FYTGVNDDGL EELVSALNCV
GGCQII VSQG WVLIDFLFF IPTLVMHLY SKIFLIAKQQ AIKIETSSK VESSSES YKI R

The following DNA sequence nGPCR-Seq2021 <SEQ ID NO. 41> was identified in *H. sapiens*:

ATTATTCATTCCTTTAGACATTAAACATTCATTGAGCACCTGCTGTATGCAAAGCACTGG
GCACCCACACTAAGGATGAAAACCAAGGATAAGTAAGACAGCATGTAGATTCTAGCTGCC
TGGTTGAGAGGTTACAGTCAGAAAAGTCCTTATAGCCATTGAGTACATACAGATAGGGAT
AGGAGAGGAAATGGGGTGAGCACAGGGAAGGGATAAGTATAGGGTCAGGGCTACCACCTT
TCTTTTCCCCATGACCCCATGGGGGCAAATATGTCCTGTCTCTTCTGGGTGGGTGATGT
TCACTGCCCTTTCTCCATTCCAATTGGAACCTCTAGATTGAGCCCCGAAGCTAGACTTGC
AGATCACAATTTTAAGAAAAGTTGGATGTTCTGCAACAGGTTACACAGGAGCTATCATTGA
GTCATCTTTTCGTTACCCCAATCATTTATTCATTTCATTCAACAAGTATTTCCCAAG
CACCAATTCATCCTCAACAAAAGACTCCTAAATCACAGGCCAGATGAAAGACGTCACCTA
TTCATTGGAAAAATTCAGCTGATTATGATCCTGGTCGGAGTGTA CTACAGCGTCC

The following amino acid sequence <SEQ ID NO. 101> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 41:

YSFL *TLNIH*APA VCKALGTHTK DENQG*VRQH VDSSCLVERL QSESPYSHSV
TYR *G*ERKW GEHREGISIG SGLPPFFSP* PHGGKYVLSL PGWVMFTA PF
SIPIGTSRLS PKLDLQITL RKLDVLQQVT QELSLSHLFV HPIIYSFIHS
TSISQAPIPS STKDS*ITGQ MKDVTHLEK FS*L*SWSEC TQR

The following DNA sequence nGPCR-Seq2022 <SEQ ID NO. 42> was identified in *H. sapiens*:

ATGGAATTAGAAAAATGAGAAAGTAATCAAAGATTGTA AAAAATACTGAGATAGAATTAA
AAGGAATAAAAAATTTGTAATCAAATATGTAATCTTTTAAAGTTGACACATTGTAATT
TTATATATTTGTGGAGTATGATTTGGTACATTAATTTGTATATGTGTTGTATGCTGATCA
AATCAGGGTATGTACTAGGCCATTTTGCATTGGTATAAAGAAATACCTGAAGCTGGGTA
ATTTAAAGAAAAGAAGTTATTTGACTCATGGTTCTATAGGCTGTGAACAACATCTGCTT
GGCTTCTGGTGGGAGCCTCGGAAAGCTTTCAATAGTGGCAGAAGGGGAAGGGGAAGCTGG
AGTATCACATGGTGTGAAAGGGAGCAAGAGAGAGAGAGAGAGACAGGAGGTCTAGACTT
TTAAACAACAGATCTTGTGTGAACATTTTCATGTGACTAAGAACTCATTTCATCACCAG
CGGAAGGTGCCAAGTCATTGAGGATCCACCCTCATAATACACTACCTTCCACCAAG
TCTCACTTACAACATTGGGAATGACATTTACGATAAGATTTGGAGAGGACAAAATGTCCA
AACTATATCAGGGTAGTTAGCTCATTTCATCACCTCATGTCTTTATCATTTC

The following amino acid sequence <SEQ ID NO. 102> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 42:

NDKDMR** MS*LP*YSLD ICPLQILC*N VIPNVVSETW WKVVYYEGGS LMNDLAPSAW
**MSS*SHEI VHTRSGCLKV *DLLSLSLSL APFHTM*YSS FPFPFCHY*K LSEAPTRSQA

DVVHSL*NHE SNKLLFFKLP SFRYFFIPMQ KWPSTYPDLI SIQHIYKLMY
 QILHKYIKL QCVNLKRITY LIYKFFIPFN SISVFFTFD YFLIFLIP

The following DNA sequence nGPCR-Seq72 <SEQ ID NO. 43> was identified in *H. sapiens*:

ATGTAAAGGGCCTTTTGAAGAAAACCTGTAACTCCACTGTGGGGCCATTAAAGAAGTCT
 TGAATACATAGATTAAATCCCTTGGTTTGAGATAATAAACTCTCAATATTTACCATGCT
 TTTGTCATTTAAATACAAATTGTGGACATTTTTACCAGGGCAACAGATGAGTTACAACCA
 TCCTTTTATCAGTTGCACAGAATCTTATTGAATGGGTATATCCTACTTATGTCAGTTCTT
 AGTAGTGAATATTAGGTTGTTTCTAATTTTTCCATATTAGAAAACATGTTAAAAGAAGTCT
 GCTCTTATTTGTGTTTCTTATGTCTACACTAGTATTCAATACCTTTCTAGGAGTGGAAAT
 TCCTGGCTCAAAACAACTGCCTTCCAAGAAGATTACTAATATACATTCTACTAATGCT
 GTTTTAGAATGCCTTTTTCTCCATATTCCTATGAACACTGAGTGTTCTCTTTTAAACACT
 TTTTTCCTCAATCTACTAGACTCCTTCTAAAAATATATACTTTTCAAAACGCCTGCTTAC
 CCTTCAATATATTGTCTTTTAAAGATTATTTGTAGGTACTGTTTATGTGTTAGGTTGGT
 GGAAAATTAATTGTGATTTTGCAAAAACCTGCAATTACTTTTGCACCAACCTAATTATACAT
 GTAGA

The following amino acid sequence <SEQ ID NO. 103> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 43:

M*RAFWKKTV NSTVGPLKKS *HRLNPLV* DNKTLNIYHA FVI*IQIVDI FTRATDELQP
 SFYQLHRILL NGYILLMSVL SSEY*VVS NF SILETMLKEL ALICVSYVYT SIQYLSRSGN
 SWLKQTAFAQE DLLIYIPTNA VLECLFLHIP MNTECSLFNT FFPQSTRLLL KYILFKTPAY
 PSYCLLDY L*VLFMC*VG GKLIVLQKL QLLHQPNII HV

The following DNA sequence nGPCR-Seq2024 <SEQ ID NO. 44> was identified in *H. sapiens*:

TCTCTTTTGGTTCCCTTTTTCTCCTCATTACCTACCTCTTCTCCTTTGCTGGTCCCTCACA
 TCTTCCTGGCCTCTTCTTTGTCTGCATTTACTTGTGTGGTCTTCCGTCTTTAACACATCT
 ACCCATCAGCTACTCCCAAATGTATATATCTATTCCCGGACCTTTCCTCTGAACCTCCAGA
 TTTGTATTTCCAACTACCTACTCAATAGTACCTTCTTGATATTTATTAATAATTTGAATC
 ACGACATGCCTAAAATTGAACCTCCTATCTCTGAAGCAAAGCCCTATCCTTCTATTGTTT
 TTCCCATCCCAATAAATTGCCACTCATTCTCCAGATGCTTGGGCAACATTTTGCAGTC
 ATCTTTGATTTCTTCTTTCTTTGATATCCACATACATTACACGACATATGCTGCCCTG
 TCTACATTTTAAACATAACCAGCATCCAACATTTCTACAATTGCTACTAGCCTTGATAG
 CCCTATCCTCTCTCCTCTGGATTACTGTATTAGCCTCTGAAGTGGGATCCCGCTTCAACC
 CTTTCCAACCTCCTCCTCCCAAAGCCAACCTCTGTGAACAGCAGCTAAAGTTGTTCTTTCA
 AAAA

The following amino acid sequence <SEQ ID NO. 104> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 44:

LFWFPPFLI TYLFSFAGPS HLPGLFFVCI YLCGLPSLTH LPISYSQMYI SIPGPFL*TP
 DLYFQLPTQ* YLLGYLLKFE SRHA*N*TSY L*SKALSFYC FSHPNKLPLI LPDAWATFLQ
 SSLISFFL*Y PTYIHHMLP CLHFKHNQHP TFLQLLALY SPILSPLDYC ISL*TGIPLO
 PFPTSSSQSQ LCEQQLKLF QK

The following DNA sequence nGPCR-Seq2025 <SEQ ID NO. 45> was identified in *H. sapiens*:

CAACCCTGGTAAAGCATCGCACCTTGGGTTATGTACCTCAGGGTATTTGACGCACTGGG
 CTAAAATGTTGAAGGACATCCTGTTTCCAGGTGGGGACTGGAACAGAGCCTGGACTGTTT
 TAGCCAATGGCTCCTTACCTCAGGATGTTGCATTCCAGCACATTCTGGTTGGTGTGAG
 AACTACAAACAAGAAAGTGGGAAGAACTGTTCTGCACCATTTATGTAACTTCTAGGAAA
 GCAAACATAATGTATTGTGACAGAAGGAAGATGAGTGATTGCTTAAACACAAGGGAGGAAT
 GCTACACAGGGAAGGTCTGGAGAGTTGGATTACAAAGAGAGACAAGGACACTTTTGGGAG
 AGATGGATATGTTTATTATCTTGTCTATGGTGATAGTTTCATAGGTCCATAAATCCCAAA
 AGCATCTCATTGTACACTAACTATGTATGATTTATTTATTAATTATACCTCAATAAAG
 TTGTTTTTTAAAAAGTTACCACTTAATCCTGTAAATAGACCAGGAAGGCAATTAATTAA

TATTTTCTAGTTTACTTTTGAGAACTAAAGCTTAGTA

The following amino acid sequence <SEQ ID NO. 105> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 45:

NP GKASHL GLCTSGLFDA LG*NVEGHPV SRWGLEQSLD CFSQWLLTSG CCIPSTFWLV
LRTTNKKVGR TVLHHLCKLL GKQTNVL*QK EDE*LLKHKG GMLHREGLES WTKRDKDTF
GRDGYVYYLA YGDSFIGP*I PKASHCTLM YDLFILIPQ *SCFLKKLPL NPVNRPRQL
INIF*FTFEK LKLS

The following DNA sequence nGPCR-Seq2026 <SEQ ID NO. 46> was identified in *H. sapiens*:

AGTTTATGGACCAGCCTTCCCTGTGAAATTTGACTTTTCCCTCTTTGCTGAATTGGTCAG
GTTAACAATGGTTACCCCTGGATTACAGGAAGGGCATGTGCTAAAAGCCTCTTTGGAGAC
CCACATGGCCCTCAGATGAGCAATTGTTTCAGATTCCTTTTCTTTTCTTTTCCATGGGAA
TAAGCTTTCCCTCTCTCCAAAGTACATGTTTTAGGCTTTTTTATTTTCTTGCTACTCCCAA
GGACCTGGTGATATTTTTCTTTACCATGCATTAAACAGAATCTGTGAGTCTTTTCTGGAA
AAAAAAGGAGGAGGGAACATACTAGTTAAAAAGTTTCTGGGTACACTACCAAGATGT
ACCTATTTATTGATATACAAATGGCATAAGTTATTGAATGCTTGCTATAGGCATTCTCTA
AGAACTTTGTAAGAATTGACTTACATGAGCTACTTCATAGCAGTTCGATGATATACATGT
TGTTATTATCACCACITTACAGATAAGGAAATAGAGACAGACATACTGAATGACATGCTC
AACGCCACTCCACTAGCAAGTGGCAGAACCCAAGC

The following amino acid sequence <SEQ ID NO. 106> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 46:

LG FCHL LVEWR*ACHS VCLSLFPYL* SGDNNNMYII ELL*SSSCKS ILTKFLENAY SKHSITYAIC
ISINRYILVV YPETF*LVCS LLPFFFPEKT HRFCLMHGKE KYHQVLGSSK KIKPKTKTCL
ERGLIPMEK KKKRNLNCS SEGHVGLQRG F*HMPFL*SR GNHC*PDQFS KEGKVKFHRE
GWSIN

The following DNA sequence nGPCR-Seq2027 <SEQ ID NO. 47> was identified in *H. sapiens*:

CGTGGCAGGTTGCACCAACTTTTAAACCCACAAGCAATTATGAGAGGTTTCAATTTCCCTTC
ACTCACAACAAACTGCATCTTATCACGTTTAAAGAAATCTTTGCCATTTTGCTGGGATT
AACTTGCTCTCATTATTCTATATTTGCATTTCTAAGCTATTAAGCTGAATAATTTCCA
TATGGGCCATTTGTATTTGCAAAACAAACACTACCCCTTCAATGATTTTGCTGGCTTCT
GCCTTCACTAGTATTTATTGCCTCTTTAAACACTAAGTTAATAGTTTTATTGTTCTCT
TGTCAGCCTCCTCTGAAAATGATGACACTTTTCAAACAGTACCACATCTTTCTACTCATT
TCAGTTCAATGCTCATATAGGGCATTGTGCATACTGACTGTCCAAGCTGTGCACTAAGCA
GGTGAATCTTCCCTGCCCTTGGATCGAGTAATAACAGAACTTAAAGAAGGCTCCTGGGTA
GGAAAATCATGGGTACTGGTAACAGAGAGATATGGATTCAAATCCTGGCTTCTCTACTTA
CTCACTCAA

The following amino acid sequence <SEQ ID NO. 107> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 47:

VAGCTNF *THKQL *EVH FPSLTTKLHL ITF*EIFAIL LGLTCLSLFY ICISKLLSLN NFHMGHLYLQ
NKHYPFNDA WLLPSLVFIA SLKH*VNSFI CSFVSL *K* *HFSNSTTSF YSFQFNAHIG
HCAY*LSKLC TKQVNLPCPW IE**QNLKKA PG*ENHGYW* QRDMSNPGF STYSL

The following DNA sequence nGPCR-Seq2028 <SEQ ID NO. 48> was identified in *H. sapiens*:

ACACCAGGAACACACTTGGATGCCCATCGGCCCCAGGTTTCTTCTGCTGGTCCTGTCTGG
CCATGTGTTTGGGTTTGAAAGTGTCCAGATTGCCTGGTTCTCCTGGATCTTCACGCAAAA
GAAACGAGCACATGATGGTGACCTGGAACCTCTCCTCGCTGGCGTCACTGCATTTTTGCAA
AGCCTGTAACCTGCTGTCTGCATTCTGGGCTCCAAGGCTCAGTCTCTGATCTTTCTG
ACCTGTCTTCCCTAGGCTGCCTTCTCTTTTCTTATTACAGTAAAGTTCTGTATGT
ACTGCAGCATATTCCATTTATTGGGAATTGAATATATTTCTTCTATGCCAGGATTTAAAA

TTAGGATTGTTAATATTGTGGTTTGTGCTCTGGTTACAGAATTTCTAAGGTTTGGGTGTT
 CTATCCCAGCACCATATTTCTCAAAGCCTTGCTCTCTGCAGTGGGTGATTTTGCACAAT
 GCAAACCTTCTCAGGTACTTTCTCTGAGCTCCAGGTCCCATATCCAACATCTACTCAAC
 ATCTTATTCTGAGATGTTACCTCAAACATGTGAGAATCAACATGTCAACATGTCAATAC
 CTCTTGCAAGGATTTCTAACTCCACAGATGGTATCCGTCCAATTGTGCAAGCCAAGAGCA
 AGGCGCCAGCTGGGACGTTTCCCATACCCAATCTATCATCATGTCCCATTAATTTTACC
 AGTAGT

The following amino acid sequence <SEQ ID NO. 108> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 48:

TRNTLGC PSAPGFFCWS CLAMCLGLKV SRLPGSPGSS RKRNEHMMVT WNSPRWRHCI
 FAKPVTVLSA FWAPRLSPLI FPDLSFP*AA FLFLITVKF CMYCSIFHLL GIEYISSMPG
 FKIRIVNIVV CALVTEFLRF GCSIPAPYFL KALLSAVGDF AQCKLLRYFL LSSRSPYPTS
 TQHLILRCSP QTCENQHVNM SIPLAGFPNS TDGIRPIVQA KSKAPAGTFP IPNLSSCPIK FYQ*

The following DNA sequence nGPCR-Seq2029 <SEQ ID NO. 49> was identified in *H. sapiens*:

CACTTGAGAGGTGATCTCATCTATAAAGAGAGTATATTTAAGGAGCTAATTTACACAGGT
 AGATGACAAAACCTTACACCAACTCTTCAAGCACAGGAAGCACCTTACACGAAACATTT
 GGTGAATGCTCATTTCTACTCAATTTTAACTAAATTCAACTGAAAATACCTCATTTTAA
 AGAGGATATTCAAGTGTGACTCACTGGGGAAAAACAATTGGATAAACTGGTTGTTTGCCTT
 ACCGAGATAAAATCACTGATAAGTTGAATGCATTTTTTGAATGTGTCAAGACAGATGGCT
 TTAATAGTCACACATATTAAGTATGGGATATGTGGCGAGGAATAGAGGTTTTTATATACA
 GAAGTAAGAACTGTAGAGGGGGGAAACCATGAAAGATAGAAAAAGATGAGAAGAAAGAGG
 ACAGAGATGATACACTCAAGAAAAGCTGCCTATTTTCAGAGTAGAATATATTGTAAGCCCC
 AGTATAGTTGAATGCTTACAAGAGGAGAAGCTTTTAGCAACTCCTTTGTTTCTTAATGTA
 TATATTATATCTGAACAGAATGCTTCTTCTGTGAGCTAGACAGTAGGAAGTAATCTAT
 CTCAACCTTGTGTTGGTGTGTAAATAAACTTT

The following amino acid sequence <SEQ ID NO. 109> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 49:

KFYLHTKQ G*R*ITSYCL AHRKEAFCSD IYTLRNKGV AKSFSSCKHS TILGLTIYST
 LK*AAFLECI ISVLFLIFF YLSWFPPSTV LTSVYKNLYS SPHIPYLICV TIKAICLDTL
 QKCIQLISDF ISVRANNQFI QLFFPSESTE YPL*NEVFSV EFSLKLSRNE HSPKCFV*GA
 SCA*RVGVRF CHLPV*ISSL NILSL*MRSP LK

The following DNA sequence nGPCR-Seq2030 <SEQ ID NO. 50> was identified in *H. sapiens*:

GTGATACGGTTTCGGCTGTGTCCCCATCCAAATCTAATCTTGAATTACAGCTCCCATAAAT
 TCCATGTGTTGTGGAAGGGGCCTGGTGGGAGATAACCGAATCATGGGGGCGGCTCCCCC
 ATACTGTTCTCTTGGTAGTGAATAAGTCTCATAAGATCTGATCGTTTTATAAGGGGAAAC
 CCTTTTGTGTTGTTCTTATTCTCTCTTTGCTGGCTGCCATGTAAGATGCTTCTTTGCTC
 TTCCTTTGTGTTCTGCCATGACTGTGGGGCCTCTCCAGCCATGTGGAAATGTGAGGAAAT
 TAAACCTCTTTCCTTTATAAATTGCCAGTCTTGGGTATGTCTTTATCAGCAGTGTGAAA
 TGGACTAATAACACAGAAAGTTCAAGACTAGCTTGGGCAACACAGTAAGACCCTGTCTGTA
 TAAAGAAAGAATAAGAAAAAGAAAAATATCAGTGGCATAATATTAGACAGAATACTATAA
 AACTGATTAAGGCACATTAATATAGCCAGAATAATTATTCTGATTATATCATTTTGAAAG
 ACCAGATAATCAATATAACTGATTTTTATCCCAGTAGCTCAGACTTGCAAGCATGCACT
 ACCATACTTGGATAATT

The following amino acid sequence <SEQ ID NO. 110> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 50:

*YGS AVSPSKSNLE LQLP*FPCVV EGAWWEITES WGRLPYCSL GSE*VS*DLI VL*GETPFAW
 FLFSLCWLPC KMLLCSSFVF CHDCGASPAM WKCEEIKPLS FINCPVLGMS LSAV*NGLIH
 QKFKTSLGNT VRPCLYKERI RKRKISVA*Y *TEYYKTD*G TLI*PE*LF* LYHFERPDNQ
 YN*FLSRVAQ TCKHALPYLD N

The following DNA sequence nGPCR-Seq63 <SEQ ID NO. 51> was identified in *H. sapiens*:

CAGTGAGCCG AGATGGTGCC ATTGCACTCT AGCCTGGGGC AACAGAGCCA GACTCCATCT
 CCAAAAAAAAA AAGGCCATTC TGAGGATCAA GGCACCACTA GCAACAGGGA GCCCCATGGG
 TCTCAGACCC TCTCCCCACA TCTCTGGTC CCTGCCCCCA CCTGGCGTAC AGGGACCAGC
 CCCACGGAAG GCTCTTGAGG CCAGGTAACC ATGGGGAGGG GAGGAATGGG GACACCTTC
 TCCTGAGTGT CTTAGGGAAG AGAAGCTTAG GTCAGGTGGC TGAGGGTGGA AATGAGAGAG
 GGGTCTCCTC CTGGAGGGTC TCACCATTCC ETTGGTCACC CACCCAATC TCATCTCCCC
 TGATGTGGGG AGGAGCAGGG GGCATGGATT CCTGAGCCCC AGACTCAACT GTTGTGGTTT
 ACAGGGGCAT CAGGAGAGAG AGCGAGCAGA ACACACTCCT GCAGCATCCC CTGGCCCCC
 GCCCCATGAT GGAGCCCAGA GAAGCTGGAC AGCACGTGGG GGCCGCCAAC GGCGCCCAG
 AGGATGTGGC CTTCAACCTC ATCATCCTGT CCCTCACCGA GGGGCTCGGC CTCGGTGGGC
 TGCTGGGGA TGGGGCAGTC CTCTGGCTGC TCAGCTCAA TGTCTACAGA AACCCCTTCG
 CCATCTACCT CCTGGACGTG GCCTGCGCGG ATCTCATCTT CCTTGGCTGC CACATGGTGG
 CCATCGTCCC CGACTTGCTG CAAGGCCGGC TGGACTTCCC GGGCTTCGTG CAGACCAGCC
 TGGCAACGCT GCGCTTCTT TGCTACATCG TGGGCTGAG TCTCCTGGCG GCCGTACGG
 TGAGCAGTG CCTGGCCGCC CTCTCCCAG CCTGGTACTC GTGCCGCCG CCACGCCACC
 TGACCACCTG TGTGTGCGCC CTCACCTGGG CCCTCTGCCT GCTGCTGCAC CTGCTGCTCA
 GCGGCGCTG CACCCAGTTC TTCGGGGAGC CCAGCCGCCA CTTGTGCCGG ACGCTGTGGC
 TGGTGGCAGC GGTGCTGCTG GCTCTGCTGT GTTGACCAT GTGTGGGGCC AGCCTTATGC
 TGCTGCTGCG GGTGGAGCGA GGCCCCCAGC GGCCCCCACC CCGGGGCTTC CCTGGGCTCA
 TCCTCCTCAC CGTCCTCTC TCTCTTCT GCGGCTGCC CTTCCGCATC TACTGGCTGT
 CCCGGAACCT GCTCTGGTAC ATCCCCCACT ACTTCTACCA CTTACGCTTC CTCATGGCCG
 CCGTGCACTG CGCGGCCAAG CCGTCTGTCT ACTTCTGCCT GGGCAGTGCC CAGGGCCGCA
 GGCTGCCCCC CCGGCTGGTC CTCCAGCGAG CGCTGGGAGA CGAGGCTGAG CTGGGGGCCG
 TCAGGGAGAC CTCCCGCCGG GGCCTGGTGG ACATAGCAGC CTGAGCCCTG GGGCCCCCGA
 CCCCAGCTGC AGCCCCCGTG AGGCAAGAGG GTGACGTGGG GAAGGTGGTG GGTTCAGAGG
 CTGGGGCCAG CCGGACCTGG AGGAGGCCTT GGTGGGTGAC CCGGTCAATG TGTGTCAAAG
 TTGTGACCTT TGGTCTGGAG CATGAGGCTC CCCTGGGAGG CAGCTGGAAA GG

The following amino acid sequence <SEQ ID NO. 111> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 51:

MMEPREAGQHVGAANGAQEDVAFNLILSLTEGLGLGGLLNGNAVWL
 SNVYRNPFAYLLDVACADLIFLGCHMVAIVPDLLQGRDLDFPGFVQTS
 LTRFCYIVLGSLLAAVSVEQCLAALFPAWYSCRPRHLTTCVCALTWALC
 LLLHLLSGACTOFFGEPsrHLcRTLWLVAAVLLALLCCTMCGASLMLLL
 RVERGPQRPPPRGFPGLLLTVLLFLFCGLPFGIYWLSRNLWYIPHYFY
 HFSFLMAAVHCAAKPVVYFCLGSAQGRRLPLRLVLQRALGDEABLGA
 VRETSRRGLVDIAA

The following DNA sequence nGPCR-Seq70 <SEQ ID NO. 52> was identified in *H. sapiens*:

ATGACGTCCACCTGCACCAACAGCACGCGGAGAGTAACAGCAGCCACACGTGCATGCCC
 CTCTCCAAAATGCCCATCAGCCTGGCCACGGCATCATCCGCTCAACCGTGTGTTATC
 TTCTCGCCGCTCTTTCTGTCGGCAACATAGTGCTGGCGTAGTGTGTCAGCGCAAGCCG
 CAGCTGCTGCAGGTGACCAACCGTTTTATCTTTAACTCTCTGTCACCGACCTGCTGCAG
 ATTTGCTCGTGGCCCCCTGGGTGGTGGCCACCTCTGTGCCTCTCTTCTGGCCCCCTAAC
 AGCCACTTCTGCACGGCCCTGGTTAGCCTCACCCACCTGTTTCGCCTTCGCCAGCGTCAAC
 ACCATTGTCGTGGTGTGTCAGTGGATCGCTACTTGTCCATCATCCACCTCTCTCTACCCG
 TCCAAGATGACCCAGCGCCGCGGTTACCTGCTCCTCTATGGCACCTGGATTGTGGCCATC
 CTGCAGAGCACTCTCCACTCTACGGCTGGGGCCAGGCTGCCTTTGATGAGCGCAATGCT
 CTCTGCTCCATGATCTGGGGGGCCAGCCCCAGCTACACTATCTCAGCGTGGTGTCTTC
 ATCGTCATTCCACTGATTGTGTCATGATTGCCTGCTACTCCGTGGTGTCTGTGCAAGCCGG
 AGGCAGCATGCTCTGCTGTACAATGTCAAGAGACACAGCTTGGAAGTGCGAGTCAAGGAC
 TGTGTGGAGAATGAGGATGAAGAGGGAGCAGAGAAGAAGGAGGAGTTCAGGATGAGAGT
 GAGTTTCGCCGCCAGCATGAAGGTGAGGTCAAGGCCAAGGAGGGCAGAATGGAAGCCAAG
 GACGGCAGCCTGAAGGCCAAGGAAGGAAGCACGGGGACAGTGAGAGTAGTGTAGAGGCC
 AGGGGCAGCGAGGAGGTCAGAGAGAGCAGCACGGTGGCCAGCGACGGCAGCATGGAGGGT
 AAGGAAGGCAGCACCAAGTTGAGGAGAACAGCATGAAGGCAGACAAGGGTTCGACAGAG

GTCAACCACTGCAGCATTGACTTGGGTGAAGATGACATGGAGTTTGGTGAAGACGACATC
 AATTTCACTGAGGATGACGTCGAGGCAGTGAACATCCCGGAGAGCCTCCCACCCAGTCG
 CGTAACAGCAACAGCAACCTCTCTGCCCCAGGTGCTACCACTGCAAAGCTGCTAAAGTG
 ATCTTCATCATCATTTTCTCCTATGTGCTATCCCTGGGGCCCTACTGCTTTTATGCAGTC
 CTGGCCGTGTGGGTGGATGTCGAAACCCAGGTACCCCACTGGGTGATCACCATAATCATC
 TGGCTTTTCTCCTGCACTGCTGCATCCACCCCTATGTCTATGGCTACATGCACAAGACC
 ATTAAGAAGGAAATCCAGGACATGCTGAAGAAGTTCTTCTGCAAGGAAAAGCCCCGAAA
 GAAGATAGCCACCCAGACCTGCCCCGAACAGAGGGTGGGACTGAAGGCAAGATTGTCCCT
 TCCTACGATTCTGCTACTTTTCCTTGA

The following amino acid sequence <SEQ ID NO. 112> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 52:

MTSTCTNSTRESNSSHTCMPLSKMPISLAHGHIRSTVLVIFLAASFVGNIVLALVLQRKP
 QLLQVTNRIFNLLVTDLLQISLVAPWVAVTSVPLFWPLNSHFCTALVSLTHLFAFASVN
 TIVVVSVDRLYSIIHPLSYPSKMTQRRGYLLLYGTWIVAILQSTPPLYGWGQAAFDERNA
 LCSMIWGAASPSYITLSVVSFIVPLIVMIACYSVVFCAARRQHALLYNVKRHSLEVRVKD
 CVNEDEEGAEEKKEEFQDESEFRQHEGEVKAKEGRMEAKDGSLLAKEGSTGTSESSVEA
 RGSEEVRESSTVASDGSMEGKEGSTKVEENSMKADKGRTEVNQCSIDLGEDDMFEFGDDI
 NFESEDDVEAVNIPESLPPSRNSNSNPPLPRCYQCKAAKVIFIIISYVLSLGPYCFNAV
 LAVVWDVETQVPQWVITHIWLFFLQCCIHYPVYGYMHKTIKKEIQDMLKKFFCKEKKPPK
 EDSPDLPGTEGGTEGKIVPSYDSATFP

The following DNA sequence nGPCR-Seq63 <SEQ ID NO. 53> was identified in *H. sapiens*:

ATGAT GGAGCCCAGA GAAGCTGGAC AGCACGTGGG GGCCGCCAAC AGCGCCCAGG
 AGGATGTGGC CTTCACCTC ATCATCCTGT CCCTACCGA GGGGCTCGGC CTCGGTGGGC
 TGCTGGGGAA TGGGGCAGTC CTCTGGCTGC TCAGCTCCAA TGTCTACAGA AACCCTTCG
 CCATCTACCT CCTGGACGTG GCCTGCGCGG ATCTCATCTT CCTTGGCTGC CACATGGTGG
 CCATCGTCCC CGACTTGCTG CAAGGCCGGC TGGACTTCCC GGGCTTCGTG CAGACCAAGC
 TGGCAACGCT GCGCTTCTTC TGCTACATCG TGGGCCTGAG TCTCCTGGCG GCCGTACGCG
 TGGAGCAGTG CCTGGCCGCC CTCTTCCCAG CTTGGTACTC GTGCCGCCGC CCACGCCACC
 TGACCACCTG TGTGTGCGCC CTCACCTGGG CCCTCTGCCT GCTGCTGCAC CTGCTGCTCA
 GCGGCGCCTG CACCCAGTTC TTCGGGGAGC CCAGCCGCCA CTTGTGCCGG ACGCTGTGGC
 TGGTGGCAGC GGTGCTGCTG GCTCTGCTGT GTTGCAACCAT GTGTGGGGCC AGCCTTATGC
 TGCTGCTGCG GGTGGAGCGA GGCCCCCAGC GGCCCCCACC CCGGGGCTTC CCTGGGCTCA
 TCCTCTCAGC CGTCTCTCTC TTCCTCTTCT GCGGCCTGCC CTTCGGCATC TACTGGCTGT
 CCGGGAACCT GCTCTGGTAC ATCCCCCACT ACTTCTACCA CTTAGCTTC CTCATGGCCG
 CCGTGCACTG CGCGGCCAAG CCGTCTGTCT ACTTCTGCCT GGGCAGTGCC CAGGGCCGCA
 GGCTGCCCCC CCGGCTGGTC CTCCAGCGAG CGCTGGGAGA CGAGGCTGAG CTGGGGGCCG
 TCAGGGAGAC CTCCCGCCGG GGCCTGGTGG ACATAGCAGC CTGA

The following amino acid sequence <SEQ ID NO. 113> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 53:

MMEPREAGQHVGAAANSAQEDVAFNLILSLTEGLGLGGLLGNGLVWLLSSNVYR
 NPFAIYLLDVACADLIFLGCHMVAIVPDLQGRLDFFPGFVQTSLATLRFCTIVGL
 SLLAAVSVEQCLAALFPAWYSCRPRHLTTCVCALTWALCLLLHLLSGACTQFF
 GEPSRHLCRTLWLVAAVLLALLCCTMCGASLMLLLRVERGPQRPVPRGFPGLILL
 TVLLFLFCGLPFGIYWLNRLLWYIPHYFYHFSFLMAAVHCAAKPVVYFCLGSAQ
 GRRPLRLVLQRALGDEAELGAVRETSRRGLVDIAA

The following DNA sequence nGPCR-Seq42 <SEQ ID NO. 54> was identified in *H. sapiens*:

GGAGCCTCGC CGGCCGCCAT GTGGAGCTGC AGCTGGTTCA ACGGCACAGG GCTGGTGGAG
 GAGCTGCCTG CCTGCCAGGA CCTGCAGCTG GGGCTGTAC TGTGTGCTGCT GCTGGGCCTG
 GTGGTGGGCG TGCCAGTGGG CCTGTGCTAC AACGCCCTGC TGGTGTGGC CAACCTACAC
 AGCAAGGCCA GCATGACCAT GCCGGACGTG TACTTTGTCA ACATGGCAGT GGCAGGCCTG
 GTGCTCAGCG CCTGGCCCC TGTGCACCTG CTCGGCCCCC CGAGCTCCCG GTGGGCGCTG
 TGGAGTGTGG GCGGCGAAGT CCACGTGGCA CTGCAGATCC CCTTCAATGT GTCCTCACTG

GTGGCCATGT ACTCCACCGC CCTGCTGAGC CTCGACCACT ACATCGAGCG TGCAGTGCCG
 CGGACCTACA TGGCCAGCGT GTACAACACG CGGCACGTGT GCGGCTTCGT GTGGGGTGGC
 GCGCTGCTGA CCAGCTTCTC CTCGCTGCTC TTCTACATCT GCAGCCATGT GTCCACCCGC
 GCGTAGAGT GCGCCAAGAT GCAGAACGCA GAAGCTGCCG ACGCCACGCT GGTGTTTCATC
 GGCTACGTGG TGCCAGCACT GGCCACCCTC TACGCGCTGG TGCTACTCTC CCGCGTCCGC
 AGGGAGGACA CGCCCCTGGA CCGGGACACG GGCCGGCTGG AGCCCTCGGC ACACAGGCTG
 CTGGTGGCCA CCGTGTGCAC GCAGTTTGGG CTCTGGACGC CACACTATCT GATCCTGCTG
 GGGCACACGG TCATCATCTC GCGAGGGAAG CCCGTGGACG CACACTACCT GGGGCTACTG
 CACTTTGTGA AGGATTTCTC CAAACTCCTG GCCTTCTCCA GCAGCTTTGT GACACCACTT
 CTCTACCGCT ACATGAACCA GAGCTTCCCC AGCAAGCTCC AACGGCTGAT GAAAAAGCTG
 CCCTGCGGGG ACCGGCACTG CTCCCCGGAC CACATGGGGG TGCAGCAGGT GCTGGCGTAG
 GCGGCCCCAG CCTCCTGGGG AGACGTGACT CTGGTGGACG CAGAGCACTT AGTTACCCTG
 GACGCTCCCC ACATCCTTC AGAAGGAGAC GAGCTGCTGG AAGAGAAGCA GGAGGGGTGT
 TTTTCTTGAA GTTTCTTTT TCCACAAAT GCCACTTTG GGCCAAGGCT GTGGTCCCCG
 TGGCTGGCAT CTGGCTTGG TCTCCCCGAG GCCTGTGCGT CTCCCAAACA CGCAGCTCAA
 GGTCCACATC CGCAAAAGCC TCCTCGCCTT CAGCCTCCTC AGCATTCAGT TTGTCAATGA
 AGTGATGAAA GCTTAGAGCC AGTATTTATA CTTTGTGGTT AAAATACTTG ATTCCCCCTT
 GTTTGTTTAA CAAAAACAGA TGTTTCCTAG AAAAATGACA AATAGTAAAA TGAACAAAAC
 CCTACGAAAG AATGGCAACA GCCAGGGTGG CCGGGCCCTG CCAGTGGGCG GCGTGTGCTA
 GCAAGGCCTG CCGGGTGTGC CGCAGTCACC ACAGGGTTCT GAGAACATTT CACAGAAAGT
 CCTGAGACGC GGAGACATGG CTGGTGTAA ATGGAGCTAT TCAATAGCAG TGACGCGCTC
 TCCTCAGCCA CCAAAATGTC CTGACACCCT CCCCAGCCCC CACAGATAAC ATCAGCTGAG
 GTTTTTTCA GTATGAACCT GTCCTAAAT AATTCCTCAA AGTGTGCACA AACTAAAGA
 ATATAAATAA ACAAAGAAA GGCAAAAAA AAAAAAA

The following amino acid sequence <SEQ ID NO. 114> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 54:

MWSCSWFNGTGLVEELPACQDLQLGLSLLGLVVGVPVGLCYNALLVL
 ANLHASKASMTMPDVYFVNMAVAGLVLSALAPVHLLGPPSSRWALWSVGGE
 VHVALQIPFNVSSLVAMYSTALLSLDHYIERALPRTYMASVYNTRHVCGF
 VWGGALLTSFSSLLFYICSHVSTRALECAKMQNAEADATLVFIGYVPA
 LATLYALVLLSRVRREDTPLDRDTGRLEPSAHRLLVATVCTQFGLWTPHY
 LILLGHTVVISRGKPVDAHYLGLLHFVKDFSKLLAFSSSFVTPLLYRYMN
 QSFPSKLQRLMKKLPCGDRHCSPDHMGVQQVLA

The following DNA sequence nGPCR-Seq46 <SEQ ID NO. 55> was identified in *H. sapiens*:

ATGGGGAA CGATTCTGTC AGCTACGAGT ATGGGGATTA CAGCGACCTC TCGGACCGCC
 CTGTGGACTG CCTGGATGGC GCCTGCCTGG CCATCGACCC GCTGCGCGTG GCCCCGCTCC
 CACTGTATGC CGCCATCTTC CTGGTGGGGG TGCCGGGCAA TGCCATGGTG GCCTGGGTGG
 CTGGGAAGGT GGCCCGCCGG AGGGTGGGTG CCACCTGGTT GCTCCACCTG GCCGTGGCGG
 ATTTGCTGTG CTGTTTGTCT CTGCCATCC TGGCAGTGCC CATTGCCCCG GGAGGCCACT
 GGCCGTATGG TGCAGTGGC TGTCGGGCGC TGCCCTCCAT CATCCTGCTG ACCATGTATG
 CCAGCGTCT GCTCCTGGCA GCTCAGTG CCGACCTCTG CTTCCTGGCT CTCGGGCGCTG
 CCTGGTGGTC TACGGTTTAC CGGGCGTGCG GGTGTCAGGT GGCCTGTGGG GCAGCTGGA
 CACTGGCCTT GCTGCTCACC GTGCCCTCCG CCATCTACCG CCGGCTGCAC CAGGAGCACT
 TCCAGCCCCG GCTGCACTGT GTGGTGGACT ACGGCGGCTC CTCCAGCACC GAGAATGCGG
 TGAAGTCCAT CCGGTTTCTT TTTGGCTTCC TGGGGCCCCT GGTGGCCGTG GCCAGCTGCC
 ACAGTGCCCT CCTGTGCTGG GCAGCCCGAC GCTGCCGGCC GCTGGGCACA GCCATTGTGG
 TGGGGTTTTT TGTCTGCTGG GCACCCTACC ACCTGCTGGG GCTGGTGCTC ACTGTGGCGG
 CCCCAGACTC CGCACTCTG GCCAGGGCCC TGCGGGCTGA ACCCTCATC GTGGGCCTTG
 CCTCGCTCA CAGTGCCTC AATCCCATG TCTTCTGTA TTTTGGGAGG GCTCAACTCC
 GCCGGTCACT GCCAGCTGCC TGTCACTGGG CCTGAGGGA GTCCAGGGC CAGGACGAAA
 GTGTGGACAG CAAGAAATCC ACCAGCCATG ACCTGGTCTC GGAGATGGAG GTGTAG

The following amino acid sequence <SEQ ID NO. 115> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 55:

MGNDSVSYEYGDYSDLSRDPVDCLDGACLAIDPLRVAPLPLYAAIFLVGV
 PGNAMVAWVAGKVARRRVGATWLLHLAVADLLCCLSLPILAVPIARGGHW

PYGAVGCRALPSIILLTMYASVLLLAALSADLCFLALGPAWWSTVQRACG
VQVACGAAWTLALLLTVPSTAIYRRLHQEHFARLQCVVDYGGSSSTENAV
TAIRFLGFLGPLVAVASCHSALLCWAARRCRPLGTAVVGGFFVCWAPYH
LLGLVLTVAAPNSALLARALRAEPLIVGLALAHSLNPMLFLYFGRAQLR
RSLPAACHWALRESQGQDESVDSSKSTSHDLVSEMEV

The following DNA sequence nGPCR-Seq48 <SEQ ID NO. 56> was identified in *H. sapiens*:

ATGGCACCT TCTCATCGGG CATCACAGGT GGGGTTTTGC CCCACCCCTG AACGCCCTCT
 GTGGCGCCTT CCACCCACCT GTAGGCCAG AAGGATGTCG GTCTGCTACC GTCCCCCAGG
 GAACGAGACA CTGCTGAGCT GGAAGACTTC GCGGGCCACA GGCACAGCCT TCCTGCTGCT
 GGCGGCGCTG CTGGGGCTGC CTGGCAACGG CTTCGTGGTG TGGAGCTTGG CGGGCTGGCG
 GCCTGCACGG GGGCGACCGC TGGCGGCCAC GCTTGTGCTG CACCTGGCGC TGGCCGACGG
 CGCGGTGCTG CTGCTACGC CGCTCTTTGT GGCCTTCCTG ACCCGGCAGG CCTGGCCGCT
 GGGCCAGGCG GGCTGCAAGG CGGTGTACTA CGTGTGCGCG CTCAGCATGT ACGCCAGCGT
 GCTGCTCACC GGCCTGCTCA GCCTGCAGCG CTGCCTCGCA GTCACCCGCC CCTTCCTGGC
 GCCTCGGCTG CGCAGCCCGG CCCTGGCCCG CCGCCTGCTG CTGGCGGTCT GGCTGGCCGC
 CCTGTTGCTC GCCGTCCCGG CCGCCGTCTA CCGCCACCTG TGGAGGGACC GCGTATGCCA
 GCTGTGCCAC CCGTCGCCCG TCCACGCCG CGCCACCTG AGCCTGGAGA CTCTGACCGC
 TTTCGTGCTT CCTTTCGGGC TGATGCTCGG CTGCTACAGC GTGACGCTGG CACGGCTGCG
 GGGCGCCCCG TGGGGCTCCG GCGCGCACGG GCGCGGGTG GGCCGGCTGG TGAGCGCCAT
 CGTGCTTGCC TTCGGCTTGC TCTGGGCCCC CTACCACGCA GTCAACCTTC TGCAGGCGGT
 CGCAGCGCTG GCTCCACCGG AAGGGGCCTT GGCGAAGCTG GGCGGAGCCG GCCAGGCGGC
 GCGAGCGGGA ACTACGGCCT TGGCCTTCTT CAGTTCTAGC GTCAACCCGG TGCTCTACGT
 CTTCACCGCT GGAGATCTGC TGCCCCGGG AGGTCCCCGT TTCCTCACGC GGCTCTTCGA
 AGGCTCTGGG GAGGCCCGAG GGGGCGGCCG CTCTAGGGAA GGGACCATGG AGCTCCGAAC
 TACCCCTCAG CTGAAAGTGG TGGGGCAGGG CCGCGGCAAT GGAGACCCGG GGGGTGGGAT
 GGAGAAGGAC GGTCCGGAAT GGGACCTTTG A

The following amino acid sequence <SEQ ID NO. 116> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 56:

MAPSHRASQVGFCTPERPLWRLPPTCRPRRMSVCYRPPGNETLLSWKTS
 RATGTAFLLLAALLGLPNGFVWVSLAGWRPARGRPLAATLVHLALADG
AVLLLTPLFVAFLTRQAWPLGQAGCKAVYYVCALSMYASVLLTGLLSLQR
CLAVTRPFLAPRLRSPALARLLAVWLAALLAVPAAVYRHLWRDRVCQ
 LCHPSPVHAAHLSLETLTAFVLPFGLMLGCYSVTLARLRGARWGSGRHG
 ARVGRLVSAIVLAFGLLWAPYHAVNLLQAVAALAPPEGALAKLGAGQAA
 RAGTTALAFFSSVNPVLYVFTAGDLLPRAGPRFLTRLFEGSGEARGGGR
 SREGTMELRTTPQLKVVGQGRGNGDPGGMEKDGPEWDL

The following DNA sequence nGPCR-Seq51 <SEQ ID NO. 57> was identified in *H. sapiens*:

CCGCCGCGCG GGGAGGACGC GAGCACCCAG CTTTAATCCC TGGAAAGTCC ACGAACAATG
 AATCCATTTT ATGCATCTTG TTGGAACACC TCTGCCGAAC TTTTAAACAA ATCCTGGAAT
 AAAGAGTTTG CTTATCAAAC TGCCAGTGTG GTAGATACAG TCATCCTCCC TTCCATGATT
 GGGATTATCT GTTCAACAGG GCTGGTTGGC AACATCCTCA TTGTATTCAC TATAATAAGA
 TCCAGGAAAA AAACAGTCCC TGACATCTAT ATCTGCAACC TGGCTGTGGC TGATTTGGTC
 CACATAGTTG GAATGCCTTT TCTTATTCAC CAATGGGCCC GAGGGGGAGA GTGGGTGTTT
 GGGGGGCCCTC TCTGCACCAT CATCACATCC CTGGATACTT GTAACCAATT TGCCTGTAGT
 GCCATCATGA CTGTAATGAG TGTGGACAGG TACTTTGCCC TCGTCCAACC ATTTGCACTG
 ACACGTTGGA GAACAAGGTA CAAGACCATC CGGATCAATT TGGGCCTTTG GGCAGCTTCC
 TTTATCCTGG CATTGCCTGT CTGGGTCTAC TCGAAGGTCA TCAAATTTAA AGACGGTGTT
 GAGAGTTGTG CTTTTGATTT GACATCCCCT GACGATGTAC TCTGGTATAC ACTTTATTTG
 ACGATAACAA CTTTTTTTTT CCCTCTACCC TTGATTTTGG TGTGCTATAT TTTAATTTTA
 TGCTATACTT GGGAGATGTA TCAACAGAAT AAGGATGCCA GATGCTGCAA TCCCAGTGTA
 CAAAACAGA GAGTGATGAA GTTGACAAAG ATGGTGCTGG TGCTGGTGGT AGTCTTTATC
 CTGAGTGCTG CCCCTTATCA TGTGATACAA CTGGTGAAC TACAGATGGA ACAGCCACA
 CTGGCCTTCT ATGTGGGTTA TTACCTCTCC ATCTGTCTCA GCTATGCCAG CAGCAGCATT
 AACCCTTTTC TCTACATCCT GCTGAGTGGA AATTTCCAGA AACGTCTGCC TCAAATCCAA

AGAAGAGCGA CTGAGAAGGA AATCAACAAT ATGGGAAACA CTCTGAAATC ACACCTTTAG
 GAAAGTACAT GGATCACCAT GAGTCTAGAC ATGATTGTCT ATCTTACTGG TATTATTAGA
 AAGGGCAGGT GTACCGATAT GTTTATGCCC ATTCTTCTTG TGTACTTGTG ACTCTTAGCA
 GCATGGAAGA GAAGTGTAAC CATGCAATA CAATGAGCTT AATATGCTAA CTTTAGCAAG
 ATGTAAATG TTGATCTATA TTGTGGGTAG GGAATGGGAT AGTCTGAGAT ACCCAGGCTT
 CATGATGGTG TATATTATTT CAGCATATTA TAACTAGTC ACTAATGAAA ATGGCCATCC
 ATGACCATTG ACTCAAACT CACCAAGGAA CCTGACCTTG CCCTCCACAC TGTGGCCTCA
 CTGTAACAGT TTCCTCAAGG TTCCTAGGAG GGTATCACCT TAGAGTGAAG TCTAAAATTT
 GGCTATTTTT TATCTATAAA AAATGTCAGT TTTATATGGT CCAATACTAA TACCCTCAAC
 AACTAAGCCC CACCTTTTAG AATAAGTTAC CATTTATTGC ACACATGCAA TGTGTAAGAT
 TACATGTAAC AAACCTGTGA AATAAGTATT ATTACCTTTG TTGCTAAGG CTCAGAAAGG
 AGAAATGATA GGCCTAATGC TGCAACAGCT ATCTAAGAGC TGAGCTAACA TTCAGCTCTG
 CCTGTTTCTT TTCTACTGCC GACCTTGACA ACCTTTACTT ATCATACTGG AGAACCCAGT
 AACTTGGAGT TTCTTTTGTCT TTCTCCTGTA GCCCTACAAG AGGAGAACTA AAGTCTGATA
 GAAATGAGTT GATGTTTTAA GCATCATTTT GGATTATCTT GTTCTCACAC CTGCTAACTG
 TAGAACTGG CATCTGGACT TTAATAATAA TACTTTACTT CTGGA

The following amino acid sequence <SEQ ID NO. 117> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 57:

MNPFHASCWNTSABLLNKSWNKEFAYQTASVVDTVILPSMIGHCSTGLVGNILIVFTIHSRKKTV
 DIYICNLAVADLV HIVGMPFLIHQWARGGEWVFGGPLCTHTSLDTCNQFACSAIMTVMSVDR
 YFALVQPFRLTRWRTRYKTIRINLGLWAASFILALPVWVYSKVIKFKDGV
 ESCAFDLTSPDDVLWYTLYLTTTFFFLPLILVCYILLCYTWEMYQQN
 KDARCCNPSPVKQRMKLTGMVLVLVVVFILSAAPYHVIQLVNLQMEQPT
 LAFYVGYLLSICLSYASSINPFLYILLSGNFQKRLPQIQRRATEKEINN
 MGNTLKSHF

The following DNA sequence nGPCR-Seq52 <SEQ ID NO. 58> was identified in *H. sapiens*:

CCATGACCAG CAATTTTTCC CAACCTGTTG TGCAGCTTTG CTATGAGGAT GTGAATGGAT
 CTTGTATTGA AACTCCCTAT TCTCCTGGGT CCCGGGTAAT TCTGTACACG GCGTTTAGCT
 TTGGGTCTTT GCTGGCTGTA TTGGAAATC TCTTAGTAAT GACTTCTGTT CTTCAATTTA
 AGCAGCTGCA CTCTCCAACC AATTTTCTCA TTGCCTCTCT GGCCTGTGCT GACTTCTTGG
 TAGGTGTGAC TGTGATGCTT TTCAGCATGG TCAGGACGGT GGAGAGCTGC TGGTATTTTG
 GAGCCAAATT TTGTACTCTT CACAGTTGCT GTGATGTGGC ATTTTGTTAC TCTTCTGTCC
 TCCACTGTG TCTCATCTGC ATCGACAGGT ACATTGTGGT TACTGATCCC CTGGTCTATG
 CTACCAAGTT CACCGTGTCT GTGTCGGGAA TTGTCATCAG CGTGTCTGG ATTCTGCCTC
 TCACGTACAG CGGTGCTGTG TTCTACACAG GTGTCAATGA TGATGGGCTG GAGGAATTAG
 TAAGTGCTCT CAACTGCGTA GGTGGCTGTC AAATTATTGT AAGTCAAGGC TGGGTGTTGA
 TAGATTTTCT GTTATTCTTC ATACCTACCC TTGTTATGAT AATTCTTTAC AGTAAGATTT
 TTCTTATAGC TAAACAACAA GCTATAAAAA TTGAAACTAC TAGTAGCAAA GTAGAATCAT
 CCTCAGAGAG TTATAAAATC AGAGTGGCCA AGAGAGAGAG GAAAGCAGCT AAAACCCTGG
 GGGTCACGGT ACTAGCATTG GTTATTTTCA GTTACCGTA TACAGTTGAT ATATTAATTG
 ATGCCTTTAT GGGCTTCTG ACCCCTGCCT ATATCTATGA AATTGCTGT TGGAGTGCTT
 ATTATAACTC AGCCATGAAT CCTTTGATTT ATGCTCTATT TTATCCTTGG TTAGGAAAG
 CCATAAACT TATTTTAAAGT GGAGATGTTT TAAAGGCTAG TTCATCAACC ATTAGTTTAT
 TTTTAGAATA A

The following amino acid sequence <SEQ ID NO. 118> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 58:

MTSNFSQPV VQLCYEDVNG SCIEPTYSPG SRVILYTAFS FGSLLAVFGN LLVMTSVLHF
 KQLHSPTNFI IASLACADFL VGVTVMLFSM VRTVESCWYF GAKFCTLHSC CDVAFCYSSV
 LHLFCIDR YIVVTDPLVY ATKFTVSVSG ICISVSWILP LTYSGAVFYT
 GVNDGGLLEL VSALNCVGGC QIVSQGWVL IDFLFFIPT LVMILYSKI
 FLIAKQQA IETTSSKVES SSES YKIRVA KRERKAAKTL GVTVLAFVIS
 WLPYTV DILI DAFMGFLTPA YIYEICWWSA YYNSAMNPLI YALFYPWFRK
 AIKLILSGDV LKASSSTISL FLE

The following DNA sequence nGPCR-Seq49 <SEQ ID NO. 59> was identified in *H. sapiens*:

A TGCCACTCCC TGTGCCCCCA GCGGGGGCAC AAAAGACTCC TGAGGACCAT GTCTGTCTCC
ATCTTGCAGG TCCCTCGCCA GCACCTCTG AGCCGGCCAG GATGTTTGGG CTGTTCGGCC
TCTGGAGAAC CTTGACAGT GTGGTCTTCT ACCTGACGCT GATCGTGGG CTCGGGGGAC
CGGTAGGTAA CGGGCTGGT CTCTGGAACC TCGGCTTCCG CATCAAGAAG GGCCCTTCT
CCATCTACCT GCTGCACCTG GCCGCCGCC ACTTCTGT CTCTCTCTGC CGTGTGGGCT
TCTCCGTGGC TCAGGCTGCC CTGGGCGCCC AGGACACACT CACTTCTGTG CTCACCTTCC
TGTGGTTCGC GGTGGGGCTC TGGCTGCTGG CGGCCTCAG CGTGAGCGC TGCCTCTCCG
ACCTCTTCCC CGCCTGCTAC CAGGGCTGCC GGCCAGACA CGCTCGGCC GTCCTCTGCG
CCCTGGTGTG GACCCGACC CTGCCGGCCG TGCCGCTGCC CGCCAACGCC TCGGGCCTGC
TGCGCAACAG CGCGTGCCCC CTGGTCTGCC CGCGTACCA CGTGCCAGC GTCACCTGGT
TCCTGGTGCT GGCCGCGTC GCCTGGACGG CTGGCGTGGT CCTCTTTGTC TGGGTGACCT
GCTGCTCCAC TCGCCGCGG CCCAGGCTCT ACGGCATCGT CCTGGGCGCG CTGCTCTGC
TCTTCTCTG TGGCCTGCC TCGGTCTTCT ACTGGAGCCT GCAGCCCCTG CTGAACCTCC
TGCTGCCCCG GTTTTCCCCG CTGGCCACGC TGCTGGCCTG CGTCAACAGC AGCTCCAAGC
CCCTCATCTA CTCGGGGTTG GGCCGACAG CCGGAAGCG GGAGCCGCTG AGGTCGGTAC
TGCGGAGGGC CCTGGGGGAG GCGCCGAGC TGGTGCCAG GGGACAGTCC CTGCCATGG
GTCTCTATA A

The following amino acid sequence <SEQ ID NO. 119> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 59:

MPLVPPAGA QKTPEDH VCLHLAGSPAPSEPARMFGLFGLWRTFDSVVFYLT LIVGLGGP
VGNGLVLWNLGFRKKGPSIYLLHLAAADFLFLSCRVGFSVAQAALGAQDTLYFVLTFLWFAVG
LWLLAAFSVERCLSDLFPACYQGCRRHASAVLCALVWTPTLPAVPLPACGLLRNSACPLVCP
RYHVASVTWFLVLARVAWTAGVVLFWVTCCSTRPRPRLYGIVLGALLLFFCGLPSVF YWSLQP
LLNFLLPVESPLATLLACVNSSSKPLIYSGLRQPGKREPLRSVLRRALGEGAE LGARGQSLPMGLL

The following DNA sequence nGPCR-Seq61 <SEQ ID NO. 60> was identified in *H. sapiens*:

ATGAACAACAATACAACATGTATTCAACCATCTATGATCTCTTCCATGGCTTTACCAATC
ATTTACATCCTCCTTTGTATTGTTGGTGT TTTTGGAAACACTCTCTCTCAATGGATATTT
TTAACAAAAATAGGTAAAAAACATCAACGCACATCTACCTGTCACACCTTGTGACTGCA
AACTTACTTGTGTGCACTGCCATGCCTTTCATGAGTATCTATTTCTGAAAGGTTTCCAA
TGGGAATATCAATCTGCTCAATGCAGAGTGGTCAATTTTCTGGAACTCTATCCATGCAT
GCAAGTATGTTTGTGAGTCTCTTAATTTTAAGTTGGATTGCCATAAGCCGCTATGCTACC
TTAATGCAAAAGGATTCTCGCAAGAGACTACTTCATGCTATGAGAAAAATATTTTATGGC
CATTTACTGAAAAAATTTGCGCCAGCCCAACTTTGCTAGAAAACTATGCATTTACATATGG
GGAGTTGTA CTGGGCATAATCATTCCAGTTACCGTATACTACTCAGTCATAGAGGCTACA
GAAGGAGAAGAGAGCCTATGCTACAATCGGCAGATGGAAGTAGGAGCCATGATCTCTCAG
ATTGCAGGTCTCATTGGAACCATTTATTGGATTTTCTTTTATAGTACTAACATCA
TACTACTCTTTTGTAAAGCCATCTGAGAAAAATAAGAACCTGTACGTCCATTATGGAGAAA
GATTTGACTTACAGTTCTGTGAAAAGACATCTTTTGGTCATCCAGATTCTACTAATAGTT
TGCTTCCTTCCTTATAGTATTTTAAACCCATTTTATGTTCTACACCAAAGAGATAAC
TGTCAGCAATTGAATTATTTAATAGAAACAAAAACATTCTCACCTGTCTTGCTTCGGCC
AGAAGTAGCACAGACCCCATTAATTTCTTTTATTAGACAAAACATTCAAGAAGACACTA
TATAATCTCTTTACAAAGTCTAATTCAGCACATATGCAATCATATGGTTGA

The following amino acid sequence <SEQ ID NO. 120> is the predicted amino acid sequence derived from the DNA sequence of SEQ ID NO. 60:

MNNNTTCIQPSMISSMALPIIYILLCIVGVFGNTLSQWIFLTKIGKKTSTHIYLSHLVT
ANLLVCSAMPFMSIYFLKGFQWEYQSAQCRVNFGLTSMHASM FVSLILSWIAISRY
ATLMQKDSSQETTSCYEKIFYGHLKKFRQPNFARKLCIYIWGVVLGHIIPVTVYYSVI
EATEGEESLCYNRMELGAMISQIAGLIGTTFIGFSFLVVLTSYYSFVSHLRKIRTCT
IMEKDLTYSSVKRHLLVIQILLIVCFLPYSIFKPIFYVLHQRDNCQQLNYLIETKNILT
CLASARSSTDPIIFLLDKTFKKTLYNLFKSN SAHMQSYG

Example 2: Cloning of nGPCR-x

cDNAs may be sequenced directly using an ABI377 or ABI373A fluorescence-based sequencer (Perkin Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI PRISM Ready Dye-Deoxy Terminator kit with Taq FS polymerase. Each ABI cycle
5 sequencing reaction contains about 0.5 µg of plasmid DNA. Cycle-sequencing is performed using an initial denaturation at 98C for 1 minute, followed by 50 cycles: 98C for 30 seconds, annealing at 50C for 30 seconds, and extension at 60C for 4 minutes. Temperature cycles and times are controlled by a Perkin-Elmer 9600 thermocycler. Extension products are purified using Centriflex gel filtration (Advanced Genetic Technologies Corp., Gaithersburg, MD). Each
10 reaction product is loaded by pipette onto the column, which is then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B table top centrifuge) at 1500 x g for 4 minutes at room temperature. Column-purified samples are dried under vacuum for about 40 minutes and then dissolved in 5 µl of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples are then heated to 90C for three minutes and loaded
15 into the gel sample wells for sequence analysis by the ABI377 sequencer. Sequence analysis is done by importing ABI373A files into the Sequencer program (Gene Codes, Ann Arbor, MI). Generally, sequence reads of 700 bp are obtained. Potential sequencing errors are minimized by obtaining sequence information from both DNA strands and by re-sequencing difficult areas using primers at different locations until all sequencing ambiguities are removed.

20 To isolate a cDNA clone encoding full length nGPCR, a DNA fragment corresponding to a nucleotide sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60, or a portion thereof, can be used as a probe for hybridization screening of a phage cDNA library. The DNA fragment is amplified by the polymerase chain reaction (PCR) method. The PCR reaction mixture of 50 µl contains polymerase mixture (0.2 mM dNTPs, 1x PCR Buffer and
25 0.75 µl Expand High Fidelity Polymerase (Roche Biochemicals)), 1 µg of 3206491 plasmid, and 50 pmoles of forward primer and 50 pmoles of reverse primer. The primers are preferably 10 to 25 nucleotides in length and are determined by procedures well known to those skilled in the art. Amplification is performed in an Applied Biosystems PE2400 thermocycler, using the following program: 95C for 15 seconds, 52C for 30 seconds and 72C for 90 seconds; repeated
30 for 25 cycles. The amplified product is separated from the plasmid by agarose gel electrophoresis, and purified by Qiaquick gel extraction kit (Qiagen).

A lambda phage library containing cDNAs cloned into lambda ZAPII phage-vector is plated with E. coli XL-1 blue host, on 15 cm LB-agar plates at a density of 50,000 pfu per plate, and grown overnight at 37C; (plated as described by Sambrook et al., supra). Phage plaques are

transferred to nylon membranes (Amersham Hybond NJ), denatured for 2 minutes in denaturation solution (0.5 M NaOH, 1.5 M NaCl), renatured for 5 minutes in renaturation solution (1 M Tris pH 7.5, 1.5 M NaCl), and washed briefly in 2xSSC (20x SSC: 3 M NaCl, 0.3 M Na-citrate). Filter membranes are dried and incubated at 80C for 120 minutes to cross link the phage DNA to the membranes.

The membranes are hybridized with a DNA probe prepared as described above. A DNA fragment (25 ng) is labeled with α -32P-dCTP (NEN) using Rediprime random priming (Amersham Pharmacia Biotech), according to manufacturers instructions. Labeled DNA is separated from unincorporated nucleotides by S200 spin columns (Amersham Pharmacia Biotech), denatured at 95C for 5 minutes and kept on ice. The DNA-containing membranes (above) are pre-hybridised in 50 ml ExpressHyb (Clontech) solution at 68C for 90 minutes. Subsequently, the labeled DNA probe is added to the hybridization solution, and the probe is left to hybridise to the membranes at 68C for 70 minutes. The membranes are washed five times in 2x SSC, 0.1% SDS at 42C for 5 minutes each, and finally washed 30 minutes in 0.1x SSC, 0.2% SDS. Filters are exposed to Kodak XAR film (Eastman Kodak Company, Rochester, N.Y., USA) with an intensifying screen at -80C for 16 hours. One positive colony is isolated from the plates, and replated with about 1000 pfu on a 15 cm LB plate. Plating, plaque lift to filters and hybridization are performed as described above. About four positive phage plaques are isolated from this secondary screening.

cDNA containing plasmids (pBluescript SK-) are rescued from the isolated phages by in vivo excision by culturing XL-1 blue cells co-infected with the isolated phages and with the Excision helper phage, as described by manufacturer (Stratagene). XL-blue cells containing the plasmids are plated on LB plates and grown at 37C for 16 hours. Colonies (18) from each plate are replated on LB plates and grown. One colony from each plate is stricken onto a nylon filter in an ordered array, and the filter is placed on a LB plate to raise the colonies. The filter is then hybridized with a labeled probe as described above. About three positive colonies are selected and grown up in LB medium. Plasmid DNA is isolated from the three clones by Qiagen Midi Kit (Qiagen) according to the manufacturer's instructions. The size of the insert is determined by digesting the plasmid with the restriction enzymes NotI and SalI, which establishes an insert size. The sequence of the entire insert is determined by automated sequencing on both strands of the plasmids.

nGPCR-70

The PCR reaction was performed in 50 μ l containing 31 μ l H₂O, 5 μ l Buffer II (PE Applied Biosystems AmpliTaq Gold system), 6 μ l 25 mM MgCl₂, 2 μ l 10 mM dNTP mix, 5 μ l

Marathon Ready whole human brain cDNA (Clontech #7400-1), 0.3 µl primer VR70C (1 µg/µl)(SEQ ID NO:121), 0.3 µl primer VR70D (1 µg/µl)(SEQ ID NO:122), and 0.4 µl AmpliTaq Gold™ DNA Polymerase. The primer sequence for VR70C is 5'-TTCAAAGCTTATGACGTCCACCTGCACC-3' (SEQ ID NO:121), corresponding to the 5' end of the coding region and containing a HindIII restriction site. The primer sequence for VR70D is 5'-TTCACCTCGAGTCAAGGAAAAGTAGCAGAATCGTAG-3' (SEQ ID NO:122), corresponding to the 3' end of the coding region and containing an XhoI restriction site (Genosys).

The PCR reaction was carried out using a GeneAmp PCR 9700 thermocycler (Perkin Elmer Applied Biosystems) and started with 1 cycle of 80C for 20 minutes followed by 95C for 10 minutes, then 12 cycles at 95C for 30 seconds, 72C for 2 minutes decreasing 1C each cycle, 72C for 1 minute, followed by 35 cycles at 95C for 30 seconds, 60C for 30 seconds, 72C for 1 minute. The PCR reaction was loaded on a 0.75% gel. The DNA band was excised from the gel and the DNA was eluted from the agarose using a QIAquick gel extraction kit (Qiagen). The eluted DNA was ethanol-precipitated and resuspended in 4 µl H₂O for ligation. The ligation reaction consisted of 4 µl of fresh ethanol-precipitated PCR product and 1 µl of pCRII-TOPO vector (Invitrogen). The reaction was gently mixed and allowed to incubate for 5 minutes at room temperature followed by the addition of 1 µl of 6x TOPO cloning stop solution and mixing for 10 seconds at room temperature. The sample was then placed on ice and 2 µl was transformed in 50 µl of One Shot cells (Invitrogen) and plated onto ampicillin plates. Seven white colonies were chosen and the presence of an insert was verified by PCR in the following manner. Each colony was resuspended in 2 ml LB broth and incubated at 37C for 2 hours. A 500 µl aliquot was spun down in the microfuge, the supernatant discarded, and the pellet resuspended in 25 µl of H₂O. A 16 µl aliquot was removed and boiled for 5 minutes and the sample was placed on ice. The sample was microfuged briefly to pellet any bacterial debris and PCR was carried out as described above with 15 µl of sample using primers VR70C (SEQ ID NO:121) and VR70D (SEQ ID NO:122).

nGPCR-63

Isolation of a clone for nGPCR-63 from genomic DNA was performed by PCR in a 50 µl reaction containing Herculase DNA Polymerase blend (Stratagene), with buffer recommendations as supplied by the manufacturer, 200 ng each primers PSK16 and 17 (SEQ ID NO:123 and SEQ ID NO:124, respectively), 150 ng of human genomic DNA (Clontech) and 4% DMSO. The PCR reaction was performed on a Robocycler thermocycler (Stratagene) starting with 1 cycle of 94C for 2 minutes followed by 35 cycles of 94C for 30 seconds, 65C for

30 seconds, 72C for 2 minutes. The PCR reaction was purified by the QiaQuick PCR Purification Kit (Qiagen) and eluted in TE. The PCR primer sequences were: PSK16 5'-GATCGAATTCATGATGGAGCCCCAGAGAAGCTGGAC-3' (SEQ ID NO:123) and PSK17 5'-GATCCTCGAGTCAGGCTGCTATGTCCACCAGGCC-3' (SEQ ID NO:124). Translation initiation and termination codons are shown above in bold.

The PCR product was ligated into the pCR-BluntII-TOPO vector (Invitrogen) using the Zero Blunt Topo PCR TA cloning kit as follows. 3 µl PCR product DNA, 1 µl pCRII-TOPO vector, and 1 µl TOPOII salt solution (1.2M NaCl, 0.06M MgCl₂) was incubated for 5 minutes at room temperature. To the ligation reaction one microliter of 6X TOPO Cloning Stop Solution was added then the reaction was placed on ice. Two microliters of the ligation reaction was transformed in One-Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42C, placed on ice for two minutes, 250 µl of SOC was added, then incubated at 37C with shaking for one hour and then plated onto ampicillin plates supplemented with Xgal and IPTG. Single colonies were screened by restriction digestion for the presence of the insert, and a plasmid DNA from colony 63-4-23 was purified using a Qiagen Endo-Free plasmid purification kit.

The clone containing nGPCR-63 was sequenced directly using an ABI377 fluorescence-based sequencer (Perkin Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI BigDye™ Terminator Cycle Sequencing Ready Reaction kit with Taq FSTM polymerase. Each ABI cycle sequencing reaction contained about 0.5 µg of plasmid DNA. Cycle-sequencing was performed using an initial denaturation at 98C for 1 minute, followed by 50 cycles: 96C for 30 seconds, annealing at 50C for 30 seconds, and extension at 60C for 4 minutes. Temperature cycles and times were controlled by a Perkin-Elmer 9600 thermocycler. Extension products were purified using AGTC (R) gel filtration block (Edge Biosystems, Gaithersburg, MD). Each reaction product was loaded by pipette onto the column, which was then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B tabletop centrifuge) at 1500 x g for 4 minutes at room temperature. Column-purified samples were dried under vacuum for about 40 minutes and then dissolved in 3 µl of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples were then heated to 90C for 3.5 minutes and loaded into the gel sample wells for sequence analysis by the ABI377 sequencer. Sequence analysis was performed by importing ABI377 files into the Sequencer program (Gene Codes, Ann Arbor, MI).

nGPCR-42

PCR was performed in a 50 µl reaction containing 36.7 µl H₂O, 5 µl 10X TT buffer (140 mM Ammonium Sulfate, 0.1 % gelatin, 0.6 M Tris-tricine pH 8.4), 5 µl 15 mM MgSO₄, 2 µl 10 mM dNTP, 0.3 µl 6541947H1 DNA (1.4 Tg/Tl), 0.3 µl of LW1579 (1 µg/µl), 0.3 µl of LW1580 (1 µg/µl), 0.4 µl High Fidelity Taq polymerase (Boehringer Mannheim). The PCR reaction was performed on a Robocycler thermocycler (Stratagene) starting with 1 cycle of 94C for 2 minutes followed by 15 cycles of 94C for 30 seconds, 55C for 30 seconds, 68C for 1.3 minutes. The PCR reaction was loaded onto a 1.2 % agarose gel. The DNA band was excised from the gel, placed in GenElute Agarose spin column (Supelco) and spun for 10 minutes at maximum speed in a microcentrifuge. The eluted DNA was EtOH precipitated and resuspended in 4µl H₂O for ligation. The forward PCR primer was: LW1579 5'-GCATAAGCTTCCATGTGGAGCTGC AGCTGGTTCAACG-3' (SEQ ID NO:125), and the reverse PCR primer was: LW1580 5'-GCATCTCGAGCCTACGCCAGCACCTGCTGCACC-3' (SEQ ID NO:126). The ligation reaction used solutions from the TOPO TA Cloning Kit (Invitrogen) which consisted of 4µl PCR product DNA and 1 µl pCRII-TOPO vector that was incubated for 5 minutes at room temperature. To the ligation reaction one microliter of 6X TOPO Cloning Stop Solution was added then the reaction was placed on ice. Two microliters of the ligation reaction was transformed in One-Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42C, placed on ice for two minutes, 250 µl of SOC was added, then incubated at 37C with shaking for one hour and then plated onto ampicillin plates. A single colony containing an insert was used to inoculate a 5 ml culture of LB medium. Plasmid DNA was purified using a Concert Rapid Plasmid Miniprep System (GibcoBRL) and then sequenced.

nGPCR-46

PCR was performed in a 50 µl reaction using components that come with PLATINUM[®] Pfx DNA Polymerase (GibcoBRL) containing 30.5 µl H₂O, 5 µl 10X Pfx Amplification buffer, 5 µl 10X Enhancer solution, 1.5 µl 50mM MgSO₄, 2 µl 10 mM dNTP, 5 µl human genomic DNA (0.3µg/µl)(Clontech), 0.3 µl of LW1626 (1 µg/µl), 0.3 µl of LW1627 (1 µg/µl), 0.4 µl PLATINUM[®] Pfx DNA Polymerase (2.5 U/µl). The PCR reaction was performed in a Robocycler Gradient 96 (Stratagene) starting with 1 cycle of 94C for 5 minutes followed by 30 cycles at 94C for 40 seconds, 55C for 2 minutes, 68C for 3 minutes. Following the final cycle, 0.5 µl of AmpliTaq DNA Polymerase (5 U/µl) was added and the tube was incubated at 72C for 5 minutes. The PCR reaction was loaded onto a 1.2 % agarose gel. The DNA band was excised from the gel, placed in GenElute Agarose spin column (Supelco) and spun for 10 minutes at maximum speed in a microcentrifuge. The eluted DNA was EtOH precipitated and resuspended

in 12 µl H₂O for ligation. The forward PCR primer was: LW1626 5'-GCATAAGCTTCCATGGGGAACGATTCTGTCAGC-3' (SEQ ID NO:127) and the reverse PCR primer was: LW1627 5'-GCATCTCGAGCCTACACCTCCATCTCCGAGACC-3' (SEQ ID NO:128). The ligation reaction used solutions from the TOPO TA Cloning Kit (Invitrogen) which consisted of 4 µl PCR product DNA and 1 µl pCRII-TOPO vector that was incubated for 5 minutes at room temperature. To the ligation reaction one microliter of 6X TOPO Cloning Stop Solution was added then the reaction was placed on ice. Two microliters of the ligation reaction was transformed in One-Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42C, placed on ice for two minutes, 250 µl of SOC was added, then incubated at 37C with shaking for one hour and then plated onto ampicillin plates. A single colony containing an insert was used to inoculate a 5 ml culture of LB medium. Plasmid DNA was purified using a Concert Rapid Plasmid Miniprep System (GibcoBRL) and then sequenced.

nGPCR-48

PCR was performed in a 50 µl reaction using components that come with PLATINUM[®] Pfx DNA Polymerase (GibcoBRL) containing 30.5 µl H₂O, 5 µl 10X Pfx Amplification buffer, 5 µl 10X Enhancer solution, 1.5 µl 50mM MgSO₄, 2 µl 10 mM dNTP, 5 µl human genomic DNA (0.3 µg /µl)(Clontech), 0.3 µl of LW1572 (1 µg/µl), 0.3 µl of LW1573 (1 µg/µl), 0.4 µl PLATINUM[®] Pfx DNA Polymerase (2.5 U/µl). The PCR reaction was performed in a Robocycler Gradient 96 (Stratagene) starting with 1 cycle of 94C for 5 minutes followed by 30 cycles at 94C for 40 seconds, 55C for 2 minutes, 68C for 3 minutes. Following the final cycle, 0.5 µl of AmpliTaq DNA Polymerase (5 U/Tl) was added and the tube was incubated at 72C for 5 minutes. The PCR reaction was loaded onto a 1.2 % agarose gel. The DNA band was excised from the gel, placed in GenElute Agarose spin column (Supelco) and spun for 10 minutes at maximum speed in a microcentrifuge. The eluted DNA was EtOH precipitated and resuspended in 12 µl H₂O for ligation. The forward primer for PCR was: LW1572 5'-GATCAAGCTTGCA TGGCACCTTCTCATCGGG-3' (SEQ ID NO:129) and the reverse primer was: LW1573 5'-GATCCTCGAGTCAAAGGTCCCATTCGGACC-3' (SEQ ID NO:130). The ligation reaction used solutions from the TOPO TA Cloning Kit (Invitrogen) which consisted of 4 µl PCR product DNA and 1 µl pCRII-TOPO vector that was incubated for 5 minutes at room temperature. To the ligation reaction one microliter of 6X TOPO Cloning Stop Solution was added then the reaction was placed on ice. Two microliters of the ligation reaction was transformed in One-Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42C, placed on ice for two minutes, 250 µl of SOC was added, then incubated

at 37C with shaking for one hour and then plated onto ampicillin plates. A single colony containing an insert was used to inoculate a 5 ml culture of LB medium. Plasmid DNA was purified using a Concert Rapid Plasmid Miniprep System (GibcoBRL) and then sequenced.
nGPCR-49

5 The PCR reaction used components that come with PLATINUM[®] Pfx DNA Polymerase (GibcoBRL) containing 30.5 µl H₂O, 5 µl 10X Pfx Amplification buffer, 5 µl 10X Enhancer Solution, 1.5 µl 50mM MgSO₄, 2 µl 10 mM dNTP, 5 µl human genomic DNA (0.3µg/µl) (Clontech), 0.3 µl of LW1726 (1 µg/µl) (SEQ ID NO:131), 0.3 µl of LW1727 (1 µg/µl) (SEQ ID NO:132), 0.4 µl PLATINUM[®] Pfx DNA Polymerase (2.5 U/µl). The PCR reaction was
10 performed in a Robocycler Gradient 96 (Stratagene) starting with 1 cycle of 94C for 2 minutes followed by 35 cycles at 94C for 30 seconds, 55C for 30 seconds, 68C for 2 minutes. Following the final cycle, 0.5 µl of AmpliTaq DNA Polymerase (5 U/µl) was added and the tube was incubated at 72C for 5 minutes. The sequence of LW1726 is: 5'-CATAAGCTTTGGATGCCA
15 CTCCCTGTGCCCCC-3'(SEQ ID NO:131) and for LW1727 is: 5'-GCATCTCGAGTTATAG
GAGACCCATGGGCAGGG-3' (SEQ ID NO:132). The underlined portion of the primer matches the 5' and 3' areas, respectively, of the coding region. The ligation reaction used solutions from the TOPO TA Cloning Kit (Invitrogen) which consisted of 4 µl PCR product DNA, 1 µl of salt solution and 1 µl pCRII-TOPO vector that was incubated for 5 minutes at
20 room temperature then the reaction was placed on ice. Two microliters of the ligation reaction was transformed in One-Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42C, placed on ice for two minutes, 250 µl of SOC was added, then incubated at 37C with shaking for one hour and then plated onto ampicillin plates. A single colony containing an insert was used to inoculate a 5 ml culture of LB medium. Plasmid DNA was purified using a Concert Rapid Plasmid Miniprep System (GibcoBRL) and
25 then sequenced.

 The mutation in SEQ-49 in the plasmid above was repaired using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The PCR reaction contained 40 µ H₂O, 5 µl 10x Reaction buffer, 1 µl mini-prep DNA, 1 µl LW1741 (125 ng/µl) (SEQ ID NO:133), 1µl LW1742 (125 ng/µl) (SEQ ID NO:134), 1µl 10 mM dNTP, 1 µl Pfu DNA polymerase. The
30 cycle conditions were 95C for 30 seconds then 14 cycles at 95C for 30 seconds, 55C for 1 minute, 68C for 12 minutes. The tube was placed on ice for 2 minutes, then 1 µl of DpnI was added and the tube incubated at 37C for one hour. One microliter of the DpnI-treated DNA was transformed into Epicurian coli XL1-Blue supercompetent cells and the entire insert was re-sequenced. The primer sequences are for LW1741: 5'-

GGTGCTCTGGAACCTCGGCTTCGCATCAAGAAGGGCCCC-3' (SEQ ID NO:133) and for LW1742 was: 5'-GGGGCCCTTCTTGATGCGGAAGCCGAGGTTCAGAGCACC-3' (SEQ ID NO:134).

nGPCR-61

5 The PCR reaction was performed in 50 µl containing 34.5 µl H₂O, 5 µl Buffer II (PE Applied Biosystems AmpliTaq Gold system), 6 µl 25 mM MgCl₂, 2 µl 10 mM dNTP mix, 1.5 µl human genomic DNA (Clontech #6550-1, 0.1 µg/µl), 0.3 µl primer VR61C (1 µg/µl) (SEQ ID NO:135), 0.3 µl primer VR61D (1 µg/µl) (SEQ ID NO:136), and 0.4 µl AmpliTaq Gold™ DNA Polymerase. The primer sequence for VR61C was: 5'-TTCAAAGCTTATGAACAAC
10 AATACAACATGTATTCAAC-3' (SEQ ID NO:135), corresponding to the 5' end of the coding region and containing a HindIII restriction site, and the primer sequence for VR61D was: 5'-TTCACCTCGAGTCAAACATATGATTGCATATGTG-3' (SEQ ID NO:136), corresponding to the 3' end of the coding region and containing an XhoI restriction site(Genosys). The PCR reaction was carried out using a GeneAmp PCR9700 thermocycler (Perkin Elmer Applied
15 Biosystems) and started with 1 cycle of 95C for 10 minutes, then 14 cycles at 95C for 30 seconds, 72C for 2 minutes decreasing 1C each cycle, 72C for 1 minute, followed by 30 cycles at 95C for 30 seconds, 60C for 30 seconds, 72C for 1 minute. The PCR reaction was loaded on a 0.75% agarose gel. The DNA band was excised from the gel and the DNA was eluted from the agarose using a QIAquick gel extraction kit (Qiagen). The eluted DNA was ethanol-precipitated
20 and resuspended in 4µl H₂O for ligation. The ligation reaction consisted of 4µl of fresh ethanol-precipitated PCR product and 1 µl of pCRII-TOPO vector (Invitrogen). The reaction was gently mixed and allowed to incubate for 5 minutes at room temperature followed by the addition of 1 µl of 6x TOPO cloning stop solution and mixing for 10 seconds at room temperature. The sample was then placed on ice and 2 µl was transformed in 50µl of One Shot cells (Invitrogen)
25 and plated onto ampicillin plates. Four white colonies were chosen and the presence of an insert was verified by PCR in the following manner. Each colony was resuspended in 50 µL H₂O. A 16 µl aliquot was removed and boiled for 5 minutes and the sample was placed on ice for 5 minutes. The sample was microfuged briefly to pellet any bacterial debris and PCR was carried out with 15 µl sample using primers VR61C and VR61D, above.

30 Colonies from the positive clones identified by PCR were used to inoculate a 4 ml culture of LB medium containing 100 µg/ml ampicillin. Plasmid DNA was purified using the Wizard Plus Minipreps DNA purification system (Promega). Since the primers used to PCR SEQ-61 from genomic DNA were engineered to have HindIII and XhoI sites, the cDNA obtained from the minipreps was digested with these restriction enzymes. Clones were verified

as having an insert of the correct size by gel electrophoresis. cDNA from one of the clones was then submitted for sequencing. Two mutations were found (bp 939 T→C and bp1004 G→T). The mutation at bp 939 was found to be a silent mutation and was not repaired. The mutation at bp 1004 was repaired as described below.

5 The mutation at bp 1004 in SEQ-61 was repaired using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The PCR reaction contained 38.1 µl H₂O, 5 µl 10x reaction buffer, 50 ng mini-prep cDNA from above, 1.25 µl primer VR61G (100 ng/µl) (SEQ ID NO:137), 1.25 µl primer VR61H (100 ng/µl) (SEQ ID NO:138), 2 µl 10 mM dNTP mix, and 1 µl Pfu DNA polymerase. The primer sequence for VR61G was: 5'-GCACATATGCAATCATA
10 TGGTTGACTCGAGTGAAAAGGG-3' (SEQ ID NO:137) and the primer sequence for VR61H was: 5'- CCCTTTTCACTCGAGTCAACCATATGATTGCATATGTGC-3' (SEQ ID NO:138), where the base highlighted and underlined is the one being corrected. The PCR cycle conditions were 95C for 30 seconds, then 12 cycles at 95C for 30 seconds, 55C for 1 minute, 68C for 11 minutes. One µl of DpnI was added and the reaction was incubated at 37C for 1
15 hour. One µl of the DpnI-treated DNA was transformed into 50 µl Epicurian coli XL1-Blue supercompetent cells and plated onto ampicillin plates. Two colonies were chosen and miniprep DNA was purified as described above. The presence of an insert was verified by restriction digest/gel electrophoresis. DNA from both of the samples was submitted for sequencing. Sequencing information showed that the mutation was repaired in both clones. One of the clones
20 was chosen for use in subsequent work.

 The clone described above was sequenced directly using an ABI377 fluorescence-based sequencer (Perkin Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI BigDye™ Terminator Cycle Sequencing Ready Reaction kit with Taq FSTM polymerase. Each ABI cycle sequencing reaction contained 0.5 µg of plasmid DNA. Cycle-sequencing was
25 performed using an initial denaturation at 98C for 1 minute, followed by 50 cycles: 96C for 30 seconds, annealing at 50C for 30 seconds, and extension at 60C for 4 minutes. Temperature cycles and times were controlled by a Perkin-Elmer 9600 thermocycler. Extension products were purified using AGTC (R) gel filtration block (Edge Biosystems, Gaithersburg, MD). Each reaction product was loaded by pipette onto the column, which was then centrifuged in a
30 swinging bucket centrifuge (Sorvall model RT6000B tabletop centrifuge) at 1500 x g for 4 minutes at room temperature. Column-purified samples were dried under vacuum for about 40 minutes and then dissolved in 3 µl of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples were then heated to 90C for 3.5 minutes and loaded into the gel sample wells for sequence analysis by the ABI377 sequencer. Sequence

analysis was performed by importing ABI377 files into the Sequencer program (Gene Codes, Ann Arbor, MI).

nGPCR-51

The cDNA clone for nGPCR-51 was isolated by Life Technologies, Inc. using their
5 GENETRAPPER® cDNA Positive Selection System (Cat. No. 10356-020). Double-stranded plasmid DNA from the SUPERScript Human Fetal Brain cDNA Library (Cat. No. 10662-013) was used as a substrate. The library was made with fetal brain cDNA directionally cloned into the *NotI-SalI* site of pCMV-SPORT2. An oligonucleotide probe 5'-CTCCATCTGTCTC
AGCTATGCCAGCAGCAG-3' (SEQ ID NO:139) was designed from Celera sequence
10 GA_11007426 and then biotinylated for solution hybridization to single-stranded fetal brain DNA (prepared from total cDNA library) and selection with paramagnetic beads.

Preparation of dsDNA from a Plasmid cDNA Library

One hundred ml of Terrific Broth containing 100 mg/ml ampicillin was inoculated with cells from an amplified library. The cells were grown to saturation at 30C. The sample was
15 centrifuged at 4,800 g for 15 minutes at 4C. The supernatant was decanted, and the cell pellet was resuspended in a total volume of 10 ml of buffer I with RNase (15 mM Tris-HCl (pH 8.0), 10 mM EDTA, RNase A(100 µg/ml), RNase T1 (1,200 units/ml)). Ten ml of buffer II (0.2 M NaOH, 1% SDS) was added to the resuspended cells, and the sample was inverted to mix and allowed to incubate for 5 minutes at room temperature. Ten ml of cold 7.5 M NH₄OAc was
20 added to the cell mixture, and the sample was inverted to mix and allowed to incubate on ice for 10 minutes. The sample was centrifuged at 3,000 g (4,000 rpm in an HS4 rotor) for 15 minutes at 4C. The supernatant was poured through cheesecloth into a fresh 50-ml centrifuge tube. An equal volume of cold isopropanol (-20C) was added to the tube, mixed well, and the sample was centrifuged at 3,000 g for 15 minutes at 4C. The supernatant was discarded, and the pellet was
25 resuspended in 1 ml of buffer I with RNase and transferred to a microcentrifuge tube. The solution was clarified by centrifugation at 4C for 1 minute at 14,000 g. The supernatant was transferred to a fresh microcentrifuge tube, and incubated at 37C for 30 minutes, after which the tube was incubated at 65C for 5 minutes. The sample was split into two equal parts (~500 µl each) in 1.5-ml microcentrifuge tubes. An equal volume of phenol: chloroform:isoamyl alcohol
30 (25:24:1) was added to each sample and the tube was vortexed. The sample was centrifuged at room temperature for 5 minutes at 14,000 g. Four hundred fifty µl of the upper aqueous phase was transferred to fresh microcentrifuge tubes. The phenol:chloroform extraction procedure above was repeated 3 times. An equal volume of isopropanol (-20C) was added to each tube. The tube was centrifuged at 4C for 15 minutes at 14,000 g, and the supernatant was discarded.

Five hundred μ l of 70% ethanol was carefully added to each tube. The tubes were centrifuged at 4C for 5 minutes at 14,000 g. The supernatant was discarded, and the pellet was dried at room temperature for 10 minutes. The pellets were resuspended in a total of 200 μ l TE buffer.

Generation of ssDNA

5 Five μ g ds phagemid cDNA (1 μ g/ μ l), 2 μ l 10X Gene II Buffer, and sufficient autoclaved, distilled water to bring the volume to 19 μ l was added to a 1.5 ml microcentrifuge tube at room temperature. To each sample, 1 μ l of Gene II (phage F1 endonuclease) was added. The sample was vortexed and centrifuged at room temperature for 2 s at 14,000 g to collect the contents to the bottom of the tube. The tubes were incubated in a 30C water bath for 25
10 minutes. The mixture was heated at 65C for 5 minutes and immediately chilled on ice for 1 minute. Two μ l of Exo III were added, and the tube was vortexed and centrifuged at room temperature for 2 s at 14,000 g. The tubes were incubated at 37C for 60 minutes. An equal volume (20 μ l) of phenol:chloroform:isoamyl alcohol (25:24:1) was added to each tube, vortexed thoroughly, and centrifuged at room temperature for 5 minutes at 14,000 g to separate
15 the phases. Eighteen μ l of the upper aqueous phase was transferred to a fresh 1.5-ml microcentrifuge tube.

Biotinylation Reaction

The following components were added to a 1.5 ml microcentrifuge tube:
5 μ l 5X TdT Buffer; 3 μ g oligonucleotide (SEQ ID NO:139), 5 μ l Biotin-14-dCTP, sufficient
20 autoclaved, distilled water to bring the volume to 23 μ l, and 2 μ l TdT (Terminal Deoxynucleotidyl Transferase). Each tube is vortexed gently and centrifuged for 2 s at 14,000 g. The tubes were incubated for 1 hour at 30C. After 1 hour, 1 μ l of Glycogen (20 μ g/ μ l), 26 μ l of 1 M Tris-HCl (pH 7.5), and 120 μ l of ethanol were added to the oligonucleotide biotinylation reaction. Each sample was vortexed and stored on dry ice for 10 minutes. Each tube was
25 centrifuged at 4C for 30 minutes at 14,000 g. The supernatant was removed from the microcentrifuge tubes, and 200 μ l of 70% ethanol (-20C) was layered over the pellet. Each tube was centrifuged at 4C for 2 minutes at 14,000 g. The ethanol wash was removed from the microcentrifuge tubes, and the ethanol wash was repeated once. The pellets were dried at room temperature for 10 minutes or until completely dry. The biotinylated oligonucleotide was
30 resuspended in 20 μ l TE buffer.

Oligonucleotide Hybridization

The biotinylated oligonucleotide was diluted to 20 ng/ μ l in TE buffer. The 4X Hybridization Buffer was incubated for 2 minutes at 37C, mixed well, and 6 μ l was added to the remaining 17 μ l of Gene II/Exo III-treated DNA. The DNA was denatured in a 95C water bath

for 1 minutes, and then chilled immediately on ice for 1 minute. One μ l of diluted biotinylated oligonucleotide (20 ng) was added to the denatured DNA. The tube was incubated at 37C in a water bath or incubator for 1 hour.

Streptavidin Paramagnetic Bead Preparation

- 5 The beads were gently mixed by pipetting until the beads at the bottom of the tube were completely resuspended. For each reaction, 45 μ l of the mixed beads were transferred to the bottom of a microcentrifuge tube. The tubes were placed in the magnet and allowed to sit for 2 minutes. With the tubes still in the magnet, the supernatant was removed by pipetting. One hundred μ l of TE buffer was immediately added to the beads. The tubes were removed from the magnet and the beads were resuspended by finger-tapping or vortexing at the lowest setting. The tubes were reinserted into the magnet, and after 2 min, the supernatant was removed. The beads were resuspended in 30 μ l of TE buffer.

cDNA Capture

- 15 The hybridization mixture was removed from the 37C water bath and centrifuged at room temperature for 2 s at 14,000 g. The prepared paramagnetic beads were pipetted into the mixture and gently mixed by pipetting. The suspension was incubated for 30 minutes at room temperature. The suspension was gently mixed frequently to resuspend the beads. The tubes were inserted into the magnet, and after 2 min, the supernatant was removed and discarded. One hundred μ l of Wash Buffer was then added to the beads. The beads were resuspended and the tubes reinserted into the magnet for 2 minutes. The supernatant was removed and discarded. The washing step was repeated one more time. One hundred μ l of Wash Buffer was added to the beads. The beads were gently resuspended by pipetting up and down (not by vortexing) and the solution was transferred to a new tube. The tubes were inserted into the magnet for 5 minutes. The supernatant was removed from the paramagnetic beads and discarded. One hundred μ l of Wash Buffer was immediately added and the tubes mixed by finger tapping or gently vortexing. The tubes were placed into the magnet for 5 minutes. For each elution, 14 μ l of TE buffer (pH 8.0) was mixed with 7 μ l of the 3X Elution Buffer. After the 5 minute incubation, the supernatant was removed and discarded from the paramagnetic beads; 20 μ l of 1X elution buffer was added to the beads, and mixed well. The beads were incubated for 5 minutes at room temperature. During the incubation, the beads were mixed for 10 seconds every minute. The tube was inserted into the magnet and allowed to sit for 5 minutes. The supernatant (containing the captured cDNA clone) was collected and transferred to a fresh tube, and the beads were resuspended in 15 μ l of TE buffer. The tube was inserted into the magnet and allowed to sit for 5 minutes. The supernatant was transferred from the tube and combined with the previous

supernatant. The tube containing the combined supernatants was inserted into the magnet for 10 minutes to remove any remaining paramagnetic beads and the supernatant was transferred to a fresh microcentrifuge tube. To the supernatant (~35 µl), 1 µl of Glycogen, 18 µl of 7.5 M NH₄OAc, and 135 µl of ethanol (-20C) were added. The tube was mixed well and stored on ice for 5 10 minutes. The tube was centrifuged at 4C for 30 minutes at 14,000 g. The supernatant was removed from the small pellets. One hundred µl of 70% ethanol was added to each tube. The tubes were centrifuged at room temperature for 2 minutes at 14,000 g. The ethanol was removed and the pellets dried at room temperature until dry. The pellets were resuspended in 5 µl of TE buffer and stored at 4C.

10 *Repair of Captured cDNA: Repair Reaction*

The thermal cycler is programmed for one cycle as described below:
90C denature step for 1 minute; 55C annealing step for 30 seconds; 70C extension step for 15 minutes. A DNA primer/repair mix was prepared for each capture reaction by adding the following to the captured cDNA: captured DNA (5 µl), autoclaved, distilled water (11 µl), 50 ng 15 oligonucleotide (SEQ ID NO:139; not biotinylated)(1 µl), 10 mM dNTP Mix (0.5 µl), 10X Repair Buffer (2 µl), Repair Enzyme (0.5 µl). The tubes were mixed and centrifuged at room temperature for 2 s at 14,000 g. The DNA primer/repair mix was incubated at 90C for 1 minute. The mix was transferred to 55C and incubated for 30 seconds. The mix was transferred to 70C and incubated for 15 minutes to allow primer extension. The mix was centrifuged at room 20 temperature for 2 s at 14,000 g. The repaired DNA was precipitated by adding 1 µl Glycogen, 11 µl 7.5 M ammonium acetate, and 90 µl of -20C ethanol to each tube. The tubes were vortexed and placed in ice for 10 minutes. The tubes were centrifuged at 4C for 30 minutes at 14,000 g. The ethanol was removed from the small pellet and 100 µl of 70% ethanol (-20C) was layered on the pellet. The tubes were centrifuged at 4C for 2 minutes at 14,000 g. The ethanol 25 was removed and the pellets dried at room temperature until dry. The pellets were dissolved in 10 µl of TE buffer.

Transformation with ULTRAMAX DH5a a-FT Cells

Competent cells were removed from -70C freezer and thawed on wet ice. The required number of 17 × 100 polypropylene tubes (Falcon 2059) were placed on ice. Immediately after 30 thawing, the cells were gently mixed, then 100 µl of cells were aliquotted into chilled polypropylene tubes. Three µl of the DNA were mixed into each individual tube of cells. The cells were incubated on ice for 30 minutes. Cells were heat-shocked for 45 seconds in a 42C water bath, and then placed on ice for 2 minutes. To each tube, 0.9 ml of room temperature S.O.C medium was added. The tubes were shaken at 225 rpm (37C) for 1 hour. For captured or

repaired cDNA samples, 100 µl and 200 µl aliquots were plated onto LB plates containing 100 µg/ml ampicillin. The plates were incubated overnight in a 37C incubator.

Identification of Desired cDNA Clones by Colony PCR

A PCR master mix was prepared with the following components: 22.5 µl/clone of 1X
5 PCR SUPERMIX, forward and reverse primers at a final concentration of 200 nM/primer, and autoclaved, distilled water to a final volume of 25 µl. Using a micropipette tip or sterile toothpick, each colony was picked and placed into an individual tube containing master mix. The PCR reaction was as follows: 1 cycle at 94C, 1 minute, then 30 cycles of 94C, 30 seconds; 55C, 30 seconds; 72C, 1 minute. The PCR primer pairs used in colony screening were, forward
10 primer: 5'-CCATCTGTCTCAGCTATGCC-3' (SEQ ID NO:140), and the reverse primer: 5'-TCCTTCTCAGTCGCTCTTC-3' (SEQ ID NO:141).

nGPCR-52

Two microliters of a human genomic library (~10⁸ PFU/ml) (Clontech) were added to 6 ml of an overnight culture of K802 cells (Clontech), then distributed as 250 µl aliquots into each
15 of 24 tubes. The tubes were incubated at 37C for 15 minutes. Seven milliliters of 0.8% agarose was added to each tube, mixed, then poured onto LB agar + 10 mM MgSO₄ plates and incubated overnight at 37C. To each plate 5 ml of SM (0.1M NaCl, 8.1 mM MgSO₄·7H₂O, 50mM Tris-Cl (pH 7.5), 0.0001% gelatin) phage buffer was added and the top agarose was removed with a microscope slide and placed in a 50 ml centrifuge tube. A drop of chloroform was added and the
20 tube was placed in a 37C shaker for 15 minutes, then centrifuged for 20 minutes at 4000 RPM (Sorvall RT6000 table top centrifuge) and the supernatant stored at 4C as a stock solution.

The PCR reaction was performed in 20 µl containing 8.8 µl H₂O, 4 µl 5X Rapid-Load Buffer (Origene), 2 µl 10xPCR buffer II (Perkin-Elmer), 2 µl 25 mM MgCl₂, 0.8 µl 10 mM dNTP, 0.12 µl LW1632 (SEQ ID NO:142) (1 µg/µl), 0.12 µl LW1633 (SEQ ID NO:143) (1
25 µg/µl), 0.2 µl AmpliTaq Gold polymerase (Perkin Elmer) and 2 µl of phage from each of the 24 tubes. The PCR reaction involved 1 cycle at 80C for 20 minutes, 95C for 10 minutes, then 22 cycles at 95C for 30 seconds, 72C for 4 minutes decreasing 1C each cycle, 68C for 2 minutes, followed by 30 cycles at 95C for 30 seconds, 55C for 30 seconds, 68C for 60 seconds. The reaction was loaded onto a 2 % agarose gel. From the tube that gave a PCR product of the
30 correct size, 5 µl was used to set up five 1:10 dilutions that were plated onto LB agar + 10 mM MgSO₄ plates and incubated overnight. A BA85 nitrocellulose filter (Schleicher & Schuell) was placed on top of each plate for 1 hour. The filter was removed, placed phage side up in a petri dish, and covered with 4 ml of SM for 15 minutes to elute the phage. One milliliter of SM was removed from each plate and used to set up a PCR reaction as above. The plate of the lowest

dilution to give a PCR product was subdivided, filter-lifted and the PCR reaction was repeated. The series of dilutions and subdividing of the plate was continued until a single plaque was isolated that gave a positive PCR band. Once a single plaque was isolated, 10 µl phage supernatant was added to 100 µl SM and 200 µl of K802 cells per plate with a total of 8 plates set up. The plates were incubated overnight at 37C. The top agarose was removed by adding 8 ml of SM, then scrapping off the agarose with a microscope slide and collected in a centrifuge tube. To the tube, 3 drops of chloroform was added, vortexed, incubated at 37C for 15 minutes then centrifuged for 20 minutes at 4000 RPM (Sorvall RT6000 table top centrifuge) to recover the phage, which was used to isolate genomic phage DNA using the Qiagen Lambda Midi Kit. The sequence for primer LW1632 was 5'-CCTCCACTTGTGCTTCATC-3' (SEQ ID NO:142) and for LW1633: 5'-AAAATCTATCAACACCCAGCC-3' (SEQ ID NO:143).

For subcloning the coding region of nGPCR-52, PCR was performed in a 50 µl reaction containing 33 µl H₂O, 5 µl 10X TT buffer (140 mM Ammonium Sulfate, 0.1 % gelatin, 0.6 M Tris-tricine pH 8.4), 5 µl 15 mM MgSO₄, 2 µl 10 mM dNTP, 4 µl genomic phage DNA (0.1 µg/µl), 0.3 µl LW1643 (SEQ ID NO:144) (1 µg/µl), 0.3 µl LW1644 (SEQ ID NO:145) (1 µg/µl), 0.4 µl High Fidelity Taq polymerase (Boehringer Mannheim). The PCR reaction was started with 1 cycle of 94C for 2 minutes followed by 15 cycles at 94C for 30 seconds, 55C for 60 seconds, and 68C for 2 minutes. The PCR reaction was loaded onto a 2 % agarose gel. The DNA band was excised from the gel, placed in GenElute Agarose spin column (Supelco) and spun for 10 minutes at maximum speed. The eluted DNA was EtOH precipitated and resuspended in 12µl H₂O for ligation. The PCR primer sequence for LW1643: 5'-GATCAAGCTTACCATGACCAGCAATTTTCCC-3' (SEQ ID NO:144) and for LW1644 was: 5'-GATCCTCGAGCTTATTCTAAAAATAAACTAATGG-3' (SEQ ID NO:145). The ligation reaction used solutions from the TOPO TA Cloning Kit (Invitrogen) which consisted of 4µl PCR product DNA and 1 µl pCRII-TOPO vector that was incubated for 5 minutes at room temperature. To the ligation reaction one microliter of 6X TOPO Cloning Stop Solution was added then the reaction was placed on ice. Two microliters of the ligation reaction was transformed in One-Shot TOP10 cells (Invitrogen), and placed on ice for 30 minutes. The cells were heat-shocked for 30 seconds at 42C, placed on ice for two minutes, 250 µl of SOC was added, then incubated at 37C with shaking for one hour and then plated onto ampicillin plates. A single colony containing an insert was used to inoculate a 5 ml culture of LB medium. Plasmid DNA was purified using a Concert Rapid Plasmid Miniprep System (GibcoBRL) and then sequenced.

nGPCR-52 genomic phage DNA was sequenced using the ABI PRISM™ 310 Genetic Analyzer (PE Applied Biosystems) which uses advanced capillary electrophoresis technology and the ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit. The cycle-sequencing reaction contained 14 µl of H₂O, 16 µl of BigDye Terminator mix, 7 µl genomic phage DNA (0.1 µg/µl), and 3 µl primer (25 ng/µl). The reaction was performed in a Perkin-Elmer 9600 thermocycler at 95C for 5 minutes, followed by 99 cycles of 95C for 30 seconds, 55C for 20 seconds, and 60C for 4 minutes. The product was purified using a Centriflex™ gel filtration cartridges, dried under vacuum, then dissolved in 16 µl of Template Suppression Reagent. The samples were heated at 95C for 5 minutes then placed in the 310 Genetic Analyzer

Example 3: Subcloning of the Coding Region of nGPCR-x Via PCR

Additional experiments may be conducted to subclone the coding region of nGPCR and place the isolated coding region into a useful vector. Two additional PCR primers are designed based on the coding region of nGPCR, corresponding to either end. To protect against exonucleolytic attack during subsequent exposure to enzymes, *e.g.*, Taq polymerase, primers are routinely synthesized with a protective run of nucleotides at the 5' end that were not necessarily complementary to the desired target.

PCR is performed in a 50 µl reaction containing 34 µl H₂O, 5 µl 10X TT buffer (140 mM ammonium sulfate, 0.1% gelatin, 0.6 M Tris-tricine, pH 8.4), 5 µl 15 mM MgSO₄, 2 µl dNTP mixture (dGTP, dATP, dTTP, and dCTP, each at 10 mM), 3 µl genomic phage DNA (0.25 µg/µl), 0.3 µl Primer 1 (1 µg/µl), 0.3 µl Primer 2 (1 µg/µl), 0.4 µl High Fidelity Taq polymerase (Boehringer Mannheim). The PCR reaction was started with 1 cycle of 94C for 2 minutes; followed by 25 cycles at 94C for 30 seconds, 55C for 30 seconds, and 72C for 1.3 minutes.

The contents from the PCR reaction are loaded onto a 2% agarose gel and fractionated. The DNA band of expected size is excised from the gel, placed in a GenElute Agarose spin column (Supelco) and spun for 10 minutes at maximum speed in a microfuge. The eluted DNA is precipitated with ethanol and resuspended in 6 µl H₂O for ligation.

The PCR-amplified DNA fragment containing the coding region is cloned into pCR2.1 using a protocol standard in the art. In particular, the ligation reaction consists of 6 µl of GPCR DNA, 1 µl 10X ligation buffer, 2 µl pCR2.1 (25 ng/µl, Invitrogen), and 1 µl T4 DNA ligase (Invitrogen). The reaction mixture is incubated overnight at 14C and the reaction is then stopped by heating at 65C for 10 minutes. Two microliters of the ligation reaction are transformed into One Shot cells (Invitrogen) and plated onto ampicillin plates. A single colony containing a recombinant pCR2.1 bearing an insert is used to inoculate a 5 ml culture of LB medium.

Plasmid DNA is purified using the Concert Rapid Plasmid Miniprep System (GibcoBRL) and sequenced. Following confirmation of the sequence, a 50 ml culture of LB medium is inoculated with the transformed One Shot cells, cultured, and processed using a Qiagen Plasmid Midi Kit to yield purified pCR-GPCR.

5 *nGPCR-70*

Colonies from the positive clones identified by PCR were used to inoculate a 4 ml culture of LB medium containing 100 µg/ml ampicillin. Plasmid DNA was purified using the Wizard Plus Minipreps DNA purification system (Promega). Since the primers used to PCR SEQ-70 from human brain cDNA were engineered to have HindIII and XhoI sites, the DNA
10 obtained from the minipreps was digested with these restriction enzymes. Five of the clones were verified by gel electrophoresis to give a DNA band of the correct size. cDNA from each of these clones was then submitted for sequencing. Each of the clones was found to have two or more mutations. The clone containing the fewest mutations (clone #7-2 mutations at bp 561 G→A and bp 1093 G→A) was repaired as described as below.

15 The mutations in SEQ-70 were repaired sequentially using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The mutation at bp 561 was repaired first and the primer sequences used were: VR70G 5'-CATGATCTGGGGGCCAGCCCCAGC-3' (SEQ ID NO:146) and VR70H 5'-GCTGGGGCTGGCCCCCCAGATCATG-3' (SEQ ID NO:147) where the base highlighted and underlined is the one being corrected. The PCR reaction contained 38.4
20 µl H₂O, 5 µl 10x reaction buffer, 50 ng mini-prep cDNA from clone #7, 2 µl 10 mM dNTP mix, and 1 µl Pfu DNA polymerase. The cycle conditions were 95C for 30 seconds, then 12 cycles at 95C for 30 seconds, 55C for 1 minute, 68C for 11 minutes. One µl of DpnI was added and the reaction was incubated at 37C for 1 hour. One µl of the DpnI-treated DNA was transformed into 50 µl Epicurian coli XL1-Blue supercompetent cells and plated onto ampicillin
25 plates. Four colonies were chosen and miniprep DNA was purified as described above. DNA from one of the preps was used as a template to repair the second mutation at bp 1093. The primer sequences used were: VR70I 5'-GACATCAATTTTCAGTGAGGATGACGTCGAGGCAG-3' (SEQ ID NO:148) and VR70J 5'-CTGCCTCGACGTCATCCTCACTGAAATTGATGTC-3' (SEQ ID NO:149), where the base highlighted and underlined is the one being corrected.
30 The PCR and transformation reactions were carried out as described above. Mini-prep DNA was prepared from three colonies, and the presence of an insert was verified by restriction digest/gel electrophoresis. DNA from one of the samples was submitted for sequencing. Sequencing information showed that both mutations were repaired but that an additional mutation at bp 560 (G→A) had been introduced. This mutation was adjacent to the original mutation at bp 561 and

was encompassed in the sequence of the primer that was used. Since it could not be ruled out that there was an error in the synthesis of the primers, the same exact sequence corresponding to primers VR70G (SEQ ID NO:146) and VR70H (SEQ ID NO:147) was reordered and repair of the mutation with the new primers was carried out as above. DNA from 2 clones was submitted for sequencing. One of the clones had no mutations and was used for subsequent work.

The clone described above was sequenced directly using an ABI377 fluorescence-based sequencer (Perkin Elmer/Applied Biosystems Division, PE/ABD, Foster City, CA) and the ABI BigDye™ Terminator Cycle Sequencing Ready Reaction kit with Taq FSTM polymerase. Each ABI cycle sequencing reaction contained 0.5 µg of plasmid DNA. Cycle-sequencing was performed using an initial denaturation at 98C for 1 minute, followed by 50 cycles: 96C for 30 seconds, annealing at 50C for 30 seconds, and extension at 60C for 4 minutes. Temperature cycles and times were controlled by a Perkin-Elmer 9600 thermocycler. Extension products were purified using AGTC (R) gel filtration block (Edge Biosystems, Gaithersburg, MD). Each reaction product was loaded by pipette onto the column, which was then centrifuged in a swinging bucket centrifuge (Sorvall model RT6000B tabletop centrifuge) at 1500 x g for 4 minutes at room temperature. Column-purified samples were dried under vacuum for about 40 minutes and then dissolved in 3 µl of a DNA loading solution (83% deionized formamide, 8.3 mM EDTA, and 1.6 mg/ml Blue Dextran). The samples were then heated to 90C for 3.5 minutes and loaded into the gel sample wells for sequence analysis by the ABI377 sequencer. Sequence analysis was performed by importing ABI377 files into the Sequencer program (Gene Codes, Ann Arbor, MI).

nGPCR-42

The DNA subcloned into pCRII was sequenced using the ABI PRISM™ 310 Genetic Analyzer (PE Applied Biosystems) which uses advanced capillary electrophoresis technology and the ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit. Each cycle-sequencing reaction contained 6 µl of H₂O, 8 µl of BigDye Terminator mix, 5 µl mini-prep DNA (0.1 µg/µl), and 1 µl primer (25 ng/µl) and was performed in a Perkin-Elmer 9600 thermocycler with 25 cycles of 96C for 10 seconds, 50C for 10 seconds, and 60C for 4 minutes. The product was purified using a Centriflex™ gel filtration cartridge, dried under vacuum, then dissolved in 16 µl of Template Suppression Reagent (PE Applied Biosystems). The samples were heated at 95C for 5 minutes then placed in the 310 Genetic Analyzer.

nGPCR-46

The DNA subcloned into pCRII was sequenced using the ABI PRISM™ 310 Genetic Analyzer (PE Applied Biosystems) which uses advanced capillary electrophoresis technology

and the ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit. Each cycle-sequencing reaction contained 6 µl of H₂O, 8 µl of BigDye Terminator mix, 5 µl mini-prep DNA (0.1 µg/µl), and 1 µl primer (25 ng/µl) and was performed in a Perkin-Elmer 9600 thermocycler with 25 cycles of 96C for 10 seconds, 50C for 10 seconds, and 60C for 4 minutes. The product was purified using a Centriflex™ gel filtration cartridge, dried under vacuum, then dissolved in 16 µl of Template Suppression Reagent (PE Applied Biosystems). The samples were heated at 95C for 5 minutes then placed in the 310 Genetic Analyzer.

The mutation found in the clone was repaired using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The PCR reaction contained 39 µl H₂O, 5 µl 10xReaction buffer, 1 µl mini-prep DNA (150 ng/µl), 2µl 10 mM dNTP, 1 µl Pfu DNA polymerase, 1 µl LW1638 (SEQ ID NO:150) (125 ng/µl), and 1 µl LW1639 (SEQ ID NO:151) (125 ng/µl). The cycle conditions were 95C for 30 seconds then 12 cycles at 95C for 30 seconds, 55C for 1 minute, 68C for 12 minutes. The tube was placed on ice for 2 minutes, then 1 µl of DpnI was added and the tube incubated at 37C for one hour. Two microliters of the *DpnI*-treated DNA was transformed into Epicurian coli XL1-Blue supercompetent cells and the entire insert was re-sequenced. The forward PCR primer sequence was: LW1638 5'-CGAACTCCGCACTCCTGG CCAGGGCCCTGCGGGC-3' (SEQ ID NO:150) and the reverse PCR primer sequence was: LW1639 5'-GCCCGCAGGGCCCTGGCCAGGAGTGCGGAGTTC-3' (SEQ ID NO:151).
nGPCR-48

The DNA subcloned into pCRII was sequenced using the ABI PRISM™ 310 Genetic Analyzer (PE Applied Biosystems) which uses advanced capillary electrophoresis technology and the ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit. Each cycle-sequencing reaction contained 6 µl of H₂O, 8 µl of BigDye Terminator mix, 5 µl mini-prep DNA (0.1 µg/µl), and 1 µl primer (25 ng/µl) and was performed in a Perkin-Elmer 9600 thermocycler with 25 cycles of 96C for 10 seconds, 50C for 10 seconds, and 60C for 4 minutes. The product was purified using a Centriflex™ gel filtration cartridge, dried under vacuum, then dissolved in 16 µl of Template Suppression Reagent (PE Applied Biosystems). The samples were heated at 95C for 5 minutes then placed in the 310 Genetic Analyzer.

nGPCR-49

The DNA subcloned into pCRII was sequenced using the ABI PRISM™ 310 Genetic Analyzer (PE Applied Biosystems) which uses advanced capillary electrophoresis technology and the ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit. Each cycle-sequencing reaction contained 6 µl of H₂O, 8 µl of BigDye Terminator mix, 5 µl mini-prep DNA (0.1 µg/µl), and 1 µl primer (25 ng/µl) (SEQ ID NO:131 and SEQ ID NO:132) and was

performed in a Perkin-Elmer 9600 thermocycler with 25 cycles of 96C for 10 seconds, 50C for 10 seconds, and 60C for 4 minutes. The product was purified using a Centriflex™ gel filtration cartridge, dried under vacuum, then dissolved in 16 µl of Template Suppression Reagent (PE Applied Biosystems). The samples were heated at 95C for 5 minutes then placed in the 310

5 Genetic Analyzer.

nGPCR-52

The DNA subcloned into pCRII was sequenced using the ABI PRISM™ 310 Genetic Analyzer (PE Applied Biosystems) which uses advanced capillary electrophoresis technology and the ABI PRISM™ BigDye™ Terminator Cycle Sequencing Ready Reaction Kit. Each
10 cycle-sequencing reaction contained 6 µl of H₂O, 8 µl of BigDye Terminator mix, 5 µl mini-prep DNA (0.1 µg/µl), and 1 µl primer (25 ng/µl) and was performed in a Perkin-Elmer 9600 thermocycler with 25 cycles of 96C for 10 seconds, 50C for 10 seconds, and 60C for 4 minutes. The product was purified using a Centriflex™ gel filtration cartridge, dried under vacuum, then dissolved in 16 µl of Template Suppression Reagent (PE Applied Biosystems). The samples
15 were heated at 95C for 5 minutes then placed in the 310 Genetic Analyzer.

Example 4: Hybridization Analysis to Demonstrate nGPCR-X Expression in Brain

The expression of nGPCR-x in mammals, such as the rat, may be investigated by *in situ* hybridization histochemistry. To investigate expression in the brain, for example, coronal and sagittal rat brain cryosections (20 µm thick) are prepared using a Reichert-Jung cryostat.
20 Individual sections are thaw-mounted onto silanized, nuclease-free slides (CEL Associates, Inc., Houston, TX), and stored at -80C. Sections are processed starting with post-fixation in cold 4% paraformaldehyde, rinsed in cold phosphate-buffered saline (PBS), acetylated using acetic anhydride in triethanolamine buffer, and dehydrated through a series of alcohol washes in 70%, 95%, and 100% alcohol at room temperature. Subsequently, sections are delipidated in
25 chloroform, followed by rehydration through successive exposure to 100% and 95% alcohol at room temperature. Microscope slides containing processed cryosections are allowed to air dry prior to hybridization. Other tissues may be assayed in a similar fashion.

A nGPCR-x-specific probe is generated using PCR. Following PCR amplification, the fragment is digested with restriction enzymes and cloned into pBluescript II cleaved with the
30 same enzymes. For production of a probe specific for the sense strand of nGPCR-x, the nGPCR-x clone in pBluescript II is linearized with a suitable restriction enzyme, which provides a substrate for labeled run-off transcripts (*i.e.*, cRNA riboprobes) using the vector-borne T7 promoter and commercially available T7 RNA polymerase. A probe specific for the antisense strand of nGPCR-x is also readily prepared using the nGPCR-x clone in pBluescript II by

cleaving the recombinant plasmid with a suitable restriction enzyme to generate a linearized substrate for the production of labeled run-off cRNA transcripts using the T3 promoter and cognate polymerase. The riboprobes are labeled with [³⁵S]-UTP to yield a specific activity of about 0.40×10^6 cpm/pmol for antisense riboprobes and about 0.65×10^6 cpm/pmol for sense-strand riboprobes. Each riboprobe is subsequently denatured and added (2 pmol/ml) to hybridization buffer which contained 50% formamide, 10% dextran, 0.3 M NaCl, 10 mM Tris (pH 8.0), 1 mM EDTA, 1X Denhardt's Solution, and 10 mM dithiothreitol. Microscope slides containing sequential brain cryosections are independently exposed to 45 μ l of hybridization solution per slide and silanized cover slips are placed over the sections being exposed to hybridization solution. Sections are incubated overnight (15-18 hours) at 52C to allow hybridization to occur. Equivalent series of cryosections are exposed to sense or antisense nGPCR-x-specific cRNA riboprobes.

Following the hybridization period, coverslips are washed off the slides in 1X SSC, followed by RNase A treatment involving the exposure of slides to 20 μ g/ml RNase A in a buffer containing 10 mM Tris-HCl (pH 7.4), 0.5 M EDTA, and 0.5 M NaCl for 45 minutes at 37C. The cryosections are then subjected to three high-stringency washes in 0.1 X SSC at 52C for 20 minutes each. Following the series of washes, cryosections are dehydrated by consecutive exposure to 70%, 95%, and 100% ammonium acetate in alcohol, followed by air drying and exposure to Kodak BioMax™ MR-1 film. After 13 days of exposure, the film is developed. Based on these results, slides containing tissue that hybridized, as shown by film autoradiograms, are coated with Kodak NTB-2 nuclear track emulsion and the slides are stored in the dark for 32 days. The slides are then developed and counterstained with hematoxylin. Emulsion-coated sections are analyzed microscopically to determine the specificity of labeling. The signal is determined to be specific if autoradiographic grains (generated by antisense probe hybridization) are clearly associated with cresyl violet-stained cell bodies. Autoradiographic grains found between cell bodies indicates non-specific binding of the probe.

Expression of nGPCR-x in the brain provides an indication that modulators of nGPCR-x activity have utility for treating neurological disorders, including but not limited to, mental disorder, affective disorders, ADHD/ADD (*i.e.*, Attention Deficit-Hyperactivity Disorder/Attention Deficit Disorder), and neural disorders such as Alzheimer's disease, Parkinson's disease, migraine, and senile dementia. Some other diseases for which modulators of nGPCR-x may have utility include depression, anxiety, bipolar disease, epilepsy, neuritis, neurasthenia, neuropathy, neuroses, and the like. Use of nGPCR-x modulators, including

nGPCR-x ligands and anti-nGPCR-x antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

In Situ Hybridization of SEQ-51

Coronal and sagittal oriented rat brain sections were cryosectioned (20 μ m thick) using a
5 Leica CM3050 cryostat. The individual sections were thaw-mounted onto silanated, nuclease-free slides (CEL Associates, Inc., Houston, TX), and stored at -80C. The sections were processed starting with post-fixation in cold 4% paraformaldehyde, rinsed in cold PBS, acetylated using acetic anhydride in triethanolamine buffer and dehydrated through 70%, 95%, and 100% alcohols at room temperature (RT). This was followed with delipidation in
10 chloroform then rehydration in 100% and 95% alcohol at RT. Sections were allowed to air dry prior to hybridization. For nGPCR-51, a 250 bp PCR fragment (spanning nt 83 to 332) was generated that contained T7 polymerase on either the 5' end (sense) with primers LW1743 5'-GCGTAATACGACTCACTATAGGGAGACCTGCCAGTGTGGTAGATACAG-3' (SEQ ID NO:152) and LW1746 5'-GGATGTGATGATGGTGCAG-3' (SEQ ID NO:153) or the 3' end
15 (antisense) with primers LW1744 5'-GCGTAATACGACTCACTATAGGGAGACCGGATGTGATGATGGTGCAG-3' (SEQ ID NO:154) and LW1745 5'-TGCCAGTGTGGTAGATACAG-3' (SEQ ID NO:155). nGPCR-51 was labeled with 35 S-UTP to yield a specific activity of 0.655×10^6 cpm/pmol for antisense and 0.675×10^6 cpm/pmol for sense probe. Both riboprobes were denatured and added to hybridization buffer which contained 50% formamide, 10%
20 dextran, 0.3M NaCl, 10 mM Tris, 1 mM EDTA, 1X Denhardt's, and 10 mM DTT. Sequential brain cryosections were hybridized with 45 μ l/slide of the sense and antisense riboprobe hybridization mixture then coverslipped with silanized glass coverslips. The sections were hybridized overnight (15-18 hours) at 50C in an incubator.

Coverslips were washed off the slides in 1X SSC, followed by RNase A treatment, and
25 high temperature stringency washes (3X; 20 minutes at 49C) in 0.1X SSC. Slides were dehydrated with 70%, 95% and 100% NH_4OAc alcohols, air dried and exposed to Kodak BioMax MR-1 film. After 8 days of exposure, the film was developed. This was followed with coating selected tissue slides with Kodak NTB-2 nuclear track emulsion and storing the slides in the dark for 16 days. The slides were then developed and counterstained with hematoxylin.
30 Emulsion-coated sections were analyzed microscopically to determine the specificity of labeling. Presence of autoradiographic grains (generated by antisense probe hybridization) over cell bodies (versus between cell bodies) was used as an index of specific hybridization.

Sense and antisense 35 S-labeled RNA probes were generated using a 250-bp fragment of nGPCR-51 for *in situ* hybridization histochemistry. Specific labeling with the antisense probe

showed wide spread distribution of nGPCR-51 mRNA. Localization appears in the piriform ctx, habenula, bed nucleus of stria terminalis, islands of Calleja, olfactory tubercle, hippocampus, hypothalamus, PVN, red nucleus, interpeduncular nucleus, dorsal raphe, substantia nigra pars compacta, and reticular thalamus. Expression of nGPCR-51 in these brain regions provided an indication that modulators of nGPCR-51 activity have utility for treating disorders, including but not limited to, schizophrenia, major depression, bipolar disease, anxiety disorder, Parkinson's disease, endocrine disorders, Alzheimer's disease and the like.

In Situ Hybridization SEQ-52

Coronal and sagittal oriented rat brain sections were cryosectioned (20 μ m thick) using a Leica CM3050 cryostat. The individual sections were thaw-mounted onto silanated, nuclease-free slides (CEL Associates, Inc., Houston, TX), and stored at -80C. The sections were processed starting with post-fixation in cold 4% paraformaldehyde, rinsed in cold PBS, acetylated using acetic anhydride in triethanolamine buffer and dehydrated through 70%, 95%, and 100% alcohols at room temperature. This was followed with delipidation in chloroform then rehydration in 100% and 95% alcohol at room temperature. Sections were allowed to air dry prior to hybridization. For nGPCR-52, a 292 bp PCR fragment (spanning nt 2920 to 3211) was generated that contained T7 polymerase on either the 5' end (sense) with primers LW1682 5'-GCGTAATACGACTCACTATAGGGAGACCACCAGCAATTTTCCCAACC-3' (SEQ ID NO:156) and LW1685 5'-AATACCAGCAGCTCTCCAC-3' (SEQ ID NO:157) or the 3' end (antisense) with primers LW1683 5'-GCGTAATACGACTCACTATAGGGAGACCAATACCAGCAGCTCTCCAC-3' (SEQ ID NO:158) and LW1784 5'-ACCAGCAATTTTCCCAACC-3' (SEQ ID NO:159). nGPCR-52 was labeled with 35 S-UTP to yield a specific activity of 0.686×10^6 cpm/pmol for the antisense probe and 0.601×10^6 cpm/pmol for the sense probe. Both riboprobes were denatured and added to hybridization buffer which contained 50% formamide, 10% dextran, 0.3M NaCl, 10 mM Tris, 1 mM EDTA, 1X Denhardts, and 10 mM DTT. Sequential brain cryosections were hybridized with 45 TI/slide of the sense and antisense riboprobe hybridization mixture then coverslipped with silanized glass coverslips. The sections were hybridized overnight (15-18 hours) at 49C in an incubator.

Coverslips were washed off the slides in 1X SSC, followed by RNase A treatment, and high temperature stringency washes (3X, 20 minutes at 48C) in 0.1X SSC. Slides were dehydrated with 70%, 95% and 100% NH_4OAc alcohols, air dried and exposed to Kodak BioMax MR-1 film. After 8 days of exposure, the film was developed. This was followed with coating selected tissue slides with Kodak NTB-2 nuclear track emulsion and storing the slides in the dark for 16 days. The slides were then developed and counterstained with hematoxylin.

Emulsion-coated sections were analyzed microscopically to determine the specificity of labeling. Presence of autoradiographic grains (generated by antisense probe hybridization) over cell bodies (versus between cell bodies) was used as an index of specific hybridization.

To determine which regions of the brain nGPCR-52 is expressed in, a 292 bp fragment of nGPCR-52 was used to generate sense and antisense ³⁵S-labeled RNA probes for *in situ* hybridization histochemistry. Specific labeling with the antisense probe showed wide spread distribution of nGPCR-52 mRNA. Localization appears in the cortex, piriform ctx, habenula, islands of Calleja, hippocampus, hypothalamus, red nucleus, dorsal raphe, substantia nigra pars compacta, and reticular thalamus. The regions where nGPCR-52 is expressed are within the limbic and neuroendocrine circuitry of the brain.

Example 5: Tissue Expression Profiling

A PCR-based system (RapidScan™ Gene Expression Panel, OriGene Technologies, Rockville, MD) may be used to generate a comprehensive expression profile of the putative nGPCR-x in human tissue, and in human brain regions. The RapidScan Expression Panel is comprised of first-strand cDNAs from various human tissues and brain regions that are serially diluted over a 4-log range and arrayed into a multi-well PCR plate. Human tissues in the array may include: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle, stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, prostate, skin, PBL, bone marrow, fetal brain, and fetal liver.

Expression of nGPCR-x in various tissues is detected using PCR primers designed based on the available sequence of the receptor that will prime the synthesis of a predetermined size fragment in the presence of the appropriate cDNA.

PCR is performed in a 50 µl reaction containing 34 µl H₂O, 5µl 10X TT buffer (140 mM ammonium sulfate, 0.1% gelatin, 0.6 M Tris-tricine, pH 8.4), 5 µl 15 mM MgSO₄, 2 µl dNTP mixture (dGTP, dATP, dTTP, and dCTP, each at 10 mM), 0.3 µl forward primer (1 µg/µl), 0.3 µl reverse primer (1 µg/µl), 0.4 µl High Fidelity Taq polymerase (Boehringer Mannheim). The PCR reaction mixture is added to each well of the PCR plate. The plate is placed in a MJ Research PTC100 thermocycler, and is then exposed to the following cycling parameters: Pre-soak 94C for 3 minutes; denaturation at 94C for 30 seconds; annealing at primer 57C for 45 seconds; extension 72C for 2 minutes; for 35 cycles. PCR productions are then separated and analyzed by electrophoresis on a 1.2% agarose gel stained with ethidium bromide. The 4-log dilution range of cDNA deposited on the plate ensures that the amplification reaction is within the linear range and, hence, facilitates semi-quantitative determination of relative mRNA accumulation in the various tissues or brain regions examined.

nGPCR-70

Tissue specific expression of the cDNA encoding nGPCR-70 was detected using a PCR-based method. Multiple Choice™ first strand cDNAs (OriGene Technologies, Rockville, MD) from 6 human tissues were serially diluted over a 3-log range and arrayed into a multi-well PCR plate. This array was used to generate a comprehensive expression profile of the putative GPCR in human tissues. Human tissues arrayed included: brain, heart, kidney, peripheral blood leukocytes, lung and testis. PCR primers were designed based on the available sequence of the Celera sequence GA_16417344. The forward primer used was: 5'-GTGACTAACTCTGCCT GCG-3' (SEQ ID NO:160). The reverse primer used was: 5'-TTGCGCTGCAACACTAGCG-3' (SEQ ID NO:161). This primer set primed the synthesis of a 286 base pair fragment in the presence of the appropriate cDNA. For detection of expression within brain regions, the same primer set was used with the Human Brain Rapid Scan™ Panel (OriGene Technologies, Rockville, MD). This panel represented serial dilutions over a 2 log range of first strand cDNA from the following brain regions arrayed in a 96 well format: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord. Primers were synthesized by Genosys Corp., The Woodlands, TX. PCR reactions were assembled using the components of the Expand Hi-Fi PCR System™ (Roche Molecular Biochemicals, Indianapolis, IN). Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at (94C for 3 minutes) followed by 35 cycles of 94C for 45 seconds, 53C for 2 minutes and 72C for 45 seconds. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel stained with ethidium bromide.

nGPCR-70 was expressed in the brain, heart and lung. Within the brain, nGPCR-70 was expressed in regions including but not limited to, cerebellum, hippocampus, substantia nigra, thalamus, frontal lobe, caudate nucleus, and spinal cord. Expression of the nGPCR-70 in the brain provides an indication that modulators of nGPCR-70 activity have utility for treating neurological disorders, including but not limited to, movement disorders, affective disorders, metabolic disorders, inflammatory disorders and cancers. Use of nGPCR-70 modulators, including nGPCR-70 ligands and anti-nGPCR-70 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-63

Tissue specific expression of the putative nGPCR-63 was detected using a PCR-based RapidScanTM Gene Expression Panel (OriGene Technologies, Rockville, MD). The RapidScan Expression Panel is comprised of first-strand cDNAs from 12 human tissues that are serially diluted over a 3-log range and arrayed into a multi-well PCR plate. This array was used to generate a comprehensive expression profile of the putative GPCR in human tissues. Human tissues arrayed included: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle, stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, prostate, skin, PBL, bone marrow, fetal brain, fetal liver. PCR primers were designed based on the available sequence of the Celera sequence HUM_IDS|Contig|11000258115466. The forward primer used was: 5'-ACAGCCCCAAAGCCAAACAC-3' (SEQ ID NO:162). The reverse primer was: 5'-CCGCAGGAGCAATGAAAATCAG-3' (SEQ ID NO:163). This primer set primed the synthesis of a 220 base pair fragment in the presence of the appropriate cDNA. For detection of expression within brain regions, the same primer set was used with the Human Brain RapidScanTM Panel (OriGene Technologies, Rockville, MD). This panel represents serial dilutions over a 2 log range of first strand cDNA from the following brain regions arrayed in a 96 well format: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord. Primers were synthesized by Genosys Corp., The Woodlands, TX. PCR reactions were assembled using the components of the Expand Hi-Fi PCR SystemTM (Roche Molecular Biochemicals, Indianapolis, IN). Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at (94 for 3minutes) followed by 35 cycles of 94C for 45 seconds, 54C for 2 minutes, 72C for 45 seconds. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel, stained with ethidium bromide.

nGPCR-63 was expressed in the brain, heart, kidney, liver, muscle, ovary, prostate, small intestine, spleen, testis, peripheral blood leukocytes, and lung. Within the brain, nGPCR-63 was expressed in regions including but not limited to, cerebellum, amygdala, hypothalamus, medulla, temporal lobe, pons, hippocampus, substantia nigra, thalamus, frontal lobe, caudate nucleus, and spinal cord. Expression of the nGPCR-63 in the brain provides an indication that modulators of nGPCR-63 activity have utility for treating neurological disorders, including but not limited to, movement disorders, affective disorders, metabolic disorders, inflammatory disorders and cancers. Use of nGPCR-63 modulators, including nGPCR-63 ligands and anti-

nGPCR-63 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-42

Expression of nGPCR-42 in the various tissues was detected by using PCR primers designed based on the sequence of the receptor that prime the synthesis of a 110 bp fragment in the presence of the appropriate cDNA. The forward primer used to detect expression of nGPCR-42 was: 5'-TCTCCAAACTCCTGGCCTTC-3' (SEQ ID NO:164) and the reverse primer was: 5'-GCAGGGCAGCTTTTTCATCC-3' (SEQ ID NO:165). Primers were synthesized by Genosys Corp., The Woodlands, TX. The primer set was assembled into a PCR reaction using the components of the Expand Hi-Fi PCR System™ (Roche Molecular Biochemicals). Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp PCR9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The plate was then exposed to the following cycling parameters: Pre-soak 94C for 3 minutes; denaturation at 94C for 30 seconds; annealing at primer T_m for 45 seconds; extension 72C for 2 minutes; for 35 cycles. PCR productions were then separated and analyzed by electrophoresis on a 2.0% agarose gel.

The 4-log dilution range of cDNA deposited on the plate ensured that the amplification reaction was within the linear range and, facilitated semi-quantitative determination of relative mRNA accumulation in the various tissues or brain regions examined.

nGPCR-42 was expressed in the brain, peripheral blood leukocytes, bone marrow, placenta, salivary gland, liver, ovary, uterus, testis, fetal liver, heart, thyroid gland, kidney, adrenal gland, spleen, pancreas, colon, lung, prostate, small intestine, skin, muscle, fetal brain, and stomach. Within the brain, GPCR-42 was expressed in the temporal lobe, cerebellum, substantia nigra, caudate nucleus, amygdala, frontal lobe, thalamus, hippocampus, hypothalamus, pons, medulla, and spinal cord. Expression of the nGPCR-42 in the brain provided an indication that modulators of nGPCR-42 activity have utility for treating disorders, including but not limited to, schizophrenia, affective disorders, metabolic disorders, inflammatory disorders, cancers, ADHD/ADD (i.e., Attention Deficit-Hyperactivity Disorder/Attention Deficit Disorder), and neural disorders such as Alzheimer's disease, Parkinson's disease, migraine, and senile dementia. Some other diseases for which modulators of nGPCR-42 may have utility include depression, anxiety, bipolar disease, epilepsy, neuritis, neurasthenia, neuropathy, neuroses, and the like. Use of nGPCR-42 modulators, including nGPCR-42 ligands and anti-nGPCR-42 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-46

Tissue specific expression of the cDNA encoding nGPCR-46 was detected using a PCR-based method. Multiple Choice™ first strand cDNAs (OriGene Technologies, Rockville, MD) from 12 human tissues are serially diluted over a 3-log range and arrayed into a multi-well PCR plate. This array is used to generate a comprehensive expression profile of nGPCR-46 in human tissues. Human tissues arrayed include: brain, heart, kidney, peripheral blood leukocytes, liver, lung, muscle, ovary, prostate, small intestine, spleen and testis. The forward PCR primer was: 5'-ACGCCCCGCTGAACCGTATAC-3' (SEQ ID NO:166) and the reverse primer used was: 5'-GGGTGCCACCTGGTTGCTC-3' (SEQ ID NO:167). This primer set will prime the synthesis of a 242 base pair fragment in the presence of the appropriate cDNA. For detection of expression within brain regions, the same primer set was used with the Human Brain Rapid Scan™ Panel (OriGene Technologies, Rockville, MD). This panel represents serial dilutions over a 2 log range of first strand cDNA from the following brain regions arrayed in a 96 well format: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord. Primers were synthesized by Genosys Corp., The Woodlands, TX. PCR reactions were assembled using the components of the Expand Hi-Fi PCR System™ (Roche Molecular Biochemicals, Indianapolis, IN). Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at (94C for 3 minutes) followed by 35 cycles of 94C for 45 seconds, 53C for 2 minutes, 72C for 45 seconds. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel stained with ethidium bromide.

nGPCR-46 was expressed in the brain, peripheral blood lymphocytes, testis, heart, kidney, spleen, prostate, ovary, liver, lung, small intestine, and muscle. Within the brain, nGPCR-46 was expressed in frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla, and spinal cord. Expression of the nGPCR-46 in the brain indicates that modulators of nGPCR-46 activity have utility for treating neurological disorders, including but not limited to, movement disorders, affective disorders, metabolic disorders, inflammatory disorders and cancers. Use of nGPCR-46 modulators, including nGPCR-46 ligands and anti-nGPCR-46 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-48

Tissue specific expression of the cDNA encoding nGPCR-48 was detected using a PCR-based RapidScan™ Gene Expression Panel (OriGene Technologies, Rockville, MD). The RapidScan Expression Panel is comprised of first-strand cDNAs from 24 human tissues that are serially diluted over a 3-log range and arrayed into a multi-well PCR plate. This array is used to generate a comprehensive expression profile of the putative GPCR in human tissues. Human tissues arrayed include: brain, heart, kidney, spleen, liver, colon, lung, small intestine, muscle, stomach, testis, placenta, salivary gland, thyroid, adrenal gland, pancreas, ovary, uterus, prostate, skin, PBL, bone marrow, fetal brain, fetal liver. The forward PCR primer was 5'-ATGGCACCTTCTCATCGG-3' (SEQ ID NO:168) and the reverse primer was 5'-ACGTAGTACACCGCCTTG-3' (SEQ ID NO:169). This primer set will prime the synthesis of a 392 base pair fragment in the presence of the appropriate cDNA. For detection of expression within brain regions, the same primer set was used with the Human Brain Rapid Scan™ Panel (OriGene Technologies, Rockville, MD). This panel represents serial dilutions over a 2 log range of first strand cDNA from the following brain regions arrayed in a 96 well format: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord. Primers were synthesized by Genosys Corp., The Woodlands, TX. PCR reactions were assembled using the components of the Expand Hi-Fi PCR System™ (Roche Molecular Biochemicals, Indianapolis, IN). Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR Thermocycler (PE Applied Biosystems). The following cycling program was executed: Pre-soak at (94°C for 3min.) followed by 35 cycles of 94°C for 45 seconds, 53°C for 2 minutes, 72°C for 45 seconds. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel, stained with ethidium bromide.

The 4-log dilution range of cDNA deposited on the plate ensured that the amplification reaction was within the linear range and, facilitated semi-quantitative determination of relative mRNA accumulation in the various tissues or brain regions examined.

nGPCR-48 was expressed in the ovary, prostate, skin, stomach bone marrow, placenta, fetal liver, brain, heart, spleen, liver, colon, uterus, lung, small intestine, peripheral blood leukocytes, testis, and fetal brain. Within the brain, nGPCR-48 was expressed in the substantia nigra, frontal lobe, temporal lobe, cerebellum, hippocampus, caudate nucleus, thalamus and spinal cord. Expression of nGPCR-48 in the brain provided an indication that modulators of nGPCR-48 activity have utility for treating disorders, including but not limited to, schizophrenia, affective disorders, ADHD/ADD (i.e., Attention Deficit-Hyperactivity Disorder/Attention Deficit Disorder), neural disorders such as Alzheimer's disease, Parkinson's

disease, migraine, senile dementia, depression, anxiety, bipolar disease, epilepsy, neuritis, neurasthenia, neuropathy, neuroses, metabolic disorders, inflammatory disorders, cancers and the like. Use of nGPCR-48 modulators, including nGPCR-48 ligands and anti-nGPCR-48 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-49

Tissue specific expression of the cDNA encoding SEQ-49 was detected using a PCR-based method. Multiple Choice™ first strand cDNAs (OriGene Technologies, Rockville, MD) from 6 human tissues were serially diluted over a 3-log range and arrayed into a multi-well PCR plate. This array was used to generate a comprehensive expression profile of the putative GPCRs in human tissues. Human tissues arrayed included: brain, heart, kidney, peripheral blood leukocytes, lung, and testis. PCR primers were designed based on the available sequence of the Celera sequence GA_11585051. The forward primer used was 5'-AGCAGGTAGATGGAGAA GG-3' (SEQ ID NO:170). The reverse primer used was 5'-GACTCCTGAGGACCATGTC- 3' (SEQ ID NO:171). This primer set primed the synthesis of a 320 base pair fragment in the presence of the appropriate cDNA. PCR reactions were performed in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at 94C for 3 minutes followed by 35 cycles of 94C for 45 seconds, 53.5C for 2 minutes, 72C for 45 seconds. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel stained with ethidium bromide.

nGPCR-49 was expressed in the brain, heart, testis, peripheral blood leukocytes, kidney, liver, muscle, ovary, prostate, small intestine, spleen, and lung. Within the brain, nGPCR-49 was expressed in regions including but not limited to, cerebellum, hippocampus, substantia nigra, thalamus, hypothalamus, frontal lobe, temporal lobe, amygdala, pons, medulla, caudate nucleus, and spinal cord. Expression of the nGPCR-49 in the brain provides an indication that modulators of nGPCR-49 activity have utility for treating neurological disorders, including but not limited to, movement disorders, affective disorders, metabolic disorders, inflammatory disorders and cancers. Use of nGPCR-49 modulators, including nGPCR-49 ligands and anti-nGPCR-49 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-61

Tissue specific expression of the cDNA encoding SEQ-61 was detected using a PCR-based method. Multiple Choice™ first strand cDNAs (OriGene Technologies, Rockville, MD) from 6 human tissues were serially diluted over a 3-log range and arrayed into a multi-well PCR

plate. This array was used to generate a comprehensive expression profile of the putative GPCRs in human tissues. Human tissues arrayed included: brain, heart, kidney, peripheral blood leukocytes, lung, and testis. PCR primers were designed based on the available sequence of the Celera sequence GA_13368549. The forward primer used was 5'-CATTGGAACCACATTTAT
5 TGG-3' (SEQ ID NO:172). The reverse primer used was 5'-AAGCAAGACAGGTGAGAATG-
3' (SEQ ID NO:173). This primer set primed the synthesis of a 284 base pair fragment in the presence of the appropriate cDNA. PCR reactions were performed in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at 94C for 3 minutes followed by 35 cycles of 94C for 45 seconds, 53.5C for 2 minutes,
10 72C for 45 seconds. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel stained with ethidium bromide.

nGPCR-61 was expressed in the brain, heart, testis, peripheral blood leukocytes, and lung. Expression of the nGPCR-61 in the brain provides an indication that modulators of nGPCR-61 activity have utility for treating neurological disorders, including but not limited to,
15 movement disorders, affective disorders, metabolic disorders, inflammatory disorders and cancers. Use of nGPCR-61 modulators, including nGPCR-61 ligands and anti-nGPCR-61 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-51

20 Tissue specific expression of the cDNA encoding SEQ-51 was detected using a PCR-based method. Multiple Choice™ first strand cDNAs (OriGene Technologies, Rockville, MD) from 12 human tissues were serially diluted over a 3-log range and arrayed into a multi-well PCR plate. This array was used to generate a comprehensive expression profile of the putative GPCR in human tissues. Human tissues arrayed include: brain, heart, kidney, peripheral blood
25 leukocytes, liver, lung, muscle, ovary, prostate, small intestine, spleen and testis. PCR primers were designed based on the sequence of nGPCR-51 provided herein as SEQ ID NO:39 and SEQ ID NO:57. The forward primer used was 5'-CCATCTGTCTCAGCTATGCC-3' (SEQ ID NO:174), corresponding base pairs 929 through 948 of SEQ ID NO:57. The reverse primer used was 5'-TCCTTCTCAGTCGCTCTTC-3' (SEQ ID NO:175) corresponding to base pairs 1022
30 through 1038 of SEQ ID NO:57. This primer set primes the synthesis of a 112 base pair fragment in the presence of the appropriate cDNA. For detection of expression within brain regions, the same primer set was used with the Human Brain Rapid Scan™ Panel (OriGene Technologies, Rockville, MD). This panel represents serial dilutions over a 3 log range of first strand cDNA from the following brain regions arrayed in a 96 well format: frontal lobe,

temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord. Primers were synthesized by Genosys Corp., The Woodlands, TX. PCR reactions were assembled using the components of the Expand Hi-Fi PCR SystemTM (Roche Molecular Biochemicals, Indianapolis, IN). Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at 94C for 3 minutes followed by 35 cycles of 94C for 45 seconds, 52C for 2 minutes, 72C for 45 seconds. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel stained with ethidium bromide.

nGPCR-51 was expressed in the brain, heart, peripheral blood leukocytes, liver, prostate, testis, lung, small intestine, and spleen. Within the brain, nGPCR-51 was expressed in the cerebellum, hippocampus, substantia nigra, thalamus, hypothalamus, pons, frontal lobe, temporal lobe, caudate nucleus, medulla, spinal cord, and amygdala. Expression of the nGPCR-51 in the brain provides an indication that modulators of nGPCR-51 activity have utility for treating neurological disorders, including but not limited to, movement disorders, affective disorders, metabolic disorders, inflammatory disorders, cancers, attention disorders, anxiety, depression, and obesity. Use of nGPCR-51 modulators, including nGPCR-51 ligands and anti-nGPCR-51 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

nGPCR-52

Tissue specific expression of the cDNA encoding SEQ-52 was detected using a PCR-based method. Multiple ChoiceTM first strand cDNAs (OriGene Technologies, Rockville, MD) from 12 human tissues were serially diluted over a 3-log range and arrayed into a multi-well PCR plate. This array was used to generate a comprehensive expression profile of nGPCR-52 in human tissues. Human tissues arrayed include: brain, heart, kidney, peripheral blood leukocytes, liver, lung, muscle, ovary, prostate, small intestine, spleen and testis. The forward primer used was 5'-CAAACAACAAACAGCAGAACC-3' (SEQ ID NO:176) and the reverse primer was 5'-TCACAGTCACACCTACCAAG-3' (SEQ ID NO:177). This primer set primed the synthesis of a 274 base pair fragment in the presence of the appropriate cDNA. For detection of expression within brain regions, the same primer set was used with the Human Brain Rapid ScanTM Panel (OriGene Technologies, Rockville, MD). This panel represents serial dilutions over a 2 log range of first strand cDNA from the following brain regions arrayed in a 96 well format: frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, thalamus, hypothalamus, pons, medulla and spinal cord. Primers were synthesized

by Genosys Corp., The Woodlands, TX. PCR reactions were assembled using the components of the Expand Hi-Fi PCR SystemTM (Roche Molecular Biochemicals, Indianapolis, IN).

Twenty-five microliters of the PCR reaction mixture was added to each well of the RapidScan PCR plate. The plate was placed in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at 94C for 3 minutes followed by 35 cycles of 94C for 45 seconds, 53C for 2 minutes, 72C for 45 seconds. PCR reaction products were then separated and analyzed by electrophoresis on a 2.0% agarose gel stained with ethidium bromide.

nGPCR-52 was expressed in the brain, the lungs, muscle, small intestine, spleen, testis, heart, peripheral blood leukocytes, and liver. Within the brain, nGPCR-52 was expressed in the frontal lobe, temporal lobe, cerebellum, hippocampus, substantia nigra, caudate nucleus, amygdala, hypothalamus, and medulla. Expression of nGPCR-52 in the brain provides an indication that modulators of nGPCR-52 activity have utility for treating neurological disorders, including but not limited to, movement disorders, affective disorders, metabolic disorders, inflammatory disorders and cancers. Use of nGPCR-52 modulators, including nGPCR-52 ligands and anti-nGPCR-52 antibodies, to treat individuals having such disease states is intended as an aspect of the invention.

Example 6: Chromosomal Localization

nGPCR-51

The chromosomal location of the gene encoding SEQ51 was determined using the Stanford G3 Radiation Hybrid Panel (Research Genetics, Inc., Huntsville, AL). This panel contains 83 radiation hybrid clones of the entire human genome created by the Stanford Human Genome Center. PCR reactions were assembled containing 25ng of DNA from each clone and the the components of the Expand Hi-Fi PCR SystemTM (Roche Molecular Biochemicals, Indianapolis, IN) in a final reaction volume of 15 ul. PCR primers were synthesized by Genosys Corp., The Woodlands, TX. PCR primers were designed based on the available sequence of the Celera sequence GA_11007426. The forward primer used was 5'-CCATCTGTCTCAGCTAT GCC-3' (SEQ ID NO:178) corresponding base pairs 241 through 260 of GA_11007426. The reverse primer used was 5'-TCCTTCTCAGTCGCTCTTC-3' (SEQ ID NO:179) corresponding to base pairs 334 through 352 of GA_11007426. This primer set will prime the synthesis of a 112 base pair fragment in the presence of the appropriate genomic DNA. PCR reactions were incubated in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at 94C for 3 minutes, and 35 cycles at 94C for 30 seconds, 52C for 60 seconds, 72C for 2 minutes. PCR reaction products were then

separated and analyzed by electrophoresis on a 2.0% agarose gel, stained with ethidium bromide. Lanes were scored for the presence or absence of the expected PCR product and the results submitted to the Stanford Human Genome Center via e-mail for analysis (world wide web of the Internet at, for example, shgc.stanford.edu/RH/rhserverformnew.html). G3

- 5 Radiation Hybrid Panel Analysis of the SEQ51 places it on chromosome 6, most nearly linked to Stanford marker SHGC-34355 with a LOD score of 12.32. This marker lies at position 6q21. Chromosome 6q21-q22.3 contains a highly significant disease locus for schizophrenia (Cao *et al.*, Genomics 43: 1-8, (1997)). Genes which map to this region of the chromosome are candidate genes for schizophrenia. Any genes localized to chromosomal regions in linkage with
- 10 schizophrenia are candidate genes for disease susceptibility. Genes in these regions with the potential to play a biochemical/functional role in the disease process (like G protein coupled receptors) have a high probability of being a disease modifying locus. nGPCR-51, because of its chromosomal location, is an attractive target therefor for screening ligands useful in modulating cellular processes involved in schizophrenia.

15 *nGPCR-52*

- The chromosomal location of the gene encoding Seq-52 was determined using the Stanford G3 Radiation Hybrid Panel (Research Genetics, Inc., Huntsville, AL). This panel contains 83 radiation hybrid clones of the entire human genome created by the Stanford Human Genome Center. PCR reactions were assembled containing 25ng of DNA from each clone and
- 20 the components of the Expand Hi-Fi PCR SystemTM (Roche Molecular Biochemicals, Indianapolis, IN) in a final reaction volume of 15 μ l. PCR primers were synthesized by Genosys Corp., The Woodlands, TX. The forward primer used was RRH421: 5'-GTCTATG CTACCAAGTTTACC-3' (SEQ ID NO:180) corresponding to base pairs 3328 through 3348. The reverse primer used was RRH422: 5'-ATTCTTCCAGCCCATCATC-3' (SEQ ID NO:181)
- 25 corresponding to base pairs 3433 through 3451. This primer set will prime the synthesis of a 124 base pair fragment in the presence of the appropriate genomic DNA. PCR reactions were incubated in a GeneAmp 9700 PCR thermocycler (Perkin Elmer Applied Biosystems). The following cycling program was executed: Pre-soak at 94C for 3 minutes, and 35 cycles of 94C for 30 seconds, 55C for 60 seconds, 72C for 2 minutes. PCR reaction products were then
- 30 separated and analyzed by electrophoresis on a 2.0% agarose gel, stained with ethidium bromide. Lanes were scored for the presence or absence of the expected PCR product and the results submitted to the Stanford Human Genome Center via e-mail for analysis (world wide web of the Internet at, for example, shgc.stanford.edu/RH/rhserverformnew.html). The chromosomal location of the gene encoding nGPCR-52 was determined using the Stanford G3

Radiation Hybrid Panel (Research Genetics, Inc., Huntsville, AL). This panel contains 83 radiation hybrid clones of the entire human genome created by the Stanford Human Genome Center. Lanes were scored for the presence or absence of the expected PCR product and the results submitted to the Stanford Human Genome Center via e-mail for analysis. The analysis of nGPCR-52 places it on chromosome 6, most nearly linked to Stanford marker SHGC-1836 with a LOD score of 15.65. This marker lies at position 6q21. Chromosome 6q21-q22.3 contains a highly significant disease locus for schizophrenia (Cao *et al.*, Genomics 43: 1-8, (1997)). Genes which map to this region of the chromosome are candidate genes for schizophrenia. Any genes localized to chromosomal regions in linkage with schizophrenia are candidate genes for disease susceptibility. Genes in these regions with the potential to play a biochemical/functional role in the disease process (like G protein coupled receptors) have a high probability of being a disease modifying locus. nGPCR-52 because of its chromosomal location is an attractive target therefor for screening ligands useful in modulating cellular processes involved in schizophrenia.

Example 7: Northern Blot Analysis

Northern blots are performed to examine the expression of nGPCR-x mRNA. The sense orientation oligonucleotide and the antisense-orientation oligonucleotide, described above, are used as primers to amplify a portion of the GPCR-x cDNA sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60. Multiple human tissue northern blots from Clontech (Human II # 7767-1) are hybridized with the probe. Pre-hybridization is carried out at 42C for 4 hours in 5xSSC, 1X Denhardt's reagent, 0.1% SDS, 50% formamide, 250 mg/ml salmon sperm DNA. Hybridization is performed overnight at 42C in the same mixture with the addition of about 1.5×10^6 cpm/ml of labeled probe. The probe is labeled with α - 32 P-dCTP by Rediprime™ DNA labeling system (Amersham Pharmacia), purified on Nick Column™ (Amersham Pharmacia) and added to the hybridization solution. The filters are washed several times at 42C in 0.2x SSC, 0.1% SDS. Filters are exposed to Kodak XAR film (Eastman Kodak Company, Rochester, N.Y., USA) with intensifying screen at -80C.

Example 8: Recombinant Expression of nGPCR-x in Eukaryotic Host Cells

Expression of nGPCR-x in Mammalian Cells

To produce nGPCR-x protein, a nGPCR-x-encoding polynucleotide is expressed in a suitable host cell using a suitable expression vector and standard genetic engineering techniques. For example, the nGPCR-x-encoding sequence described in Example 1 is subcloned into the commercial expression vector pzeoSV2 (Invitrogen, San Diego, CA) and transfected into Chinese Hamster Ovary (CHO) cells using the transfection reagent FuGENE6™ (Boehringer-Mannheim) and the transfection protocol provided in the product insert. Other

eukaryotic cell lines, including human embryonic kidney (HEK293) and COS cells, are suitable as well. Cells stably expressing nGPCR-x are selected by growth in the presence of 100 µg/ml zeocin (Stratagene, LaJolla, CA). Optionally, nGPCR-x may be purified from the cells using standard chromatographic techniques. To facilitate purification, antisera is raised against one or
5 more synthetic peptide sequences that correspond to portions of the nGPCR-x amino acid sequence, and the antisera is used to affinity purify nGPCR-x. The nGPCR-x also may be expressed in-frame with a tag sequence (*e.g.*, polyhistidine, hemagglutinin, FLAG) to facilitate purification. Moreover, it will be appreciated that many of the uses for nGPCR-x polypeptides, such as assays described below, do not require purification of nGPCR-x from the host cell.

10 *Expression of nGPCR-x in 293 cells*

For expression of nGPCR-x in mammalian cells HEK293 (transformed human, primary embryonic kidney cells), a plasmid bearing the relevant nGPCR-x coding sequence is prepared, using vector pSecTag2A (Invitrogen). Vector pSecTag2A contains the murine IgK chain leader sequence for secretion, the c-myc epitope for detection of the recombinant protein with the anti-
15 myc antibody, a C-terminal polyhistidine for purification with nickel chelate chromatography, and a Zeocin resistant gene for selection of stable transfectants. The forward primer for amplification of this GPCR cDNA is determined by routine procedures and preferably contains a 5' extension of nucleotides to introduce the *HindIII* cloning site and nucleotides matching the GPCR sequence. The reverse primer is also determined by routine procedures and preferably
20 contains a 5' extension of nucleotides to introduce an *XhoI* restriction site for cloning and nucleotides corresponding to the reverse complement of the nGPCR-x sequence. The PCR conditions are 55C as the annealing temperature. The PCR product is gel purified and cloned into the *HindIII-XhoI* sites of the vector.

The DNA is purified using Qiagen chromatography columns and transfected into 293
25 cells using DOTAP™ transfection media (Boehringer Mannheim, Indianapolis, IN). Transiently transfected cells are tested for expression after 24 hours of transfection, using western blots probed with anti-His and anti-nGPCR-x peptide antibodies. Permanently transfected cells are selected with Zeocin and propagated. Production of the recombinant protein is detected from both cells and media by western blots probed with anti-His, anti-Myc or anti-GPCR peptide
30 antibodies.

Expression of nGPCR-x in COS cells

For expression of the nGPCR-x in COS7 cells, a polynucleotide molecule having a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60 can be cloned into vector p3-CI. This vector is a pUC18-derived plasmid that contains the HCMV (human

cytomegalovirus) promoter-intron located upstream from the bGH (bovine growth hormone) polyadenylation sequence and a multiple cloning site. In addition, the plasmid contains the dhfr (dihydrofolate reductase) gene which provides selection in the presence of the drug methotrexane (MTX) for selection of stable transformants.

5 The forward primer is determined by routine procedures and preferably contains a 5' extension which introduces an *XbaI* restriction site for cloning, followed by nucleotides which correspond to a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60. The reverse primer is also determined by routine procedures and preferably contains 5'-extension of nucleotides which introduces a *Sall* cloning site followed by nucleotides which
10 correspond to the reverse complement of a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60. The PCR consists of an initial denaturation step of 5 minutes at 95C, 30 cycles of 30 seconds denaturation at 95C, 30 seconds annealing at 58C and 30 seconds extension at 72C, followed by 5 minutes extension at 72C. The PCR product is gel purified and ligated into the *XbaI* and *Sall* sites of vector p3-CI. This construct is transformed into *E. coli*
15 cells for amplification and DNA purification. The DNA is purified with Qiagen chromatography columns and transfected into COS 7 cells using Lipofectamine™ reagent from BRL, following the manufacturer's protocols. Forty-eight and 72 hours after transfection, the media and the cells are tested for recombinant protein expression.

 nGPCR-x expressed from a COS cell culture can be purified by concentrating the cell-
20 growth media to about 10 mg of protein/ml, and purifying the protein by, for example, chromatography. Purified nGPCR-x is concentrated to 0.5 mg/ml in an Amicon concentrator fitted with a YM-10 membrane and stored at -80C.

Expression of nGPCR-x in Insect Cells

 For expression of nGPCR-x in a baculovirus system, a polynucleotide molecule having a
25 sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60 can be amplified by PCR. The forward primer is determined by routine procedures and preferably contains a 5' extension which adds the *NdeI* cloning site, followed by nucleotides which correspond to a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60. The reverse primer is also determined by routine procedures and preferably contains a 5'
30 extension which introduces the *KpnI* cloning site, followed by nucleotides which correspond to the reverse complement of a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60.

 The PCR product is gel purified, digested with *NdeI* and *KpnI*, and cloned into the corresponding sites of vector pACHTL-A (Pharmlngen, San Diego, CA). The pAcHTL

expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV), and a 6XHis tag upstream from the multiple cloning site. A protein kinase site for phosphorylation and a thrombin site for excision of the recombinant protein precede the multiple cloning site is also present. Of course, many other baculovirus vectors could be used in place of pAcHTL-A, such as pAc373, pVL941 and pAcIM1. Other suitable vectors for the expression of GPCR polypeptides can be used, provided that the vector construct includes appropriately located signals for transcription, translation, and trafficking, such as an in-frame AUG and a signal peptide, as required. Such vectors are described in Luckow *et al.*, Virology 170:31-39, among others. The virus is grown and isolated using standard baculovirus expression methods, such as those described in Summers *et al.* (A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bulletin No. 1555 (1987)).

In a preferred embodiment, pAcHLT-A containing nGPCR-x gene is introduced into baculovirus using the "BaculoGold™" transfection kit (Pharmingen, San Diego, CA) using methods established by the manufacturer. Individual virus isolates are analyzed for protein production by radiolabeling infected cells with ³⁵S-methionine at 24 hours post infection. Infected cells are harvested at 48 hours post infection, and the labeled proteins are visualized by SDS-PAGE. Viruses exhibiting high expression levels can be isolated and used for scaled up expression.

For expression of a nGPCR-x polypeptide in a Sf9 cells, a polynucleotide molecule having a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60 can be amplified by PCR using the primers and methods described above for baculovirus expression. The nGPCR-x cDNA is cloned into vector pAcHLT-A (Pharmingen) for expression in Sf9 insect. The insert is cloned into the *NdeI* and *KpnI* sites, after elimination of an internal *NdeI* site (using the same primers described above for expression in baculovirus). DNA is purified with Qiagen chromatography columns and expressed in Sf9 cells. Preliminary Western blot experiments from non-purified plaques are tested for the presence of the recombinant protein of the expected size which reacted with the GPCR-specific antibody. These results are confirmed after further purification and expression optimization in HiG5 cells.

Example 9: Interaction Trap/Two-Hybrid System

In order to assay for nGPCR-x-interacting proteins, the interaction trap/two-hybrid library screening method can be used. This assay was first described in Fields *et al.*, *Nature*, 1989, 340, 245, which is incorporated herein by reference in its entirety. A protocol is published in Current Protocols in Molecular Biology 1999, John Wiley & Sons, NY, and Ausubel, F. M. *et*

al. 1992, Short protocols in molecular biology, Fourth edition, Greene and Wiley-interscience, NY, each of which is incorporated herein by reference in its entirety. Kits are available from Clontech, Palo Alto, CA (Matchmaker Two-Hybrid System 3).

A fusion of the nucleotide sequences encoding all or partial nGPCR-x and the yeast transcription factor GAL4 DNA-binding domain (DNA-BD) is constructed in an appropriate plasmid (*i.e.*, pGBKT7) using standard subcloning techniques. Similarly, a GAL4 active domain (AD)-fusion library is constructed in a second plasmid (*i.e.*, pGADT7) from cDNA of potential GPCR-binding proteins (for protocols on forming cDNA libraries, see Sambrook *et al.* 1989, Molecular cloning: a laboratory manual, second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY), which is incorporated herein by reference in its entirety. The DNA-BD/nGPCR-x fusion construct is verified by sequencing, and tested for autonomous reporter gene activation and cell toxicity, both of which would prevent a successful two-hybrid analysis. Similar controls are performed with the AD/library fusion construct to ensure expression in host cells and lack of transcriptional activity. Yeast cells are transformed (*ca.* 10⁵ transformants/mg DNA) with both the nGPCR-x and library fusion plasmids according to standard procedures (Ausubel *et al.*, 1992, Short protocols in molecular biology, fourth edition, Greene and Wiley-interscience, NY, which is incorporated herein by reference in its entirety). *In vivo* binding of DNA-BD/nGPCR-x with AD/library proteins results in transcription of specific yeast plasmid reporter genes (*i.e.*, lacZ, HIS3, ADE2, LEU2). Yeast cells are plated on nutrient-deficient media to screen for expression of reporter genes. Colonies are dually assayed for β -galactosidase activity upon growth in Xgal (5-bromo-4-chloro-3-indolyl- β -D-galactoside) supplemented media (filter assay for β -galactosidase activity is described in Breeden *et al.*, Cold Spring Harb. Symp. Quant. Biol., 1985, 50, 643, which is incorporated herein by reference in its entirety). Positive AD-library plasmids are rescued from transformants and reintroduced into the original yeast strain as well as other strains containing unrelated DNA-BD fusion proteins to confirm specific nGPCR-x/library protein interactions. Insert DNA is sequenced to verify the presence of an open reading frame fused to GAL4 AD and to determine the identity of the nGPCR-x-binding protein.

Example 10: Mobility Shift DNA-Binding Assay Using Gel Electrophoresis

A gel electrophoresis mobility shift assay can rapidly detect specific protein-DNA interactions. Protocols are widely available in such manuals as Sambrook *et al.* 1989, *Molecular cloning: a laboratory manual*, second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY and Ausubel, F. M. *et al.*, 1992, *Short Protocols in Molecular Biology*, fourth edition, Greene and Wiley-interscience, NY, each of which is incorporated herein by reference in its entirety.

Probe DNA(<300 bp) is obtained from synthetic oligonucleotides, restriction endonuclease fragments, or PCR fragments and end-labeled with ^{32}P . An aliquot of purified nGPCR-x (ca. 15 μg) or crude nGPCR-x extract (ca. 15 ng) is incubated at constant temperature (in the range 22-37C) for at least 30 minutes in 10-15 μl of buffer (*i.e.* TAE or TBE, pH 8.0-8.5) containing radiolabeled probe DNA, nonspecific carrier DNA (ca. 1 μg), BSA (300 $\mu\text{g}/\text{ml}$), and 10% (v/v) glycerol. The reaction mixture is then loaded onto a polyacrylamide gel and run at 30-35 mA until good separation of free probe DNA from protein-DNA complexes occurs. The gel is then dried and bands corresponding to free DNA and protein-DNA complexes are detected by autoradiography.

10 **Example 11: Antibodies to nGPCR-x**

Standard techniques are employed to generate polyclonal or monoclonal antibodies to the nGPCR-x receptor, and to generate useful antigen-binding fragments thereof or variants thereof, including "humanized" variants. Such protocols can be found, for example, in Sambrook *et al.* (1989) and Harlow *et al.* (Eds.), *Antibodies A Laboratory Manual*; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988). In one embodiment, recombinant nGPCR-x polypeptides (or cells or cell membranes containing such polypeptides) are used as antigen to generate the antibodies. In another embodiment, one or more peptides having amino acid sequences corresponding to an immunogenic portion of nGPCR-x (*e.g.*, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more amino acids) are used as antigen. Peptides corresponding to extracellular portions of nGPCR-x, especially hydrophilic extracellular portions, are preferred. The antigen may be mixed with an adjuvant or linked to a hapten to increase antibody production.

Polyclonal or Monoclonal antibodies

As one exemplary protocol, recombinant nGPCR-x or a synthetic fragment thereof is used to immunize a mouse for generation of monoclonal antibodies (or larger mammal, such as a rabbit, for polyclonal antibodies). To increase antigenicity, peptides are conjugated to Keyhole Lympet Hemocyanin (Pierce), according to the manufacturer's recommendations. For an initial injection, the antigen is emulsified with Freund's Complete Adjuvant and injected subcutaneously. At intervals of two to three weeks, additional aliquots of nGPCR-x antigen are emulsified with Freund's Incomplete Adjuvant and injected subcutaneously. Prior to the final booster injection, a serum sample is taken from the immunized mice and assayed by western blot to confirm the presence of antibodies that immunoreact with nGPCR-x. Serum from the immunized animals may be used as polyclonal antisera or used to isolate polyclonal antibodies

that recognize nGPCR-x. Alternatively, the mice are sacrificed and their spleen removed for generation of monoclonal antibodies.

To generate monoclonal antibodies, the spleens are placed in 10 ml serum-free RPMI 1640, and single cell suspensions are formed by grinding the spleens in serum-free RPMI 1640, supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 µg/ml streptomycin (RPMI) (Gibco, Canada). The cell suspensions are filtered and washed by centrifugation and resuspended in serum-free RPMI. Thymocytes taken from three naive Balb/c mice are prepared in a similar manner and used as a Feeder Layer. NS-1 myeloma cells, kept in log phase in RPMI with 10% fetal bovine serum (FBS) (Hyclone Laboratories, Inc., Logan, Utah) for three days prior to fusion, are centrifuged and washed as well.

To produce hybridoma fusions, spleen cells from the immunized mice are combined with NS-1 cells and centrifuged, and the supernatant is aspirated. The cell pellet is dislodged by tapping the tube, and 2 ml of 37C PEG 1500 (50% in 75 mM HEPES, pH 8.0) (Boehringer-Mannheim) is stirred into the pellet, followed by the addition of serum-free RPMI. Thereafter, the cells are centrifuged, resuspended in RPMI containing 15% FBS, 100 µM sodium hypoxanthine, 0.4 µM aminopterin, 16 µM thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer-Mannheim) and 1.5×10^6 thymocytes/ml, and plated into 10 Corning flat-bottom 96-well tissue culture plates (Corning, Corning New York).

On days 2, 4, and 6 after the fusion, 100 µl of medium is removed from the wells of the fusion plates and replaced with fresh medium. On day 8, the fusions are screened by ELISA, testing for the presence of mouse IgG that binds to nGPCR-x. Selected fusion wells are further cloned by dilution until monoclonal cultures producing anti-nGPCR-x antibodies are obtained.

Humanization of anti-nGPCR-x monoclonal antibodies

The expression pattern of nGPCR-x as reported herein and the proven track record of GPCRs as targets for therapeutic intervention suggest therapeutic indications for nGPCR-x inhibitors (antagonists). nGPCR-x-neutralizing antibodies comprise one class of therapeutics useful as nGPCR-x antagonists. Following are protocols to improve the utility of anti-nGPCR-x monoclonal antibodies as therapeutics in humans by "humanizing" the monoclonal antibodies to improve their serum half-life and render them less immunogenic in human hosts (*i.e.*, to prevent human antibody response to non-human anti-nGPCR-x antibodies).

The principles of humanization have been described in the literature and are facilitated by the modular arrangement of antibody proteins. To minimize the possibility of binding complement, a humanized antibody of the IgG4 isotype is preferred.

For example, a level of humanization is achieved by generating chimeric antibodies comprising the variable domains of non-human antibody proteins of interest with the constant domains of human antibody molecules. (See, *e.g.*, Morrison *et al.*, Adv. Immunol., 44:65-92 (1989)). The variable domains of nGPCR-x-neutralizing anti-nGPCR-x antibodies are cloned
5 from the genomic DNA of a B-cell hybridoma or from cDNA generated from mRNA isolated from the hybridoma of interest. The V region gene fragments are linked to exons encoding human antibody constant domains, and the resultant construct is expressed in suitable mammalian host cells (*e.g.*, myeloma or CHO cells).

To achieve an even greater level of humanization, only those portions of the variable
10 region gene fragments that encode antigen-binding complementarity determining regions ("CDR") of the non-human monoclonal antibody genes are cloned into human antibody sequences. (See, *e.g.*, Jones *et al.*, Nature 321:522-525 (1986); Riechmann *et al.*, Nature 332:323-327 (1988); Verhoeven *et al.*, Science 239:1534-36 (1988); and Tempest *et al.*, Bio/Technology 9: 266-71 (1991)). If necessary, the β -sheet framework of the human antibody
15 surrounding the CDR3 regions also is modified to more closely mirror the three dimensional structure of the antigen-binding domain of the original monoclonal antibody. (See Kettleborough *et al.*, Protein Engin., 4:773-783 (1991); and Foote *et al.*, J. Mol. Biol., 224:487-499 (1992)).

In an alternative approach, the surface of a non-human monoclonal antibody of interest
20 is humanized by altering selected surface residues of the non-human antibody, *e.g.*, by site-directed mutagenesis, while retaining all of the interior and contacting residues of the non-human antibody. See Padlan, Molecular Immunol., 28(4/5):489-98 (1991).

The foregoing approaches are employed using nGPCR-x-neutralizing anti-nGPCR-x monoclonal antibodies and the hybridomas that produce them to generate humanized nGPCR-
25 x-neutralizing antibodies useful as therapeutics to treat or palliate conditions wherein nGPCR-x expression or ligand-mediated nGPCR-x signaling is detrimental.

Human nGPCR-x-Neutralizing Antibodies from Phage Display

Human nGPCR-x-neutralizing antibodies are generated by phage display techniques such as those described in Aujame *et al.*, Human Antibodies 8(4):155-168 (1997);
30 Hoogenboom, TIBTECH 15:62-70 (1997); and Rader *et al.*, Curr. Opin. Biotechnol. 8:503-508 (1997), each of which is incorporated herein by reference in its entirety. For example, antibody variable regions in the form of Fab fragments or linked single chain Fv fragments are fused to the amino terminus of filamentous phage minor coat protein pIII. Expression of the fusion protein and incorporation thereof into the mature phage coat results in phage particles that

present an antibody on their surface and contain the genetic material encoding the antibody. A phage library comprising such constructs is expressed in bacteria, and the library is screened for nGPCR-x-specific phage-antibodies using labeled or immobilized nGPCR-x as antigen-probe.

Human nGPCR-x-neutralizing antibodies from transgenic mice

- 5 Human nGPCR-x-neutralizing antibodies are generated in transgenic mice essentially as described in Bruggemann *et al.*; Immunol. Today 17(8):391-97 (1996) and Bruggemann *et al.*, Curr. Opin. Biotechnol. 8:455-58 (1997). Transgenic mice carrying human V-gene segments in germline configuration and that express these transgenes in their lymphoid tissue are immunized with a nGPCR-x composition using conventional immunization protocols. Hybridomas are
10 generated using B cells from the immunized mice using conventional protocols and screened to identify hybridomas secreting anti-nGPCR-x human antibodies (e.g., as described above).

Example 12: Assays to Identify Modulators of nGPCR-x Activity

- Set forth below are several nonlimiting assays for identifying modulators (agonists and antagonists) of nGPCR-x activity. Among the modulators that can be identified by these assays
15 are natural ligand compounds of the receptor; synthetic analogs and derivatives of natural ligands; antibodies, antibody fragments, and/or antibody-like compounds derived from natural antibodies or from antibody-like combinatorial libraries; and/or synthetic compounds identified by high-throughput screening of libraries; and the like. All modulators that bind nGPCR-x are useful for identifying nGPCR-x in tissue samples (e.g., for diagnostic purposes, pathological
20 purposes, and the like). Agonist and antagonist modulators are useful for up-regulating and down-regulating nGPCR-x activity, respectively, to treat disease states characterized by abnormal levels of nGPCR-x activity. The assays may be performed using single putative modulators, and/or may be performed using a known agonist in combination with candidate antagonists (or visa versa).

25 A. *cAMP Assays*

- In one type of assay, levels of cyclic adenosine monophosphate (cAMP) are measured in nGPCR-x-transfected cells that have been exposed to candidate modulator compounds. Protocols for cAMP assays have been described in the literature. (See, e.g., Sutherland *et al.*, Circulation 37: 279 (1968); Frandsen *et al.*, Life Sciences 18: 529-541 (1976); Dooley *et al.*,
30 Journal of Pharmacology and Experimental Therapeutics 283 (2): 735-41 (1997); and George *et al.*, Journal of Biomolecular Screening 2 (4): 235-40 (1997)). An exemplary protocol for such an assay, using an Adenylyl Cyclase Activation FlashPlate® Assay from NEN™ Life Science Products, is set forth below.

Briefly, the nGPCR-x coding sequence (*e.g.*, a cDNA or intronless genomic DNA) is subcloned into a commercial expression vector, such as pzeoSV2 (Invitrogen), and transiently transfected into Chinese Hamster Ovary (CHO) cells using known methods, such as the transfection protocol provided by Boehringer-Mannheim when supplying the FuGENE 6 transfection reagent. Transfected CHO cells are seeded into 96-well microplates from the FlashPlate® assay kit, which are coated with solid scintillant to which antisera to cAMP has been bound. For a control, some wells are seeded with wild type (untransfected) CHO cells. Other wells in the plate receive various amounts of a cAMP standard solution for use in creating a standard curve.

One or more test compounds (*i.e.*, candidate modulators) are added to the cells in each well, with water and/or compound-free medium/diluent serving as a control or controls. After treatment, cAMP is allowed to accumulate in the cells for exactly 15 minutes at room temperature. The assay is terminated by the addition of lysis buffer containing [¹²⁵I]-labeled cAMP, and the plate is counted using a Packard Topcount™ 96-well microplate scintillation counter. Unlabeled cAMP from the lysed cells (or from standards) and fixed amounts of [¹²⁵I]-cAMP compete for antibody bound to the plate. A standard curve is constructed, and cAMP values for the unknowns are obtained by interpolation. Changes in intracellular cAMP levels of cells in response to exposure to a test compound are indicative of nGPCR-x modulating activity. Modulators that act as agonists of receptors which couple to the G_s subtype of G proteins will stimulate production of cAMP, leading to a measurable 3-10 fold increase in cAMP levels. Agonists of receptors which couple to the G_{i/o} subtype of G proteins will inhibit forskolin-stimulated cAMP production, leading to a measurable decrease in cAMP levels of 50-100%. Modulators that act as inverse agonists will reverse these effects at receptors that are either constitutively active or activated by known agonists.

nGPCR-51

Modulators that act as agonists at receptors which couple to the G_s subtype of G proteins will activate adenylyl cyclase leading to a 3-10 fold increase in cyclic adenosine monophosphate (cAMP). Compounds to be tested for the ability to activate nGPCR-51 were assayed for cAMP using an Adenylyl Cyclase Activation FlashPlate® Assay from NEN™ Life Science Products. Briefly, nGPCR-51 cDNA is subcloned into the commercial expression vector pCMVSPORT (Gibco/Life Technologies) and transiently transfected into CHO or COS 7 cells using the transfection reagent FuGENE 6 (Boehringer-Mannheim) and the transfection protocol provided in the product insert. 24 hours post transfection the cells are harvested by dislodging from the culture flask using Versene (Gibco/BRL). The cells are counted and prepared as a suspension in

a buffer included in the assay kit that contains the phosphodiesterase inhibitor isobutylmethylxanthine. The assay is conducted in a special 96 well microplate included in the kit which is coated with solid scintillant to which antisera to cAMP has been bound. Dilutions of test compounds to be tested for activation of nGPCR-51 are added to assay wells. Several wells
5 on the plate receive various amounts of cAMP standard solution. After the addition of cells transiently expressing nGPCR-51, cAMP is allowed to accumulate for exactly 15 minutes at room temperature. The assay is terminated by the addition of lysis buffer containing [125 I] cAMP, and the plate is covered and allowed to incubate at room temperature for 2-24 hours. The plate is then counted using a Packard Topcount™ 96-well microplate scintillation counter.
10 Unlabelled cAMP from cells (or standards) competes with fixed amounts of [125 I] cAMP for antibody bound to the plate. A standard curve is constructed and cAMP values for the unknowns are obtained by interpolation. Data were analyzed using GraphPad Prism (San Diego, CA). There was no increase in cAMP observed after stimulation with the test compounds at concentrations up to 10 μ M.

15 B. *Aequorin Assays*

In another assay, cells (e.g., CHO cells) are transiently co-transfected with both a nGPCR-x expression construct and a construct that encodes the photoprotein apoaequorin. In the presence of the cofactor coelenterazine, apoaequorin will emit a measurable luminescence that is proportional to the amount of intracellular (cytoplasmic) free calcium. (See generally, Cobbold,
20 et al. "Aequorin measurements of cytoplasmic free calcium," In: McCormack J.G. and Cobbold P.H., eds., Cellular Calcium: A Practical Approach. Oxford:IRL Press (1991); Stables et al., Analytical Biochemistry 252: 115-26 (1997); and Haugland, Handbook of Fluorescent Probes and Research Chemicals, Sixth edition. Eugene OR: Molecular Probes (1996).)

In one exemplary assay, nGPCR-x is subcloned into the commercial expression vector pzeoSV2 (Invitrogen) and transiently co-transfected along with a construct that encodes the
25 photoprotein apoaequorin (Molecular Probes, Eugene, OR) into CHO cells using the transfection reagent FuGENE 6 (Boehringer-Mannheim) and the transfection protocol provided in the product insert.

The cells are cultured for 24 hours at 37C in MEM (Gibco/BRL, Gaithersburg, MD)
30 supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin and 10 μ g/ml streptomycin, at which time the medium is changed to serum-free MEM containing 5 μ M coelenterazine (Molecular Probes, Eugene, OR). Culturing is then continued for two additional hours at 37C. Subsequently, cells are detached from the plate using VERSEN (Gibco/BRL), washed, and resuspended at 200,000 cells/ml in serum-free MEM.

Dilutions of candidate nGPCR-x modulator compounds are prepared in serum-free MEM and dispensed into wells of an opaque 96-well assay plate at 50 μ l/well. Plates are then loaded onto an MLX microtiter plate luminometer (Dynex Technologies, Inc., Chantilly, VA). The instrument is programmed to dispense 50 μ l cell suspensions into each well, one well at a time, and immediately read luminescence for 15 seconds. Dose-response curves for the candidate modulators are constructed using the area under the curve for each light signal peak. Data are analyzed with SlideWrite, using the equation for a one-site ligand, and EC₅₀ values are obtained. Changes in luminescence caused by the compounds are considered indicative of modulatory activity. Modulators that act as agonists at receptors which couple to the G_q subtype of G proteins give an increase in luminescence of up to 100 fold. Modulators that act as inverse agonists will reverse this effect at receptors that are either constitutively active or activated by known agonists.

nGPCR-51

Agonist activation of receptors that couple to the G_q subtype of G proteins will lead to the release of intracellular calcium. The photoprotein aequorin emits a characteristic luminescence in the presence of calcium and may be expressed in cells along with the receptor of interest in order to report agonist signalling. Peptide A was tested for the ability to activate nGPCR-51 using an assay for aequorin. Peptide A, a cyclic peptide via a disulfide bond between the Cys residues, has the following amino acid sequence: Asp Phe Asp Met Leu Arg Cys Met Leu Gly Arg Val Tyr Arg Pro Cys Trp Gln Val (SEQ ID NO:183). Preferably, Peptide A is used in a solution containing 0.17M acetic acid, or the like, and a stabilizer such as a 0.2% BSA:acetonitrile 90:10. Briefly, nGPCR-51 cDNA is subcloned into the commercial expression vector pCMVSPORT (Gibco/Life Technologies) and transiently transfected along with the expression construct mtAequorin (Molecular Probes, Eugene, OR) into COS 7 cells using the transfection reagent FuGENE 6 (Boehringer-Mannheim) and the transfection protocol provided in the product insert. 24 hours post transfection the cells are harvested by dislodging from the culture flask using Versene (Gibco/BRL) and prepared as a suspension in assay buffer (Dulbecco's Modified Eagle's Medium with high glucose, pyridoxine HCl, L-glutamine, sodium pyruvate, and 0.1% fetal bovine serum (Gibco/BRL)) and containing the cofactor coelenterazine (Molecular Probes). The cell suspension is incubated for 4 hours at room temperature with gentle stirring. After the coelenterazine loading incubation, the cells are counted and diluted to 1×10^6 cells/ml in assay buffer. Dilutions of test compound are prepared in assay buffer and pipetted into wells of an opaque 96-well assay plate, 50 μ l/well. Plates are loaded onto an MLX microtiter plate luminometer (Dynex Technologies, Inc., Chantilly, VA). The instrument is

programmed to dispense 50 μ l cell suspension into each well, one well at a time, and immediately read luminescence for 20 seconds. Dose response curves are constructed using the area under the curve for each light signal peak. Data are analyzed with SlideWrite, using the equation $y = a^0 * a^1 / (x + a^1) + a^2$ where a^0 is the maximum response minus the baseline; a^1 is the EC_{50} ; and a^2 is the maximum response.

Peptide A stimulation of nGPCR-51 expressing COS 7 cells resulted in a dose dependent increase in aequorin luminescence with an EC_{50} of approximately 40 nM and a maximum response of 52-fold over baseline.

C. Luciferase Reporter Gene Assay

The photoprotein luciferase provides another useful tool for assaying for modulators of nGPCR-x activity. Cells (e.g., CHO cells or COS 7 cells) are transiently co-transfected with both a nGPCR-x expression construct (e.g., nGPCR-x in pzeoSV2) and a reporter construct which includes a gene for the luciferase protein downstream from a transcription factor binding site, such as the cAMP-response element (CRE), AP-1, or NF-kappa B. Agonist binding to receptors coupled to the G_s subtype of G proteins leads to increases in cAMP, thereby activating the CRE transcription factor and resulting in expression of the luciferase gene. Agonist binding to receptors coupled to the G_q subtype of G protein leads to production of diacylglycerol that activates protein kinase C, which activates the AP-1 or NF-kappa B transcription factors, in turn resulting in expression of the luciferase gene. Expression levels of luciferase reflect the activation status of the signaling events. (See generally, George *et al.*, *Journal of Biomolecular Screening*, 2(4): 235-240 (1997); and Stratowa *et al.*, *Current Opinion in Biotechnology* 6: 574-581 (1995)). Luciferase activity may be quantitatively measured using, e.g., luciferase assay reagents that are commercially available from Promega (Madison, WI).

In one exemplary assay, CHO cells are plated in 24-well culture dishes at a density of 100,000 cells/well one day prior to transfection and cultured at 37C in MEM (Gibco/BRL) supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin and 10 μ g/ml streptomycin. Cells are transiently co-transfected with both a nGPCR-x expression construct and a reporter construct containing the luciferase gene. The reporter plasmids CRE-luciferase, AP-1-luciferase and NF-kappaB-luciferase may be purchased from Stratagene (LaJolla, CA). Transfections are performed using the FuGENE 6 transfection reagent (Boehringer-Mannheim) according to the supplier's instructions. Cells transfected with the reporter construct alone are used as a control. Twenty-four hours after transfection, cells are washed once with PBS pre-warmed to 37C. Serum-free MEM is then added to the cells either alone (control) or with one or more candidate modulators and the cells are incubated at 37C for five hours. Thereafter,

cells are washed once with ice-cold PBS and lysed by the addition of 100 μ l of lysis buffer per well from the luciferase assay kit supplied by Promega. After incubation for 15 minutes at room temperature, 15 μ l of the lysate is mixed with 50 μ l of substrate solution (Promega) in an opaque-white, 96-well plate, and the luminescence is read immediately on a Wallace model
5 1450 MicroBeta scintillation and luminescence counter (Wallace Instruments, Gaithersburg, MD).

Differences in luminescence in the presence versus the absence of a candidate modulator compound are indicative of modulatory activity. Receptors that are either constitutively active or activated by agonists typically give a 3 to 20-fold stimulation of luminescence compared to cells
10 transfected with the reporter gene alone. Modulators that act as inverse agonists will reverse this effect.

nGPCR-51

nGPCR-51 was transfected in N7 cells, stable HOS (human osteosarcoma) cells expressing NF κ B-Luciferase reporter gene. Briefly, LipofectAMINE, PLUS reagent, and 4 μ g
15 DNA were added to cells in Opti-MEM. After 4 hours, serum-containing medium was added to each plate. Twenty-four hour after transfection the cells were trypsinized and seeded in COSTAR white 96-well plate at a cell density of about 20,000 cells per well. Another 24 hours later the culture medium was replaced with fresh growth medium and Peptide A was added. After 5-hr incubation with Peptide A, the medium was aspirated and 100 μ L diluted Steady Glo
20 was added. The plates were gently shake at room temperature for 30 minutes and luminescence determined by TopCount at the SPC mode.

The dose-response effect of Peptide A on luciferase expression in Seq51-transfected N7 cells was tested in 2 separate experiments. The EC₅₀ value of Peptide A for the 2 experiments was 1.6 nM and 1.7 nM, respectively. Salmon Peptide B (Asp Thr Met Arg Cys Met Val Gly
25 Arg Val Tyr Arg Pro Cys Trp Glu Val; SEQ ID NO:184), a variant of Peptide A, and another variant of Peptide A were also tested in the second experiment. The EC₅₀ value for salmon Peptide B was approximately 25 nM while variant of Peptide A had no effect on these Seq51-transfected cells at concentration up to 1 μ M.

Peptide A, a cyclic heptadecapeptide, is a prominent hypothalamic neuropeptide
30 expressed in cells which are part of an extensive network of neurons projecting to multiple parts of the brain. Despite the large numbers of hypothalamic Peptide A-expressing cells, the Peptide A cell groups are not part of the major hypothalamic nuclei (paraventricular, supraoptic, dorsomedial, ventromedial, arcuate, lateral tuberal or mammillary) (Knigge *et al.*, *J. Peptides*, 1996, 17, 1063-1073), but they have terminal projections to most of these hypothalamic nuclei.

Additionally, Peptide A projections from the hypothalamus to the rest of the brain are extensive, including to the cerebellar cortex, subcortical nuclei, limbic areas, thalamus, brain stem and spinal cord.

Peptide A projections are included in the circuitry involved in processing visual and auditory information, suggesting a general role in arousal and sensorimotor integration (Hervieu *et al.*, *Eur. J. Neurosci.*, **2000**, *12*, 1194-1216). Intracerebroventricular injection of Peptide A causes a decrease in the conditioning amplitude of the second of a pair of auditory evoked potentials recorded from the hippocampus (hippocampal auditory gating paradigm) and reverses the increases in the conditioning amplitude induced by alpha MSH (Miller *et al.*, *Peptides*, **1993**, *14*, 431-440). These data would suggest that Peptide A inhibits the normal auditory gating process. Schizophrenics also present with a loss of auditory gating which may contribute to an inability to filter inappropriate information. Dysregulation of Peptide A may contribute to this phenotype in humans and antagonists active at the Peptide A receptors may effectively treat these deficits in schizophrenia.

Major portions of the Peptide A cell group are in areas considered to be part of the extrapyramidal motor circuits. It has been suggested that this location would afford the Peptide A neuronal system the capability of coordinating hypothalamic visceral activity with appropriate motor activity (Knigge *et al.*, **1996**).

Peptide A localization in the hippocampal formation, the amygdaloid regions, the bed nucleus of the stria terminalis all suggest a role in cognition and learning and in support of this Peptide A has been shown to alter passive avoidance performance (McBride *et al.*, *Peptides*, **1994**, *15*, 757-759).

Central injections of Peptide A in rats leads to a reduction in peak circadian ACTH levels and inhibit stress-induced ACTH secretion (Bluet Pajot *et al.*, *J. Neuroendocrinol.*, **1995**, *7*, 297-303; and Ludwig *et al.*, *Am. J. Physiology*, **1998**, *274*, E627-E633). However, injections of Peptide A into the medial preoptic area of the hypothalamus of rats result in decreases in time spent in open arms in the elevated plus maze assay indicative of increased anxiety. Injections of the peptide also stimulated female sexual receptivity (Gonzalez *et al.*, *Peptides*, **1996**, *17*, 171-177).

The lateral hypothalamus has a prominent role in feeding-related behaviors and in fact Peptide A has been shown to be involved in energy balance and food intake. Ob/ob mice express more Peptide A mRNA compared with lean littermates (Qu *et al.*, *Nature*, **1996**, *380*, 243-247). Additionally, fasting increases hypothalamic Peptide A mRNA levels (Qu *et al.*, **1996**).

Intracerebroventricular injection of Peptide A leads to an increase in food intake in rats (Qu *et al.*, *Endocrinology*, 1997, 138, 351-355).

Targeted deletion of the gene which encodes the preprohormone for Peptide A resulted in mice which have reduced body weight and are lean due to reduced feeding. Additionally
5 these mice have an increased metabolic rate in the presence of decreased leptin levels and POMC levels (Shimada *et al.*, *Nature*, 1998, 396, 670-673). These mice also have a loss of expression of the NEI peptide as well as Peptide A. Nevertheless, the prominent phenotypic feature of these mice is their reduced size. Antagonists of Peptide A receptors may be effective in the treatment of obesity.

10 The SLC-1 gene product was recently identified as a G-protein coupled receptor which is potently activated by Peptide A (Chambers *et al.*, *Nature*, 1999, 400, 261-265; and Saito *et al.*, *Nature*, 1999, 400, 265-269). nGPCR-51 has been identified as a gene encoding a second Peptide A receptor which is also potently activated by Peptide A. Like that of the SLC-1 gene, expression of nGPCR-51 is extensive throughout the brain. The multiple actions of Peptide A
15 could be differentially mediated by each of the two Peptide A receptors. Selective agonism or antagonism at nGPCR-51 could result in a therapeutic effective in treating schizophrenia, attention disorders, anxiety, depression, obesity, and the like.

D. Intracellular calcium measurement using FLIPR

Changes in intracellular calcium levels are another recognized indicator of G protein-
20 coupled receptor activity, and such assays can be employed to screen for modulators of nGPCR-x activity. For example, CHO cells stably transfected with a nGPCR-x expression vector are plated at a density of 4×10^4 cells/well in Packard black-walled, 96-well plates specially designed to discriminate fluorescence signals emanating from the various wells on the plate. The cells are incubated for 60 minutes at 37C in modified Dulbecco's PBS (D-PBS) containing 36
25 mg/L pyruvate and 1 g/L glucose with the addition of 1% fetal bovine serum and one of four calcium indicator dyes (Fluo-3TM AM, Fluo-4TM AM, Calcium GreenTM-1 AM, or Oregon GreenTM 488 BAPTA-1 AM), each at a concentration of 4 μ M. Plates are washed once with modified D-PBS without 1% fetal bovine serum and incubated for 10 minutes at 37C to remove residual dye from the cellular membrane. In addition, a series of washes with modified D-PBS
30 without 1% fetal bovine serum is performed immediately prior to activation of the calcium response.

A calcium response is initiated by the addition of one or more candidate receptor agonist compounds, calcium ionophore A23187 (10 μ M; positive control), or ATP (4 μ M; positive control). Fluorescence is measured by Molecular Device's FLIPR with an argon laser (excitation

at 488 nm). (See, e.g., Kuntzweiler et al., Drug Development Research, 44(1):14-20 (1998)).

The F-stop for the detector camera was set at 2.5 and the length of exposure was

0.4 milliseconds. Basal fluorescence of cells was measured for 20 seconds prior to addition of candidate agonist, ATP, or A23187, and the basal fluorescence level was subtracted from the response signal. The calcium signal is measured for approximately 200 seconds, taking readings every two seconds. Calcium ionophore A23187 and ATP increase the calcium signal 200% above baseline levels. In general, activated GPCRs increase the calcium signal approximately 10-15% above baseline signal.

nGPCR-51

HEK293 cells were transiently transfected with an expression vector for nGPCR-51 and empty vector using Lipofectamine plus (Gibco) according to the manufacturer's instructions. The next day, the cells were seeded into 96-well plates at 25,000 cells per well. The following day, cells were loaded with 1 μ M Fluo-4-acetoxymethyl fluorescent indicator dye (Molecular Probes) in MEM (minimal essential media) containing 0.1% bovine serum albumin, 0.04% pluronic acid and 2.5 mM probenecid for 30 minutes at 37°C. The cells were washed with pre-warmed (37°C) assay buffer (Hanks buffer containing 15 mM HEPES, 2.5 mM probenecid and 0.1% bovine serum albumin). Assay buffer (100 μ l) was added to each well and plates were incubated at 37°C for 15 minutes. Various concentrations (0.03 pM-10 nM) of human Peptide A or salmon Peptide B were added and fluorescence produced by fluo-4 (a calcium sensitive dye) was measured every second for 150 seconds on a fluorometric imaging plate reader (FLIPR1; Molecular Devices). Human Peptide A and salmon Peptide B-induced calcium mobilization in nGPCR-51-transfected cells with EC₅₀ values of 3 nM and 6 nM, respectively. Human Peptide A and salmon Peptide B had no effect on vector-transfected cells.

E. Mitogenesis Assay

In a mitogenesis assay, the ability of candidate modulators to induce or inhibit nGPCR-x-mediated cell division is determined. (See, e.g., Lajiness et al., Journal of Pharmacology and Experimental Therapeutics 267(3): 1573-1581 (1993)). For example, CHO cells stably expressing nGPCR-x are seeded into 96-well plates at a density of 5000 cells/well and grown at 37°C in MEM with 10% fetal calf serum for 48 hours, at which time the cells are rinsed twice with serum-free MEM. After rinsing, 80 μ l of fresh MEM, or MEM containing a known mitogen, is added along with 20 μ l MEM containing varying concentrations of one or more candidate modulators or test compounds diluted in serum-free medium. As controls, some wells on each plate receive serum-free medium alone, and some receive medium containing 10% fetal

bovine serum. Untransfected cells or cells transfected with vector alone also may serve as controls.

After culture for 16-18 hours, 1 μ Ci of [3 H]-thymidine (2 Ci/mmol) is added to the wells and cells are incubated for an additional 2 hours at 37C. The cells are trypsinized and collected
5 on filter mats with a cell harvester (Tomtec); the filters are then counted in a Betaplate counter. The incorporation of [3 H]-thymidine in serum-free test wells is compared to the results achieved in cells stimulated with serum (positive control). Use of multiple concentrations of test compounds permits creation and analysis of dose-response curves using the non-linear, least squares fit equation: $A = B \times [C / (D + C)] + G$ where A is the percent of serum stimulation; B is
10 the maximal effect minus baseline; C is the EC_{50} ; D is the concentration of the compound; and G is the maximal effect. Parameters B, C and G are determined by Simplex optimization.

Agonists that bind to the receptor are expected to increase [3 H]-thymidine incorporation into cells, showing up to 80% of the response to serum. Antagonists that bind to the receptor will inhibit the stimulation seen with a known agonist by up to 100%.

15 F. [35 S]GTP γ S Binding Assay

Because G protein-coupled receptors signal through intracellular G proteins whose activity involves GTP binding and hydrolysis to yield bound GDP, measurement of binding of the non-hydrolyzable GTP analog [35 S]GTP γ S in the presence and absence of candidate modulators provides another assay for modulator activity. (See, e.g., Kowal et al.,
20 *Neuropharmacology* 37:179-187 (1998).)

In one exemplary assay, cells stably transfected with a nGPCR-x expression vector are grown in 10 cm tissue culture dishes to subconfluence, rinsed once with 5 ml of ice-cold Ca^{2+}/Mg^{2+} -free phosphate-buffered saline, and scraped into 5 ml of the same buffer. Cells are pelleted by centrifugation (500 x g, 5 minutes), resuspended in TEE buffer (25 mM Tris, pH 7.5,
25 5 mM EDTA, 5 mM EGTA), and frozen in liquid nitrogen. After thawing, the cells are homogenized using a Dounce homogenizer (one ml TEE per plate of cells), and centrifuged at 1,000 x g for 5 minutes to remove nuclei and unbroken cells.

The homogenate supernatant is centrifuged at 20,000 x g for 20 minutes to isolate the membrane fraction, and the membrane pellet is washed once with TEE and resuspended in
30 binding buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM $MgCl_2$, 1 mM EDTA). The resuspended membranes can be frozen in liquid nitrogen and stored at -70C until use.

Aliquots of cell membranes prepared as described above and stored at -70C are thawed, homogenized, and diluted into buffer containing 20 mM HEPES, 10 mM $MgCl_2$, 1 mM EDTA, 120 mM NaCl, 10 μ M GDP, and 0.2 mM ascorbate, at a concentration of 10-50 μ g/ml. In a final

volume of 90 μ l, homogenates are incubated with varying concentrations of candidate modulator compounds or 100 μ M GTP for 30 minutes at 30C and then placed on ice. To each sample, 10 μ l guanosine 5'-O-(3[35 S]thio) triphosphate (NEN, 1200 Ci/mmol; [35 S]-GTP γ S), was added to a final concentration of 100-200 pM. Samples are incubated at 30C for an additional 30 minutes, 1
5 ml of 10mM HEPES, pH 7.4, 10 mM MgCl₂, at 4C is added and the reaction is stopped by filtration.

Samples are filtered over Whatman GF/B filters and the filters are washed with 20 ml ice-cold 10 mM HEPES, pH 7.4, 10 mM MgCl₂. Filters are counted by liquid scintillation spectroscopy. Nonspecific binding of [35 S]-GTP γ S is measured in the presence of 100 μ M GTP
10 and subtracted from the total. Compounds are selected that modulate the amount of [35 S]-GTP γ S binding in the cells, compared to untransfected control cells. Activation of receptors by agonists gives up to a five-fold increase in [35 S]GTP γ S binding. This response is blocked by antagonists.

G. MAP Kinase Activity Assay

Evaluation of MAP kinase activity in cells expressing a GPCR provides another assay to
15 identify modulators of GPCR activity. (See, e.g., Lajiness et al., Journal of Pharmacology and Experimental Therapeutics 267(3):1573-1581 (1993) and Boulton et al., Cell 65:663-675 (1991).)

In one embodiment, CHO cells stably transfected with nGPCR-x are seeded into 6-well plates at a density of 70,000 cells/well 48 hours prior to the assay. During this 48-hour period,
20 the cells are cultured at 37C in MEM medium supplemented with 10% fetal bovine serum, 2mM glutamine, 10 U/ml penicillin and 10 μ g/ml streptomycin. The cells are serum-starved for 1-2 hours prior to the addition of stimulants.

For the assay, the cells are treated with medium alone or medium containing either a candidate agonist or 200 nM Phorbol ester- myristoyl acetate (i.e., PMA, a positive control), and
25 the cells are incubated at 37C for varying times. To stop the reaction, the plates are placed on ice, the medium is aspirated, and the cells are rinsed with 1 ml of ice-cold PBS containing 1mM EDTA. Thereafter, 200 μ l of cell lysis buffer (12.5 mM MOPS, pH 7.3, 12.5 mM glycerophosphate, 7.5mM MgCl₂, 0.5mM EGTA, 0.5 mM sodium vanadate, 1mM benzamidine, 1mM dithiothreitol, 10 μ g/ml leupeptin, 10 μ g/ml aprotinin, 2 μ g/ml pepstatin A, and 1 μ M
30 okadaic acid) is added to the cells. The cells are scraped from the plates and homogenized by 10 passages through a 23 3/4 G needle, and the cytosol fraction is prepared by centrifugation at 20,000 x g for 15 minutes.

Aliquots (5-10 μ l containing 1-5 μ g protein) of cytosol are mixed with 1 mM MAPK Substrate Peptide (APRTPGGRR; SEQ ID NO:182), Upstate Biotechnology, Inc., N.Y.) and

50 μ M [γ - 32 P]ATP (NEN, 3000 Ci/mmol), diluted to a final specific activity of ~2000 cpm/pmol, in a total volume of 25 μ l. The samples are incubated for 5 minutes at 30C, and reactions are stopped by spotting 20 μ l on 2 cm² squares of Whatman P81 phosphocellulose paper. The filter squares are washed in 4 changes of 1% H₃PO₄, and the squares are subjected to liquid
5 scintillation spectroscopy to quantitate bound label. Equivalent cytosolic extracts are incubated without MAPK substrate peptide, and the bound label from these samples are subtracted from the matched samples with the substrate peptide. The cytosolic extract from each well is used as a separate point. Protein concentrations are determined by a dye binding protein assay (Bio-Rad Laboratories). Agonist activation of the receptor is expected to result in up to a five-fold
10 increase in MAPK enzyme activity. This increase is blocked by antagonists.

H. [3 H]Arachidonic Acid Release

The activation of GPCRs also has been observed to potentiate arachidonic acid release in cells, providing yet another useful assay for modulators of GPCR activity. (See, e.g., Kanterman et al., Molecular Pharmacology 39:364-369 (1991).) For example, CHO cells that
15 are stably transfected with a nGPCR-x expression vector are plated in 24-well plates at a density of 15,000 cells/well and grown in MEM medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin and 10 μ g/ml streptomycin for 48 hours at 37C before use. Cells of each well are labeled by incubation with [3 H]-arachidonic acid (Amersham Corp., 210 Ci/mmol) at 0.5 μ Ci/ml in 1 ml MEM supplemented with 10mM HEPES, pH 7.5, and 0.5%
20 fatty-acid-free bovine serum albumin for 2 hours at 37C. The cells are then washed twice with 1 ml of the same buffer.

Candidate modulator compounds are added in 1 ml of the same buffer, either alone or with 10 μ M ATP and the cells are incubated at 37C for 30 minutes. Buffer alone and mock-transfected cells are used as controls. Samples (0.5 ml) from each well are counted by liquid
25 scintillation spectroscopy. Agonists which activate the receptor will lead to potentiation of the ATP-stimulated release of [3 H]-arachidonic acid. This potentiation is blocked by antagonists.

I. Extracellular Acidification Rate

In yet another assay, the effects of candidate modulators of nGPCR-x activity are assayed by monitoring extracellular changes in pH induced by the test compounds. (See, e.g.,
30 Dunlop et al., Journal of Pharmacological and Toxicological Methods 40(1):47-55 (1998).) In one embodiment, CHO cells transfected with a nGPCR-x expression vector are seeded into 12 mm capsule cups (Molecular Devices Corp.) at 4×10^5 cells/cup in MEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 10 U/ml penicillin, and 10 μ g/ml streptomycin. The cells are incubated in this medium at 37C in 5% CO₂ for 24 hours.

Extracellular acidification rates are measured using a Cytosensor microphysiometer (Molecular Devices Corp.). The capsule cups are loaded into the sensor chambers of the microphysiometer and the chambers are perfused with running buffer (bicarbonate-free MEM supplemented with 4 mM L-glutamine, 10 units/ml penicillin, 10 µg/ml streptomycin, 26 mM NaCl) at a flow rate of 100 µl/minute. Candidate agonists or other agents are diluted into the running buffer and perfused through a second fluid path. During each 60-second pump cycle, the pump is run for 38 seconds and is off for the remaining 22 seconds. The pH of the running buffer in the sensor chamber is recorded during the cycle from 43-58 seconds, and the pump is re-started at 60 seconds to start the next cycle. The rate of acidification of the running buffer during the recording time is calculated by the Cytosoft program. Changes in the rate of acidification are calculated by subtracting the baseline value (the average of 4 rate measurements immediately before addition of a modulator candidate) from the highest rate measurement obtained after addition of a modulator candidate. The selected instrument detects 61 mV/pH unit. Modulators that act as agonists of the receptor result in an increase in the rate of extracellular acidification compared to the rate in the absence of agonist. This response is blocked by modulators which act as antagonists of the receptor.

J. Radioligand Binding Assay

HEK 293 or COS7 cells transiently expressing nGPCR-51, or CHO K-1 cells stable expressing nGPCR-51, were grown to sub-confluence (2 days post-transfection for transients), harvested from flasks in Dulbecco's PBS and pelleted by low speed centrifugation (2500 rpm) for 10 minutes. Cell pellets were homogenized in 10 ml tissue buffer (50 mM Hepes, 10 mM MgCl₂, 2 mM EGTA, 1 µg/ml aprotinin, 1 µg/ml leupeptin hemisulfate, 1 µg/ml pepstatin A, pH 7.0) using a dounce, 10 strokes. Homogenate was centrifuged at 47,000 x g for 15 minutes. Membrane pellet was resuspended in 1 ml tissue buffer using the dounce, 10 strokes. An aliquot of the membrane preparation was used to determine protein concentration. For measurement of saturation binding, 10 µg of cell membranes were incubated with various concentrations of [¹²⁵I] Peptide A (iodinated by routine procedures via the Tyr residue) in 300 µl binding assay buffer (tissue buffer plus 0.15 mM Bacitracin and 0.1% ovalbumin) for 90 minutes at room temperature in 96-well plates. Non-specific binding was defined by the inclusion of 1 µM Peptide A. After the binding incubation, plates were harvested onto GF/C filters presoaked in 0.3% non-fat dry milk. Filters were dried, and 30 µl scintillant was added to each well. Filter plates were then counted in a Packard Topcount™ 96-well microplate scintillation counter. Data were analyzed using GraphPad Prism (San Diego, CA) and K_d and B_{max} values were calculated.

In a saturation binding experiment using COS 7 cells transiently expressing nGPCR-51 the K_d for [¹²⁵I] Peptide A was determined to be 0.254 nM, with a B_{max} of 75 fmol/mg. HEK 293 cells transiently expressing nGPCR-51 were shown to have an estimated B_{max} of 108 fmol/mg. Untransfected cells have no specific radioligand binding for [¹²⁵I] Peptide A.

5 **Example 13: Using nGPCR-x Proteins to Isolate Neurotransmitters**

The isolated nGPCR-x proteins, particularly nGPCR-42, 46, 48, 49, 51, 52, 61, 63, or 70 (SEQ ID Numbers 61, 62, 68, 91, 94, 96, 97, 99, 100, and 111-120) can be used to isolate novel or known neurotransmitters (Saito et al., Nature, 400: 265-269, 1999). The cDNAs that encode the isolated nGPCR-x can be cloned into mammalian expression vectors and used to stably or
10 transiently transfect mammalian cells including CHO, Cos or HEK293 cells. Receptor expression can be determined by Northern blot analysis of transfected cells and identification of an appropriately sized mRNA band (predicted size from the cDNA). Brain regions shown by mRNA analysis to express each of the nGPCR-x proteins could be processed for peptide extraction using any of several protocols ((Reinscheid R.K. et al., Science 270: 243-247, 1996; Sakurai, T., et al., Cell 92: 573-585, 1998; Hinuma, S., et al., Nature 393: 272-276, 1998).
15 Chromatographic fractions of brain extracts could be tested for ability to activate nGPCR-x proteins by measuring second messenger production such as changes in cAMP production in the presence or absence of forskolin, changes in inositol 3-phosphate levels, changes in intracellular calcium levels or by indirect measures of receptor activation including receptor stimulated mitogenesis, receptor mediated changes in extracellular acidification or receptor mediated
20 changes in reporter gene activation in response to cAMP or calcium (these methods should all be referenced in other sections of the patent). Receptor activation could also be monitored by co-transfecting cells with a chimeric G_i/13 to force receptor coupling to a calcium stimulating pathway (Conklin et al., Nature 363: 274-276, 1993). Neurotransmitter mediated activation of
25 receptors could also be monitored by measuring changes in [³⁵S]-GTPγS binding in membrane fractions prepared from transfected mammalian cells. This assay could also be performed using baculoviruses containing nGPCR-x proteins infected into SF9 insect cells.

The neurotransmitter which activates nGPCR-x proteins can be purified to homogeneity through successive rounds of purification using nGPCR-x proteins activation as a measurement
30 of neurotransmitter activity. The composition of the neurotransmitter can be determined by mass spectrometry and Edman degradation if peptidergic. Neurotransmitters isolated in this manner will be bioactive materials which will alter neurotransmission in the central nervous system and will produce behavioral and biochemical changes.

Example 14: Using nGPCR-x Proteins to Isolate and Purify G Proteins

cDNAs encoding nGPCR-x proteins are epitope-tagged at the amino terminus end of the cDNA with the cleavable influenza-hemagglutinin signal sequence followed by the FLAG epitope (IBI, New Haven, CT). Additionally, these sequences are tagged at the carboxyl terminus with DNA encoding six histidine residues. (Amino and Carboxyl Terminal Modifications to Facilitate the Production and Purification of a G Protein-Coupled Receptor, B.K. Kobilka, Analytical Biochemistry, Vol. 231, No. 1, Oct 1995, pp. 269-271). The resulting sequences are cloned into a baculovirus expression vector such as pVL1392 (Invitrogen). The baculovirus expression vectors are used to infect SF-9 insect cells as described (Guan *et al.*, (1992) J. Biol. Chem. 267, 21995-21998). Infected SF-9 cells could be grown in 1000-ml cultures in SF900 II medium (Life Technologies, Inc.) containing 5% fetal calf serum (Gemini, Calabasas, CA) and 0.1 mg/ml gentamicin (Life Technologies, Inc.) for 48 hours at which time the cells could be harvested. Cell membrane preparations could be separated from soluble proteins following cell lysis. nGPCR-x protein purification is carried out as described for purification of the θ 2 receptor (Kobilka, Anal. Biochem., 231 (1): 269-271, 1995) including solubilization of the membranes in 0.8-1.0 % n-dodecyl-D-maltoside (DM) (CalBiochem, La Jolla, CA) in buffer containing protease inhibitors followed by Ni-column chromatography using chelating Sepharose™ (Pharmacia, Uppsala, Sweden). The eluate from the Ni-column is further purified on an M1 anti-FLAG antibody column (IBI). Receptor containing fractions are monitored by using receptor specific antibodies following western blot analysis or by SDS-PAGE analysis to look for an appropriate sized protein band (appropriate size would be the predicted molecular weight of the protein). This method of purifying G protein is particularly useful to isolate G proteins that bind to the nGPCR-x proteins in the absence of an activating ligand.

Some of the preferred embodiments of the invention described above are outlined below and include, but are not limited to, the following embodiments. As those skilled in the art will appreciate, numerous changes and modifications may be made to the preferred embodiments of the invention without departing from the spirit of the invention. It is intended that all such variations fall within the scope of the invention. The entire disclosure of each publication cited herein is incorporated herein by reference in its entirety.

Example 15: Clone Deposit Information

In accordance with the Budapest Treaty, clones of the present invention have been deposited at the Agricultural Research Culture Collection (NRRL) International Depository

Authority, 1815 N. University Street, Peoria, Illinois 61604, U.S.A. Accession numbers and deposit dates are provided below in Table 6.

Table 6: Deposit Information

	Clone	SEQ ID NO:	NRRL Accession Number	Budapest Treaty Deposit Date
5	nGPCR-42	31, 54	B-30246	2000 January 18
	nGPCR-48	36, 56	B30263	2000 February 22
	nGPCR-46	34, 55	B-30269	2000 March 10
10	nGPCR-52	40, 58	B-30270	2000 March 10
	nGPCR-70	8, 52	B-30300	2000 June 2
	nGPCR-61	1, 60	B-30301	2000 June 2
	nGPCR-49	37, 59	B-30313	2000 July 6
	nGPCR-51	39, 57	B-30314	2000 July 6
15	nGPCR-63	3, 51, 53	B-30315	2000 July 6

What is claimed is:

1. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to sequences selected from the group consisting of: SEQ ID NO:61 to SEQ ID NO:120, said nucleic acid molecule encoding at least a portion of nGPCR-x.
2. The isolated nucleic acid molecule of claim 1 comprising a sequence that encodes a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:61 to SEQ ID NO:120.
3. The isolated nucleic acid molecule of claim 1 comprising a sequence homologous to a sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:60.
4. The isolated nucleic acid molecule of claim 1 comprising a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:60.
5. The isolated nucleic acid molecule of claim 4 comprising a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:60.
6. The isolated nucleic acid molecule of claim 4 wherein said nucleotide sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:8, SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, and SEQ ID NO:60.
7. The isolated nucleic acid molecule of claim 1 wherein said nucleic acid molecule is DNA.
8. The isolated nucleic acid molecule of claim 1 wherein said nucleic acid molecule is RNA.
9. An expression vector comprising a nucleic acid molecule of any one of claims 1 to 5.

10. The expression vector of claim 9 wherein said nucleic acid molecule comprises a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:60.
11. The expression vector of claim 9 wherein said nucleic acid molecule comprises a
5 nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:8, SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, and SEQ ID NO:60.
- 10 12. The expression vector of claim 9 wherein said vector is a plasmid.
13. The expression vector of claim 9 wherein said vector is a viral particle.
14. The expression vector of claim 13 wherein said vector is selected from the group
15 consisting of adenoviruses, baculoviruses, parvoviruses, herpesviruses, poxviruses, adeno-associated viruses, Semliki Forest viruses, vaccinia viruses, and retroviruses.
15. The expression vector of claim 9 wherein said nucleic acid molecule is operably
20 connected to a promoter selected from the group consisting of simian virus 40, mouse mammary tumor virus, long terminal repeat of human immunodeficiency virus, maloney virus, cytomegalovirus immediate early promoter, Epstein Barr virus, rous sarcoma virus, human actin, human myosin, human hemoglobin, human muscle creatine, and human metallothionein.
16. A host cell transformed with an expression vector of claim 9.
25
17. The transformed host cell of claim 16 wherein said cell is a bacterial cell.
18. The transformed host cell of claim 17 wherein said bacterial cell is E. coli.
- 30 19. The transformed host cell of claim 16 wherein said cell is yeast.
20. The transformed host cell of claim 19 wherein said yeast is S. cerevisiae.
21. The transformed host cell of claim 16 wherein said cell is an insect cell.

22. The transformed host cell of claim 21 wherein said insect cell is *S. frugiperda*.
23. The transformed host cell of claim 16 wherein said cell is a mammalian cell.
- 5 24. The transformed host cell of claim 23 wherein mammalian cell is selected from the group consisting of chinese hamster ovary cells, HeLa cells, African green monkey kidney cells, human 293 cells, and murine 3T3 fibroblasts.
- 10 25. An isolated nucleic acid molecule comprising a nucleotide sequence complementary to at least a portion of a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:60, said portion comprising at least 10 nucleotides.
- 15 26. The nucleic acid molecule of claim 25 wherein said molecule is an antisense oligonucleotide directed to a region of a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:60.
- 20 27. The nucleic acid molecule of claim 26 wherein said oligonucleotide is directed to a regulatory region of a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:60.
- 25 28. The nucleic acid molecule of claim 25 wherein said molecule is an antisense oligonucleotide directed to a region of nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:8, SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, and SEQ ID NO:60.
- 30 29. A composition comprising a nucleic acid molecule of any one of claims 1 to 5 or 25 and an acceptable carrier or diluent.
30. A composition comprising a recombinant expression vector of claim 9 and an acceptable carrier or diluent.

31. A method of producing a polypeptide that comprises a sequence selected from the group of sequences consisting SEQ ID NO:61 to SEQ ID NO:120, and homologs thereof, said method comprising the steps of:

- a) introducing a recombinant expression vector of claim 10 into a compatible host cell;
- b) growing said host cell under conditions for expression of said polypeptide; and
- c) recovering said polypeptide.

32. The method of claim 31 wherein said host cell is lysed and said polypeptide is recovered from the lysate of said host cell.

33. The method of claim 31 wherein said polypeptide is recovered by purifying the culture medium without lysing said host cell.

34. An isolated polypeptide encoded by a nucleic acid molecule of claim 1.

35. The polypeptide of claim 34 wherein said polypeptide comprises a sequence selected from the group of sequences consisting of SEQ ID NO:61 to SEQ ID NO:120.

36. The polypeptide of claim 34 wherein said polypeptide comprises an amino acid sequence homologous to a sequence selected from the group of sequences consisting of SEQ ID NO:61 to SEQ ID NO:120.

37. The polypeptide of claim 34 wherein said sequence homologous to a sequence selected from the group of sequences consisting of SEQ ID NO:61 to SEQ ID NO:120 comprises at least one conservative amino acid substitution compared to the sequences in the group of sequences consisting of SEQ ID NO:61 to SEQ ID NO:120.

38. The polypeptide of claim 34 wherein said polypeptide comprises an allelic variant of a polypeptide with a sequence selected from the group of sequences consisting of SEQ ID NO:61 to SEQ ID NO:120.

39. The polypeptide of claim 34 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:68, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100,

SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, and SEQ ID NO:120.

- 5
40. A composition comprising a polypeptide of claim 34 and an acceptable carrier or diluent.
41. An isolated antibody which binds to an epitope on a polypeptide of claim 34.
42. The antibody of claim 41 wherein said antibody is a monoclonal antibody.
- 10 43. A composition comprising an antibody of claim 41 and an acceptable carrier or diluent.
44. A method of inducing an immune response in a mammal against a polypeptide of claim 34 comprising administering to said mammal an amount of said polypeptide sufficient to induce said immune response.
- 15 45. A method for identifying a compound which binds nGPCR-x comprising the steps of:
- a) contacting nGPCR-x with a compound; and
 - b) determining whether said compound binds nGPCR-x.
- 20 46. The method of claim 45 wherein the nGPCR-x comprises an amino acid sequence selected from the group consisting of SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:68, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, and SEQ ID NO:120.
- 25 47. The method of claim 45 wherein binding of said compound to nGPCR-x is determined by a protein binding assay.
- 30 48. The method of claim 45 wherein said protein binding assay is selected from the group consisting of a gel-shift assay, Western blot, radiolabeled competition assay, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross linking, interaction trap/two-hybrid analysis, southwestern analysis, and ELISA.
49. A compound identified by the method of claim 45.

50. A method for identifying a compound which binds a nucleic acid molecule encoding nGPCR-x comprising the steps of:

- a) contacting said nucleic acid molecule encoding nGPCR-x with a compound; and
- b) determining whether said compound binds said nucleic acid molecule.

5

51. The method of claim 50 wherein binding is determined by a gel-shift assay.

52. A compound identified by the method of claim 50.

10 53. A method for identifying a compound which modulates the activity of nGPCR-x comprising the steps of:

- a) contacting nGPCR-x with a compound; and
- b) determining whether nGPCR-x activity has been modulated.

15 54. The method of claim 53 wherein the nGPCR-x comprises an amino acid sequence selected from the group consisting of SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:68, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, and SEQ ID NO:120.

20

55. The method of claim 53 wherein said activity is neuropeptide binding.

56. The method of claim 53 wherein said activity is neuropeptide signaling.

25 57. A compound identified by the method of claim 53.

58. A method of identifying an animal homolog of nGPCR-x comprising the steps:

- a) comparing the nucleic acid sequences of the animal with a sequence selected from the group of sequence consisting of SEQ ID NO:1 to SEQ ID NO:60, and portions thereof, said
30 portions being at least 10 nucleotides; and
- b) identifying nucleic acid sequences of the animal that are homologous to said sequence selected from the group sequence consisting of SEQ ID NO:1 to SEQ ID NO:60, and portions thereof.

59. The method of claim 58 wherein comparing the nucleic acid sequences of the animal with a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:60, and portions thereof, said portions being at least 10 nucleotides, is performed by DNA hybridization.

60. The method of claim 58 wherein comparing the nucleic acid sequences of the animal with a sequence selected from the group of sequences consisting of SEQ ID NO:1 to SEQ ID NO:60, and portions thereof, said portions being at least 10 nucleotides, is performed by computer homology search.

61. A method of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor, comprising the steps of:

a) assaying nucleic acid of a human subject to determine a presence or an absence of a mutation altering an amino acid sequence, expression, or biological activity of at least one nGPCR that is expressed in the brain, wherein the nGPCR comprises an amino acid sequence selected from the group consisting of SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:68, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, and SEQ ID NO:120, and allelic variants thereof, and wherein the nucleic acid corresponds to a gene encoding the nGPCR; and

b) diagnosing the disorder or predisposition from the presence or absence of said mutation, wherein the presence of a mutation altering the amino acid sequence, expression, or biological activity of the nGPCR in the nucleic acid correlates with an increased risk of developing the disorder.

62. The method of claim 61, wherein the nGPCR is nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70, or an allelic variant thereof.

63. The method of claim 61, wherein the nGPCR is nGPCR-51 or nGPCR-52 or an allelic variant thereof.

64. The method of claim 61, wherein the disease is a mental disorder.

65. The method of claim 61, wherein the assaying step comprises at least one procedure selected from the group consisting of:

a) comparing nucleotide sequences from the human subject and reference sequences and determining a difference of either

5 at least a nucleotide of at least one codon between the nucleotide sequences from the human subject that encodes an nGPCR-42 allele and an nGPCR-42 reference sequence;

 at least a nucleotide of at least one codon between the nucleotide sequences from the human subject that encodes an nGPCR-46 allele and an nGPCR-46 reference
10 sequence;

 at least a nucleotide of at least one codon between the nucleotide sequences from the human subject that encodes an nGPCR-48 allele and an nGPCR-48 reference sequence;

 at least a nucleotide of at least one codon between the nucleotide sequences from the human subject that encodes an nGPCR-49 allele and an nGPCR-49 reference
15 sequence;

 at least a nucleotide of at least one codon between the nucleotide sequences from the human subject that encodes an nGPCR-51 allele and an nGPCR-51 reference sequence;

20 at least a nucleotide of at least one codon between the nucleotide sequences from the human subject that encodes an nGPCR-52 allele and an nGPCR-52 reference sequence;

 at least a nucleotide of at least one codon between the nucleotide sequences from the human subject that encodes an nGPCR-61 allele and an nGPCR-61 reference
25 sequence;

 at least a nucleotide of at least one codon between the nucleotide sequences from the human subject that encodes an nGPCR-63 allele and an nGPCR-63 reference sequence; or

 at least a nucleotide of at least one codon between the nucleotide sequences from the human subject that encodes an nGPCR-70 allele and an nGPCR-70 reference
30 sequence;

b) performing a hybridization assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences;

c) performing a polynucleotide migration assay to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences; and

5 d) performing a restriction endonuclease digestion to determine whether nucleic acid from the human subject has a nucleotide sequence identical to or different from one or more reference sequences.

66. The method of claim 65 wherein the assaying step comprises: performing a polymerase chain reaction assay to amplify nucleic acid comprising nGPCR-42, nGPCR-46, nGPCR-48,
10 nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 coding sequence, and determining nucleotide sequence of the amplified nucleic acid.

67. A method of screening for an nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 hereditary mental disorder genotype in a
15 human patient, comprising the steps of:

a) providing a biological sample comprising nucleic acid from said patient, said nucleic acid including sequences corresponding to alleles of nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70; and

b) detecting the presence of one or more mutations in the nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 allele;
20 wherein the presence of a mutation in a nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 allele is indicative of a hereditary mental disorder genotype.

25 68. The method of claim 67 wherein said biological sample is a cell sample.

69. The method of claim 67 wherein said detecting the presence of a mutation comprises sequencing at least a portion of said nucleic acid, said portion comprising at least one codon of said nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61,
30 nGPCR-63, or nGPCR-70 allele.

70. The method of claim 67 wherein said nucleic acid is DNA.

71. The method of claim 67 wherein said nucleic acid is RNA.

72. A kit for screening a human subject to diagnose a mental disorder or a genetic predisposition therefor, comprising, in association:

- a) an oligonucleotide useful as a probe for identifying polymorphisms in a human nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 gene, the oligonucleotide comprising 6-50 nucleotides in a sequence that is identical or complementary to a sequence of a wild type human nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 gene sequence or nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 coding sequence, except for one sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide substitution; and
- b) a media packaged with the oligonucleotide, said media containing information for identifying polymorphisms that correlate with mental disorder or a genetic predisposition therefor, the polymorphisms being identifiable using the oligonucleotide as a probe.

15

73. A method of identifying a nGPCR allelic variant that correlates with a mental disorder, comprising the steps of:

- a) providing a biological sample comprising nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny;
- b) detecting in the nucleic acid the presence of one or more mutations in an nGPCR that is expressed in the brain, wherein the nGPCR comprises an amino acid sequence selected from the group consisting of SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:68, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, and SEQ ID NO:120, and allelic variants thereof, and wherein the nucleic acid includes sequence corresponding to the gene or genes encoding nGPCR;

25

wherein the one or more mutations detected indicates an allelic variant that correlates with a mental disorder.

30

74. The method of claim 73 wherein the nGPCR is nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70, or an allelic variant thereof.

75. A purified and isolated polynucleotide comprising a nucleotide sequence encoding a nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 allelic variant identified according to claim 74.

5 76. A host cell transformed or transfected with a polynucleotide according to claim 75 or with a vector comprising the polynucleotide.

77. A purified polynucleotide comprising a nucleotide sequence encoding nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or
10 nGPCR-70 of a human with a mental disorder;
wherein said polynucleotide hybridizes to the complement of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:8, SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, and SEQ ID
15 NO:60 under the following hybridization conditions:

a) hybridization for 16 hours at 42C in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate; and

b) washing 2 times for 30 minutes at 60C in a wash solution comprising 0.1x SSC and 1% SDS;

20 wherein the polynucleotide that encodes nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 amino acid sequence of the human differs from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:8, SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57,
25 SEQ ID NO:58, SEQ ID NO:59, and SEQ ID NO:60 by at least one residue.

78. A vector comprising a polynucleotide according to claim 77.

79. A host cell that has been transformed or transfected with a polynucleotide according to
30 claim 77 and that expresses the nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 protein encoded by the polynucleotide.

80. The host cell of claim 79 that has been co-transfected with a polynucleotide encoding and expressing the nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52,

nGPCR-61, nGPCR-63, or nGPCR-70 amino acid sequence set forth in SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:68, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, and SEQ ID NO:120.

81. A method for identifying a modulator of biological activity of nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 comprising the steps of:

- 10 a) contacting a cell according to claim 79 in the presence and in the absence of a putative modulator compound; and
 - b) measuring nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 biological activity in the cell;
- wherein decreased or increased nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 biological activity in the presence versus absence of the putative modulator is indicative of a modulator of biological activity.

82. A method to identify compounds useful for the treatment of a mental disorder, said method comprising the steps of:

- 20 a) contacting a composition comprising nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 with a compound suspected of binding nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70; and
 - 25 b) detecting binding between nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 and the compound suspected of binding nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70;
- wherein compounds identified as binding nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 are candidate compounds useful for the treatment of a mental disorder.

83. A method for identifying a compound useful as a modulator of binding between nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or

nGPCR-70 and a binding partner of nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 comprising the steps of:

a) contacting the binding partner and a composition comprising nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 in the presence and in the absence of a putative modulator compound; and

b) detecting binding between the binding partner and nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70;

wherein decreased or increased binding between the binding partner and nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 in the presence of the putative modulator, as compared to binding in the absence of the putative modulator is indicative a modulator compound useful for the treatment of a mental disorder.

84. The method of claim 82 or claim 83 wherein the composition comprises a cell expressing nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70 on its surface.

85. The method of claim 84 wherein the composition comprises a cell transformed or transfected with a polynucleotide that encodes nGPCR-42, nGPCR-46, nGPCR-48, nGPCR-49, nGPCR-51, nGPCR-52, nGPCR-61, nGPCR-63, or nGPCR-70.

86. A method of purifying a G protein from a sample containing said G protein comprising the steps of:

a) contacting said sample with a polypeptide of claim 1 for a time sufficient to allow said G protein to form a complex with said polypeptide;

b) isolating said complex from remaining components of said sample;

c) maintaining said complex under conditions which result in dissociation of said G protein from said polypeptide; and

d) isolating said G protein from said polypeptide.

87. The method of claim 86 wherein said sample comprises an amino acid sequence selected from the group of sequences consisting of SEQ ID NO:61 to SEQ ID NO:120.

88. The method of claim 86 wherein said polypeptide comprises an amino acid sequence homologous to a sequence selected from the group of sequences consisting of SEQ ID NO:61 to SEQ ID NO:120.

5 89. The method of claim 86 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:68, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, and SEQ ID NO:120.

10

90. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to SEQ ID NO:117.

15 91. The nucleic acid molecule of claim 90 wherein said polypeptide comprises SEQ ID NO:117.

92. An isolated nucleic acid molecule comprising SEQ ID NO:57.

20 93. An isolated polypeptide comprising an amino acid sequence homologous to SEQ ID NO:117.

94. The polypeptide of claim 93 comprising SEQ ID NO:117.

25 95. A method of identifying a compound that binds to nGPCR-51 comprising the steps of:
a) contacting a composition comprising nGPCR-51, or a polypeptide homologous thereto, and a polypeptide comprising SEQ ID NO:183, or a polypeptide homologous thereto, with said test compound; and
b) determining whether said test compound binds to nGPCR-51.

30 96. The method of claim 95 wherein said determining whether said test compound binds to nGPCR-51 is by measuring the displacement of said polypeptide comprising SEQ ID NO:183 from a complex between said polypeptide and nGPCR-51.

97. The method of claim 95 wherein said polypeptide comprising SEQ ID NO:183 is radiolabeled.

98. The method of claim 97 wherein step b) is determined by comparatively measuring radioactivity of nGPCR-51 bound to said radiolabeled polypeptide comprising SEQ ID NO:183 with the radioactivity of nGPCR-51 in the presence of the test compound.

99. The method of claim 95 wherein step b) comprises a binding assay selected from the group consisting of filter binding, scintillation proximity assay, gel-shift assay, radiolabeled competition assay, and ELISA.

100. A method for identifying a compound that modulates the activity of nGPCR-51 comprising the steps of :

- a) contacting nGPCR-51 with a compound; and
- b) determining whether nGPCR-51 activity has been modulated.

101. The method of claim 100 wherein said activity is neuropeptide binding.

102. The method of claim 101 wherein said neuropeptide binding is determined by binding to a polypeptide comprising SEQ ID NO:183.

103. The method of claim 101 wherein said neuropeptide binding is determined by binding to a polypeptide comprising SEQ ID NO:184.

104. The method of claim 100 wherein said activity is neuropeptide signaling.

105. The method of claim 104 wherein said neuropeptide signalling is determined by binding to a polypeptide comprising SEQ ID NO:183.

106. The method of claim 104 wherein said neuropeptide signalling is determined by binding to a polypeptide comprising SEQ ID NO:184.

107. A method of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor, comprising the steps of:

a) assaying nucleic acid of a human subject to determine a presence or an absence of a mutation altering an amino acid sequence, expression, or biological activity of nGPCR-51, or an allelic variant thereof; and

5 b) diagnosing the disorder or predisposition from the presence or absence of said mutation, wherein the presence of a mutation altering the amino acid sequence, expression, or biological activity of the nGPCR in the nucleic acid correlates with an increased risk of developing the disorder.

10 108. The method of claim 107 wherein the disorder is schizophrenia.

109. The method of claim 107 wherein the disorder is an attention disorder.

110. The method of claim 107 wherein the disorder is anxiety.

15 111. The method of claim 107 wherein the disorder is depression.

112. The method of claim 107 wherein the disorder is obesity.

20 113. A kit for screening a human subject to diagnose a mental disorder or a genetic predisposition therefor, comprising, in association:

a) an oligonucleotide useful as a probe for identifying polymorphisms in a human nGPCR-51, the oligonucleotide comprising 6-50 nucleotides in a sequence that is identical or complementary to a sequence of a wild type human nGPCR-51 gene sequence or nGPCR-51 coding sequence, except for one sequence difference selected from the group consisting of a
25 nucleotide addition, a nucleotide deletion, or nucleotide substitution; and

b) a media packaged with the oligonucleotide, said media containing information for identifying polymorphisms that correlate with mental disorder or a genetic predisposition therefor, the polymorphisms being identifiable using the oligonucleotide as a probe.

30 114. A method of identifying a nGPCR allelic variant that correlates with a mental disorder, comprising the steps of:

a) providing a biological sample comprising nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny;

b) detecting in the nucleic acid the presence of one or more mutations in an nGPCR that is expressed in the brain, wherein the nGPCR comprises SEQ ID NO:117 or an allelic variant thereof, and wherein the nucleic acid includes sequence corresponding to the gene or genes encoding nGPCR;

5 wherein the one or more mutations detected indicates an allelic variant that correlates with a mental disorder.

115. A method for identifying a modulator of biological activity of nGPCR-51 comprising the steps of:

10 a) contacting a cell according to claim 79 in the presence and in the absence of a putative modulator compound; and

 b) measuring nGPCR-51 biological activity in the cell;

 wherein decreased or increased nGPCR-51 biological activity in the presence versus absence of the putative modulator is indicative of a modulator of biological activity.

15 116. A method of identifying a compound useful for the treatment of a mental disorder, said method comprising the steps of:

 a) contacting a composition comprising nGPCR-51 with a compound suspected of binding nGPCR-51; and

20 b) detecting binding between nGPCR-51 and the compound suspected of binding nGPCR-51;

 wherein a compound identified as binding nGPCR-51 is a candidate compound useful for the treatment of a mental disorder.

25 117. A method for identifying a compound useful as a modulator of binding between nGPCR-51 and a binding partner of nGPCR-51 comprising the steps of:

 a) contacting the binding partner and a composition comprising nGPCR-51 in the presence and in the absence of a putative modulator compound; and

 b) detecting binding between the binding partner and nGPCR-51;

30 wherein decreased or increased binding between the binding partner and nGPCR-51 in the presence of the putative modulator, as compared to binding in the absence of the putative modulator is indicative a modulator compound useful for the treatment of a mental disorder.

118. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence homologous to SEQ ID NO:118.
119. The nucleic acid molecule of claim 118 wherein said polypeptide comprises SEQ ID NO:118.
120. An isolated nucleic acid molecule comprising SEQ ID NO:58.
121. An isolated polypeptide comprising an amino acid sequence homologous to SEQ ID NO:118.
122. The polypeptide of claim 93 comprising SEQ ID NO:118.
123. A method of identifying a compound that binds to nGPCR-52 comprising the steps of:
- a) contacting a composition comprising nGPCR-52, or a polypeptide homologous thereto, and a polypeptide comprising SEQ ID NO:183, or a polypeptide homologous thereto, with said test compound; and
 - b) determining whether said test compound binds to nGPCR-52.
124. The method of claim 123 wherein said determining whether said test compound binds to nGPCR-52 is by measuring the displacement of said polypeptide comprising SEQ ID NO:183 from a complex between said polypeptide and nGPCR-52.
125. The method of claim 123 wherein said polypeptide comprising SEQ ID NO:183 is radiolabeled.
126. The method of claim 125 wherein step b) is determined by comparatively measuring radioactivity of nGPCR-52 bound to said radiolabeled polypeptide comprising SEQ ID NO:183 with the radioactivity of nGPCR-52 in the presence of the test compound.
127. The method of claim 123 wherein step b) comprises a binding assay selected from the group consisting of filter binding, scintillation proximity assay, gel-shift assay, radiolabeled competition assay, and ELISA.

128. A method for identifying a compound that modulates the activity of nGPCR-52 comprising the steps of:

- a) contacting nGPCR-52 with a compound; and
- b) determining whether nGPCR-52 activity has been modulated.

129. The method of claim 128 wherein said activity is neuropeptide binding.

130. The method of claim 129 wherein said neuropeptide binding is determined by binding to a polypeptide comprising SEQ ID NO:183.

131. The method of claim 129 wherein said neuropeptide binding is determined by binding to a polypeptide comprising SEQ ID NO:184.

132. The method of claim 128 wherein said activity is neuropeptide signaling.

133. The method of claim 132 wherein said neuropeptide signalling is determined by binding to a polypeptide comprising SEQ ID NO:183.

134. The method of claim 132 wherein said neuropeptide signalling is determined by binding to a polypeptide comprising SEQ ID NO:184.

135. A method of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition therefor, comprising the steps of:

- a) assaying nucleic acid of a human subject to determine a presence or an absence of a mutation altering an amino acid sequence, expression, or biological activity of nGPCR-52, or an allelic variant thereof; and
- b) diagnosing the disorder or predisposition from the presence or absence of said mutation, wherein the presence of a mutation altering the amino acid sequence, expression, or biological activity of the nGPCR in the nucleic acid correlates with an increased risk of developing the disorder.

136. The method of claim 135 wherein the disorder is schizophrenia.

137. A kit for screening a human subject to diagnose a mental disorder or a genetic predisposition therefor, comprising, in association:

a) an oligonucleotide useful as a probe for identifying polymorphisms in a human nGPCR-52, the oligonucleotide comprising 6-50 nucleotides in a sequence that is identical or complementary to a sequence of a wild type human nGPCR-52 gene sequence or nGPCR-52 coding sequence, except for one sequence difference selected from the group consisting of a nucleotide addition, a nucleotide deletion, or nucleotide substitution; and

b) a media packaged with the oligonucleotide, said media containing information for identifying polymorphisms that correlate with mental disorder or a genetic predisposition therefor, the polymorphisms being identifiable using the oligonucleotide as a probe.

138. A method of identifying a nGPCR allelic variant that correlates with a mental disorder, comprising the steps of:

a) providing a biological sample comprising nucleic acid from a human patient diagnosed with a mental disorder, or from the patient's genetic progenitors or progeny;

b) detecting in the nucleic acid the presence of one or more mutations in an nGPCR that is expressed in the brain, wherein the nGPCR comprises SEQ ID NO:118 or an allelic variant thereof, and wherein the nucleic acid includes sequence corresponding to the gene or genes encoding nGPCR;

wherein the one or more mutations detected indicates an allelic variant that correlates with a mental disorder.

139. A method for identifying a modulator of biological activity of nGPCR-52 comprising the steps of:

a) contacting a cell according to claim 79 in the presence and in the absence of a putative modulator compound; and

b) measuring nGPCR-52 biological activity in the cell;

wherein decreased or increased nGPCR-52 biological activity in the presence versus absence of the putative modulator is indicative of a modulator of biological activity.

140. A method of identifying a compound useful for the treatment of a mental disorder, said method comprising the steps of:

a) contacting a composition comprising nGPCR-52 with a compound suspected of binding nGPCR-52; and

b) detecting binding between nGPCR-52 and the compound suspected of binding nGPCR-52;

wherein a compound identified as binding nGPCR-52 is a candidate compound useful for the treatment of a mental disorder.

5

141. A method for identifying a compound useful as a modulator of binding between nGPCR-52 and a binding partner of nGPCR-52 comprising the steps of:

a) contacting the binding partner and a composition comprising nGPCR-52 in the presence and in the absence of a putative modulator compound; and

10 b) detecting binding between the binding partner and nGPCR-52;

wherein decreased or increased binding between the binding partner and nGPCR-52 in the presence of the putative modulator, as compared to binding in the absence of the putative modulator is indicative a modulator compound useful for the treatment of a mental disorder.

15

SEQUENCE LISTING

<110> Pharmacia & Upjohn Company
Vogeli, Gabriel
Parodi, Luis A.
Hiebsch, Ronald R.
Lind, Peter
Kaytes, Paul S.
Ruff, Valerie
Huff, Rita M.
Wood, Linda S.

<120> Novel G Protein-Coupled Receptors Cross-Reference To Related Applications

<130> 00325.PCT1

<150> 60/184,305

<151> 2000-02-23

<150> 60/184,304

<151> 2000-02-23

<150> 60/184,303

<151> 2000-02-23

<150> 60/184,397

<151> 2000-02-23

<150> 60/184,247

<151> 2000-02-23

<150> 60/188,880

<151> 2000-03-13

<150> 60/217,369

<151> 2000-07-11

<150> 60/217,370

<151> 2000-07-11

<150> 60/218,492

<151> 2000-07-20

<150> 60/186,810

<151> 2000-03-03

<150> 60/188,064

<151> 2000-03-09

<150> 60/186,457

<151> 2000-03-02

<150> 60/213,861

<151> 2000-06-23

<150> 60/194,344

<151> 2000-04-03

<150> 60/218,337

<151> 2000-07-14

<160> 184

<170> PatentIn version 3.0

<210> 1

<211> 545

<212> DNA

<213> Homo sapiens

<400> 1

```

cctatgctac aatcggcaga tgggaactag gagccatgat ctctcagatt gcaggtctca      60
ttggaaccac atttattgga ttttcctttt tagtagtact aacatcatac tactcttttg      120
taagccatct gagaaaaata agaacctgta cgtccattat ggagaaagat ttgacttaca      180
gttctgtgaa aagacatctt ttggatcatc agattctact aatagtttgc ttccttcctt      240
atagtatttt taaaccattt ttttatgttc tacaccaaag agataactgt cagcaattga      300
attatttaat agaaacaaaa aacattctca cctgtcttgc ttcggccaga agtagcacag      360
acccattat atttctttta ttagacaaaa cattcaagaa gacactatat aatctcttta      420
caaagtctaa ttcagcacat atgcaatcat atggttgact tttgaatgga aaaccccaca      480
atattaagaa aagcattcat gtgactttat tagggacact aaactacatc attaacatgt      540
cacag                                             545

```

<210> 2

<211> 1611

<212> DNA

<213> Homo sapiens

<400> 2

```

cagtgaagccg agatggtgcc attgcactct agcctggggc aacagagccg actccatctc      60
caaaaaaaaa aggccattct gaggatcaag gcaccactag caacaggag ccccatgggt      120
ctcagaccct ctccccacat ctctggtcc ctgccccac ctggcgtaca gggaccagcc      180
ccacggaagg ctcttgaggc caggtaacca tggggagggg aggaatggg acaccttct      240
cctgagtgtc ttagggaaga gaagcttagg tcaggtggct gagggtgga atgagagagg      300
ggtctcctcc tggaggggtc caccattccc ttggtcacc acccaactct catctccct      360
gatgtgggga ggagcagggg gcatggattc ctgagccca gactcaactg ttgtggttta      420
caggggcatac aggagagaga gcgagcagaa cacactcctg cagcatcccc tggccccccg      480
cccatgatg gagccagag aagctggaca gcacgtggg gccgccaacg gcgcccagga      540
ggaatgggcc ttcaacctca tcactcgtc cctcaccgag gggctcggcc tcggtgggct      600

```

```

gctggggaat ggggcagtcc totggctgct cagctccaat gtctacagaa accccttcgc 660
catctacctc ctggacgtgg cctgcgcgga tctcatcttc cttggctgcc acatggtggc 720
catcgtcccc gacttgctgc aaggccgget ggacttcccg ggcttcgtgc agaccagcct 780
ggcaacgctg cgtttcttct gctacatcgt gggcctgagt ctctggcgcg ccgtcagcgt 840
ggagcagtgc ctggccgccc tcttcccagc ctggtactcg tgccgcgcgc cagccacct 900
gaccacctgt gtgtgcgccc tcacctgggc cctctgcctg ctgctgcacc tgctgctcag 960
cggcgctgc acccagttct tgggggagcc cagccgccac ttgtgccgga cgtgtggct 1020
gggtggcagcg gtgctgctgg ctctgctgtg ttgcaccatg tgtggggcca gccttatgct 1080
gctgctgcgg gtggagcgag gccccagcg gccccaccc cggggcttcc ctgggctcat 1140
cctctcacc gtcctcctct tctcttctg cggcctgcc ttcgcatct actggctgtc 1200
ccggaacctg ctctggtaca tccccacta cttctaccac ttcagcttcc tcatggccgc 1260
cgtgcactgc gggccaagc ccgtcgtcta cttctgcctg ggcagtgcc agggccgcag 1320
gctgcccctc cggctggtcc tccagcgagc gctgggagac gaggctgagc tgggggccgt 1380
cagggagacc tcccgcggg gcctggtgga catagcagcc tgagccctgg ggccccgcac 1440
cccagctgca gccccgtga ggcaagaggg tgacgtggg aaggtggtgg ggtcagaggc 1500
tggggccagc cggacctgga ggaggccttg gtgggtgacc cggtcatgtg ctgtcaaagt 1560
tgtgaccctt ggtctggagc atgaggctcc cctgggaggc agctggaaag g 1611

```

<210> 3
<211> 930
<212> DNA
<213> Homo sapiens

```

<400> 3
aaaattgctc ttctcctga gcttgtagac aatgattgag ttcaagatga agaagatgga 60
gcagggcacc aggtagacgg tgaagcagtg gatccagatg aggacgtgat gcacagaggt 120
gctgatgtag tcttcagtcc agatgttggg ccaccagtaa taggggatgc tggtcaggaa 180
gcaggtgatg taaacactta caatgacttt ccgggtgcgg gctgggtatg agaccgtgtg 240
gtacttgagc ggggtggcaga cagcgatata cctgtcaatg gttaacggta cagtaatcca 300
tatggaggtg tggatggatg agaattccag cacttctatg atcttgtcgg ggacctgagg 360
catctgcatg ttcaagatga aatottccaa caggaagtcc acaaacta tgaaaaagag 420
gaccaagatg tcggcagcag cgagtgccaa gagatagttg taggaggact tctgttctct 480
tgccaccagc tgggagagga tgatcactgt caagatattt gctgtggaga gaagaaaaac 540

```

tggtttagct ctgaagcaaa gatgacttcg ttggctccta tgggggccct aggcataatgt 600
 ttattttgca ctcccatgga agtgaaaatg attgaatcaa tgcttttgag ggacaacctc 660
 agcattacaa atagcacctc atacaattag tggatactat tttaaagtta tgcttatatt 720
 ctaacacaac catgagaggt ggtgcctcca ttctcctcat cttagaagtg aaactggggc 780
 tetgagagcc tcacacagcc atgagaggtg gtgccgccat tctcctcaca caaccatgag 840
 tgggtgttgc gccattctcc tcacacaaca atgagaggtg gtgccaccat tcttctcaca 900
 caaccgtgag aggcgatgct gccattatcc 930

<210> 4
 <211> 533
 <212> DNA
 <213> Homo sapiens

<400> 4
 ggcccgctcc cacgctgtgt agtgtacttt cattttcaat aaatcacttc attccttcct 60
 tgctttgttt gtgcgttttg tccaattctt tgttcaagac gccagaacc tggacagcct 120
 ccaccattaa gaatacaaga gcagtttctg tcacatgtac atatgggggt gggtggatct 180
 cgctcagcct ttccaggaca cagcggtttg atggaatgct tttctgaaac tcgtggcaga 240
 atgagtacgg aagagggctg atagccgaat tcagccagtg gagccagaag cgtgtctcat 300
 agagaaagtg ctggacatgt gacccgtagc aggcagctcc gatgatcacg agcagtgtag 360
 ggagcccagc acaggacaaa tgcacacacc atgacgtcaa gcgacgtgga cgctcatttg 420
 tccggggaga cgccgtgctg gggaggtctg gctgtctgct gccattgcag gcgttctcgc 480
 tgccctgtag cgggtcttct gcgtaggatt atcaagtcca cctgcagagg tga 533

<210> 5
 <211> 589
 <212> DNA
 <213> Homo sapiens

<400> 5
 tacttttacc caaaactatt atgttcatta ttagagtttc ctagaaaaat acctaggag 60
 ttaatggttt catatctttt gctctattat gaagaagaaa aatgttttac aaatatattc 120
 attattggag ctttttttgt tgtagtgaa attatcaaaa ctaggattga tttctattct 180
 gtttactttt gttataatct ttatcctttt ctcttaattt ctgtattttg gatgcctaac 240
 ttagaataca ttaccaaagt taccttttca ttagtctct caatacaaga tgatttaaaa 300
 catttatggg tacctttttt aatttttttg ctatgcaa atttataaaaagg gcaaagtctt 360
 tgtgctctaa taatacctgc tttctcatgt ttacatgtt ctacgattta ttttgttttt 420

ataatgtaat tttcgtttac ctaattgtgc acatagtga taatagatta taatgaagaa 480
aacttggatt aaaatctatt gttaaaaagg tttttcaggc aataataaat cattggattt 540
ttctgatgta ttttaaaaag atatgtttat ttttgagcaa ctcgtgtgc 589

<210> 6
<211> 864
<212> DNA
<213> Homo sapiens

<400> 6
ggctacttgt tatgaaaag ttatgattgg tgtagaactg tacaggttgc ttctggcact 60
tgaagaaagc cttgagcgtg gcggtgccca tgggtcggaa ccgcttgctg atgaagcagt 120
agaggaagaa gttgatggct gtgttcagaa gggctagcat gttggcaatg tcggacatga 180
tgtgtaccag ccagcgggtc tggatgggag ccccatagag gtggtaaaga atcatgatga 240
tgcggggggc ccaaagtgtg gcaaagatgg aggtaatgg gaacaagatg gcggtggtct 300
tccccgtgga gtagccacgg agacgaaaat tgctcttctt cctgagcttg tacacaatga 360
ttgagttcaa gatgaagaac atggagcagg gcaccaagta gacggtgaag cagtggatcc 420
agatgaggac gtgatgcaca gaggtgctga tgtaatcttc agtccagatg ttgggccacc 480
agtaataggg gatgctggtc aggaagcagg tgatgtaaac acttacaatg actttccggg 540
tgcgggctgg gtatgagacc gtgtggtact tgagcgggtg gcagacagcg atatacctgt 600
caatgggttaa cggtagagta atccatatgg aggtgtggat ggatgagaat tccagcactt 660
ctatgatctt gtcggggacc tgaggcatct gcatgttcaa gatgaaatct tccaacagga 720
agtccacaaa cactatgaaa aagaggacca agatgtcggc agcagcgagt gccaagagat 780
agttgtagga ggacttctgt cttcttgcca ccagctggga gaggatgatc actgtcaaga 840
tatttgctgt ggagagaaga aaac 864

<210> 7
<211> 823
<212> DNA
<213> Homo sapiens

<400> 7
gacacctgcc aacatgttca ttatcaacct cgcggtcagc gacttcctca tgccttcac 60
ccaggccctt gtcttcttca ccagtagcct ctataagcag tggctctttg gggagacagg 120
tagatgctgg ggctcccttt tgctggaggg aggaggaggg ttttgacctg gggatgcctt 180
caatggaggg tggcccaaag gaggtgattt gctgcttctg ggcagagagt gggtagctgc 240

cctcagtcct gtgagtaagc aagaagggaa gatgcagtgt tggtcctaag gcctctgcca 300
gccttggcca gatgtggcag gtggaggggg tggagtgcgc tcagtcctgc tcttcctgtg 360
aggtgaaggc cagagcagag tctaccctgt cccagaccc tctccccag gactcagagc 420
aggggctgtg cccacaggct gcgagttcta tgccttctgt ggagctctct ttggcatttc 480
ctccatgac accctgacgg ccatogccct ggaccgctac ctggtaatca cagccccgct 540
ggccaccttt ggtgtggcgt ccaagaggcg tgcggcattt gtctgctgg gcgtttggct 600
ctatgccctg gcctggagtc tgccaccctt ctctggtggt agtaagtggg ctgctggaac 660
tggaaggggg gcagatgggc tgggaggggc acattcaagg gtaagtaggt gacttgggtc 720
agccagctgg cgggagcagg gtgccaggga gctacctgag cctcaggtga gatggacatt 780
cagggggaca tgactggcag caagggaac tgacactgcc cca 823

<210> 8
<211> 619
<212> DNA
<213> Homo sapiens

<400> 8
ttctcccctt gacgggtgac taactctgcc tgcgtgtttc tttgtcacc agcataggca 60
ctgagtgcgg tctgtgcacc cctttgccac ccaccggtgc cggcactgag cctgcaacct 120
gtctcagccc ctctggctgt tgccatgacg tccacctgca ccaacagcac gcgcgagagt 180
aacagcagcc acacgtgcat gccctctcc aaaatgccc tcagcctggc ccacggcatc 240
atccgctcaa ccgtgctggt tatcttcctc gcgcctctt tcgtcggcaa catagtgtgt 300
gcgctagtgt tgcagcgcaa gcgcgagctg ctgcaggtga ccaaccgttt tatctttaac 360
ctctcgtca ccgacctgct gcagatttct ctctgtggcc cctgggtggt ggccacctct 420
gtgcctctct tctggcccct caacagccac ttctgcacgg ccttggttag cctcaccac 480
ctgttcgct tcgccagcgt caacaccatt gtcgtggtgt cagtggatcg ctacttgtcc 540
atcatccacc ctctcttcta cccgtccaag atgaccacgc gccgcgggta cctgctcctc 600
tatggcacct ggattgtgg 619

<210> 9
<211> 550
<212> DNA
<213> Homo sapiens

<400> 9
aggacaacga tggtcactga tttggtgacc ttcgacagtc tccgggcgct ggctccggtc 60
gggcgtcctc cggctaccgc ggcccctcct ttggtccccg ccgcgcggcg gtcggcgatg 120

aagcgcacca gcagcaggta gcacaagata atgatgcca gcggcagcac gaagcccagc 180
agcaccttct gcgagtggta gaggccagc cagaactgcc tgtcgcggcc cagcaacttg 240
tccgggaaac gcaccaggca cagctcctcg cccatcacct tgaccgtggg ggagaaaatg 300
gcactgggca gcgaggccag cgcggccaaa gccagatcc acacacacag cgccttggcc 360
gagaagcagc agctgtcccc caggctccgg ccgcagcagt cgcgccggcc gtgtcctcgg 420
gtcccgggtg ctcttcagag ccgaggccac cgaatggtag cgcgtcacac tcatggcagt 480
gaggaagaac acgctggcgt acatgttcat gggacgtcac catggacacg atcttacaca 540
tggccttgcc 550

<210> 10
<211> 1104
<212> DNA
<213> Homo sapiens

<400> 10
ctggaaaggg tgctggtggc gcgcgcgac gccgcggcgc gactgcctgc ctggtactca 60
acctcttctg cgcggacctg ctcttcatca gcgctatccc tctggtgctg gccgtgcgct 120
ggactgaggc ctggctgctg ggccccgttg cctgccacct gctcttctac gtgatgacct 180
tgagcggcag cgtcaccatc ctacgctgg ccgcggtcag cctggagcgc atggtgtgca 240
tcgtgcacct gcagcgcggc gtgcggggtc ctgggcggcg ggccgcggga gtgctgctgg 300
cgctcatctg gggctattcg gcggtgcgcg ctctgcctct ctgcgtcttc ttccgagtcg 360
tcccgcacag gctccccggc gcgaccagg tgagcgcccc tctgtgtgtg ccgggcaggt 420
gtcctgcgca ggctgggaag cggggccccc acggaagctg ggatgaggat gatcaagaac 480
aacaatagcc atttattgca cttaatcgtt gtgccaaatc ttgtgcccac ggctgtgaag 540
tttaatctct taaatctcac tacaacgctg tgcacacgcc ctctaaatg atgtaagtgg 600
agtcccccaa attcttgcaa aatgcaatga ctgttgcgag gttaattaac gagtagttta 660
ggagcgagac ggaactttgg ggggtgcaggg tggccaaaca ctttgtattg aatcatgatt 720
cctcgccagg tgctacaata ctgttattat cacaccatt tcacagatga gaaccagagg 780
cacaccgaag tgtataataa cttgccaga gtattttatc cgtaattcga ggaggagatg 840
ggctccttcc agaagtttac ccgtaattca aggaggagt gggtcctgt ccagggttgg 900
gttatggtcc tgctttgaaa gcgcgcggac aggcattgta gaccgggga cccagatgc 960
aatgctgtct ttaggggact tgtgacagaa ttcccttccg gggctctcag tttttcagc 1020
tgcaaaacgg aaggattaca ctagaccttc gaggtgtcct gggcgctga aatgtgcaga 1080

ttacagaggc tggaccgacg agct

1104

<210> 11

<211> 591

<212> DNA

<213> Homo sapiens

<400> 11

ttaatccctg gaagtcacg aacaatgaat ccatttcacg catcttggtg gaacacctct	60
gccgaacttt taaacaaatc ctggaataaa gagtttgctt atcaaactgc cagtgtggta	120
gatacagtca tcctcccttc catgattggg attatctggt caacagggct ggttggaac	180
atcctcattg tattcactat aataaggtaa ggaatggctc cttttttttt tttttccttc	240
catacttttag gaaactacag tcaaagctcc ctaaagagt cttttccctt gtagcatttt	300
gcttaatgaa atgcaatttt ggaaatatit gcttaagata attaatgaag attctacaga	360
tattttcgtc atgcattagg taacatctca gttgcaaac tcaacatgct aagacctagg	420
ccaatgctta ctgctgggtc agtgagtttt tagggaaatg actctcactc tcagtcttag	480
ctgcatatta gaatcatctg gggagcttta aaaactcctg atatgcagtt tcacccacaga	540
cccattaact cagaatctct aagggtaggg cccgggtaag atttaaaact g	591

<210> 12

<211> 378

<212> DNA

<213> Homo sapiens

<400> 12

gggtgacagg aactctggaa ggtgatagtt ttccagggtga agaagggaca gtaggtttcc	60
ctgctttact gctatctccc tatggccttc ggtcaggcct gaactgtgat gagagtctct	120
gccctgctc tttgggattc ctcaaataac ctcccttcat tgttccctga attatctaga	180
tcaatacaaa ccaatccctc ctctgcttaa aacttttaat tgcttacagg ggaaagtgc	240
gactccttag ctggcgaca agccttttgc acctggcaca catagagctt tctagggcta	300
tctcctgcca ttctctagcc tgtctccttc tgcctctgggt ctccagaact gccatgaat	360
tcctcacat gcctttct	378

<210> 13

<211> 503

<212> DNA

<213> Homo sapiens

<400> 13

cctatgcttt cctatagctc atggaccaag ccatttctcc aacatcataa tttttcctta	60
---	----

```

tcatecccttt ccttgcattha ttctccagat gaaaaaagtt caaatgcctc ctccctatatt 120
tcagetgaga aggtgagatg cccgtgcctg gatttccagg ctctgcctg cttggcagac 180
cactgtgacc gtgcacgact aagtccactc ttcccagcca gcatcccctg ctctccccag 240
gccaacttct ttgtgttcta ttcatctcta tctccttgcc ggaactactc agaccctct 300
gtctttctgc ctcttgccca atcttccagg ctctagtgtg ctggctttct gcctccaaaa 360
atgattttta gcatttgtga gtctttctct ccacagaact ccagactctt tgaaaatgcc 420
gtagtctgta aattacttcc aatatttaag aagtgttat catgttccc tgcgggttca 480
tgctcttttg tattgatttt cct 503

```

```

<210> 14
<211> 671
<212> DNA
<213> Homo sapiens

```

```

<400> 14
caaatgaggt ggatgcactt agaaggaagg gtagaacaaa tattcgttga tgatatacaa 60
tgtgtcagat acagagatac acagactagg gctgtgggaa tctcagattt taatttgtca 120
acagtgtgtt ttgatttttt tgttttgtat atttgcctcc ccaattaatt tcacaggctt 180
aatcatcttt acaagacatt attttaaaga gaaagcgaac ttactgaagt tttatgcttc 240
cctgattgtg atgagctggt tgattctagc tctagtttca atgttctgga aaatactgaa 300
gtacttccac ctggtggcac ttagtgaaca ttgcagaacc gagtaatagg ttattccggt 360
gggtttctcg aacaaatctg agttatagct aggaactctc aactaacaat ttatgagaac 420
cttctgctac acatgtgaat ttacatattt attcctttgc agttgaagga tgggatgtat 480
gcaaaggaga atgaactcta ctacagtaat ggaaagaagt gatagaagat gaaactccaa 540
aatgcctatc tgctacttga gtggaactca ctagaatata tcaaatgcag agagaaacat 600
gtgactaggg tctagtcaaa caattgtcat caaatacttg ctgaatatat aacacatttt 660
agggagctgt g 671

```

```

<210> 15
<211> 383
<212> DNA
<213> Homo sapiens

```

```

<400> 15
aaaaaataac attcctgtat ggaagactaa atattaaaga aaaaaacagt tatccatatg 60
ttgtttcata gctttaagta tcctagtcta aaatccaaag ggactttttt ggggactcaa 120

```

```

aaaaaaaaat tctaaagttg atccagaaga gtaaagagac taatatagtc aaaataatat   180
ttgaaaaggt taaataatta tgggaaaaca tgcttagcaa aaatataaac aaacaaaact   240
tcaaacagac aaaaacccta tgaaaaacca aaaacctatt taaaaactaa attctaaatg   300
agaactaaca tacaaatcaa gaatcagcat agatagctaa gaagcaaatt atagcatata   360
aactaattca atttattata aag                                           383

```

<210> 16
 <211> 742
 <212> DNA
 <213> Homo sapiens

```

<400> 16
ctaggctgct cctgtgtggt tataatgaat ctcatcagct acaatcattt cccaaaaagg   60
acagaaagtg aatctgtctt ataaagatgg ttttcaaagc caactacaga tatcatagaa   120
aaaaaaaaaa aaacagtggc agataagacc tttcatcttt ttcttatccc atgggctttt   180
ctgcctccag atttcttgc acatcaaggg ggttctgtgc aaatcagtgg gcctggccct   240
ctgcccaccc tgggctaagc tgtggttgcc atggctacga agacaagaat gacccttggg   300
tttatagagc cctgggtccc ttgctcacag gccttttcag ttgatatttc tttcatcttc   360
ttcagaaccc catgtggcag gtgcaacaag gagttcacca atgctccggc caaagtgagt   420
aatgagggac acatgcacga ccaggcagag cagccctgaa gaagtgggtt gtgaggggtg   480
ggaggaaggg cttgcttcca cactctgcac ttctgggtcc taaggcacta atcacacctg   540
gctcaggcat cattctcagc ctcatgctac ttttgtccag ggacagaaca agaggtgcc   600
gcactcaagg gaatcctgca ccacaacagg caggggacca tcatgactgc tgaaataggc   660
agcaggagtc cgaactatgg cataaaaatg tcacagcaac accacagggg ggaaccctg   720
gggggaagta ggggcatggt ga                                           742

```

<210> 17
 <211> 228
 <212> PRT
 <213> Homo sapiens

<400> 17

```

Ala Thr Thr Ala Thr Cys Thr Cys Cys Ala Thr Thr Ala Thr Gly Cys
1          5          10          15

Thr Cys Thr Ala Thr Cys Ala Gly Thr Thr Thr Cys Thr Thr Thr Ala
          20          25          30

Thr Ala Gly Ala Ala Thr Ala Thr Gly Ala Thr Thr Ala Cys Thr Ala
          35          40          45

```

Cys Thr Thr Ala Gly Thr Gly Ala Thr Ala Ala Ala Gly Cys Thr Thr
 50 55 60
 Cys Cys Thr Thr Thr Gly Cys Thr Ala Ala Gly Ala Thr Thr Thr Cys
 65 70 75 80
 Ala Gly Cys Cys Thr Ala Cys Gly Ala Ala Cys Cys Ala Thr Gly Ala
 85 90 95
 Thr Cys Cys Ala Ala Ala Cys Cys Cys Thr Ala Cys Thr Thr Cys Thr
 100 105 110
 Ala Ala Ala Ala Cys Ala Thr Ala Thr Ala Ala Ala Cys Ala Thr Gly
 115 120 125
 Cys Thr Thr Thr Ala Cys Ala Ala Gly Thr Ala Thr Cys Cys Thr Ala
 130 135 140
 Thr Ala Thr Ala Thr Gly Gly Ala Ala Ala Ala Gly Thr Cys Cys Thr
 145 150 155 160
 Thr Gly Gly Ala Ala Thr Thr Ala Thr Thr Thr Gly Gly Gly Thr Ala
 165 170 175
 Ala Thr Thr Ala Ala Cys Cys Thr Gly Gly Thr Ala Thr Thr Ala Cys
 180 185 190
 Ala Thr Gly Thr Gly Thr Thr Ala Thr Thr Thr Cys Cys Thr Gly Ala
 195 200 205
 Thr Cys Thr Ala Cys Thr Ala Thr Thr Gly Cys Ala Ala Ala Thr Thr
 210 215 220
 Gly Ala Cys Ala
 225

<210> 18
 <211> 751
 <212> DNA
 <213> Homo sapiens

<400> 18
 tcttgattta cacaaaaaac cataactaac taaaatagaa aacttttaaat tatctgtatt 60
 gttgtataaa atgttttata tattaggaat ctaaaaattt gttttttgct tttatcctct 120
 gtcataggaa gaagacatca tgtctctgtt tactgtaacc attaataaag gctaataaca 180
 gacagtacat gatgatactt ttaactaggg caaacaaaag taatatttta acaatgaggt 240
 ttgggtctttg ctatctatac ctcatgtcta attttcccta caatgtaaat gtcattcctc 300
 ctctctaccc atttgtaagg gtctcagttt tctgctcttg catgacttat tttaaagggt 360
 cacaataagg ccaggtaatt catattttta aaattccatt tagaataatt acatctaaaa 420
 attcacaaga aagacaattt caatataaaa taataaatta ctaatattgg aatttcaagc 480

attagtcacg gcaaaaaaga gataatttgt agcagaatat tttaatggca actttcttat 540
 tctatcactt attgtgttct atttgttatg accaaagaaa ttactctata tccactacaa 600
 ttcataaaac aggcacggaa gaagtccttt ttttcttggg gctcatgtct aagaagatga 660
 acctcagaag tatgtcattt ttcaatacta tgttctgaac agacagcaca cattatcttt 720
 gaatggacac caaatctcaa acatatatag a 751

<210> 19
 <211> 657
 <212> DNA
 <213> Homo sapiens

<400> 19
 gtcctaataa tcttcaatga attttaacta attttcaggg ataacaaagc acttcagatt 60
 gaagtcaatt catgtatact atttactcag gaacttttaa tttttcctat cacatacatg 120
 ctggtgctgg gtttcttatt tgttaaaaga tatttcattc cctactgtgt ttaccctttg 180
 ttagcaaaagt tggtttagag tgacatagcc tgatgaaacc cataaaacag ccataaattg 240
 ctcttatatg ggataaaaca atatttgaac actatatctt ttaaaaatat aatcttatat 300
 tgggtgggta gaagtgatct tcacatcgtg tgtgtgtgtg tgtgtgtgtg tgtaatatat 360
 aatatgaaag acttttaaaa gtaactttta aaatacatat ttttatatac atattttcat 420
 acatatttac atacattttc tgttttcaat tcatctaggt ttacattaga ctatgtcctt 480
 agtttgagtg ttaaaactat aaaaagagaa taaagttaca gcagaattaa ttgccaaagg 540
 tatgacagtt cgagcactac agtaaaaaat gagacacagg tttataaaaa catttaaatt 600
 ctgaattttt gctttcttag gtttctctgt cagtaataga taattgttag tatgaaa 657

<210> 20
 <211> 509
 <212> DNA
 <213> Homo sapiens

<400> 20
 tttctaaatc tttgttacat tcttctttac tctgaggggt tttagtcacg tgctagtata 60
 ctagttagtc ctttccgtca gctgggtaaa aagctataaa tggttttcaa ctctatgcag 120
 ctcccctggg ttgctcattt gatctgagcc aggtttgaag ttgggccatt gagaatgatc 180
 tgctctcatg atgtagggg tgactccagc caattcttaa tattgctgga attaatat 240
 tttgattcct ctaactgaaa gagggcattt tactctaccg tgtattatta aataccttat 300
 aacttgattt ttttgatttt gtttcttgc tcagtgaagta cttaaaatat ccctgccgat 360
 atagtaattt gttccctgtt taatatggct ttttctttg tttactctgg actcaagtct 420

ttgtagcttg tttttctaag tcagctcaaa agttgctggt cattggattt ggcagccttt 480
tcaagcttta cccaccagaa tcctacagg 509

<210> 21
<211> 582
<212> DNA
<213> Homo sapiens

<400> 21
cccggcccag tctccacatc ttgtaagtgg ggagataaaa cctatctaag ggggatatta 60
tgaggagcag gagagaaggc atgtcattct cctaattaat tggcattcac taaagagtta 120
tgtgattatt aaatacataa taaaatataa aaatataagg tgctctagtt atataatcat 180
gaggctctgag gatggatgat actgcacttc agtggactac cttatgaggg actgactgtc 240
aagaagctct gtgcatgtgt gcttggtgtgt gtgcatctgt gtattatata tatacatata 300
cggatatata ataggcactt ttattatata agaaaatgat gtcacagtaa aaatgcataa 360
atattattga gcatgtttgt ataaaocagt gaacaaagag acatttggga tgcaagacca 420
gtggtataat ctgcccaaac acaagccccg ttttactgtt gctaatacac aaagagaggg 480
ctggcagaca tggcctgcat gctctgtaca cctgcccatc tgcaccacac tcccccatgg 540
tcttgctggt gttgctgtgt tgggctcctc ccgctctca ca 582

<210> 22
<211> 307
<212> DNA
<213> Homo sapiens

<400> 22
aggcagagat tatgtgagac tttgcatgat aggggtctgt gcattcttgc gcatttctta 60
gctctgtgtg agcaatattt aagtagtcat tacataaaat ctattgaacc tatacaaaga 120
agtgaacaca ctgtgatgag ttggctccta ccaagtaagg cctggggggtt ggtcctttat 180
ggttccccag cacacatctt aaaatagtgc ctttgtggat aaactctctt tgaattattc 240
tattttgagt gtgccatctg attcttgtta ggactctgac tttaaaaagg tagagcattg 300
ctctcat 307

<210> 23
<211> 633
<212> DNA
<213> Homo sapiens

<400> 23
caaattgatt aatttacata tggatgaaca tgatctgttg ctctccaggc cccaaaggat 60

```

acataagaag aaaaatttag tgatgttact ggatgatgtc ttttaagaca acacaataca      120
atatctgagt atgtaccctt acgacataga gaagggattt tcaaaatatt ttaacttaaa      180
tagattcact aaaagaaatc accttccaac cactgttctt tgtctctggg caattagggt      240
cataatattg ttttcattgt attacaaaag gtaagaatgt aactgtata aatgaataaa      300
taatatagat tactagataa gcagataaat aaatacaaaa gcacaaaaat acaaaagcaa      360
atgaccactc aactcacttc caccacttc aaggaaaaca cagtctcttt atcatagtta      420
ctattagaag tctttcctgt cttcattttc ctacaagcat gcagaaatat atatgtggac      480
acatttgtgc cagaattcct ttttttctga cactcacttt tttcctctta ctccacaata      540
tgtcaggaca attttctaca agatatagca aatggagtaa catagaatag agcaaaacat      600
gaaaacctca aactcattag tggatgatgt ttt                                     633

```

```

<210> 24
<211> 674
<212> DNA
<213> Homo sapiens

```

```

<400> 24
gggaaggctc ttctaagaaa ccacgccac acacaaatta gtaaattcga caaaacagga      60
aacaacaaaa aattttgtgt taaaagtaac actaaatcaa aatgaaaaga taaaaggcaa      120
acacaaaatt gacaaggatg cttgcaactt gtgtaactga taaagggcta ttttctgaa      180
tatatttctc tattctataa ttactttctt taatatattt taaaaacttc tgtaagtaag      240
tatgaaatag acaaatgata agaacagtta tcagaaaatg aaatacaaat gattcaaaca      300
tgaaaagatg ctcgagctca gtctataata atagaccctt aaaagtataa tgaaatatct      360
ttttttaaac ccctatctga ttagcaaaga ccagcaagtt ggaaaaacag agggcttttt      420
caaagatcaa gcttgtgagc caaactaaag gattctgtgc tttcaagaat tacactgttt      480
agagtttgga ctttttgaaa aaaatgtaca tgtctatgaa ataaattggc cttttaaaaa      540
agagtttgca gcaatgctga aagtagtggc caaagcatg atcaagagat aggatattca      600
tctaattctc aaccatctcc ctacaagcta tttatcaatt acaaagtga aaatactaac      660
tgcacagtgg tgaa                                                         674

```

```

<210> 25
<211> 600
<212> DNA
<213> Homo sapiens

```

```

<400> 25

```



```

acaaaagtca ctctctgtct caaaatcttt gcacggtttc ctgctgtact tggaatacaa      60
ccccaaagtcc ttctctaggg cactagcctt gtattggcct tgatcactgc tctgcccac      120
ctcataccac ttgtcatttg gccattatag tccaacaaca tccactcatc cgctttctcg      180
caggccctgg aatattctaa gcactttccc atctcagggg gttgtgaatg ctgtttctc      240
tacctgtctc catctcccca ctctttatca actaagttct cacatacaca tgtttgatct      300
caagctgtgt gtgtttactt gtttgttatt tgaagcacta tgctgagcca tagtggaatc      360
tgaggtaaaa ggaaaaataa gtaatatga ctctgagttt atgtaatat ttgatttttt      420
cccatgaagg aattttgcat taatttttat tttaaaaata ttgtattaaa attttattta      480
tcttgattac tgagtatttt ggtgtcccct taaaattctc accaaaggac aagtgcctcg      540
ctcacctcac cttttttcca gtactggtea ttggtctgtc ccaccaaact gtaagtaaac      600

```

```

<210> 26
<211> 709
<212> DNA
<213> Homo sapiens

```

```

<400> 26
ccgagggcct tccctgtgag aatcagtttc aaatatgagg ttgattttat tttcccggg      60
tgcaattaac tgaaaaaat atttcaaagc tgtataatta aaggccggca ttttattagg      120
gtttaaaata gtcgctatga aatttgctcc tgccattggg aattacaacg tacatcttaa      180
tatccccctg cttgccagcc ccgagataac agcgtgtgt gtgctgcatt tggtttgca      240
gagaaggtaa aatccttate ttatctccat ctgcacacaa caaccagcct ctcttccaat      300
tcaaccctaa tcttcttagt aaataatact gatatttttc accataacaa aatggagctg      360
gtgccagatt ctactgata acacctctcg ttacacacc attctctgtc aaaatcggcc      420
cgatttttct taatctcttt aacttatcaa aaaaaatact tttacattt ggccatagta      480
agttcttttc taccaaataa taatattata aataaatccc ttgcctaca gctgactcat      540
tgaaaagata ctcagcctcc tcattttctt catgaatgga aattgttctg ctcttcaatt      600
ttctcccaa gtttgggggt ccacaccaag ggaattgttc ccaggcaggc cctgagccat      660
ctttgtatct tgcagggggg catcttggtc caggatgtgc atgcttctc      709

```

```

<210> 27
<211> 397
<212> DNA
<213> Homo sapiens

```

```

<400> 27
agtataaaat ctgggagaaa aatccatcaa attataaaat agaactaata atgctttcat      60

```

gggtaaagcaa tgaacaaaac caaaggtaaa ccagcggtttt aaagattgat atttctttaa 120
 gaagagaatg gaaaataaat taaaatatac attttatatt gattatcatg aagtttttct 180
 agtttcttac ctgaagtttc ctggagggaac ttttaacagca ctcatgtgac attaggaaga 240
 agccgaatgt aaataaatcc taggtggata agcataatat aatgagtaat atgatcttaa 300
 atggaaaaaa gattatgtaa agttgtttat actcttaaca ttttccaccc actacactgt 360
 gaagcagatt aaccttttct caaagggtga accttct 397

<210> 28
 <211> 537
 <212> DNA
 <213> Homo sapiens

<400> 28
 etttgaagga tgaagagaag ttcaccaagt gaacgtggag gaaaagcagt ccaggcagaa 60
 ggaacagctg ctgaaaaggt caggtgccca aaccagaaaag gcatgtgagg gaattcatgg 120
 gcagttcttg agaaccagag cagaaggaga caggctagag aatggcagga gatagcccta 180
 gaaagctcta tgtgtgccag gtgcaaaagg cttgtgcgcc agctaaggag tctgcacttt 240
 cccctgtaag caattaaaag ttttaagcag aggagggatt ggtttgtatt gatctagata 300
 attcaggga caatgaaggg aggatatttg aggaatccca aagagcaggg gcagagactc 360
 tcatcacagt tcaggcctga ccgaaggcca tagggagata gcagtaaagc agggaaacct 420
 actgtccctt cttcacctgg aaaactatca ccttcagag ttcctgtcac cccagtgaa 480
 ggcaaccact gtctcttctg ttacctaaca cgtggtacaa acagctacca tagcatg 537

<210> 29
 <211> 578
 <212> DNA
 <213> Homo sapiens

<400> 29
 tataaggtag ttgtgtagct ttaagactaa gacctotaca cctggaaatt ggtatacttt 60
 ttcaataaag catcagatag taaagttttg tgggccatat gtctctgctg caactactca 120
 gctctgccat tgtgcaaaag cagccacaga taatatgtaa atgaatgaac ttggctgttt 180
 tcacaaaaac aggcggctgt taggatttgg cttgtctgact cttaacttgg attctcactt 240
 ctgaaagcat ggtctaggag accagcagca tcagcattac ctgtgaacct gttagagata 300
 cagaatgttg agcccttct catactgatt gctctagagt ctaaaccatg tttctcaaac 360
 ttcagcatac ataggactca cctggggatc ttgtgaaagt acagactctg agatagcagg 420

gctgaacacc atactagcct tggggaggca atgttatgac ctggtcagtg ttccttgggg 480
 agtcgcgaat ctattaggag agactgctat ataaacaaat aatttcaata cagactagta 540
 aatgctataa cggaggtatc ttcagcagag gagcacca 578

<210> 30
 <211> 589
 <212> DNA
 <213> Homo sapiens

<400> 30
 attttcatgt tgatggcaat catccaagag agagcaggcc atgtcacgca ataatagaac 60
 aaggagaaat gcacactttt cttttttccat gtctctgctt gcattacatt tgctaatacc 120
 acttttagcca gataaattaa cacagcgcag cacatagtca aaaaaataga agaccagaag 180
 ttacagaaca actgacatgg tttagaaaag caattaagac catcagtga atcagtctac 240
 cacaaaagggt aattcatittg ttcacaacgc tgttgaaaag acttatcttc caagacagga 300
 aatggttctc cactgaaggg tgaagacatt tcaattttca gtcatttggg gaagagttgg 360
 atctccaacg agtaactttc atgcaaggac aagaatttag tagtgaaata gaggttattc 420
 gtttttttac cataaaataa ttaataatct tggaggcagt ttcctcatag cagttattat 480
 ggcagttgtg ttcatttaca ggaaaactga gaaactctaa gatgtttttg ggaaaaaaaa 540
 gtattttgaa agcttgcgag tgttaacttc cacaatagat atactcttc 589

<210> 31
 <211> 1750
 <212> DNA
 <213> Homo sapiens

<400> 31
 cgcacagcgc gcaggtcctc accagagctc tgggtggccac ctctgtcccg ccatgctgct 60
 caccgacagt ggccagggcc cacagcacca agaggcttgg gccacaaagt aaagggctgc 120
 ggagcctcgc cggccgccat gtggagctgc agctggttca acggcacagg gctggtggag 180
 gagctgcctg cctgccagga cctgcagctg gggctgtcac tgttgctcgt gctgggcctg 240
 gtggtgggcg tgccagtggg cctgtgctac aacgccctgc tgggtgctggc caacctacac 300
 agcaaggcca gcatgaccat gccggacgtg tactttgtca acatggcagt ggcaggcctg 360
 gtgctcagcg ccttggtccc tgtgcacctg ctgggtccc cagctcccg gtgggcgctg 420
 tggagtgtgg gggcggaagt ccacgtggca ctgcagatcc ccttcaatgt gtcctcactg 480
 gtggccatgt actccaccgc cctgctgagc ctgcaccact acatcgagcg tgcactgccg 540
 cggacctaca tggccagcgt gtacaacacg cggcacgtgt gcggcttcgt gtgggggtggc 600

gcgctgctga ccagcttctc ctgctgctc ttctacatct gcagccatgt gtccacccgc 660
 gcgctagagt gcgccaagat gcagaacgca gaagctgccg acgccacgct ggtgttcac 720
 ggctacgtgg tgccagcact ggccaccctc tacgctgtgg tgctactctc ccgctccgc 780
 agggaggaca cggccctgga ccgggacacg ggccggtgg agccctcggc acacaggctg 840
 ctgggtggcca ccgtgtgcac gcagtttggg ctctggacgc cacactatct gatcctgctg 900
 gggcacacgg gcatcatctc gcgaggggaag cccgtggacg cacactacct ggggctactg 960
 cactttgtga aggatttctc caaactcctg gccttctcca gcagctttgt gacaccaatt 1020
 ctctaccgct acatgaacca gagcttcccc agcaagctcc aacggctgat gaaaaagctg 1080
 cctgcgggg accggcactg ctccccggac cacatggggg tgcagcaggt gctggcgtag 1140
 gcggcccagc cctcctgggg agacgtgact ctgggtggacg cagagcactt agttaccctg 1200
 gacgtcccc acatccttcc agaaggagac gagctgctgg aagagaagca ggaggggtgt 1260
 tttctttgaa gtttcctttt tcccacaaat gccactcttg ggccaaggct gtggtccccg 1320
 tggctggcat ctggcttgag tctccccgag gcctgtgcgt ctcccaaaca cgcagctcaa 1380
 ggtccacatc cgcaaaagcc tcctgcctt cagcctcctc agcattcagt ttgtcaatga 1440
 agtgatgaaa gcttagagcc agtatttata ctttgtggtt aaaatacttg attccccctt 1500
 gtttgtttta caaaaacaga tgtttcctag aaaaatgaca aatagtaaaa tgaacaaaac 1560
 cctacgaaag aatggcaaca gccagggtgg ccgggccctg ccagtgggcg gcgtgtgcta 1620
 gcaaggcctg ccgggtgtgc cgcagtcacc acagggttct gagaacattt cacagaagtg 1680
 cctgagacgc ggagacatgg ctgggtgtaa atggagctat tcaatagcag tgacgcgctc 1740
 tcctcagcca 1750

<210> 32
 <211> 551
 <212> DNA
 <213> Homo sapiens

<400> 32
 ccacaagaca gtgccattta gtggcagccc taggataaag atgatactgt aggccaggga 60
 gaggtagact tgcttgtact tctctgagaa ctggcagaga cttgttcct gtgatgtatt 120
 catgtccacc ttctccatgt ccggggaggc tccctccagg agcagagctc cacgacggct 180
 cccgcttctg cttcccctgg aaggaagcaa aatggacagc ataacatcat gacctcagca 240
 tggcatcagc ctctgcccc aaccggcatt caactttgtc ccccaaagtc tagtcagagg 300
 ccttgtttta aagagaccaa cccaggaaa atagagtatt caacaagggc caaataatct 360

tccaaagctg ggcgtctaga cttaccaggt ccaaagggtt ggccttacat ggacttgat 420
 gctgtctact ctaggctggg ttgtgataga aatgggtggg ggatgacact gtcatttaaa 480
 cagggtactc agaacctcca gctctgtgtc tcctcctgct agaatccatt gcatagagtc 540
 agaaaatctc c 551

<210> 33
 <211> 426
 <212> DNA
 <213> Homo sapiens

<400> 33
 catcctaagc tcgggcacac aaagtcccag aggcacacag attcagtggc ttggggatag 60
 catattccaa ctcttgggcc cctaactcaa aatccccaac aaccctcagt cacctgtggc 120
 tccagtcctg ttttggtttt ccacagatca caaaggcatc aaggaagagg ctcacggtaa 180
 gcctggccta ctcgagagc caccagatcc gcgtgtccca gcaggacttc cggctcttcc 240
 gcacctctt ccttetaatg gtctccttct tcatcatgtg gagccccatc atcattacca 300
 tcctcctaatt cctgatccag aacttcaagc aagacctggg catctggccg tccctcttct 360
 tctgggtggg gggcttcaca ttgtctaatt cagccctaaa ccccatcctc tacaacatga 420
 cactgt 426

<210> 34
 <211> 537
 <212> DNA
 <213> Homo sapiens

<400> 34
 gctgggaagt gctcctgggtg cagccggcgg tagatggcgg agggcacggt gagcagcaag 60
 gccagtgtcc aggtgcccc acaggccacc tgcacccgcg acgcccgtg aaccgtatac 120
 caccaggcag gcccagagc caggaagcag aggtcggcac tgagagctgc caggagcagg 180
 acgctggcat acatggtcag caggatgatg gagggcagcg cccgacagcc cactgcacca 240
 tacggtcagt ggcctccacg ggcaatgggc actgccagga tgggcagaga caaacagcac 300
 agcaaatccg ccacggccag gtggagcaac caggtggcac ccacctccg gcggggccacc 360
 ttcccagcca ccaggccac catggcattg cccggcacc ccaccaggaa gatggcgga 420
 tacagtggga gcggggccac gcgcagcggg tcgatggcca ggcaggcgcc atccaggcag 480
 tccacagggc ggtccgagag gtogctgtaa tccccatact cgtagctgac agaatcg 537

<210> 35

<211> 536
 <212> DNA
 <213> Homo sapiens

<400> 35
 ggctccactg gcctttcggc aaggggctct gcaggctgac ggcgtttgtg ctctacaccg 60
 acacctacgg ggggtctacc tcatggcctg tgtgagcgtg gaccattacc cagctgtggt 120
 ctgtgccac tggggcccgt gcctccgcac ggctggccgc gccaggctgg tctgctggc 180
 catctggacc ttggtgctgc tgcagacgat gcccttgctc ttgatgccca tgaccaagcc 240
 gctggtgggc aagctggcct gcatggagta cagcagcatg gagtcagtcc tcggggctgc 300
 ccctcatggt cctggtggcc ttgtccattg gcttctgtgg gccagtgggg atcatcctgt 360
 cctgctatat gaagatcacc tggaaactgt gcagcacagc tgggagaacc cagtgaccag 420
 cgggaaagga caccaccggc ggggcagccc gggaggaccc agtgaccagc aggaaaggac 480
 gccaccggcg gggcagccca ggaggaccca gtgaccagcg ggaaaggaca ccaccg 536

<210> 36
 <211> 1449
 <212> DNA
 <213> Homo sapiens

<400> 36
 gaggcaggct gcagggaagt aaggaggagg catggcacct tctcatcggg catcacagg 60
 ggggttttgc cccacccctg aacgccctct gtggcgctt ccaccacct gtagggccag 120
 aaggatgtcg gtctgtacc gtccccagg gaacgagaca ctgctgagct ggaagacttc 180
 gcgggccaca ggcacagcct tctgtctgt ggcggcgtg ctggggctgc ctggcaacgg 240
 cttcgtggtg tggagcttgg cgggctggcg gcctgcacgg gggcgaccgc tggcgccac 300
 gcttgtgctg cacctggcgc tggccgacgg cgcggtgtg ctgctcacgc cgctctttgt 360
 ggccttcctg acccggcagg cctggccgct gggccaggcg ggctgcaagg cgggtgacta 420
 cgtgtgcgcg ctacgcatgt acgccagct gctgtcacc ggcctgctca gcctgcagcg 480
 ctgcctcgca gtcacccgcc ccttctggc gcctcggtg cgcagcccg cctggcccg 540
 ccgcctgctg ctggcggtct ggctggccgc cctgttgctc gccgtcccg ccgccgtcta 600
 ccgccacctg tggagggacc gcgtatgcca gctgtgccac ccgtcgccg tccacgccg 660
 cggccacctg agcctggaga ctctgaccgc ttctgtgctt ccttcgggc tgatgctcg 720
 ctgctacagc gtgacgctgg cacggctgcg gggcgccgc tggggctccg ggcggcacgg 780
 ggcgcgggtg ggcgggctgg tgagcgccat cgtgcttgcc ttcggttgcc tctgggcccc 840
 ctaccacgca gtcaaccttc tgcaggcggc cgcagcgctg gctccaccgg aaggggcctt 900

```

ggcgaagctg ggcggagccg gccaggcggc gcgagcggga actacggcct tggccttctt 960
cagttctagc gtcaaccccg tgctctacgt cttaccgct ggagatctgc tgccccgggc 1020
agggtcccgt ttcctcacgc ggctcttcga aggtctctggg gaggcccgag ggggcggccg 1080
ctctagggaa gggaccatgg agctcogaac taccctcag ctgaaagtgg tggggcaggg 1140
ccgcggcaat ggagacccg ggggtgggat ggagaaggac ggtccggaat ggacctttga 1200
cagcagaccc tacaacctgc tgcccttccc tgctcctttc cccccccac ccacctcca 1260
gaggtcagtg ttctgggaca tttggggacc cttctttgac tagagtttgg atctggctgg 1320
gtaggattac tatacacttg gggcaggccc aggtcctcc aaactgaggg attatgaggg 1380
tggtgatggt ccctgttaag gactattgtg tgcttgcaag ttggcatgta cccatgtgcc 1440
agcattgct 1449

```

```

<210> 37
<211> 635
<212> DNA
<213> Homo sapiens

```

```

<400> 37
ccagccgtcc aggcgacgcg ggccagcacc aggaaccagg tgacgctggc cacgtggtag 60
cgcgggcaga ccagggggca cgcgctgttg cgcagcaggc cgcaggcggt ggcgggcagc 120
ggcacggccg gcagggtcgg ggtccacacc agggcgcaga ggacggccga ggcgtgtctg 180
ggccggcagc cctggtagca ggcggggaag aggtcggaga ggcagcgctc cacgctgaag 240
gccgccagca gccagagccc caccgogaac cacaggaagg tgagcacgaa gtagagtgtg 300
tcctgggcgc ccagggcagc ctgagccacg gagaagccca cacggcagga gaggaacagg 360
aagtcggcgg cggccagggtg cagcaggtag atggagaagg ggcccttctt gatgcggaag 420
ccgaggttcc agagcaccag cccgttacct accggtcccc cgaggccac gatcagcgctc 480
aggtagaaga ccacactgtc gaaggttctc cagaggccga acagcccaa catcctggcc 540
ggctcagagg gtgctggcga gggacctgca agatggagac agacatggtc ctcaggagtc 600
ttttgtgccc ccgctggggg cacagggagt ggcat 635

```

```

<210> 38
<211> 564
<212> DNA
<213> Homo sapiens

```

```

<400> 38
atgtctacag aaaccccttc gccatctacc tcctggtacg tggcctgcag caggatctca 60

```

```

tcttccttgg ctgccacatg gtggccatcg tccccgactt gctgcaaggc cggctggact   120
tcccggggctt cgtgcagacc agcctggcaa cgctgcgctt cttctgtac atcgtgggcc   180
tgagtctcct ggccggccgc agcgtggagc agtgcctggc cgcctcttcc ccagcctggt   240
actcgtgccg ccgcccacgc cacctgacca cctgtgtgtg cgcctcacc tgggcccttt   300
gcctgtctgt gcacctgctg ctcagcagcg cctgcaccca gttcttggg gagcccagcc   360
gccacttggt ccggacgctg tggctgggtg cagcgggtgt gctggctctg ctgtgttgca   420
ccatgtgtgg ggccagcctt atgtctgtgc tgcgggtgga gcgaggcccc cagcggcccc   480
caccggggg cttccctggg ctcactcttc ctcacgtcc tcctcttct cttctgcggc   540
ctgcccttcg gcactactg gctg                                           564

```

<210> 39
 <211> 187
 <212> PRT
 <213> Homo sapiens

<400> 39

```

Val Tyr Arg Asn Pro Phe Ala Ile Tyr Leu Leu Val Arg Gly Leu Gln
1          5          10          15
Gln Asp Leu Ile Phe Leu Gly Cys His Met Val Ala Ile Val Pro Asp
          20          25          30
Leu Leu Gln Gly Arg Leu Asp Phe Pro Gly Phe Val Gln Thr Ser Leu
          35          40          45
Ala Thr Leu Arg Phe Phe Cys Tyr Ile Val Gly Leu Ser Leu Leu Ala
          50          55          60
Ala Val Ser Val Glu Gln Cys Leu Ala Ala Leu Phe Pro Ala Trp Tyr
          65          70          75          80
Ser Cys Arg Arg Pro Arg His Leu Thr Thr Cys Val Cys Ala Leu Thr
          85          90          95
Trp Ala Leu Cys Leu Leu Leu His Leu Leu Leu Ser Ser Ala Cys Thr
          100          105          110
Gln Phe Phe Gly Glu Pro Ser Arg His Leu Cys Arg Thr Leu Trp Leu
          115          120          125
Val Ala Ala Val Leu Leu Ala Leu Leu Cys Cys Thr Met Cys Gly Ala
          130          135          140
Ser Leu Met Leu Leu Leu Arg Val Glu Arg Gly Pro Gln Arg Pro Pro
          145          150          155          160
Pro Arg Gly Phe Pro Gly Leu Ile Leu Pro His Arg Pro Pro Leu Pro
          165          170          175

```


Leu Leu Arg Pro Ala Leu Arg His Leu Leu Ala
 180 185

<210> 40
 <211> 544
 <212> PRT
 <213> Homo sapiens

<400> 40

Cys Ala Ala Thr Thr Thr Thr Cys Thr Ala Thr Thr Gly Cys Cys Thr
 1 5 10 15
 Cys Thr Cys Thr Gly Gly Cys Cys Thr Gly Thr Gly Cys Thr Gly Ala
 20 25 30
 Cys Thr Thr Cys Thr Thr Gly Gly Thr Ala Gly Gly Thr Gly Thr Gly
 35 40 45
 Ala Cys Thr Gly Thr Gly Ala Thr Gly Cys Thr Thr Thr Thr Cys Ala
 50 55 60
 Gly Cys Ala Thr Gly Gly Thr Cys Ala Gly Gly Ala Cys Gly Gly Thr
 65 70 75 80
 Gly Gly Ala Gly Ala Gly Cys Thr Gly Cys Thr Gly Gly Thr Ala Thr
 85 90 95
 Thr Thr Thr Gly Gly Ala Gly Cys Cys Ala Ala Ala Thr Thr Thr Thr
 100 105 110
 Gly Thr Ala Cys Thr Cys Thr Thr Cys Ala Cys Ala Gly Thr Thr Gly
 115 120 125
 Cys Thr Gly Thr Gly Ala Thr Gly Thr Gly Gly Cys Ala Thr Thr Thr
 130 135 140
 Thr Gly Thr Thr Ala Cys Thr Cys Thr Thr Cys Thr Gly Thr Cys Cys
 145 150 155 160
 Thr Cys Cys Ala Cys Thr Thr Gly Thr Gly Cys Thr Thr Cys Ala Thr
 165 170 175
 Cys Thr Gly Cys Ala Thr Cys Gly Ala Cys Ala Gly Gly Thr Ala Cys
 180 185 190
 Ala Thr Thr Gly Thr Gly Gly Thr Thr Ala Cys Thr Gly Ala Thr Cys
 195 200 205
 Cys Cys Cys Thr Gly Gly Thr Cys Thr Ala Thr Gly Cys Thr Ala Cys
 210 215 220
 Cys Ala Ala Gly Thr Thr Cys Ala Cys Cys Gly Thr Gly Thr Cys Thr
 225 230 235 240
 Gly Thr Gly Thr Cys Gly Gly Gly Ala Ala Thr Thr Thr Gly Cys Ala
 245 250 255
 Thr Cys Ala Gly Cys Gly Thr Gly Thr Cys Cys Thr Gly Gly Ala Thr

260 265 270
 Thr Cys Thr Gly Cys Cys Thr Cys Thr Cys Ala Cys Gly Thr Ala Cys
 275 280 285
 Ala Gly Cys Gly Gly Thr Gly Cys Thr Gly Thr Gly Thr Thr Cys Thr
 290 295 300
 Ala Cys Ala Cys Ala Gly Gly Thr Gly Thr Cys Ala Ala Thr Gly Ala
 305 310 315 320
 Thr Gly Ala Thr Gly Gly Gly Cys Thr Gly Gly Ala Gly Gly Ala Ala
 325 330 335
 Thr Thr Ala Gly Thr Ala Ala Gly Thr Gly Cys Thr Cys Thr Cys Ala
 340 345 350
 Ala Cys Thr Gly Cys Gly Thr Ala Gly Gly Thr Gly Gly Cys Thr Gly
 355 360 365
 Thr Cys Ala Ala Ala Thr Thr Ala Thr Thr Gly Thr Ala Ala Gly Thr
 370 375 380
 Cys Ala Ala Gly Gly Cys Thr Gly Gly Gly Thr Gly Thr Thr Gly Ala
 385 390 395 400
 Thr Ala Gly Ala Thr Thr Thr Cys Thr Gly Thr Thr Ala Thr Thr
 405 410 415
 Cys Thr Thr Cys Ala Thr Ala Cys Cys Thr Ala Cys Cys Cys Thr Thr
 420 425 430
 Gly Thr Thr Ala Thr Gly Ala Thr Ala Ala Thr Thr Cys Thr Thr Thr
 435 440 445
 Ala Cys Ala Gly Thr Ala Ala Gly Ala Thr Thr Thr Thr Thr Cys Thr
 450 455 460
 Thr Ala Thr Ala Gly Cys Thr Ala Ala Ala Cys Ala Ala Cys Ala Ala
 465 470 475 480
 Gly Cys Thr Ala Thr Ala Ala Ala Ala Thr Thr Gly Ala Ala Ala
 485 490 495
 Cys Thr Ala Cys Thr Ala Gly Thr Ala Gly Cys Ala Ala Ala Gly Thr
 500 505 510
 Ala Gly Ala Ala Thr Cys Ala Thr Cys Cys Thr Cys Ala Gly Ala Gly
 515 520 525
 Ala Gly Thr Thr Ala Thr Ala Ala Ala Thr Cys Ala Gly Ala Gly
 530 535 540

<210> 41
 <211> 595
 <212> DNA
 <213> Homo sapiens

<400> 41

```

attattcatt cctttagaca ttaaaccattc attgagcacc tgctgtatgc aaagcactgg      60
gcacccacac taaggatgaa aaccaaggat aagtaagaca gcatgtagat tctagctgcc      120
tggttgagag gttacagtca gaaagtcctt atagccattc agtgacatac agatagggat      180
aggagaggaa atgggggtgag cacagggaag ggataagtat agggtcaggg ctaccaccct      240
tctttttccc atgaccccat gggggcaaatt atgtcctgtc tcttcctggg tgggtgatgt      300
tctactgccc tttctccatt ccaattggaa cttctagatt gagcccgaag ctgacttgc      360
agatcacaat ttttaagaaag ttggatgttc tgcaacagggt tacaacaggag ctatcattga      420
gtcatctttt cgttcaccca atcatttatt cattcattca ttcaacaagt atttcccaag      480
caccaattcc atcctcaaca aaagactcct aaatcacagg ccagatgaaa gacgtcacta      540
ttcacttgga aaaattcagc tgattatgat cctggtcgga gtgtactcag cgtcc      595

```

```

<210> 42
<211> 651
<212> DNA
<213> Homo sapiens

```

```

<400> 42
atggaattag aaaaatgaga aagtaatcaa agattgtaaa aaatactgag atagaattaa      60
aaggaataaa aaatttgtaa atcaaatatg taattctttt taagttgaca cattgtaatt      120
ttatatattt gtggagtatg atttggtaca ttaatttgta tatgtgttgt atgctgatca      180
aatcagggta tgtactaggc catTTTTgca ttggtataaa gaaatacctg aagctgggta      240
atttaaagaa aagaagttta ttgactcat ggttctatag gctgtgaaca acatctgctt      300
ggcttctggg gggagcctcg gaaagctttc aatagtggca gaaggggaag ggaagctgg      360
agtatcacat ggtgtgaaag ggagcaagag agagagagag agacaggagg tcctagactt      420
ttaaacaacc agatcttgtg tgaactatTT catgtgacta agaactcatt catcaccaag      480
cggaagggtgc caagtcattc atgagggatc caccctcata atacactacc ttccaccaag      540
tctcacttac aacattggga atgacatttc agcataagat ttggagagga caaatgtcca      600
aactatatca gggtagttag ctcatcctc acctcatgtc tttatcattt c      651

```

```

<210> 43
<211> 668
<212> DNA
<213> Homo sapiens

```

```

<400> 43
atgtaaaggg ccttttgga gaaaactgta aactccactg tggggccatt aaagaagtct      60
tgaatacata gattaaatcc cttggtttga gataataaaa ctctcaatat ttaccatgct      120

```

```

tttgtcattt aaatacaaat tgtggacatt tttaccaggg caacagatga gttacaacca 180
tcctttttatc agttgcacag aatcttattg aatgggtata tcctacttat gtcagttctt 240
agtagtgaat attaggttgt ttctaatttt tccatattag aaacaatgtt aaaagaactt 300
gctcttattt gtgtttctta tgtctacact agtattcaat acctttctag gagtggaaat 360
tcctggctca aacaaactgc cttccaagaa gatttactaa tatacattcc tactaatgct 420
gttttagaat gcctttttct ccatattcct atgaacactg agtgttctct ttttaacact 480
ttttttcttc aatctactag actccttcta aaatatatac ttttcaaac gcctgcttac 540
ccttcaatat attgtctttt aaaagattat ttgtaggtac tgtttatgtg ttaggttggt 600
ggaaaattaa ttgtgatttt gcaaaaactg caattacttt tgcaccaacc taatattata 660
catgtaga 668

```

<210> 44
 <211> 604
 <212> DNA
 <213> Homo sapiens

```

<400> 44
tctcttttgg ttcccttttt tcctcattac ctacctcttc tcctttgctg gtccctcaca 60
tcttcctggc ctcttctttg tctgcattta cttgtgtggt cttccgtctt taacacatct 120
acccatcagc tactcccaaa tgtatatatc tattcccgga cctttcctct gaactccaga 180
tttgtatttc caactaccta ctcaatagta ccttcttggg tattttattaa aatttgaatc 240
acgacatgcc taaaattgaa cttcctatct ctgaagcaa gccctatcct tctattgttt 300
ttcccatccc aataaattgc cactcattct tccagatgct tgggcaacat ttttgcagtc 360
atctttgatt tccttctttc ttgatatacc cacatacatt caccagcata tgctgccctg 420
tctacatttt aaacataacc agcatccaac atttctacaa ttgctactag ccttgtatag 480
ccctatcctc totcctctgg attactgtat tagcctctga actgggatcc cgcttcaacc 540
ctttccaacc tcctcctccc aaagccaact ctgtgaacag cagctaaagt tgttctttca 600
aaaa 604

```

<210> 45
 <211> 578
 <212> DNA
 <213> Homo sapiens

```

<400> 45
caaccctggt aaagcatcgc accttgggtt atgtacctca gggttatttg acgcactggg 60

```

```

ctaaaatggt,gaaggacatc ctgtttccag gtggggactg gaacagagcc tggactgttt 120
tagccaatgg ctccttacct caggatgttg cattcccagc acattctggt tgggtgttgag 180
aactacaaac aagaaagtgg gaagaactgt tctgcaccat ttatgtaaac ttctaggaaa 240
gcaaaactaat gtattgtgac agaaggaaga tgagtgattg cttaaacaca agggaggaat 300
gctacacagg gaaggtctgg agagttggat tacaagaga gacaaggaca cttttgggag 360
agatggatat gtttattatc ttgcttatgg tgatagtttc ataggtccat aaatcccaaa 420
agcatctcat tgtacactaa ctatgtatga tttatttata ttaattatac ctcaataaag 480
ttgtttttta aaaaagttac cacttaatcc tgtaaataga ccaggaaggc aattaattaa 540
tattttctag tttacttttg agaaactaaa gcttagta 578

```

```

<210> 46
<211> 575
<212> PRT
<213> Homo sapiens

```

```

<400> 46

```

```

Ala Gly Thr Thr Thr Ala Thr Gly Gly Ala Cys Cys Ala Gly Cys Cys
1          5          10          15
Thr Thr Cys Cys Cys Thr Gly Thr Gly Ala Ala Ala Thr Thr Thr Gly
20          25          30
Ala Cys Thr Thr Thr Cys Cys Cys Thr Cys Thr Thr Thr Gly Cys
35          40          45
Thr Gly Ala Ala Thr Thr Gly Gly Thr Cys Ala Gly Gly Thr Thr Ala
50          55          60
Ala Cys Ala Ala Thr Gly Gly Thr Thr Ala Cys Cys Cys Cys Thr Gly
65          70          75          80
Gly Ala Thr Thr Ala Cys Ala Gly Gly Ala Ala Gly Gly Gly Cys Ala
85          90          95
Thr Gly Thr Gly Cys Thr Ala Ala Ala Ala Gly Cys Cys Thr Cys Thr
100         105         110
Thr Thr Gly Gly Ala Gly Ala Cys Cys Cys Ala Cys Ala Thr Gly Gly
115         120         125
Cys Cys Cys Thr Cys Ala Gly Ala Thr Gly Ala Gly Cys Ala Ala Thr
130         135         140
Thr Gly Thr Thr Cys Ala Gly Ala Thr Thr Cys Cys Thr Thr Thr Thr
145         150         155         160
Cys Thr Thr Thr Thr Thr Cys Thr Thr Thr Thr Cys Cys Ala Thr Gly
165         170         175

```

Gly Gly Ala Ala Thr Ala Ala Gly Cys Thr Thr Thr Cys Cys Thr Cys
 180 185 190
 Thr Cys Thr Cys Cys Ala Ala Ala Gly Thr Ala Cys Ala Thr Gly Thr
 195 200 205
 Thr Thr Thr Ala Gly Gly Cys Thr Thr Thr Thr Thr Thr Ala Thr Thr
 210 215 220
 Thr Thr Cys Thr Thr Gly Cys Thr Ala Cys Thr Cys Cys Cys Ala Ala
 225 230 235 240
 Gly Gly Ala Cys Cys Thr Gly Gly Thr Gly Ala Thr Ala Thr Thr Thr
 245 250 255
 Thr Thr Cys Thr Thr Thr Ala Cys Cys Ala Thr Gly Cys Ala Thr Thr
 260 265 270
 Ala Ala Ala Cys Ala Gly Ala Ala Thr Cys Thr Gly Thr Gly Ala Gly
 275 280 285
 Thr Cys Thr Thr Thr Thr Cys Thr Gly Gly Ala Ala Ala Ala Ala Ala
 290 295 300
 Ala Ala Ala Ala Gly Gly Cys Ala Gly Gly Ala Gly Gly Gly Ala Ala
 305 310 315 320
 Cys Ala Thr Ala Cys Thr Ala Gly Thr Thr Ala Ala Ala Ala Ala Gly
 325 330 335
 Thr Thr Thr Cys Thr Gly Gly Gly Thr Ala Cys Ala Cys Thr Ala Cys
 340 345 350
 Cys Ala Ala Gly Ala Thr Gly Thr Ala Cys Cys Thr Ala Thr Thr Thr
 355 360 365
 Ala Thr Thr Gly Ala Thr Ala Thr Ala Cys Ala Ala Ala Thr Gly Gly
 370 375 380
 Cys Ala Thr Ala Ala Gly Thr Thr Ala Thr Thr Gly Ala Ala Thr Gly
 385 390 395 400
 Cys Thr Thr Gly Cys Thr Ala Thr Ala Gly Gly Cys Ala Thr Thr Cys
 405 410 415
 Thr Cys Thr Ala Ala Gly Ala Ala Cys Thr Thr Thr Gly Thr Ala Ala
 420 425 430
 Gly Ala Ala Thr Thr Gly Ala Cys Thr Thr Ala Cys Ala Thr Gly Ala
 435 440 445
 Gly Cys Thr Ala Cys Thr Thr Cys Ala Thr Ala Gly Cys Ala Gly Thr
 450 455 460
 Thr Cys Gly Ala Thr Gly Ala Thr Ala Thr Ala Cys Ala Thr Gly Thr
 465 470 475 480
 Thr Gly Thr Thr Ala Thr Thr Ala Thr Cys Ala Cys Cys Ala Cys Thr
 485 490 495

Thr Thr Ala Cys Ala Gly Ala Thr Ala Ala Gly Gly Ala Ala Ala Thr
 500 505 510

Ala Gly Ala Gly Ala Cys Ala Gly Ala Cys Ala Thr Ala Cys Thr Gly
 515 520 525

Ala Ala Thr Gly Ala Cys Ala Thr Gly Cys Thr Cys Ala Ala Cys Gly
 530 535 540

Cys Cys Ala Cys Thr Cys Cys Ala Cys Thr Ala Gly Cys Ala Ala Gly
 545 550 555 560

Thr Gly Gly Cys Ala Gly Ala Ala Cys Cys Cys Ala Ala Gly Cys
 565 570 575

<210> 47
 <211> 549
 <212> DNA
 <213> Homo sapiens

<400> 47
 cgtggcaggt tgcaccaact tttaaaccca caagcaatta tgagaggttc atttccttc 60
 actcacaaca aaactgcatc ttatcacgtt ttaagaaatc tttgccatth tgctgggatt 120
 aacttgtctc tcattattct atatttgcac ttctaagcta ttaagcttga ataatttcca 180
 tatgggccat ttgtatttgc aaaacaaaca ctacccttc aatgattttg cctggcttct 240
 gccttcacta gtatttattg cctcttttaa aactaagtt aatagtttta tttgttcctt 300
 tgtcagcctc ctctgaaaat gatgacactt ttcaaacagt accacatctt tctactcatt 360
 tcagttcaat gctcatatag ggcattgtgc atactgactg tccaagctgt gcactaagca 420
 ggtgaatctt ccttgccctt ggatcgagta ataacagaac ttaaagaagg ctctgggta 480
 ggaaaatcat gggactgggt aacagagaga tatggattca aatcctgggt tctctactta 540
 ctactcaa 549

<210> 48
 <211> 726
 <212> DNA
 <213> Homo sapiens

<400> 48
 acaccaggaa cacacttggg tgcccatcgg cccaggttt cttctgctgg tctgtctgg 60
 ccatgtgttt gggtttgaaa gtgtocagat tgctgggttc tctgggatct tcaogcaaaa 120
 gaaacgagca catgatgtg acctggaact ctctcgtctg gcgtcactgc atttttgcaa 180
 agcctgtaac tgtcctgtct gcattctggg ctccaaggct cagtcctctg atctttcctg 240
 acctgtcctt cccctaggct gccttcctct ttttccttat tacagtaaag ttctgtatgt 300

actgcagcat attccattta ttgggaattg aatataatttc ttctatgcca ggatttaaaa 360
 ttaggattgt taatattgtg gtttgtgctc tggttacaga atttctaagg tttgggtggt 420
 ctatcccagc accatatttt ctcaaagcct tgctctctgc agtgggtgat tttgcacaat 480
 gcaaacttct caggtacttt cttctgagct ccaggtcccc atatccaaca tctactcaac 540
 atcttattct gagatgttca cctcaaacat gtgagaatca acatgtcaac atgtcaatac 600
 ctcttgagg atttcctaac tocacagatg gtatccgtcc aattgtgcaa gccaaagaca 660
 aggcgccagc tgggacgttt cccataccca atctatcatc atgtcccatt aaattttacc 720
 agtagt 726

<210> 49
 <211> 633
 <212> DNA
 <213> Homo sapiens

<400> 49
 cacttgagag gtgatctcat ctataaagag agtatattta aggagctaatt ttacacaggt 60
 agatgacaaa accttacacc aactcttcaa gcacaggaag caccttacac gaaacacttt 120
 ggtgaatgct catcttctact caattttaaa cttaaattcaa ctgaaaatac ctcatctttaa 180
 agaggatatt cagttgactc actggggaaa aacaattgga taaactgggt gtttgcctt 240
 accgagataa aatcactgat aagttgaatg catcttttcta atgtgtcaag acagatggct 300
 ttaatagtca cacatattaa gtatgggata tgtggcgagg aatagagggt tttatataca 360
 gaagtaagaa ctgtagaggg gggaaaccat gaaagataga aaaagatgag aagaaagagg 420
 acagagatga tacactcaag aaaagctgcc tatttcagag tagaatatat tgtaagcccc 480
 agtatagttg aatgottaca agaggagaag cttttagcaa ctcttttgtt tcttaatgta 540
 tatattatat ctgaacagaa tgcttctttc ctgtgagcta gacagtagga agtaatctat 600
 cttcaacctt gtttggtgtg taaataaaac ttt 633

<210> 50
 <211> 618
 <212> DNA
 <213> Homo sapiens

<400> 50
 gtgatacgtg tcggctgtgt ccccatccaa atctaatttt gaattacagc tcccataatt 60
 tccatgtgtt gtggaagggg cctgggtggga gataaccgaa tcatgggggc ggctcccccc 120
 atactgttct cttggtagtg aataagtctc ataagatctg atcgttttat aaggggaaac 180
 cccttttgcg tggttcttat tctctctttg ctggctgcca tgtaagatgc ttctttgctc 240

ttcctttgtg ttctgcatg actgtggggc ctctccagcc atgtggaaat gtgaggaaat	300
taaacctctt tcctttataa attgcccagt cttgggtatg tctttatcag cagtgtgaaa	360
tggactaata caccagaagt tcaagactag cttgggcaac acagtaagac cctgtctgta	420
taaagaaaga ataagaaaaa gaaaaatatac agtggcataa tattagacag aatactataa	480
aactgattaa ggcacattaa tatagccaga ataattattc tgattatatac attttgaaag	540
accagataat caatataact gattttttatc ccgagtagct cagacttgca agcatgcact	600
accatacttg gataat	618

<210> 51
 <211> 1612
 <212> DNA
 <213> Homo sapiens

<400> 51	
cagtgagccg agatggtgcc attgcactct agcctggggc aacagagcca gactccatct	60
ccaaaaaaaaa aaggccattc tgaggatcaa ggcaccacta gcaacaggga gcccctatggg	120
tctcagaccc tctccccaca tctcctggtc cctgccccca cctggcgtagc agggaccagc	180
cccacggaag gctcttgagg ccaggttaacc atggggaggg gaggaatggg gacaccttcc	240
tcctgagtgt cttaggggaag agaagcttag gtcaggtggc tgagggtgga aatgagagag	300
gggtctctctc ctggagggtc tcaccattcc cttggtcacc caccctaactc tcatctcccc	360
tgatgtgggg aggagcaggg ggcattgatt cctgagcccc agactcaact gttgtggttt	420
acaggggcat caggagagag agcgagcaga acacactcct gcagcatccc ctggcccccc	480
gcccctatgat ggagcccaga gaagctggac agcacgtggg ggccgccaac ggcgcccagg	540
aggatgtggc cttcaacctc atcatcctgt ccctcaccga ggggctcggc ctgggtgggc	600
tgctggggaa tggggcagtc ctctggctgc tcagctcaa tgtctacaga aacccttctg	660
ccatctacct cctggacgtg gcctgcgcgg atctcatctt ccttggctgc cacatggtgg	720
ccatcgtccc cgacttgctg caaggccggc tggacttccc gggcttctgt cagaccagcc	780
tggcaacgct gcgcttcttc tgetacatcg tgggcctgag tctcctggcg gcgctcagcg	840
tggagcagtg cctggccgcc ctcttcccag cctggtactc gtgccgcgcg ccacgccacc	900
tgaccacctg tgtgtgcgcc ctcaacctgg ccctctgcct gctgctgcac ctgctgctca	960
gcggcgcttg caccagttc ttcggggagc ccagccgcca cttgtgccgg acgctgtggc	1020
tggtggcagc ggtgctgctg gctctgctgt gttgcacat gtgtggggcc agccttatgc	1080
tgctgctgcg ggtggagcga ggccccagc ggccccacc ccggggcttc cctgggctca	1140

tcctcctcac cgtcctcctc ttctcttctt ggggcctgcc cttcggcctc tactggtgt 1200
 cccggaacct gctctgttac atccccact acttctacca cttcagcttc ctcatggccg 1260
 ccgtgcactg cgcggccaag ccgctcgtct acttctgctt gggcagtgcc cagggccgca 1320
 ggctgccccct ccggctggtc ctccagcgag cgctgggaga cgaggtgag ctgggggccg 1380
 tcagggagac ctcccgccg ggctgtgtg acatagcagc ctgagccctg gggcccccga 1440
 cccagctgc agccccctg aggaagagg gtgacgtgg gaaggtggtg gggtcagagg 1500
 ctggggccag ccggacctg aggaggcctt ggtgggtgac ccggtcatgt gctgtcaaag 1560
 ttgtgaccct tggctggag catgaggctc ccctgggagg cagctggaaa gg 1612

<210> 52
 <211> 1527
 <212> DNA
 <213> Homo sapiens

<400> 52
 atgacgtcca cctgcaccaa cagcacgcgc gagagtaaca gcagccacac gtgcatgccc 60
 ctctccaaaa tgcccatcag cctggcccac ggcattcatc gctcaaccgt gctggttacc 120
 ttctcgcgcg cctctttcgt cggcaacata gtgctggcgc tagtggttga gcgcaagccg 180
 cagctgctgc aggtgaccaa ccgttttacc tttaacctcc tcgtcaccca cctgctgcag 240
 atttcgctcg tggccccctg ggtggtggcc acctctgtgc ctctcttctg gccctcaac 300
 agccacttct gcacggccct ggttagcctc accacactgt tcgccttcgc cagcgtcaac 360
 accattgtcg tgggtgtcagt ggatcgctac ttgtccatca tccaccctct ctctacccc 420
 tccaagatga cccagcgccg cggttacctg ctctctatg gcacctggat tgtggccatc 480
 ctgcagagca ctctccact ctacggctgg ggccaggctg cctttgatga gcgcaatgct 540
 ctctgctcca tgatctgggg ggccagcccc agctacacta ttctcagcgt ggtgtccttc 600
 atcgtcattc cactgattgt catgattgcc tgctactcgc tgggtgttctg tgcagcccgg 660
 aggcagcatg ctctgctgta caatgtcaag agacacagct tggaagtgcg agtcaaggac 720
 tgtgtggaga atgaggatga agaggagca gagaagaagg aggagtcca ggatgagagt 780
 gagtttcgcc gccagcatga aggtgaggtc aaggccaagg agggcagaat ggaagccaag 840
 gacggcagcc tgaaggccaa ggaaggaagc acggggacca gtgagagtag tgtagaggcc 900
 aggggcagcg aggaggtcag agagagcagc acggtggcca gcgacggcag catggagggt 960
 aaggaaggca gcaccaaagt tgaggagaac agcatgaagg cagacaaggg tcgcacagag 1020
 gtcaaccagt gcagcattga cttgggtgaa gatgacatgg agtttgggtga agacgacatc 1080

aatttcagtg aggatgacgt cgaggcagtg aacatcccgg agagcctccc acccagtcgt 1140
cgtaacagca acagcaaccc tcctctgccc aggtgctacc agtgcaaagc tgctaaagtg 1200
atcttcatca tcattttctc ctatgtgcta tccttggggc cctactgctt tttagcagtc 1260
ctggccgtgt ggggtgatgt cgaaacccag gtaccccagt gggtgatcac cataatcatc 1320
tggtttttct tcctgcagtg ctgcatccac ccctatgtct atggctacat gcacaagacc 1380
attaagaagg aaatccagga catgctgaag aagttcttct gcaaggaaaa gccccgaaa 1440
gaagatagcc acccagacct gcccggaaca gaggggtggga ctgaaggcaa gattgtccct 1500
tcctacgatt ctgctacttt tccttga 1527

<210> 53
<211> 939
<212> DNA
<213> Homo sapiens

<400> 53
atgatggagc ccagagaagc tggacagcac gtggggggccg ccaacagcgc ccaggaggat 60
gtggccttca acctcatcat cctgtccctc accgaggggc tcggcctcgg tgggctgctg 120
gggaatgggg cagtcctctg gctgtcagc tccaatgtct acagaaaccc cttcgccatc 180
tacctcctgg acgtggcctg cgcggatctc atcttccttg gctgccacat ggtggccatc 240
gtccccgact tgctgcaagg ccggtctggac ttcccgggct tcgtgcagac cagcctggca 300
acgtctgcgt tcttctgcta catcgtgggc ctgagtctcc tggcggcgt cagcgtggag 360
cagtgcctgg ccgccctctt ccagcctgg tactcgtgcc gccgccacg ccacctgacc 420
acctgtgtgt gcgcctcac ctgggccctc tgctgtctgc tgcacctgct gctcagcggc 480
gcctgcaccc agttcttcgg ggagccagc cgccacttgt gccggacgt gtggctgggtg 540
gcagcgggtg tgctggctct gctgtgttgc accatgtgtg gggccagcct tatgtgtctg 600
ctgcgggtgg agcgaggccc ccagcggccc ccacccggg gcttccttg gctcatcctc 660
ctcacgctc tcctcttctt cttctgcggc ctgcccttcg gcattactg gctgtccgg 720
aacctgctct ggtacatccc ccaactctt taccacttca gcttcctcat ggccgcctg 780
cactgcgcgg ccaagccgt cgtctacttc tgctgggca gtgccaggg ccgcaggctg 840
cccctcggc tggctctcca gcgagcgtg ggagacgagg ctgagctggg ggccgtcagg 900
gagacctccc gccggggcct ggtggacata gcagcctga 939

<210> 54
<211> 1778

<212> DNA

<213> Homo sapiens

<400> 54

```

ggagcctcgc cggccgccaat gtggagctgc agctggttca acggcacagg gctggtgagg      60
gagctgcctg cctgccagga cctgcagctg gggctgtcac tgttgctcgt gctgggcctg      120
gtggtgggcg tgccagtggg cctgtgctac aacgccctgc tggtgctggc caacctacac      180
agcaaggcca gcatgaccat gccggacgtg tactttgtca acatggcagt ggcaggcctg      240
gtgctcagcg ccctggcccc tgtgcacctg ctgggcccc cgagctcccg gtgggcgctg      300
tggagtgtgg gcggcgaagt ccacgtggca ctgcagatcc ctttcaatgt gtcctcactg      360
gtggccatgt actccaccgc cctgctgagc ctgcaccact acatcgagcg tgcactgccg      420
cggacctaca tggccagcgt gtacaacacg cggcacgtgt gcggcttcgt gtggggtggc      480
gcgctgctga ccagcttctc ctgctgctc ttctacatct gcagccatgt gtccaccgcg      540
gcgctagagt gcgccaagat gcagaacgca gaagctgccg acgccacgct ggtgttcac      600
ggctacgtgg tgccagcact ggccaccctc tacgcgctgg tgctactctc ccgcgtccgc      660
agggaggaca cggccctgga ccgggacacg ggccggctgg agccctcggc acacaggctg      720
ctggtggcca ccgtgtgcac gcagtttggg ctctggacgc cacactatct gatcctgctg      780
gggcacacgg tcatcatctc gcgaggggaag ccgctggacg cacactacct ggggctactg      840
cactttgtga aggatttctc caaactcctg gccttctcca gcagctttgt gacaccactt      900
ctctaccgct acatgaacca gagcttcccc agcaagctcc aacggctgat gaaaaagctg      960
ccctgcgggg accggcactg ctccccggac cacatggggg tgcagcaggt gctggcgtag     1020
gcggcccagc cctcctgggg agacgtgact ctggtggacg cagagcactt agttaccctg     1080
gacgctcccc acatccttcc agaaggagac gagctgctgg aagagaagca ggaggggtgt     1140
ttttcttgaa gtttctttt tcccacaaat gccactcttg ggccaaggct gtggtccccg     1200
tggctggcat ctggcttgag tctccccgag gcctgtgctg ctcccaaaca cgcagctcaa     1260
ggtccacatc cgcaaaagcc tcctcgctt cagcctctc agcattcagt ttgtcaatga     1320
agtgatgaaa gcttagagcc agtatttata ctttgtggtt aaaatacttg attccccctt     1380
gtttgtttta caaaaacaga tgtttcctag aaaaatgaca aatagtaaaa tgaacaaaac     1440
cctacgaaag aatggcaaca gccagggtgg ccggggccctg ccagtgggcg gcgtgtgcta     1500
gcaaggcctg ccgggtgtgc cgcagtcacc acagggttct gagaacattt cacagaagtg     1560
cctgagacgc ggagacatgg ctggtgttaa atggagctat tcaatagcag tgacgcgctc     1620
tcctcagcca ccaaagtcc ctgacaccct cccagcccc cacagataac atcagctgag     1680

```

gtttttttca gtatgaacct gtcctaaatc aattcctcaa agtgtgcaca aaactaaaga 1740

atataataaa acaaaagaaa ggcaaaaaaa aaaaaaaa 1778

<210> 55

<211> 1014

<212> DNA

<213> Homo sapiens

<400> 55

atggggaacg attctgtcag ctacgagtat ggggattaca ggcacctctc ggaccgcctt 60

gtggactgcc tggatggcgc ctgcctggcc atcgaccgcg tgcgcgtggc cccgctccca 120

ctgtatgccg ccatcttcct ggtgggggtg ccgggcaatg ccatgggtgc ctgggtggct 180

gggaaggtgg cccgccggag ggtgggtgcc acctggttg tccacctggc cgtggcggat 240

ttgctgtgct gtttgtctct gcccatctg gcagtgccca ttgccctgg aggccactgg 300

ccgtatggtg cagtgggctg tcgggcgtg cctccatca tctgctgac catgtatgcc 360

agcgtcctgc tctggcagc tctcagtgcc gacctctgct tctggctct cgggcctgcc 420

tggtggtcta cggttcagcg ggcgtgcggg gtgcaggtgg cctgtggggc agcctggaca 480

ctggccttgc tgctaccgt gccctccgcc atctaccgcc ggctgcacca ggagcacttc 540

ccagcccggc tgcagtgtgt ggtggaactac ggcggtcct ccagcaccga gaatgcgggtg 600

actgccatcc gggttctttt tggttctctg gggcccttg tggcctggc cagctgccac 660

agtgcctcc tgtgctgggc agcccgacgc tgccggccgc tgggcacagc cattgtggtg 720

gggttttttg tctgctgggc accctaccac ctgctggggc tgggtgtcac tgtggcggcc 780

ccgaactccg cactcctggc cagggccctg cgggtgaac cctcatcgt gggccttggc 840

ctcgtcaca gctgcctcaa tcccatgctc ttctgtatt ttgggagggc tcaactccgc 900

cggtaactgc cagctgcctg tcaactgggc ctgaggaggt ccaggggcca ggacgaaagt 960

gtggacagca agaaatccac cagccatgac ctggtctcgg agatggaggt gtag 1014

<210> 56

<211> 1170

<212> DNA

<213> Homo sapiens

<400> 56

atggcacctt ctcatcgggc atcacaggtg gggttttgcc ccaccctga acgccctctg 60

tggcgccttc caccacctg taggcccaga aggatgtcgg tctgctaccg tccccaggg 120

aacgagacac tgctgagctg gaagacttcg cgggccacag gcacagcctt cctgctgctg 180

gcggcgctgc tggggctgcc tggcaacggc ttcgtggtgt ggagcttggc gggctggcgg 240
 cctgcacggg ggcgaccgct ggcggccacg cttgtgctgc acctggcgct ggccgacggc 300
 gcggtgctgc tgcacacgcc gctctttgtg gccttcctga cccggcaggc ctggccgctg 360
 ggccaggcgg gctgcaaggc ggtgtactac gtgtgcgcgc tcagcatgta cgccagcgtg 420
 ctgctcaccg gcctgctcag cctgcagcgc tgcctgcag tcacccgcc cttcctggcg 480
 cctcggtctgc gcagcccggc cctggcccgc gcctgctgc tggcggtctg gctggccgcc 540
 ctgttgctcg ccgtcccggc cgcctctac cgccacctgt ggagggaccg cgtatgccag 600
 ctgtgccacc cgtgcgggt ccaagccgcc gccacctga gcctggagac tctgaccgct 660
 ttcgtgcttc ctttcgggct gatgctcggc tgctacagcg tgacgctggc acggctcggg 720
 ggcgcccgt ggggctccgg gcggcacggg gcgcgggtgg gccggctggt gagcgccatc 780
 gtgcttgctc tcggcttgc ctgggcccc taccacgcag tcaaccttct gcaggcggtc 840
 gcagcgctgg ctccaccgga aggggccttg gcgaagctgg gcggagccgg ccaggcggcg 900
 cgagcgggaa ctacggcctt ggccttcttc agttctagcg tcaaccgggt gctctacgtc 960
 ttcaccgctg gagatctgct gcccgggca ggtccccgtt tcctcacgcg gctcttcgaa 1020
 ggctctgggg agggccgagg gggcgccgc tctaggaag ggaccatgga gctccgaact 1080
 acccctcagc tgaaagtggg ggggcagggc cgcggcaatg gagaccggg gggtgggatg 1140
 gagaaggacg gtccggaatg ggaccttga 1170

<210> 57
 <211> 1965
 <212> DNA
 <213> Homo sapiens

<400> 57
 ccgccgcgcg gggaggacgc gagcaccag ctttaatccc tggaaagtcc acgaacaatg 60
 aatccatttc atgcatcttg ttggaacacc tctgcgaac ttttaaaca atcctggaat 120
 aaagagtttg cttatcaaac tgccagtgtg gtagatacag tcctcctccc ttccatgatt 180
 gggattatct gttcaacagg gctggttggc aacatcctca ttgtattcac tataataaga 240
 tccaggaaaa aaacagtccc tgacatctat atctgcaacc tggctgtggc tgatttggtc 300
 cacatagttg gaatgccttt tcttattcac caatgggcc gagggggaga gtgggtgttt 360
 ggggggcctc totgcacat catcacatcc ctggatactt gtaaccaatt tgctgtagt 420
 gccatcatga ctgtaatgag tgtggacagg tactttgcc tcgtccaacc atttcgactg 480
 acacgttggg gaacaaggta caagaccatc cggatcaatt tgggccttgg ggcagcttcc 540

```

tttatcctgg cattgcctgt ctgggtctac tcgaaggcca tcaaatttaa agacgggtgtt 600
gagagttgtg cttttgattt gacatcccct gacgatgtac tctggtatac actttatttg 660
acgataacaa cttttttttt ccctctaccc ttgatttttg tgtgctatat tttaatttta 720
tgctatactt gggagatgta tcaacagaat aaggatgcca gatgctgcaa tcccagtgt 780
ccaaaacaga gagtgatgaa gttgacaaag atgggtgctg tgtggtggt agtctttatc 840
ctgagtgtctg ccccttatca tgtgatacaa ctgggtgaact tacagatgga acagcccaca 900
ctggccttct atgtgggtta ttacctctcc atctgtctca gctatgccag cagcagcatt 960
aacccttttc tctacatcct gctgagtgtg aatttccaga aacgtctgcc tcaaattcaa 1020
agaagagcga ctgagaagga aatcaacaat atgggaaaca ctctgaaatc acacttttag 1080
gaaagtacat ggatcaccat gagtctagac atgattgtct atcttactgg tattattaga 1140
aagggcaggt gtaccgatat gtttatgccc attcttcttg tgtacttggt actcttagca 1200
gcatggaaga gaagtgtaac catgcaaata caatgagctt aatatgctaa ctttagcaag 1260
atgtaaaatg ttgatctata ttgtgggtag ggaatgggat agtctgagat acccaggctt 1320
catgatggtg tatattattt cagcatatta taaactagtc actaatgaaa atggccatcc 1380
atgaccattg actcaaaact caccaaggaa cctgaccttg cctccacac tgtggcctca 1440
ctgtaacagt ttctcaagg ttctaggag ggtatcacct tagagtgaag tctaaaattt 1500
ggctattttt tatctataaa aaatgtcagt tttatatggt ccaataactaa taccctcaac 1560
aactaagccc caccttttag aataagttac catttattgc acacatgcaa tgtgtaagat 1620
tacatgtaac aaacctgtga aataagtatt attaccttg tttgctaagg ctacagaagg 1680
agaaatgata ggcctaagtc tgcaacagct atctaagagc tgagctaaca ttcagctctg 1740
cctgtttctt ttctactgcc gaccttgaca acctttactt atcatactgg agaaccagt 1800
aactgggagt ttcttttgct ttctcctgta gccctacaag aggagaacta aagtctgata 1860
gaaatgagtt gatgttttaa gcatcatttt ggattatctt gttctcacac ctgctaactg 1920
tagaaactgg catctggact ttaataataa tactttactt ctgga 1965

```

```

<210> 58
<211> 1031
<212> DNA
<213> Homo sapiens

```

```

<400> 58
ccatgaccag caatttttcc caacctgttg tgcagctttg ctatgaggat gtgaatggat 60
cttgatttga aactccctat tctcctgggt cccgggtaat tctgtacacg gcgttttagct 120

```

```

ttgggtcttt gctggtgtga ttgggaaatc tottagtaat gacttctgtt cttcatttta 180
agcagctgca ctctccaacc aattttctca ttgcctctct ggctgtgct gacttcttgg 240
taggtgtgac tgtgatgctt ttcagcatgg tcaggacggt ggagagctgc tggatatttg 300
gagccaaatt ttgtactctt cacagttgct gtgatgtggc attttgttac tcttctgtcc 360
tccacttgtg cttcatctgc atcgacaggt acattgtggt tactgatccc ctggtctatg 420
ctaccaagtt caccgtgtct gtgtcgggaa ttgcatcag cgtgtcctgg attctgcctc 480
tcacgtacag cgggtgtgtg ttctacacag gtgtcaatga tgatgggctg gaggaattag 540
taagtgtctt caactgcgta ggtggctgtc aaattattgt aagtcaaggc tgggtgttga 600
tagattttct gttattcttc atacctaccc ttgttatgat aattctttac agtaagattt 660
ttcttatagc taaacaacaa gctataaaaa ttgaaactac tagtagcaaa gtagaatcat 720
cctcagagag ttataaaatc agagtggcca agagagagag gaaagcagct aaaaccctgg 780
gggtcacggt actagcattt gttatttcat ggttaccgta tacagttgat atattaattg 840
atgcctttat gggttctctg acccctgcct atatctatga aatttgctgt tggagtgcct 900
attataactc agccatgaat cctttgatth atgctctatt ttatccttgg tttaggaaag 960
ccataaaact tattttaagt ggagatgttt taaaggctag ttcatcaacc attagtttat 1020
ttttaagaata a 1031

```

```

<210> 59
<211> 972
<212> DNA
<213> Homo sapiens

```

```

<400> 59
atgccactcc ctgtgcccc agcgggggca caaaagactc ctgaggacca tgtctgtctc 60
catcttgacg gtccctcgcc agcaccctct gagccggcca ggatgtttgg gctgttcggc 120
ctctggagaa ccttcgacag tgtggtcttc tacctgacgc tgatcgtggg cctcggggga 180
ccggtaggta acgggctggt gctctggaac ctcggtctcc gcatcaagaa gggcccttc 240
tccatctacc tgetgcacct ggccgcgcgc gacttctgtt tcctctctct cctgtgtggc 300
ttctccgtgg ctcaggctgc cctgggcgcc caggacacac tctacttctg gctcaccttc 360
ctgtggttgc cgggtggggt ctggctgctg gcggccttca gcgtggagcg ctgcctctcc 420
gacctcttcc ccgctgcta ccagggtgc cggcccagac acgcctcggc cgtcctctgc 480
gcctgtgtgt ggaccccgac cctgccggcc gtgccgctgc ccgccaacgc ctgcggcctg 540
ctgcgcaaca gcgcgtgcc cctggtctgc ccgcgctacc acgtggccag cgtcacctgg 600

```



```

ttcctggtgc tggcccgcg cgcctggacg gctggcgtgg tcctctttgt ctgggtgacc 660
tgctgctoca ctgccccgog gccaggtc tacggcatcg tcctgggogc gctgctcctg 720
ctcttcttct gtggcctgcc ctgggtcttc tactggagcc tgcagcccct gctgaacttc 780
ctgctgcccg tgttttcccc gctggccacg ctgctggcct gcgtcaacag cagctccaag 840
cccctcatct actcgggggtt gggccgacag cccgggaagc gggagccgct gaggtcggtta 900
ctgcggaggg ccctggggga gggcgocgag ctgggtgcca ggggacagtc cctgcccctg 960
ggtctcctat aa 972

```

```

<210> 60
<211> 1011
<212> DNA
<213> Homo sapiens

```

```

<400> 60
atgaacaaca atacaacatg tattcaacca tctatgatct cttccatggc tttaaccaatc 60
atttacatcc tcctttgtat tgttgggtgtt tttggaaaca ctctctctca atggatatct 120
ttaacaaaaa taggtaaaaa aacatcaacg cacatctacc tgtcacacct tgtgactgca 180
aacttacttg tgtgcagtg ccatgcctttc atgagtatct atttctgaa aggtttccaa 240
tggaatatc aatctgctca atgcagagtg gtcaattttc tgggaactct atccatgcat 300
gcaagtatgt ttgtcagctc cttaatttta agttggattg ccataagccg ctatgctacc 360
ttaatgcaaa aggattcctc gcaagagact acttcatgct atgagaaaat attttatggc 420
catttactga aaaaatttcg ccagcccaac tttgctagaa aactatgcat ttacatatgg 480
ggagttgtac tgggcataat cattccagtt accgtatact actcagtc atagaggctaca 540
gaaggagaag agagcctatg ctacaatcgg cagatggaac taggagccat gatctctcag 600
attgcaggtc tcattggaac cacatttatt ggattttcct ttttagtagt actaacatca 660
tactactctt ttgtaagcca totgagaaaa ataagaacct gtacgtccat tatggagaaa 720
gatttgactt acagttctgt gaaaagacat cttttggtca tccagattct actaatagtt 780
tgcttcttct cttatagtat ttttaaacc ctttttatg ttctacacca aagagataac 840
tgtcagcaat tgaattattt aatagaaaca aaaaacattc tcacctgtct tgottcggcc 900
agaagtagca cagaccccat tatatttctt ttattagaca aaacattcaa gaagacacta 960
tataatctct ttacaaagtc taattcagca catatgcaat catatggttg a 1011

```

```

<210> 61
<211> 180
<212> PRT

```

<213> Homo sapiens

<400> 61

Tyr Ala Thr Ile Gly Arg Trp Glu Leu Gly Ala Met Ile Ser Gln Ile
 1 5 10 15
 Ala Gly Leu Ile Gly Thr Thr Phe Ile Gly Phe Ser Phe Leu Val Val
 20 25 30
 Leu Thr Ser Tyr Tyr Ser Phe Val Ser His Leu Arg Lys Ile Arg Thr
 35 40 45
 Cys Thr Ser Ile Met Glu Lys Asp Leu Thr Tyr Ser Ser Val Lys Arg
 50 55 60
 His Leu Leu Val Ile Gln Ile Leu Leu Ile Val Cys Phe Leu Pro Tyr
 65 70 75 80
 Ser Ile Phe Lys Pro Ile Phe Tyr Val Leu His Gln Arg Asp Asn Cys
 85 90 95
 Gln Gln Leu Asn Tyr Leu Ile Glu Thr Lys Asn Ile Leu Thr Cys Leu
 100 105 110
 Ala Ser Ala Arg Ser Ser Thr Asp Pro Ile Ile Phe Leu Leu Leu Asp
 115 120 125
 Lys Thr Phe Lys Lys Thr Leu Tyr Asn Leu Phe Thr Lys Ser Asn Ser
 130 135 140
 Ala His Met Gln Ser Tyr Gly Leu Leu Asn Gly Lys Pro His Asn Ile
 145 150 155 160
 Lys Lys Ser Ile His Val Thr Leu Leu Gly Thr Leu Asn Tyr Ile Ile
 165 170 175
 Asn Met Ser Gln
 180

<210> 62

<211> 530

<212> PRT

<213> Homo sapiens

<400> 62

Val Ser Arg Asp Gly Ala Ile Ala Leu Pro Gly Ala Thr Glu Pro Asp
 1 5 10 15
 Ser Ile Ser Lys Lys Lys Arg Pro Phe Gly Ser Arg His His Gln Gln
 20 25 30
 Gly Ala Pro Trp Val Ser Asp Pro Leu Pro Thr Ser Pro Gly Pro Cys
 35 40 45
 Pro His Leu Ala Tyr Arg Asp Gln Pro His Gly Arg Leu Leu Arg Pro
 50 55 60

Gly Asn His Gly Glu Gly Arg Asn Gly Asp Thr Phe Leu Leu Ser Val
 65 70 75 80
 Leu Gly Lys Arg Ser Leu Gly Gln Val Ala Glu Gly Gly Asn Glu Arg
 85 90 95
 Gly Val Ser Ser Trp Arg Val Ser Pro Phe Pro Trp Ser Pro Thr Gln
 100 105 110
 Leu Ser Ser Pro Leu Met Trp Gly Gly Ala Gly Gly Met Asp Ser Ala
 115 120 125
 Pro Asp Ser Thr Val Val Val Tyr Arg Gly Ile Arg Arg Glu Ser Glu
 130 135 140
 Gln Asn Thr Leu Leu Gln His Pro Leu Ala Pro Arg Pro Met Met Glu
 145 150 155 160
 Pro Arg Glu Ala Gly Gln His Val Gly Ala Ala Asn Gly Ala Gln Glu
 165 170 175
 Asp Val Ala Phe Asn Leu Ile Ile Leu Ser Leu Thr Glu Gly Leu Gly
 180 185 190
 Leu Gly Gly Leu Leu Gly Asn Gly Ala Val Leu Trp Leu Leu Ser Ser
 195 200 205
 Asn Val Tyr Arg Asn Pro Phe Ala Ile Tyr Leu Leu Asp Val Ala Cys
 210 215 220
 Ala Asp Leu Ile Phe Leu Gly Cys His Met Val Ala Ile Val Pro Asp
 225 230 235 240
 Leu Leu Gln Gly Arg Leu Asp Phe Pro Gly Phe Val Gln Thr Ser Leu
 245 250 255
 Ala Thr Leu Arg Phe Cys Tyr Ile Val Gly Leu Ser Leu Leu Ala Ala
 260 265 270
 Val Ser Val Glu Gln Cys Leu Ala Ala Leu Phe Pro Ala Trp Tyr Ser
 275 280 285
 Cys Arg Arg Pro Arg His Leu Thr Thr Cys Val Cys Ala Leu Thr Trp
 290 295 300
 Ala Leu Cys Leu Leu Leu His Leu Leu Leu Ser Gly Ala Cys Thr Gln
 305 310 315 320
 Phe Phe Gly Glu Pro Ser Arg His Leu Cys Arg Thr Leu Trp Leu Val
 325 330 335
 Ala Ala Val Leu Leu Ala Leu Leu Cys Cys Thr Met Cys Gly Ala Ser
 340 345 350
 Leu Met Leu Leu Leu Arg Val Glu Arg Gly Pro Gln Arg Pro Pro Pro
 355 360 365
 Arg Gly Phe Pro Gly Leu Ile Leu Leu Thr Val Leu Leu Phe Leu Phe
 370 375 380

Cys Gly Leu Pro Phe Gly Ile Tyr Trp Leu Ser Arg Asn Leu Leu Trp
 385 390 395 400
 Tyr Ile Pro His Tyr Phe Tyr His Phe Ser Phe Leu Met Ala Ala Val
 405 410 415
 His Cys Ala Ala Lys Pro Val Val Tyr Phe Cys Leu Gly Ser Ala Gln
 420 425 430
 Gly Arg Arg Leu Pro Leu Arg Leu Val Leu Gln Arg Ala Leu Gly Asp
 435 440 445
 Glu Ala Glu Leu Gly Ala Val Arg Glu Thr Ser Arg Arg Gly Leu Val
 450 455 460
 Asp Ile Ala Ala Ala Leu Gly Pro Pro Thr Pro Ala Ala Ala Pro Val
 465 470 475 480
 Arg Gln Glu Gly Asp Val Gly Lys Val Val Gly Ser Glu Ala Gly Ala
 485 490 495
 Ser Arg Thr Trp Arg Arg Pro Trp Trp Val Thr Arg Ser Cys Ala Val
 500 505 510
 Lys Val Val Thr Leu Gly Leu Glu His Glu Ala Pro Leu Gly Gly Ser
 515 520 525
 Trp Lys
 530

<210> 63
 <211> 313
 <212> PRT
 <213> Homo sapiens

<400> 63

Gly Trp Gln His Arg Leu Ser Arg Leu Cys Glu Lys Asn Gly Gly Thr
 1 5 10 15
 Thr Ser His Cys Cys Val Arg Arg Met Ala Ala Thr Pro Leu Met Val
 20 25 30
 Val Gly Glu Trp Arg His His Leu Ser Trp Leu Cys Glu Ala Leu Arg
 35 40 45
 Ala Pro Val Ser Leu Leu Arg Gly Glu Trp Arg His His Leu Ser Trp
 50 55 60
 Leu Cys Asn Ile Ser Ile Thr Leu Lys Tyr Pro Leu Ile Val Gly Ala
 65 70 75 80
 Ile Cys Asn Ala Glu Val Val Pro Gln Lys His Phe Asn His Phe His
 85 90 95
 Phe His Gly Ser Ala Lys Thr Tyr Ala Gly Pro His Arg Ser Gln Arg
 100 105 110

Ser His Leu Cys Phe Arg Ala Lys Pro Val Phe Leu Leu Ser Thr Ala
 115 120 125
 Asn Ile Leu Thr Val Ile Ile Leu Ser Gln Leu Val Ala Arg Arg Gln
 130 135 140
 Lys Ser Ser Tyr Asn Tyr Leu Leu Ala Leu Ala Ala Asp Ile Leu
 145 150 155 160
 Val Leu Phe Phe Ile Val Phe Val Asp Phe Leu Leu Glu Asp Phe Ile
 165 170 175
 Leu Asn Met Gln Met Pro Gln Val Pro Asp Lys Ile Ile Glu Val Leu
 180 185 190
 Glu Phe Ser Ser Ile His Thr Ser Ile Trp Ile Thr Val Pro Leu Thr
 195 200 205
 Ile Asp Arg Tyr Ile Ala Val Cys His Pro Leu Lys Tyr His Thr Val
 210 215 220
 Ser Tyr Pro Ala Arg Thr Arg Lys Val Ile Val Ser Val Tyr Ile Thr
 225 230 235 240
 Cys Phe Leu Thr Ser Ile Pro Tyr Tyr Trp Trp Pro Asn Ile Trp Thr
 245 250 255
 Glu Asp Tyr Ile Ser Thr Ser Val His His Val Leu Ile Trp Ile His
 260 265 270
 Cys Phe Thr Val Tyr Leu Val Pro Cys Ser Ile Phe Phe Ile Leu Asn
 275 280 285
 Ser Ile Ile Val Tyr Lys Leu Arg Arg Lys Ser Asn Phe Asp Asn Gly
 290 295 300
 Ser Ile Ala Ser His Gly Cys Val Arg
 305 310

<210> 64
 <211> 173
 <212> PRT
 <213> Homo sapiens

<400> 64

His Leu Cys Arg Trp Thr Ser Tyr Ala Glu Asp Pro Leu Gln Gly Ser
 1 5 10 15
 Glu Asn Ala Cys Asn Gly Ser Arg Gln Pro Ser Leu Pro Ser Thr Ala
 20 25 30
 Ser Pro Gly Thr Asn Glu Arg Pro Arg Arg Leu Thr Ser Trp Cys His
 35 40 45
 Leu Ser Cys Ala Gly Leu Pro Thr Leu Leu Val Ile Ile Gly Ala Ala
 50 55 60
 Cys His Gly Ser His Val Gln His Phe Leu Tyr Glu Thr Arg Phe Trp
 43

65	70										75					80				
Leu	His	Trp	Leu	Asn	Ser	Ala	Ile	Ser	Pro	Leu	Pro	Tyr	Ser	Phe	Cys					
				85					90					95						
His	Glu	Phe	Gln	Lys	Ser	Ile	Pro	Ser	Asn	Arg	Cys	Val	Leu	Glu	Arg					
			100					105					110							
Leu	Ser	Glu	Ile	His	Pro	Pro	Pro	Tyr	Val	His	Val	Thr	Glu	Thr	Ala					
		115					120					125								
Leu	Val	Phe	Leu	Met	Val	Glu	Ala	Val	Gln	Val	Leu	Gly	Val	Leu	Asn					
	130					135					140									
Lys	Glu	Leu	Asp	Lys	Thr	His	Lys	Gln	Ser	Lys	Glu	Gly	Met	Lys	Phe					
145					150					155					160					
Ile	Glu	Asn	Glu	Ser	Thr	Leu	His	Ser	Val	Gly	Ala	Gly								
				165					170											

```
<210> 65
<211> 187
<212> PRT
<213> Homo sapiens
```

<400> 65

Tyr 1	Phe	Tyr	Pro	Lys 5	Leu	Leu	Cys	Ser	Leu 10	Leu	Glu	Phe	Pro	Arg 15	Lys
Ile	Pro	Lys	Glu 20	Leu	Met	Val	Ser	Tyr 25	Leu	Leu	Leu	Tyr	Tyr 30	Glu	Glu
Glu	Lys	Cys 35	Phe	Thr	Asn	Ile	Phe 40	Ile	Ile	Gly	Ala	Phe 45	Phe	Val	Val
Ser	Glu 50	Ile	Ile	Lys	Thr	Arg 55	Ile	Asp	Phe	Tyr	Ser 60	Val	Tyr	Phe	Cys
Tyr 65	Asn	Leu	Tyr	Pro	Phe 70	Leu	Leu	Ile	Ser	Val 75	Phe	Trp	Met	Pro	Asn 80
Leu	Glu	Tyr	Ile	Thr 85	Lys	Val	Thr	Phe	Ser 90	Phe	Ser	Leu	Ser	Ile 95	Gln
Asp	Asp	Leu	Lys 100	His	Leu	Trp	Leu	Pro 105	Phe	Leu	Ile	Phe	Leu 110	Leu	Cys
Lys	Phe	Ile 115	Lys	Gly	Gln	Ser	Leu 120	Cys	Ala	Leu	Ile	Ile 125	Pro	Ala	Phe
Ser	Cys 130	Phe	Thr	Cys	Ser	Thr 135	Ile	Tyr	Phe	Val	Phe 140	Ile	Met	Phe	Ser
Phe 145	Thr	Leu	Cys	Thr	Ile 150	Ile	Asp	Tyr	Asn	Glu 155	Glu	Asn	Leu	Asp	Asn 160
Leu	Leu	Leu	Lys	Arg 165	Phe	Phe	Arg	Gln	Ile 170	Ile	Gly	Phe	Phe	Cys 175	Ile

Leu Lys Arg Tyr Val Tyr Phe Ala Thr Arg Val
180 185

<210> 66
<211> 287
<212> PRT
<213> Homo sapiens

<400> 66

Phe Leu Leu Ser Thr Ala Asn Ile Leu Thr Val Ile Ile Leu Ser Gln
1 5 10 15
Leu Val Ala Arg Arg Gln Lys Ser Ser Tyr Asn Tyr Leu Leu Ala Leu
20 25 30
Ala Ala Ala Asp Ile Leu Val Leu Phe Phe Ile Val Phe Val Asp Phe
35 40 45
Leu Leu Glu Asp Phe Ile Leu Asn Met Gln Met Pro Gln Val Pro Asp
50 55 60
Lys Ile Ile Glu Val Leu Glu Phe Ser Ser Ile His Thr Ser Ile Trp
65 70 75 80
Ile Thr Val Pro Leu Thr Ile Asp Arg Tyr Ile Ala Val Cys His Pro
85 90 95
Leu Lys Tyr His Thr Val Ser Tyr Pro Ala Arg Thr Arg Lys Val Ile
100 105 110
Val Ser Val Tyr Ile Thr Cys Phe Leu Thr Ser Ile Pro Tyr Tyr Trp
115 120 125
Trp Pro Asn Ile Trp Thr Glu Asp Tyr Ile Ser Thr Ser Val His His
130 135 140
Val Leu Ile Trp Ile His Cys Phe Thr Val Tyr Leu Val Pro Cys Ser
145 150 155 160
Met Phe Phe Ile Leu Asn Ser Ile Ile Val Tyr Lys Leu Arg Arg Lys
165 170 175
Ser Asn Phe Arg Leu Arg Gly Tyr Ser Thr Gly Lys Thr Thr Ala Ile
180 185 190
Leu Phe Thr Ile Thr Ser Ile Phe Ala Thr Leu Trp Ala Pro Arg Ile
195 200 205
Ile Met Ile Leu Tyr His Leu Tyr Gly Ala Pro Ile Gln Asn Arg Trp
210 215 220
Leu Val His Ile Met Ser Asp Ile Ala Asn Met Leu Ala Leu Leu Asn
225 230 235 240
Thr Ala Ile Asn Phe Phe Leu Tyr Cys Phe Ile Ser Lys Arg Phe Arg
245 250 255

Thr Met Ala Ala Ala Thr Leu Lys Ala Phe Phe Lys Cys Gln Lys Gln
 260 265 270

Pro Val Gln Phe Tyr Thr Asn His Asn Phe Ser Ile Thr Ser Ser
 275 280 285

<210> 67
 <211> 271
 <212> PRT
 <213> Homo sapiens

<400> 67

Thr Pro Ala Asn Met Phe Ile Ile Asn Leu Ala Val Ser Asp Phe Leu
 1 5 10 15
 Met Ser Phe Thr Gln Ala Pro Val Phe Phe Thr Ser Ser Leu Tyr Lys
 20 25 30
 Gln Trp Leu Phe Gly Glu Thr Gly Arg Cys Trp Gly Ser Leu Leu Leu
 35 40 45
 Glu Gly Gly Gly Gly Phe Pro Gly Asp Ala Leu Asn Gly Gly Trp Pro
 50 55 60
 Lys Gly Gly Asp Leu Leu Leu Leu Gly Arg Glu Trp Val Ala Ala Leu
 65 70 75 80
 Ser Pro Val Ser Lys Gln Glu Gly Lys Met Gln Cys Trp Ser Gly Leu
 85 90 95
 Cys Gln Pro Trp Pro Asp Val Ala Gly Gly Gly Gly Val Arg Ser
 100 105 110
 Val Leu Leu Phe Leu Gly Glu Gly Gln Ser Arg Val Tyr Pro Val Pro
 115 120 125
 Arg Pro Ser Ser Pro Gly Leu Arg Ala Gly Ala Val Pro Thr Gly Cys
 130 135 140
 Glu Phe Tyr Ala Phe Cys Gly Ala Leu Phe Gly Ile Ser Ser Met Ile
 145 150 155 160
 Thr Leu Thr Ala Ile Ala Leu Asp Arg Tyr Leu Val Ile Thr Arg Pro
 165 170 175
 Leu Ala Thr Phe Gly Val Ala Ser Lys Arg Arg Ala Ala Phe Val Leu
 180 185 190
 Leu Gly Val Trp Leu Tyr Ala Leu Ala Trp Ser Leu Pro Pro Phe Phe
 195 200 205
 Gly Trp Ser Lys Trp Ala Ala Gly Thr Gly Arg Gly Ala Asp Gly Leu
 210 215 220
 Gly Gly Ala His Ser Arg Val Ser Arg Trp Thr Trp Val Ser Gln Leu
 225 230 235 240
 Ala Gly Ala Gly Cys Pro Gly Ala Thr Ala Ser Gly Glu Met Asp Ile

					245						250						255
Gln	Gly	Asp	Met	Thr	Gly	Ser	Lys	Gly	Asn	His	Cys	Pro	His	Leu			
			260					265					270				
<210>	68																
<211>	204																
<212>	PRT																
<213>	Homo sapiens																
<400>	68																
Phe	Ser	Pro	Arg	Val	Thr	Asn	Ser	Ala	Cys	Val	Phe	Leu	Leu	Ser	Pro		
1				5					10					15			
Ala	Ala	Leu	Ser	Ala	Val	Cys	Ala	Pro	Leu	Cys	His	Pro	Pro	Val	Pro		
			20					25					30				
Ala	Leu	Ser	Leu	Gln	Pro	Val	Ser	Arg	Pro	Leu	Ala	Val	Ala	Met	Thr		
		35					40					45					
Ser	Thr	Cys	Thr	Asn	Ser	Thr	Arg	Glu	Ser	Asn	Ser	Ser	His	Thr	Cys		
	50					55					60						
Met	Pro	Leu	Ser	Lys	Met	Pro	Ile	Ser	Leu	Ala	His	Gly	Ile	Ile	Arg		
65					70					75					80		
Ser	Thr	Val	Leu	Val	Ile	Phe	Leu	Ala	Ala	Ser	Phe	Val	Gly	Asn	Ile		
				85					90					95			
Val	Leu	Ala	Leu	Val	Leu	Gln	Arg	Lys	Pro	Gln	Leu	Leu	Gln	Val	Thr		
			100					105					110				
Asn	Arg	Phe	Ile	Phe	Asn	Leu	Leu	Val	Thr	Asp	Leu	Leu	Gln	Ile	Ser		
		115					120					125					
Leu	Val	Ala	Pro	Trp	Val	Val	Ala	Thr	Ser	Val	Pro	Leu	Phe	Trp	Pro		
	130					135					140						
Leu	Asn	Ser	His	Phe	Cys	Thr	Ala	Leu	Val	Ser	Leu	Thr	His	Leu	Phe		
145					150					155					160		
Ala	Phe	Ala	Ser	Val	Asn	Thr	Ile	Val	Val	Val	Ser	Val	Asp	Arg	Tyr		
				165					170					175			
Leu	Ser	Ile	Ile	His	Pro	Leu	Phe	Tyr	Pro	Ser	Lys	Met	Thr	Gln	Arg		
			180					185					190				
Arg	Gly	Tyr	Leu	Leu	Leu	Tyr	Gly	Thr	Trp	Ile	Val						
		195					200										
<210>	69																
<211>	177																
<212>	PRT																
<213>	Homo sapiens																
<400>	69																
Gln	Gly	His	Val	Asp	Arg	Val	His	Gly	Asp	Val	Pro	Thr	Cys	Thr	Pro		

47

1 5 10 15
 Ala Cys Ser Ser Ser Leu Pro Val Arg Ala Thr Ile Arg Trp Pro Arg
 20 25 30
 Leu Arg Ala Thr Gly Thr Arg Gly His Gly Arg Gly Asp Cys Cys Gly
 35 40 45
 Arg Ser Leu Gly Asp Ser Cys Cys Phe Ser Ala Lys Ala Leu Cys Val
 50 55 60
 Trp Ile Trp Ala Leu Ala Ala Leu Ala Ser Leu Pro Ser Ala Ile Phe
 65 70 75 80
 Ser Thr Thr Val Lys Val Met Gly Glu Glu Leu Cys Leu Val Arg Phe
 85 90 95
 Pro Asp Lys Leu Leu Gly Arg Asp Arg Gln Phe Trp Leu Gly Leu Tyr
 100 105 110
 His Ser Gln Lys Val Leu Leu Gly Phe Val Leu Pro Leu Gly Ile Ile
 115 120 125
 Ile Leu Cys Tyr Leu Leu Leu Val Arg Phe Ile Ala Asp Arg Arg Ala
 130 135 140
 Ala Gly Thr Lys Gly Gly Ala Ala Val Ala Gly Gly Arg Pro Thr Gly
 145 150 155 160
 Ala Ser Ala Arg Arg Leu Ser Lys Val Thr Lys Ser Val Thr Ile Val
 165 170 175

Val

<210> 70
 <211> 356
 <212> PRT
 <213> Homo sapiens

<400> 70

Gly Lys Gly Ala Gly Gly Ala Pro Arg Arg Arg Gly Ala Thr Ala Cys
 1 5 10 15
 Leu Val Leu Asn Leu Phe Cys Ala Asp Leu Leu Phe Ile Ser Ala Ile
 20 25 30
 Pro Leu Val Leu Ala Val Arg Trp Thr Glu Ala Trp Leu Leu Gly Pro
 35 40 45
 Val Ala Cys His Leu Leu Phe Tyr Val Met Thr Leu Ser Gly Ser Val
 50 55 60
 Thr Ile Leu Thr Leu Ala Ala Val Ser Leu Glu Arg Met Val Cys Ile
 65 70 75 80
 Val His Leu Gln Arg Gly Val Arg Gly Pro Gly Arg Arg Ala Arg Ala
 85 90 95

Val Leu Leu Ala Leu Ile Trp Gly Tyr Ser Ala Val Ala Ala Leu Pro
 100 105 110
 Leu Cys Val Phe Phe Arg Val Val Pro Gln Arg Leu Pro Gly Ala Asp
 115 120 125
 Gln Val Ser Ala Pro Leu Cys Val Pro Gly Arg Cys Pro Ala Gln Ala
 130 135 140
 Gly Lys Arg Gly Pro Asp Gly Ser Trp Asp Glu Asp Asp Gln Glu Gln
 145 150 155 160
 Gln Pro Phe Ile Ala Leu Asn Arg Cys Ala Lys Ser Cys Ala His Gly
 165 170 175
 Cys Glu Val Ser Leu Lys Ser His Tyr Asn Ala Val His Thr Pro Ser
 180 185 190
 Met Met Val Glu Ser Pro Lys Phe Leu Gln Asn Ala Met Thr Val Ala
 195 200 205
 Arg Leu Ile Asn Glu Phe Arg Ser Glu Thr Glu Leu Trp Gly Cys Arg
 210 215 220
 Val Ala Lys His Phe Val Leu Asn His Asp Ser Ser Pro Gly Ala Thr
 225 230 235 240
 Ile Leu Leu Leu Ser His Pro Phe His Arg Glu Pro Glu Ala His Arg
 245 250 255
 Ser Val Leu Ala Gln Ser Ile Leu Ser Val Ile Arg Gly Gly Asp Gly
 260 265 270
 Leu Leu Pro Glu Val Tyr Pro Phe Lys Glu Glu Leu Gly Ser Cys Pro
 275 280 285
 Gly Leu Gly Tyr Gly Pro Ala Leu Lys Ala Arg Gly Gln Ala Cys Glu
 290 295 300
 Thr Arg Gly Pro Gln Met Gln Cys Cys Leu Gly Thr Cys Asp Arg Ile
 305 310 315 320
 Pro Phe Arg Gly Leu Gln Phe Phe Gln Leu Gln Asn Gly Arg Ile Thr
 325 330 335
 Leu Asp Leu Arg Gly Val Leu Gly Ala Asn Val Gln Ile Thr Glu Ala
 340 345 350
 Gly Pro Thr Ser
 355

<210> 71
 <211> 187
 <212> PRT
 <213> Homo sapiens

<400> 71

Leu Ile Pro Gly Ser Pro Arg Thr Met Asn Pro Phe His Ala Ser Cys
 1 5 10 15
 Trp Asn Thr Ser Ala Glu Leu Leu Asn Lys Ser Trp Asn Lys Glu Phe
 20 25 30
 Ala Tyr Gln Thr Ala Ser Val Val Asp Thr Val Ile Leu Pro Ser Met
 35 40 45
 Ile Gly Ile Ile Cys Ser Thr Gly Leu Val Gly Asn Ile Leu Ile Val
 50 55 60
 Phe Thr Ile Ile Arg Gly Met Ala Pro Phe Phe Phe Ser Phe His
 65 70 75 80
 Thr Leu Gly Asn Tyr Ser Gln Ser Ser Leu Asn Glu Ser Phe Pro Leu
 85 90 95
 His Phe Ala Asn Ala Ile Leu Glu Ile Phe Ala Asp Asn Arg Phe Tyr
 100 105 110
 Arg Tyr Phe Arg His Ala Leu Gly Asn Ile Ser Val Ala Asn Leu Asn
 115 120 125
 Met Leu Arg Pro Arg Pro Met Leu Thr Ala Gly Ser Val Ser Phe Gly
 130 135 140
 Asn Asp Ser His Ser Gln Ser Leu His Ile Arg Ile Ile Trp Gly Ala
 145 150 155 160
 Leu Lys Thr Pro Asp Met Gln Phe His Pro Arg Pro Ile Asn Ser Glu
 165 170 175
 Ser Leu Arg Val Gly Pro Gly Asp Leu Lys Leu
 180 185

<210> 72
 <211> 123
 <212> PRT
 <213> Homo sapiens

<400> 72

Val Thr Gly Thr Leu Glu Gly Asp Ser Phe Pro Gly Glu Glu Gly Thr
 1 5 10 15
 Val Gly Phe Pro Ala Leu Leu Leu Ser Pro Tyr Gly Leu Arg Ser Gly
 20 25 30
 Leu Asn Cys Asp Glu Ser Leu Cys Pro Cys Ser Leu Gly Phe Leu Lys
 35 40 45
 Tyr Pro Pro Phe Ile Val Pro Ile Ile Ile Asn Thr Asn Gln Ser Leu
 50 55 60
 Leu Cys Leu Lys Leu Leu Ile Ala Tyr Arg Gly Lys Cys Arg Leu Leu
 65 70 75 80
 Ser Trp Arg Thr Ser Leu Leu His Leu Ala His Ile Glu Leu Ser Arg
 50

85 90 95
 Ala Ile Ser Cys His Ser Leu Ala Cys Leu Leu Leu Leu Trp Val Ser
 100 105 110

Arg Thr Ala His Glu Phe Pro His Met Pro Phe
 115 120

<210> 73
 <211> 157
 <212> PRT
 <213> Homo sapiens

<400> 73

Tyr Ala Phe Leu Leu Met Asp Gln Ala Ile Ser Pro Thr Ser Phe Phe
 1 5 10 15

Leu Ile Ile Pro Phe Leu Ala Leu Phe Ser Arg Lys Lys Phe Lys Cys
 20 25 30

Leu Leu Pro Ile Phe Ser Glu Gly Glu Met Pro Val Pro Gly Phe Pro
 35 40 45

Gly Ser Cys Leu Leu Gly Arg Pro Leu Pro Cys Thr Thr Lys Ser Thr
 50 55 60

Leu Pro Ser Gln His Pro Leu Leu Ser Pro Gly Gln Leu Leu Cys Val
 65 70 75 80

Leu Phe Ile Pro Ile Ser Leu Pro Glu Leu Leu Arg Pro Leu Cys Leu
 85 90 95

Ser Ala Ser Cys Pro Ile Phe Gln Ala Leu Val Cys Trp Leu Ser Ala
 100 105 110

Ser Lys Asn Asp Phe Lys His Leu Val Phe Leu Ser Thr Glu Leu Gln
 115 120 125

Thr Leu Lys Cys Arg Ser Ser Ile Thr Ser Asn Ile Glu Val Leu Ile
 130 135 140

Met Leu Pro Cys Gly Phe Met Leu Phe Gly Ile Asp Phe
 145 150 155

<210> 74
 <211> 211
 <212> PRT
 <213> Homo sapiens

<400> 74

Lys Gly Gly Cys Thr Lys Glu Gly Asn Lys Tyr Ser Leu Met Ile Tyr
 1 5 10 15

Asn Val Ser Asp Thr Glu Ile His Arg Leu Gly Leu Trp Glu Ser Gln
 20 25 30

Ile Leu Ile Cys Gln Gln Cys Val Leu Ile Phe Leu Phe Cys Ile Phe

35 40 45
 Ala Ser Pro Ile Asn Phe Thr Gly Leu Ile Ile Phe Thr Arg His Tyr
 50 55 60
 Phe Lys Glu Lys Ala Asn Leu Leu Lys Phe Tyr Ala Ser Leu Ile Val
 65 70 75 80
 Met Ser Trp Leu Ile Leu Ala Leu Val Ser Met Phe Trp Lys Ile Leu
 85 90 95
 Lys Tyr Phe His Leu Val Ala Leu Ser Glu His Cys Arg Thr Glu Val
 100 105 110
 Ile Pro Leu Gly Phe Ser Asn Lys Ser Glu Leu Leu Gly Thr Leu Asn
 115 120 125
 Gln Phe Met Arg Thr Phe Cys Tyr Thr Cys Glu Phe Thr Tyr Leu Phe
 130 135 140
 Leu Cys Ser Arg Met Gly Cys Met Gln Arg Arg Met Asn Ser Thr Thr
 145 150 155 160
 Val Met Glu Arg Ser Asp Arg Arg Asn Ser Lys Met Pro Ile Cys Tyr
 165 170 175
 Leu Ser Gly Thr His Asn Ile Ser Asn Ala Glu Arg Asn Met Leu Gly
 180 185 190
 Ser Ser Gln Thr Ile Val Ile Lys Tyr Leu Leu Asn Ile His Ile Leu
 195 200 205
 Gly Ser Cys
 210

<210> 75
 <211> 120
 <212> PRT
 <213> Homo sapiens

<400> 75

Phe Ile Ile Asn Ile Ser Leu Tyr Ala Ile Ile Cys Phe Leu Ala Ile
 1 5 10 15
 Tyr Ala Asp Ser Phe Val Cys Phe Ser Phe Arg Ile Phe Leu Asn Arg
 20 25 30
 Phe Leu Val Phe His Arg Val Phe Val Cys Leu Lys Phe Cys Leu Phe
 35 40 45
 Ile Phe Leu Leu Ser Met Phe Ser His Asn Tyr Leu Thr Phe Ser Asn
 50 55 60
 Ile Ile Leu Thr Ile Leu Val Ser Leu Leu Phe Trp Ile Asn Phe Arg
 65 70 75 80
 Ile Phe Phe Phe Glu Ser Pro Lys Lys Ser Leu Trp Ile Leu Asp Asp
 85 90 95

Thr Ser Tyr Glu Thr Thr Tyr Gly Leu Phe Phe Ser Leu Ile Phe Ser
100 105 110

Leu Pro Tyr Arg Asn Val Phe Phe
115 120

<210> 76
<211> 239
<212> PRT
<213> Homo sapiens

<400> 76

Arg Leu Leu Leu Cys Gly Tyr Asn Glu Ser His Gln Leu Gln Ser Phe
1 5 10 15

Pro Lys Lys Asp Arg Lys Ile Cys Leu Ile Lys Met Val Phe Lys Ala
20 25 30

Asn Tyr Arg Tyr His Arg Lys Lys Lys Lys Asn Ser Gly Arg Asp Leu
35 40 45

Ser Ser Phe Ser Tyr Pro Met Gly Phe Ser Ala Ser Arg Phe Pro Cys
50 55 60

Thr Ser Arg Gly Phe Cys Ala Asn Gln Trp Ala Trp Pro Ser Ala His
65 70 75 80

Pro Gly Leu Ser Cys Gly Cys His Gly Tyr Glu Asp Lys Asn Asp Pro
85 90 95

Trp Phe Tyr Arg Ala Leu Gly Pro Leu Leu Thr Gly Leu Phe Ser Tyr
100 105 110

Phe Phe His Leu Leu Gln Asn Pro Met Trp Gln Val Gln Gln Gly Val
115 120 125

His Gln Cys Ser Gly Gln Ser Glu Gly Thr His Ala Arg Pro Gly Arg
130 135 140

Ala Ala Leu Lys Lys Trp Phe Val Arg Val Trp Arg Lys Gly Leu Leu
145 150 155 160

Pro His Ser Ala Leu Leu Gly Pro Lys Ala Leu Ile Thr Pro Gly Ser
165 170 175

Gly Ile Ile Leu Ser Leu Met Leu Leu Leu Ser Arg Asp Arg Thr Arg
180 185 190

Gly Ala Ser Thr Gln Gly Asn Pro Ala Pro Gln Gln Ala Gly Asp His
195 200 205

His Asp Cys Asn Arg Gln Gln Glu Ser Glu Leu Trp His Lys Asn Val
210 215 220

Thr Ala Thr Pro Gln Gly Gly Thr Pro Gly Gly Lys Gly His Gly
225 230 235

<210> 77
 <211> 228
 <212> DNA
 <213> Homo sapiens

<400> 77
 attatctcca ttatgctcta tcagtttctt tatagaatat gattactact tagtgataaa 60
 gcttcctttg ctaagatttc agcctacgaa ccatgatcca aaccctactt ctaaaacata 120
 taaacatgct ttacaagtat cctatatatg gaaaagtcct tggaattatt tgggtaatta 180
 acctggtatt acatgtgtta tttcctgata tactattgca aattgaca 228

<210> 78
 <211> 239
 <212> PRT
 <213> Homo sapiens

<400> 78
 Leu Ile Tyr Thr Lys Asn His Asn Leu Lys Lys Thr Phe Asn Tyr Leu
 1 5 10 15
 Tyr Cys Cys Ile Lys Cys Phe Ile Tyr Glu Ser Lys Asn Leu Phe Phe
 20 25 30
 Ala Phe Ile Leu Cys His Arg Lys Lys Thr Ser Cys Leu Cys Leu Leu
 35 40 45
 Pro Leu Ile Lys Ala Asn Asn Arg Gln Tyr Met Met Ile Leu Leu Thr
 50 55 60
 Arg Ala Asn Lys Ser Asn Ile Leu Thr Met Arg Phe Gly Leu Cys Tyr
 65 70 75 80
 Leu Tyr Leu Met Ser Asn Phe Pro Tyr Asn Val Asn Val Ile Pro Pro
 85 90 95
 Leu Tyr Pro Phe Val Arg Val Ser Val Phe Cys Ser Cys Met Thr Tyr
 100 105 110
 Phe Lys Gly Ser Gln Gly Gln Val Ile His Ile Leu Lys Ile Pro Phe
 115 120 125
 Arg Ile Ile Thr Ser Lys Asn Ser Gln Glu Arg Gln Phe Gln Tyr Lys
 130 135 140
 Ile Ile Asn Tyr Tyr Trp Asn Phe Lys His Ser Trp Gln Lys Arg Asp
 145 150 155 160
 Asn Leu Gln Asn Ile Leu Met Ala Thr Phe Leu Phe Tyr His Leu Leu
 165 170 175
 Cys Ser Ile Cys Tyr Asp Gln Arg Asn Tyr Ser Ile Ser Thr Thr Ile
 180 185 190
 His Lys Thr Gly Met Glu Glu Val Phe Phe Phe Leu Val Leu Met Ser

195 200 205
 Lys Lys Met Asn Leu Arg Ser Met Ser Phe Phe Asn Thr Met Phe Thr
 210 215 220
 Asp Ser Thr His Tyr Phe Met Asp Thr Lys Ser Gln Thr Tyr Ile
 225 230 235
 <210> 79
 <211> 203
 <212> PRT
 <213> Homo sapiens
 <400> 79
 Phe Ile Leu Thr Ile Ile Tyr Tyr Gln Arg Asn Leu Arg Lys Gln Lys
 1 5 10 15
 Phe Arg Ile Met Phe Leu Thr Cys Val Ser Phe Phe Thr Val Val Leu
 20 25 30
 Glu Leu Ser Tyr Pro Trp Gln Leu Ile Leu Leu Leu Tyr Ser Leu Phe
 35 40 45
 Ile Val Leu Thr Leu Lys Leu Arg Thr Ser Asn Val Asn Leu Asp Glu
 50 55 60
 Leu Lys Thr Glu Asn Val Cys Lys Tyr Val Lys Tyr Val Tyr Lys Asn
 65 70 75 80
 Met Tyr Phe Ser Tyr Phe Lys Ser Phe Ile Leu Tyr Ile Thr His Thr
 85 90 95
 His Thr His Thr His Thr Met Arg Ser Leu Leu Thr Thr Gln Tyr Lys
 100 105 110
 Ile Ile Phe Leu Arg Asn Ile Val Phe Lys Tyr Cys Phe Ile Pro Tyr
 115 120 125
 Lys Ser Asn Leu Trp Leu Phe Tyr Gly Phe His Gln Ala Met Ser Leu
 130 135 140
 Thr Asn Phe Ala Asn Lys Gly Thr Gln Gly Met Lys Tyr Leu Leu Thr
 145 150 155 160
 Asn Lys Lys Pro Ser Asn Ser Met Tyr Val Ile Gly Lys Ile Lys Ser
 165 170 175
 Ser Val Asn Ser Ile His Glu Leu Thr Ser Ile Ser Ala Leu Leu Ser
 180 185 190
 Leu Lys Ile Ser Asn Ser Leu Lys Ile Ile Arg
 195 200
 <210> 80
 <211> 156
 <212> PRT
 <213> Homo sapiens

<400> 80

Ser Lys Ser Leu Leu His Ser Ser Leu Leu Gly Val Leu Val Ile Cys
 1 5 10 15
 Thr Ser Ser Phe Pro Ser Ala Gly Lys Ala Ile Asn Gly Phe Gln Leu
 20 25 30
 Tyr Ala Ala Pro Leu Gly Cys Ser Phe Asp Leu Ser Gln Val Ser Trp
 35 40 45
 Ala Ile Glu Asn Asp Leu Ser Ser Cys Arg Gly Leu Gln Pro Ile Leu
 50 55 60
 Asn Ile Ala Gly Ile Asn Leu Phe Leu Leu Lys Glu Gly Ile Leu Leu
 65 70 75 80
 Tyr Arg Val Leu Leu Asn Thr Leu Leu Asp Phe Phe Asp Phe Val Phe
 85 90 95
 Leu Leu Ser Glu Tyr Leu Lys Tyr Pro Cys Arg Tyr Ser Asn Leu Phe
 100 105 110
 Pro Val Tyr Gly Phe Phe Leu Cys Leu Leu Trp Thr Gln Val Phe Val
 115 120 125
 Ala Cys Phe Ser Lys Ser Ala Gln Lys Leu Leu Val Ile Gly Phe Gly
 130 135 140
 Ser Leu Phe Lys Leu Tyr Pro Pro Glu Ser Tyr Arg
 145 150 155

<210> 81

<211> 208

<212> PRT

<213> Homo sapiens

<400> 81

Cys Glu Arg Arg Asp Glu Pro Asn Thr Ala Thr Thr Ala Arg Pro Trp
 1 5 10 15
 Gly Ser Val Val Gln Met Gly Arg Cys Thr Glu His Ala Gly His Val
 20 25 30
 Cys Gln Pro Ser Leu Cys Ala Leu Ala Thr Val Lys Arg Gly Leu Cys
 35 40 45
 Leu Gly Arg Leu Tyr His Trp Ser Cys Ile Pro Asn Val Ser Leu Phe
 50 55 60
 Thr Arg Leu Tyr Lys His Ala Gln Tyr Leu Cys Ile Phe Thr Val Thr
 65 70 75 80
 Ser Phe Ser Tyr Ile Ile Lys Val Pro Ile Tyr Ile Pro Tyr Met Tyr
 85 90 95
 Ile Tyr Asn Thr Gln Met His Thr His Lys His Thr Cys Thr Glu Leu
 100 105 110

Leu Asp Ser Gln Ser Leu Ile Leu Cys Ile Phe Thr Val Thr Ser Phe
 115 120 125
 Ser Tyr Ile Ile Lys Val Pro Ile Tyr Ile Pro Arg Ser Thr Glu Val
 130 135 140
 Gln Ser Ser Pro Ser Ser Asp Leu Met Ile Ile Leu Glu His Leu Ile
 145 150 155 160
 Phe Leu Tyr Phe Ile Met Tyr Leu Ile Ile Thr Leu Phe Ser Glu Cys
 165 170 175
 Gln Leu Ile Arg Arg Met Thr Cys Leu Leu Ser Cys Ser Ser Tyr Pro
 180 185 190
 Pro Ile Gly Phe Ile Ser Pro Leu Thr Arg Cys Gly Asp Trp Ala Gly
 195 200 205

<210> 82
 <211> 97
 <212> PRT
 <213> Homo sapiens

<400> 82

Arg Gln Arg Leu Cys Glu Thr Leu His Asp Arg Gly Leu Cys Ile Leu
 1 5 10 15
 Ala His Phe Leu Ala Leu Cys Glu Gln Tyr Leu Ser Ser His Tyr Ile
 20 25 30
 Lys Ser Ile Glu Pro Ile Gln Arg Ser Glu His Thr Val Met Ser Trp
 35 40 45
 Leu Leu Pro Ser Lys Ala Trp Gly Leu Val Leu Tyr Gly Ser Pro Ala
 50 55 60
 His Ile Leu Lys Phe Leu Cys Gly Thr Leu Phe Glu Leu Phe Tyr Phe
 65 70 75 80
 Glu Cys Ala Ile Phe Leu Leu Gly Leu Leu Lys Gly Arg Ala Leu Leu
 85 90 95

Ser

<210> 83
 <211> 201
 <212> PRT
 <213> Homo sapiens

<400> 83

Lys Trp Ile Asn Leu His Met Asp Glu His Asp Leu Leu Leu Ser Arg
 1 5 10 15
 Ser Gln Arg Ile His Lys Lys Lys Asn Leu Val Met Leu Leu Asp Asp
 20 25 30

Val Phe Asp Asn Thr Ile Gln Tyr Leu Ser Met Tyr Pro Tyr Asp Ile
 35 40 45
 Glu Lys Gly Phe Ser Lys Tyr Phe Asn Leu Asn Arg Phe Thr Lys Arg
 50 55 60
 Asn His Leu Pro Thr Thr Val Pro Cys Leu Trp Ser Ile Arg Val Ile
 65 70 75 80
 Ile Leu Phe Ser Leu Tyr Tyr Lys Arg Glu Cys Thr Leu Tyr Lys Ile
 85 90 95
 Asn Asn Ile Asp Tyr Ile Ser Arg Ile Asn Thr Lys Ala Gln Lys Tyr
 100 105 110
 Lys Ser Lys Pro Leu Asn Ser Leu Pro Pro Thr Ser Arg Lys Thr Gln
 115 120 125
 Phe Leu Tyr His Ser Tyr Tyr Lys Ser Phe Leu Ser Ser Phe Ser Tyr
 130 135 140
 Lys His Ala Glu Ile Tyr Met Trp Thr His Leu Cys Gln Asn Ser Phe
 145 150 155 160
 Phe Ser Asp Thr His Phe Phe Pro Pro Thr Pro Gln Tyr Val Arg Thr
 165 170 175
 Ile Phe Tyr Lys Ile Gln Met Glu His Arg Ile Glu Gln Asn Met Lys
 180 185 190
 Thr Ser Asn Ser Leu Val Asp Asp Val
 195 200

 <210> 84
 <211> 212
 <212> PRT
 <213> Homo sapiens

 <400> 84

 Ser Pro Leu Cys Ser Tyr Phe Ser Leu Cys Asn Ile Ala Cys Arg Glu
 1 5 10 15
 Met Val Asp Met Asn Ile Leu Ser Leu Asp His Ala Phe Gly His Tyr
 20 25 30
 Phe Gln His Cys Cys Lys Leu Phe Phe Lys Arg Pro Ile Tyr Phe Ile
 35 40 45
 Asp Met Tyr Ile Phe Phe Lys Lys Ser Lys Leu Thr Val Phe Leu Lys
 50 55 60
 Ala Gln Asn Pro Leu Val Trp Leu Thr Ser Leu Ile Phe Glu Lys Ala
 65 70 75 80
 Leu Cys Phe Ser Asn Leu Leu Val Phe Ala Asn Gln Ile Gly Val Lys
 85 90 95

Lys Ile Phe His Tyr Thr Phe Lys Gly Leu Leu Leu Thr Glu Leu Glu
 100 105 110
 His Leu Phe Met Phe Glu Ser Phe Val Phe His Phe Leu Ile Thr Val
 115 120 125
 Leu Ile Ile Cys Leu Phe His Thr Tyr Leu Gln Lys Phe Leu Lys Tyr
 130 135 140
 Ile Lys Glu Ser Asn Tyr Arg Ile Glu Lys Tyr Ile Gln Glu Asn Ser
 145 150 155 160
 Pro Leu Ser Val Thr Gln Val Ala Ser Ile Leu Val Asn Phe Val Phe
 165 170 175
 Ala Phe Tyr Leu Phe Ile Leu Ile Cys Tyr Phe His Lys Ile Phe Cys
 180 185 190
 Cys Phe Leu Phe Cys Arg Ile Tyr Phe Val Cys Gly Arg Gly Phe Leu
 195 200 205
 Glu Glu Pro Ser
 210

<210> 85
 <211> 192
 <212> PRT
 <213> Homo sapiens

<400> 85

Gln Lys Ser Leu Leu Cys Ser Lys Ser Leu His Gly Phe Leu Leu Tyr
 1 5 10 15
 Leu Glu Tyr Asn Pro Lys Ser Phe Pro Arg Ala Leu Ala Leu Tyr Trp
 20 25 30
 Pro Ser Leu Leu Leu Pro Thr Ser Tyr His Leu Ser Phe Gly His Tyr
 35 40 45
 Ser Pro Thr Thr Ser Thr His Pro Leu Ser Arg Arg Pro Trp Asn Ile
 50 55 60
 Leu Ser Thr Phe Pro Ser Gln Gly Val Val Asn Ala Val Ser Ser Thr
 65 70 75 80
 Cys Ser His Pro Pro Thr Leu Tyr Gln Leu Ser Ser His Ile His Met
 85 90 95
 Phe Asp Leu Lys Leu Cys Val Phe Thr Cys Leu Leu Phe Glu Ala Leu
 100 105 110
 Cys Ala Ile Val Glu Ser Glu Val Lys Gly Lys Ile Ser Asn Ile Asp
 115 120 125
 Ser Glu Phe Met Tyr Phe Asp Phe Phe Pro Arg Asn Phe Ala Leu Ile
 130 135 140
 Phe Ile Leu Lys Ile Leu Tyr Asn Phe Ile Tyr Leu Asp Tyr Val Phe

145 150 160
 Trp Cys Pro Leu Lys Ile Leu Thr Lys Gly Gln Val Pro Arg Ser Pro
 165 170 175
 His Pro Phe Ser Ser Thr Gly His Trp Ser Val Pro Pro Asn Cys Lys
 180 185 190

 <210> 86
 <211> 227
 <212> PRT
 <213> Homo sapiens

 <400> 86

 Glu Lys His Ala His Pro Gly Pro Arg Pro Pro Ala Arg Tyr Lys Asp
 1 5 10 15
 Gly Ser Gly Pro Ala Trp Glu Gln Phe Pro Trp Cys Gly Pro Pro Asn
 20 25 30
 Leu Gly Gly Lys Leu Lys Ser Arg Thr Ile Ser Ile His Glu Glu Asn
 35 40 45
 Glu Glu Ala Glu Tyr Leu Phe Asn Glu Ser Ala Val Gly Lys Gly Ile
 50 55 60
 Tyr Leu Tyr Tyr Tyr Leu Val Glu Lys Asn Leu Leu Trp Pro Asn Val
 65 70 75 80
 Lys Ser Ile Phe Phe Asp Lys Leu Lys Arg Leu Arg Lys Ile Gly Pro
 85 90 95
 Ile Leu Thr Glu Asn Gly Val Thr Arg Gly Val Ile Ser Glu Asn Leu
 100 105 110
 Ala Pro Ala Pro Phe Cys Tyr Gly Glu Lys Tyr Gln Tyr Tyr Leu Leu
 115 120 125
 Arg Arg Leu Gly Leu Asn Trp Lys Arg Gly Trp Leu Leu Cys Ala Asp
 130 135 140
 Gly Asp Lys Ile Arg Ile Leu Pro Ser Leu Gln Ser Gln Met Gln His
 145 150 155 160
 Thr Gln Arg Cys Tyr Leu Gly Ala Gly Lys Gln Gly Asp Ile Lys Met
 165 170 175
 Tyr Val Val Ile Thr Asn Gly Arg Ser Lys Phe His Ser Asp Tyr Phe
 180 185 190
 Lys Pro Asn Ala Gly Leu Leu Tyr Ser Phe Glu Ile Phe Phe Ser Val
 195 200 205
 Asn Cys Asn Arg Gly Lys Asn Gln Pro His Ile Asn Phe Ser Gln Gly
 210 215 220
 Lys Pro Ser
 225

<210> 87
 <211> 125
 <212> PRT
 <213> Homo sapiens

<400> 87

Glu	Gly	Tyr	Thr	Phe	Asp	Lys	Arg	Leu	Ile	Cys	Phe	Thr	Val	Trp	Val
1				5					10					15	
Glu	Asn	Val	Lys	Ser	Ile	Asn	Asn	Phe	Thr	Ser	Phe	Phe	His	Leu	Arg
		20						25					30		
Ser	Tyr	Tyr	Ser	Leu	Tyr	Tyr	Ala	Tyr	Pro	Pro	Arg	Ile	Tyr	Leu	His
		35					40					45			
Ser	Ala	Ser	Ser	Cys	Gln	Met	Ser	Ala	Val	Lys	Val	Pro	Pro	Gly	Asn
	50					55					60				
Phe	Arg	Glu	Thr	Arg	Lys	Thr	Ser	Ser	Ile	Asn	Val	Tyr	Phe	Asn	Leu
65					70					75					80
Phe	Ser	Ile	Leu	Phe	Leu	Lys	Lys	Tyr	Gln	Ser	Leu	Lys	Arg	Trp	Phe
			85						90					95	
Thr	Phe	Gly	Leu	Phe	His	Cys	Leu	Pro	Met	Lys	Ala	Leu	Leu	Val	Leu
			100					105						110	
Phe	Tyr	Asn	Leu	Met	Asp	Phe	Ser	Pro	Arg	Phe	Tyr	Thr			
		115					120					125			

<210> 88
 <211> 174
 <212> PRT
 <213> Homo sapiens

<400> 88

Met	Leu	Trp	Leu	Phe	Val	Pro	Arg	Val	Arg	Gln	Lys	Arg	Gln	Trp	Leu
1				5					10					15	
Pro	Ser	Leu	Gly	Val	Thr	Gly	Thr	Leu	Glu	Gly	Asp	Ser	Phe	Pro	Gly
			20					25					30		
Glu	Glu	Gly	Thr	Val	Gly	Phe	Pro	Ala	Leu	Leu	Leu	Ser	Pro	Tyr	Gly
		35					40					45			
Leu	Arg	Ser	Gly	Leu	Asn	Cys	Asp	Glu	Ser	Leu	Cys	Pro	Cys	Ser	Leu
	50					55					60				
Gly	Phe	Leu	Lys	Tyr	Pro	Pro	Phe	Ile	Val	Pro	Ile	Ile	Ile	Asn	Thr
65					70					75					80
Asn	Gln	Ser	Leu	Leu	Cys	Leu	Lys	Leu	Leu	Ile	Ala	Tyr	Arg	Gly	Lys
			85						90					95	
Cys	Arg	Leu	Leu	Ser	Trp	Arg	Thr	Ser	Leu	Leu	His	Leu	Ala	His	Ile
		100						105					110		

Glu Leu Ser Arg Ala Ile Ser Cys His Ser Leu Ala Cys Leu Leu Leu
 115 120 125
 Leu Trp Phe Ser Arg Thr Ala His Glu Phe Pro His Met Pro Phe Trp
 130 135 140
 Phe Gly His Leu Thr Phe Ser Ala Ala Val Pro Ser Ala Trp Thr Ala
 145 150 155 160
 Phe Pro Pro Arg Ser Leu Gly Glu Leu Leu Phe Ile Leu Gln
 165 170

<210> 89
 <211> 182
 <212> PRT
 <213> Homo sapiens

<400> 89

Tyr Lys Val Val Val Leu Asp Asp Leu Tyr Thr Trp Lys Leu Val Tyr
 1 5 10 15
 Phe Phe Asn Lys Ala Ser Asp Ser Lys Val Leu Trp Ala Ile Cys Leu
 20 25 30
 Cys Cys Asn Tyr Ser Ala Leu Pro Leu Cys Lys Ser Ser His Arg Tyr
 35 40 45
 Val Asn Glu Thr Trp Leu Phe Ser Gln Lys Gln Ala Ala Val Arg Ile
 50 55 60
 Trp Leu Ala Asp Ser Leu Gly Phe Ser Leu Leu Lys Ala Trp Ser Arg
 65 70 75 80
 Arg Pro Ala Ala Ser Ala Leu Pro Val Asn Leu Leu Glu Ile Gln Asn
 85 90 95
 Val Glu Pro Leu Leu Ile Leu Ile Ala Leu Glu Ser Lys Pro Cys Phe
 100 105 110
 Ser Asn Phe Ser Ile His Arg Thr His Leu Gly Ile Leu Lys Tyr Arg
 115 120 125
 Leu Asp Ser Arg Ala Glu His His Thr Ser Leu Gly Glu Ala Met Leu
 130 135 140
 Pro Gly Gln Cys Ser Leu Gly Ser Pro Gln Ser Ile Arg Arg Asp Cys
 145 150 155 160
 Tyr Ile Asn Lys Phe Gln Tyr Arg Leu Val Asn Ala Ile Thr Glu Val
 165 170 175
 Ser Ser Ala Glu Glu His
 180

<210> 90
 <211> 188
 <212> PRT

<213> Homo sapiens

<400> 90

Arg Val Tyr Leu Leu Trp Lys Leu Thr Leu Ala Ser Phe Gln Asn Thr
 1 5 10 15
 Phe Phe Ser Gln Lys His Leu Arg Val Ser Gln Phe Ser Cys Lys Thr
 20 25 30
 Gln Leu Pro Leu Leu Gly Asn Cys Leu Gln Asp Tyr Leu Phe Tyr Gly
 35 40 45
 Lys Lys Thr Asn Asn Leu Tyr Phe Thr Thr Lys Phe Leu Ser Leu His
 50 55 60
 Glu Ser Tyr Ser Leu Glu Ile Gln Leu Phe Pro Lys Leu Lys Ile Glu
 65 70 75 80
 Met Ser Ser Pro Phe Ser Gly Glu Pro Phe Pro Val Leu Glu Asp Lys
 85 90 95
 Ser Phe Gln Gln Arg Cys Glu Gln Met Asn Tyr Leu Leu Trp Thr Asp
 100 105 110
 Phe Thr Asp Gly Leu Asn Cys Phe Ser Lys Pro Cys Gln Leu Phe Cys
 115 120 125
 Asn Phe Trp Ser Ser Ile Phe Leu Thr Met Cys Cys Ala Val Leu Ile
 130 135 140
 Tyr Leu Ala Lys Val Val Leu Ala Asn Val Met Gln Ala Glu Thr Trp
 145 150 155 160
 Lys Lys Lys Ser Val His Phe Ser Leu Phe Tyr Tyr Cys Val Thr Trp
 165 170 175
 Pro Ala Leu Ser Trp Met Ile Ala Ile Asn Met Lys
 180 185

<210> 91

<211> 333

<212> PRT

<213> Homo sapiens

<400> 91

Met Trp Ser Cys Ser Trp Phe Asn Gly Thr Gly Leu Val Glu Glu Leu
 1 5 10 15
 Pro Ala Cys Gln Asp Leu Gln Leu Gly Leu Ser Leu Leu Ser Leu Leu
 20 25 30
 Gly Leu Val Val Gly Val Pro Val Gly Leu Cys Tyr Asn Ala Leu Leu
 35 40 45
 Val Leu Ala Asn Leu His Ser Lys Ala Ser Met Thr Met Pro Asp Val
 50 55 60

Tyr Phe Val Asn Met Ala Val Ala Gly Leu Val Leu Ser Ala Leu Ala
 65 70 75 80
 Pro Val His Leu Leu Gly Pro Pro Ser Ser Arg Trp Ala Leu Trp Ser
 85 90 95
 Val Gly Gly Glu Val His Val Ala Leu Gln Ile Pro Phe Asn Val Ser
 100 105 110
 Ser Leu Val Ala Met Tyr Ser Thr Ala Leu Leu Ser Leu Asp His Tyr
 115 120 125
 Ile Glu Arg Ala Leu Pro Arg Thr Tyr Met Ala Ser Val Tyr Asn Thr
 130 135 140
 Arg His Val Cys Gly Phe Val Trp Gly Gly Ala Leu Leu Thr Ser Phe
 145 150 155 160
 Ser Ser Leu Leu Phe Tyr Ile Cys Ser His Val Ser Thr Arg Ala Leu
 165 170 175
 Glu Cys Ala Lys Met Gln Asn Ala Glu Ala Ala Asp Ala Thr Leu Val
 180 185 190
 Phe Ile Gly Tyr Val Val Pro Ala Leu Ala Thr Leu Tyr Ala Leu Val
 195 200 205
 Leu Leu Ser Arg Val Arg Arg Glu Asp Thr Pro Leu Asp Arg Asp Thr
 210 215 220
 Gly Arg Leu Glu Pro Ser Ala His Arg Leu Leu Val Ala Thr Val Cys
 225 230 235 240
 Thr Gln Phe Gly Leu Trp Thr Pro His Tyr Leu Ile Leu Leu Gly His
 245 250 255
 Thr Gly Ile Ile Ser Arg Gly Lys Pro Val Asp Ala His Tyr Leu Gly
 260 265 270
 Leu Leu His Phe Val Lys Asp Phe Ser Lys Leu Leu Ala Phe Ser Ser
 275 280 285
 Ser Phe Val Thr Pro Leu Leu Tyr Arg Tyr Met Asn Gln Ser Phe Pro
 290 295 300
 Ser Lys Leu Gln Arg Leu Met Lys Lys Leu Pro Cys Gly Asp Arg His
 305 310 315 320
 Cys Ser Pro Asp His Met Gly Val Gln Gln Val Leu Ala
 325 330

<210> 92
 <211> 97
 <212> PRT
 <213> Homo sapiens

<400> 92

Thr Arg Leu Trp Gly Thr Lys Leu Asn Ala Gly Leu Gly Gln Arg Leu

1 5 10 15
 Met Pro Cys Gly His Asp Val Met Leu Ser Ile Leu Leu Pro Ser Arg
 20 25 30
 Gly Ser Arg Ser Gly Ser Arg Arg Gly Ala Leu Leu Leu Glu Gly Ala
 35 40 45
 Ser Arg Asp Met Glu Lys Val Asp Met Asn Thr Ser Gln Glu Gln Gly
 50 55 60
 Leu Cys Gln Phe Ser Glu Lys Tyr Lys Gln Val Tyr Leu Ser Leu Ala
 65 70 75 80
 Tyr Ser Ile Ile Phe Ile Leu Gly Leu Pro Leu Asn Gly Thr Val Leu
 85 90 95
 Trp

<210> 93
 <211> 140
 <212> PRT
 <213> Homo sapiens

<400> 93

Ser Ala Arg Ala His Lys Val Pro Glu Ala His Arg Phe Ser Gly Leu
 1 5 10 15
 Gly Ile Ala Tyr Ser Asn Ser Trp Ala Pro Asn Ser Lys Ser Pro Thr
 20 25 30
 Thr Leu Ser His Leu Trp Leu Gln Ser Cys Phe Gly Phe Pro Gln Ile
 35 40 45
 Thr Lys Ala Ser Arg Lys Arg Leu Thr Val Ser Leu Ala Tyr Ser Glu
 50 55 60
 Ser His Gln Ile Arg Val Ser Gln Gln Asp Phe Arg Leu Phe Arg Thr
 65 70 75 80
 Leu Phe Leu Leu Met Val Ser Phe Phe Ile Met Trp Ser Pro Ile Ile
 85 90 95
 Ile Thr Ile Leu Leu Ile Leu Ile Gln Asn Phe Lys Gln Asp Leu Val
 100 105 110
 Ile Trp Pro Ser Leu Phe Phe Trp Val Val Gly Phe Thr Phe Ala Asn
 115 120 125
 Ser Ala Leu Asn Pro Ile Leu Tyr Asn Met Thr Leu
 130 135 140

<210> 94
 <211> 177
 <212> PRT
 <213> Homo sapiens

<400> 94

Asp Ser Val Ser Tyr Glu Tyr Gly Asp Tyr Ser Asp Leu Ser Asp Arg
 1 5 10 15
 Pro Val Asp Cys Leu Asp Gly Ala Cys Leu Ala Ile Asp Pro Leu Arg
 20 25 30
 Val Ala Pro Leu Pro Leu Tyr Ala Ala Ile Phe Leu Val Gly Val Pro
 35 40 45
 Gly Asn Ala Met Val Ala Trp Val Ala Gly Lys Val Ala Arg Arg Arg
 50 55 60
 Val Gly Ala Thr Trp Leu Leu His Leu Ala Val Ala Asp Leu Leu Cys
 65 70 75 80
 Cys Leu Ser Leu Pro Ile Leu Ala Val Pro Ile Ala Arg Gly Gly His
 85 90 95
 Pro Tyr Gly Ala Val Gly Cys Arg Ala Leu Pro Ser Ile Ile Leu Leu
 100 105 110
 Thr Met Tyr Ala Ser Val Leu Leu Leu Ala Ala Leu Ser Ala Asp Leu
 115 120 125
 Cys Phe Leu Ala Leu Gly Pro Ala Trp Trp Tyr Thr Val Gln Arg Ala
 130 135 140
 Cys Gly Val Gln Val Ala Cys Gly Ala Ala Trp Thr Leu Ala Leu Leu
 145 150 155 160
 Leu Thr Val Pro Ser Ala Ile Tyr Arg Arg Leu His Gln Glu His Phe
 165 170 175

Pro

<210> 95
 <211> 177
 <212> PRT
 <213> Homo sapiens

<400> 95

Ala Pro Leu Ala Phe Arg Gln Gly Ala Leu Gln Ala Asp Gly Val Cys
 1 5 10 15
 Ala Leu His Arg His Leu Arg Gly Val Tyr Leu Met Ala Cys Val Ser
 20 25 30
 Val Asp His Tyr Pro Ala Val Val Cys Ala His Trp Gly Pro Cys Leu
 35 40 45
 Arg Thr Ala Gly Arg Ala Arg Leu Val Cys Val Ala Ile Trp Thr Leu
 50 55 60
 Val Leu Leu Gln Thr Met Pro Leu Leu Leu Met Pro Met Thr Lys Pro
 65 70 75 80

Leu Val Gly Lys Leu Ala Cys Met Glu Tyr Ser Ser Met Glu Ser Val
 85 90 95
 Leu Gly Ala Ala Pro His Gly Pro Gly Gly Leu Cys His Trp Leu Leu
 100 105 110
 Trp Ala Ser Gly Asp His Pro Val Leu Leu Tyr Glu Asp His Leu Glu
 115 120 125
 Ala Val Gln His Ser Trp Glu Asn Pro Val Thr Ser Gly Lys Gly His
 130 135 140
 His Arg Arg Gly Ser Pro Gly Gly Pro Ser Asp Gln Gln Glu Arg Thr
 145 150 155 160
 Pro Pro Ala Gly Gln Pro Arg Arg Thr Gln Pro Ala Gly Lys Asp Thr
 165 170 175

Thr

<210> 96
 <211> 358
 <212> PRT
 <213> Homo sapiens

<400> 96

Met Ser Val Cys Tyr Arg Pro Pro Gly Asn Glu Thr Leu Leu Ser Trp
 1 5 10 15
 Lys Thr Ser Arg Ala Thr Gly Thr Ala Phe Leu Leu Leu Ala Ala Leu
 20 25 30
 Leu Gly Leu Pro Gly Asn Gly Phe Val Val Trp Ser Leu Ala Gly Trp
 35 40 45
 Arg Pro Ala Arg Gly Arg Pro Leu Ala Ala Thr Leu Val Leu His Leu
 50 55 60
 Ala Leu Ala Asp Gly Ala Val Leu Leu Leu Thr Pro Leu Phe Val Ala
 65 70 75 80
 Phe Leu Thr Arg Gln Ala Trp Pro Leu Gly Gln Ala Gly Cys Lys Ala
 85 90 95
 Val Tyr Tyr Val Cys Ala Leu Ser Met Tyr Ala Ser Val Leu Leu Thr
 100 105 110
 Gly Leu Leu Ser Leu Gln Arg Cys Leu Ala Val Thr Arg Pro Phe Leu
 115 120 125
 Ala Pro Arg Leu Arg Ser Pro Ala Leu Ala Arg Arg Leu Leu Leu Ala
 130 135 140
 Val Trp Leu Ala Ala Leu Leu Leu Ala Val Pro Ala Ala Val Tyr Arg
 145 150 155 160

His Leu Trp Arg Asp Arg Val Cys Gln Leu Cys His Pro Ser Pro Val
 165 170 175
 His Ala Ala Ala His Leu Ser Leu Glu Thr Leu Thr Ala Phe Val Leu
 180 185 190
 Pro Phe Gly Leu Met Leu Gly Cys Tyr Ser Val Thr Leu Ala Arg Leu
 195 200 205
 Arg Gly Ala Arg Trp Gly Ser Gly Arg His Gly Ala Arg Val Gly Arg
 210 215 220
 Leu Val Ser Ala Ile Val Leu Ala Phe Gly Leu Leu Trp Ala Pro Tyr
 225 230 235 240
 His Ala Val Asn Leu Leu Gln Ala Val Ala Ala Leu Ala Pro Pro Glu
 245 250 255
 Gly Ala Leu Ala Lys Leu Gly Gly Ala Gly Gln Ala Ala Arg Ala Gly
 260 265 270
 Thr Thr Ala Leu Ala Phe Phe Ser Ser Ser Val Asn Pro Val Leu Tyr
 275 280 285
 Val Phe Thr Ala Gly Asp Leu Leu Pro Arg Ala Gly Pro Arg Phe Leu
 290 295 300
 Thr Arg Leu Phe Glu Gly Ser Gly Glu Ala Arg Gly Gly Gly Arg Ser
 305 310 315 320
 Arg Glu Gly Thr Met Glu Leu Arg Thr Thr Pro Gln Leu Lys Val Val
 325 330 335
 Gly Gln Gly Arg Gly Asn Gly Asp Pro Gly Gly Gly Met Glu Lys Asp
 340 345 350
 Gly Pro Glu Trp Asp Leu
 355

<210> 97
 <211> 211
 <212> PRT
 <213> Homo sapiens

<400> 97

Met Pro Leu Pro Val Pro Pro Ala Gly Ala Gln Lys Thr Pro Glu Asp
 1 5 10 15
 His Val Cys Leu His Leu Ala Gly Pro Ser Pro Ala Pro Ser Glu Pro
 20 25 30
 Ala Arg Met Phe Gly Leu Phe Gly Leu Trp Arg Thr Phe Asp Ser Val
 35 40 45
 Val Phe Tyr Leu Thr Leu Ile Val Gly Leu Gly Gly Pro Val Gly Asn
 50 55 60
 Gly Leu Val Leu Trp Asn Leu Gly Phe Arg Ile Lys Lys Gly Pro Phe
 68

[illegible]

```
<210> 98
<211> 187
<212> PRT
<213> Homo sapiens
```

<400> 98

Val 1	Tyr	Arg	Asn 5	Pro	Phe	Ala	Ile	Tyr	Leu 10	Leu	Val	Arg	Gly	Leu 15	Gln
Gln	Asp	Leu 20	Ile	Phe	Leu	Gly	Cys 25	His	Met	Val	Ala	Ile 30	Val	Pro	Asp
Leu	Leu 35	Gln	Gly	Arg	Leu	Asp	Phe 40	Pro	Gly	Phe	Val	Gln 45	Thr	Ser	Leu
Ala 50	Thr	Leu	Arg	Phe	Phe	Cys 55	Tyr	Ile	Val	Gly	Leu 60	Ser	Leu	Leu	Ala
Ala 65	Val	Ser	Val	Glu 70	Gln	Cys	Leu	Ala	Ala 75	Leu	Phe	Pro	Ala	Trp	Tyr 80
Ser	Cys	Arg	Arg 85	Pro	Arg	His	Leu	Thr 90	Thr	Cys	Val	Cys	Ala 95	Leu	Thr
Trp	Ala	Leu 100	Cys	Leu	Leu	Leu	His	Leu 105	Leu	Leu	Ser	Ser	Ala 110	Cys	Thr
Gln	Phe 115	Phe	Gly	Glu	Pro	Ser	Arg 120	His	Leu	Cys	Arg	Thr 125	Leu	Trp	Leu

Val Ala Ala Val Leu Leu Ala Leu Leu Cys Cys Thr Met Cys Gly Ala
 130 135 140
 Ser Leu Met Leu Leu Leu Arg Val Glu Arg Gly Pro Gln Arg Pro Pro
 145 150 155 160
 Pro Arg Gly Phe Pro Gly Leu Ile Leu Pro His Arg Pro Pro Leu Pro
 165 170 175
 Leu Leu Arg Pro Ala Leu Arg His Leu Leu Ala
 180 185
 <210> 99
 <211> 216
 <212> PRT
 <213> Homo sapiens
 <400> 99
 Gly Ser Arg Asn Thr Leu Pro His Asn Phe Tyr Gly Cys Leu Tyr Pro
 1 5 10 15
 Val Tyr Leu Asn Val Ser Ser Ala Ala Ala Ile Pro Val Tyr Gln Asn
 20 25 30
 Arg Glu Val Met Lys Leu Thr Lys Met Val Leu Val Leu Val Val Val
 35 40 45
 Phe Ile Leu Ser Ala Ala Pro Tyr His Val Ile Gln Leu Val Asn Leu
 50 55 60
 Gln Met Glu Gln Pro Thr Leu Ala Phe Tyr Val Gly Tyr Tyr Leu Ser
 65 70 75 80
 Ile Cys Leu Ser Tyr Ala Ser Ser Ser Ile Asn Pro Phe Leu Tyr Ile
 85 90 95
 Leu Leu Ser Gly Asn Phe Gln Lys Arg Leu Pro Gln Ile Gln Arg Arg
 100 105 110
 Ala Thr Glu Lys Glu Ile Asn Asn Met Gly Asn Thr Leu Lys Ser His
 115 120 125
 Phe Glu Ser Thr Trp Ile Thr Met Ser Leu Asp Met Ile Val Tyr Leu
 130 135 140
 Thr Gly Ile Ile Arg Lys Gly Arg Cys Thr Asp Met Phe Met Pro Ile
 145 150 155 160
 Leu Leu Val Tyr Leu Leu Leu Ala Ala Trp Lys Arg Ser Val Thr Met
 165 170 175
 Gln Ile Gln Ala Tyr Ala Asn Phe Ser Lys Met Asn Val Asp Leu Tyr
 180 185 190
 Cys Gly Gly Met Gly Ser Glu Ile Pro Arg Leu His Asp Gly Val Tyr
 195 200 205

Tyr Phe Ser Ile Leu Thr Ser His
210 215

<210> 100
<211> 181
<212> PRT
<213> Homo sapiens

<400> 100

Gln Phe Ser Ile Ala Ser Leu Ala Cys Ala Asp Phe Leu Val Gly Val
1 5 10 15

Thr Val Met Leu Phe Ser Met Val Arg Thr Val Glu Ser Cys Trp Tyr
20 25 30

Phe Gly Ala Lys Phe Cys Thr Leu His Ser Cys Cys Asp Val Ala Phe
35 40 45

Cys Tyr Ser Ser Val Leu His Leu Cys Phe Ile Cys Ile Asp Arg Tyr
50 55 60

Ile Val Val Thr Asp Pro Leu Val Tyr Ala Thr Lys Phe Thr Val Ser
65 70 75 80

Val Ser Gly Ile Cys Ile Ser Val Ser Trp Ile Leu Pro Leu Thr Tyr
85 90 95

Ser Gly Ala Val Phe Tyr Thr Gly Val Asn Asp Asp Gly Leu Glu Glu
100 105 110

Leu Val Ser Ala Leu Asn Cys Val Gly Gly Cys Gln Ile Ile Val Ser
115 120 125

Gln Gly Trp Val Leu Ile Asp Phe Leu Leu Phe Phe Ile Pro Thr Leu
130 135 140

Val Met Ile Ile Leu Tyr Ser Lys Ile Phe Leu Ile Ala Lys Gln Gln
145 150 155 160

Ala Ile Lys Ile Glu Thr Thr Ser Ser Lys Val Glu Ser Ser Ser Glu
165 170 175

Ser Tyr Lys Ile Arg
180

<210> 101
<211> 188
<212> PRT
<213> Homo sapiens

<400> 101

Tyr Ser Phe Leu Thr Leu Asn Ile His Ala Pro Ala Val Cys Lys Ala
1 5 10 15

Leu Gly Thr His Thr Lys Asp Glu Asn Gln Gly Val Arg Gln His Val
20 25 30

Asp Ser Ser Cys Leu Val Glu Arg Leu Gln Ser Glu Ser Pro Tyr Ser
 35 40 45
 His Ser Val Thr Tyr Arg Gly Glu Arg Lys Trp Gly Glu His Arg Glu
 50 55 60
 Gly Ile Ser Ile Gly Ser Gly Leu Pro Pro Phe Phe Ser Pro Pro His
 65 70 75 80
 Gly Gly Lys Tyr Val Leu Ser Leu Pro Gly Trp Val Met Phe Thr Ala
 85 90 95
 Pro Phe Ser Ile Pro Ile Gly Thr Ser Arg Leu Ser Pro Lys Leu Asp
 100 105 110
 Leu Gln Ile Thr Ile Leu Arg Lys Leu Asp Val Leu Gln Gln Val Thr
 115 120 125
 Gln Glu Leu Ser Leu Ser His Leu Phe Val His Pro Ile Ile Tyr Ser
 130 135 140
 Phe Ile His Ser Thr Ser Ile Ser Gln Ala Pro Ile Pro Ser Ser Thr
 145 150 155 160
 Lys Asp Ser Ile Thr Gly Gln Met Lys Asp Val Thr Ile His Leu Glu
 165 170 175
 Lys Phe Ser Leu Ser Trp Ser Glu Cys Thr Gln Arg
 180 185

<210> 102
 <211> 204
 <212> PRT
 <213> Homo sapiens

<400> 102

Asn Asp Lys Asp Met Arg Met Ser Leu Pro Tyr Ser Leu Asp Ile Cys
 1 5 10 15
 Pro Leu Gln Ile Leu Cys Asn Val Ile Pro Asn Val Val Ser Glu Thr
 20 25 30
 Trp Trp Lys Val Val Tyr Tyr Glu Gly Gly Ser Leu Met Asn Asp Leu
 35 40 45
 Ala Pro Ser Ala Trp Met Ser Ser Ser His Glu Ile Val His Thr Arg
 50 55 60
 Ser Gly Cys Leu Lys Val Asp Leu Leu Ser Leu Ser Leu Ser Leu Ala
 65 70 75 80
 Pro Phe His Thr Met Tyr Ser Ser Phe Pro Phe Pro Phe Cys His Tyr
 85 90 95
 Lys Leu Ser Glu Ala Pro Thr Arg Ser Gln Ala Asp Val Val His Ser
 100 105 110
 Leu Asn His Glu Ser Asn Lys Leu Leu Phe Phe Lys Leu Pro Ser Phe

115	120	125
Arg Tyr Phe Phe Ile Pro Met Gln Lys Trp Pro Ser Thr Tyr Pro Asp		
130	135	140
Leu Ile Ser Ile Gln His Ile Tyr Lys Leu Met Tyr Gln Ile Ile Leu		
145	150	155
His Lys Tyr Ile Lys Leu Gln Cys Val Asn Leu Lys Arg Ile Thr Tyr		
	165	170
Leu Ile Tyr Lys Phe Phe Ile Pro Phe Asn Ser Ile Ser Val Phe Phe		
	180	185
Thr Ile Phe Asp Tyr Phe Leu Ile Phe Leu Ile Pro		
195	200	

<210> 103
 <211> 215
 <212> PRT
 <213> Homo sapiens

<400> 103

Met Arg Ala Phe Trp Lys Lys Thr Val Asn Ser Thr Val Gly Pro Leu	
1	5
Lys Lys Ser Ile His Arg Leu Asn Pro Leu Val Asp Asn Lys Thr Leu	
	20
Asn Ile Tyr His Ala Phe Val Ile Ile Gln Ile Val Asp Ile Phe Thr	
	35
Arg Ala Thr Asp Glu Leu Gln Pro Ser Phe Tyr Gln Leu His Arg Ile	
	50
Leu Leu Asn Gly Tyr Ile Leu Leu Met Ser Val Leu Ser Ser Glu Tyr	
65	70
Val Val Ser Asn Phe Ser Ile Leu Glu Thr Met Leu Lys Glu Leu Ala	
	85
Leu Ile Cys Val Ser Tyr Val Tyr Thr Ser Ile Gln Tyr Leu Ser Arg	
	100
Ser Gly Asn Ser Trp Leu Lys Gln Thr Ala Phe Gln Glu Asp Leu Leu	
	115
Ile Tyr Ile Pro Thr Asn Ala Val Leu Glu Cys Leu Phe Leu His Ile	
	130
Pro Met Asn Thr Glu Cys Ser Leu Phe Asn Thr Phe Phe Pro Gln Ser	
145	150
Thr Arg Leu Leu Leu Lys Tyr Ile Leu Phe Lys Thr Pro Ala Tyr Pro	
	165
Ser Ile Tyr Cys Leu Leu Lys Asp Tyr Leu Val Leu Phe Met Cys Val	
	180

Gly Gly Lys Leu Ile Val Ile Leu Gln Lys Leu Gln Leu Leu Leu His
 195 200 205

Gln Pro Asn Ile Ile His Val
 210 215

<210> 104
 <211> 194
 <212> PRT
 <213> Homo sapiens

<400> 104

Leu Phe Trp Phe Pro Phe Phe Leu Ile Thr Tyr Leu Phe Ser Phe Ala
 1 5 10 15

Gly Pro Ser His Leu Pro Gly Leu Phe Phe Val Cys Ile Tyr Leu Cys
 20 25 30

Gly Leu Pro Ser Leu Thr His Leu Pro Ile Ser Tyr Ser Gln Met Tyr
 35 40 45

Ile Ser Ile Pro Gly Pro Phe Leu Thr Pro Asp Leu Tyr Phe Gln Leu
 50 55 60

Pro Thr Gln Tyr Leu Leu Gly Tyr Leu Leu Lys Phe Glu Ser Arg His
 65 70 75 80

Ala Asn Thr Ser Tyr Leu Ser Lys Ala Leu Ser Phe Tyr Cys Phe Ser
 85 90 95

His Pro Asn Lys Leu Pro Leu Ile Leu Pro Asp Ala Trp Ala Thr Phe
 100 105 110

Leu Gln Ser Ser Leu Ile Ser Phe Phe Leu Tyr Pro Thr Tyr Ile His
 115 120 125

Gln His Met Leu Pro Cys Leu His Phe Lys His Asn Gln His Pro Thr
 130 135 140

Phe Leu Gln Leu Leu Leu Ala Leu Tyr Ser Pro Ile Leu Ser Pro Leu
 145 150 155 160

Asp Tyr Cys Ile Ser Leu Thr Gly Ile Pro Leu Gln Pro Phe Pro Thr
 165 170 175

Ser Ser Ser Gln Ser Gln Leu Cys Glu Gln Gln Leu Lys Leu Phe Phe
 180 185 190

Gln Lys

<210> 105
 <211> 186
 <212> PRT
 <213> Homo sapiens

<400> 105

Asn Pro Gly Lys Ala Ser His Leu Gly Leu Cys Thr Ser Gly Leu Phe
 1 5 10 15
 Asp Ala Leu Gly Asn Val Glu Gly His Pro Val Ser Arg Trp Gly Leu
 20 25 30
 Glu Gln Ser Leu Asp Cys Phe Ser Gln Trp Leu Leu Thr Ser Gly Cys
 35 40 45
 Cys Ile Pro Ser Thr Phe Trp Leu Val Leu Arg Thr Thr Asn Lys Lys
 50 55 60
 Val Gly Arg Thr Val Leu His His Leu Cys Lys Leu Leu Gly Lys Gln
 65 70 75 80
 Thr Asn Val Leu Gln Lys Glu Asp Glu Leu Leu Lys His Lys Gly Gly
 85 90 95
 Met Leu His Arg Glu Gly Leu Glu Ser Trp Ile Thr Lys Arg Asp Lys
 100 105 110
 Asp Thr Phe Gly Arg Asp Gly Tyr Val Tyr Tyr Leu Ala Tyr Gly Asp
 115 120 125
 Ser Phe Ile Gly Pro Ile Pro Lys Ala Ser His Cys Thr Leu Thr Met
 130 135 140
 Tyr Asp Leu Phe Ile Leu Ile Ile Pro Gln Ser Cys Phe Leu Lys Lys
 145 150 155 160
 Leu Pro Leu Asn Pro Val Asn Arg Pro Gly Arg Gln Leu Ile Asn Ile
 165 170 175
 Phe Phe Thr Phe Glu Lys Leu Lys Leu Ser
 180 185

<210> 106
 <211> 184
 <212> PRT
 <213> Homo sapiens

<400> 106

Leu Gly Phe Cys His Leu Leu Val Glu Trp Arg Ala Cys His Ser Val
 1 5 10 15
 Cys Leu Ser Leu Phe Pro Tyr Leu Ser Gly Asp Asn Asn Asn Met Tyr
 20 25 30
 Ile Ile Glu Leu Leu Ser Ser Ser Cys Lys Ser Ile Leu Thr Lys Phe
 35 40 45
 Leu Glu Asn Ala Tyr Ser Lys His Ser Ile Thr Tyr Ala Ile Cys Ile
 50 55 60
 Ser Ile Asn Arg Tyr Ile Leu Val Val Tyr Pro Glu Thr Phe Leu Val
 65 70 75 80

Cys Ser Leu Leu Pro Phe Phe Phe Pro Glu Lys Thr His Arg Phe Cys
 85 90 95
 Leu Met His Gly Lys Glu Lys Tyr His Gln Val Leu Gly Ser Ser Lys
 100 105 110
 Lys Ile Lys Lys Pro Lys Thr Cys Thr Leu Glu Arg Gly Lys Leu Ile
 115 120 125
 Pro Met Glu Lys Lys Lys Lys Arg Asn Leu Asn Asn Cys Ser Ser Glu
 130 135 140
 Gly His Val Gly Leu Gln Arg Gly Phe His Met Pro Phe Leu Ser Arg
 145 150 155 160
 Gly Asn His Cys Pro Asp Gln Phe Ser Lys Glu Gly Lys Val Lys Phe
 165 170 175
 His Arg Glu Gly Trp Ser Ile Asn
 180

<210> 107
 <211> 170
 <212> PRT
 <213> Homo sapiens

<400> 107

Val Ala Gly Cys Thr Asn Phe Thr His Lys Gln Leu Glu Val His Phe
 1 5 10 15
 Pro Ser Leu Thr Thr Lys Leu His Leu Ile Thr Phe Glu Ile Phe Ala
 20 25 30
 Ile Leu Leu Gly Leu Thr Cys Leu Ser Leu Phe Tyr Ile Cys Ile Ser
 35 40 45
 Lys Leu Leu Ser Leu Asn Asn Phe His Met Gly His Leu Tyr Leu Gln
 50 55 60
 Asn Lys His Tyr Pro Phe Asn Asp Phe Ala Trp Leu Leu Pro Ser Leu
 65 70 75 80
 Val Phe Ile Ala Ser Leu Lys His Val Asn Ser Phe Ile Cys Ser Phe
 85 90 95
 Val Ser Leu Leu Lys His Phe Ser Asn Ser Thr Thr Ser Phe Tyr Ser
 100 105 110
 Phe Gln Phe Asn Ala His Ile Gly His Cys Ala Tyr Leu Ser Lys Leu
 115 120 125
 Cys Thr Lys Gln Val Asn Leu Pro Cys Pro Trp Ile Glu Gln Asn Leu
 130 135 140
 Lys Lys Ala Pro Gly Glu Asn His Gly Tyr Trp Gln Arg Asp Met Asp
 145 150 155 160
 Ser Asn Pro Gly Phe Ser Thr Tyr Ser Leu

165

170

<210> 108
 <211> 239
 <212> PRT
 <213> Homo sapiens

<400> 108

Thr	Arg	Asn	Thr	Leu	Gly	Cys	Pro	Ser	Ala	Pro	Gly	Phe	Phe	Cys	Trp
1				5					10					15	
Ser	Cys	Leu	Ala	Met	Cys	Leu	Gly	Leu	Lys	Val	Ser	Arg	Leu	Pro	Gly
			20					25					30		
Ser	Pro	Gly	Ser	Ser	Arg	Lys	Arg	Asn	Glu	His	Met	Met	Val	Thr	Trp
		35					40					45			
Asn	Ser	Pro	Arg	Trp	Arg	His	Cys	Ile	Phe	Ala	Lys	Pro	Val	Thr	Val
	50					55					60				
Leu	Ser	Ala	Phe	Trp	Ala	Pro	Arg	Leu	Ser	Pro	Leu	Ile	Phe	Pro	Asp
65					70					75					80
Leu	Ser	Phe	Pro	Ala	Ala	Phe	Leu	Phe	Phe	Leu	Ile	Thr	Val	Lys	Phe
				85					90					95	
Cys	Met	Tyr	Cys	Ser	Ile	Phe	His	Leu	Leu	Gly	Ile	Glu	Tyr	Ile	Ser
			100					105					110		
Ser	Met	Pro	Gly	Phe	Lys	Ile	Arg	Ile	Val	Asn	Ile	Val	Val	Cys	Ala
		115					120					125			
Leu	Val	Thr	Glu	Phe	Leu	Arg	Phe	Gly	Cys	Ser	Ile	Pro	Ala	Pro	Tyr
	130					135					140				
Phe	Leu	Lys	Ala	Leu	Leu	Ser	Ala	Val	Gly	Asp	Phe	Ala	Gln	Cys	Lys
145					150					155					160
Leu	Leu	Arg	Tyr	Phe	Leu	Leu	Ser	Ser	Arg	Ser	Pro	Tyr	Pro	Thr	Ser
				165					170					175	
Thr	Gln	His	Leu	Ile	Leu	Arg	Cys	Ser	Pro	Gln	Thr	Cys	Glu	Asn	Gln
			180				185						190		
His	Val	Asn	Met	Ser	Ile	Pro	Leu	Ala	Gly	Phe	Pro	Asn	Ser	Thr	Asp
		195					200					205			
Gly	Ile	Arg	Pro	Ile	Val	Gln	Ala	Lys	Ser	Lys	Ala	Pro	Ala	Gly	Thr
	210					215					220				
Phe	Pro	Ile	Pro	Asn	Leu	Ser	Ser	Cys	Pro	Ile	Lys	Phe	Tyr	Gln	
225					230					235					

<210> 109
 <211> 202
 <212> PRT
 <213> Homo sapiens

<400> 109

Lys Phe Tyr Leu His Thr Lys Gln Gly Arg Ile Thr Ser Tyr Cys Leu
 1 5 10 15
 Ala His Arg Lys Glu Ala Phe Cys Ser Asp Ile Ile Tyr Thr Leu Arg
 20 25 30
 Asn Lys Gly Val Ala Lys Ser Phe Ser Ser Cys Lys His Ser Thr Ile
 35 40 45
 Leu Gly Leu Thr Ile Tyr Ser Thr Leu Lys Ala Ala Phe Leu Glu Cys
 50 55 60
 Ile Ile Ser Val Leu Phe Leu Leu Ile Phe Phe Tyr Leu Ser Trp Phe
 65 70 75 80
 Pro Pro Ser Thr Val Leu Thr Ser Val Tyr Lys Asn Leu Tyr Ser Ser
 85 90 95
 Pro His Ile Pro Tyr Leu Ile Cys Val Thr Ile Lys Ala Ile Cys Leu
 100 105 110
 Asp Thr Leu Gln Lys Cys Ile Gln Leu Ile Ser Asp Phe Ile Ser Val
 115 120 125
 Arg Ala Asn Asn Gln Phe Ile Gln Leu Phe Phe Pro Ser Glu Ser Thr
 130 135 140
 Glu Tyr Pro Leu Asn Glu Val Phe Ser Val Glu Phe Ser Leu Lys Leu
 145 150 155 160
 Ser Arg Asn Glu His Ser Pro Lys Cys Phe Val Gly Ala Ser Cys Ala
 165 170 175
 Arg Val Gly Val Arg Phe Cys His Leu Pro Val Ile Ser Ser Leu Asn
 180 185 190
 Ile Leu Ser Leu Met Arg Ser Pro Leu Lys
 195 200

<210> 110

<211> 192

<212> PRT

<213> Homo sapiens

<400> 110

Tyr Gly Ser Ala Val Ser Pro Ser Lys Ser Asn Leu Glu Leu Gln Leu
 1 5 10 15
 Pro Phe Pro Cys Val Val Glu Gly Ala Trp Trp Glu Ile Thr Glu Ser
 20 25 30
 Trp Gly Arg Leu Pro Pro Tyr Cys Ser Leu Gly Ser Glu Val Ser Asp
 35 40 45
 Leu Ile Val Leu Gly Glu Thr Pro Phe Ala Trp Phe Leu Phe Ser Leu
 50 55 60

Cys Trp Leu Pro Cys Lys Met Leu Leu Cys Ser Ser Phe Val Phe Cys
 65 70 75 80
 His Asp Cys Gly Ala Ser Pro Ala Met Trp Lys Cys Glu Glu Ile Lys
 85 90 95
 Pro Leu Ser Phe Ile Asn Cys Pro Val Leu Gly Met Ser Leu Ser Ala
 100 105 110
 Val Asn Gly Leu Ile His Gln Lys Phe Lys Thr Ser Leu Gly Asn Thr
 115 120 125
 Val Arg Pro Cys Leu Tyr Lys Glu Arg Ile Arg Lys Arg Lys Ile Ser
 130 135 140
 Val Ala Tyr Thr Glu Tyr Tyr Lys Thr Asp Gly Thr Leu Ile Pro Glu
 145 150 155 160
 Leu Phe Leu Tyr His Phe Glu Arg Pro Asp Asn Gln Tyr Asn Phe Leu
 165 170 175
 Ser Arg Val Ala Gln Thr Cys Lys His Ala Leu Pro Tyr Leu Asp Asn
 180 185 190
 <210> 111
 <211> 311
 <212> PRT
 <213> Homo sapiens

<400> 111

Met Met Glu Pro Arg Glu Ala Gly Gln His Val Gly Ala Ala Asn Gly
 1 5 10 15
 Ala Gln Glu Asp Val Ala Phe Asn Leu Ile Ile Leu Ser Leu Thr Glu
 20 25 30
 Gly Leu Gly Leu Gly Gly Leu Leu Gly Asn Gly Ala Val Leu Trp Leu
 35 40 45
 Leu Ser Ser Asn Val Tyr Arg Asn Pro Phe Ala Ile Tyr Leu Leu Asp
 50 55 60
 Val Ala Cys Ala Asp Leu Ile Phe Leu Gly Cys His Met Val Ala Ile
 65 70 75 80
 Val Pro Asp Leu Leu Gln Gly Arg Leu Asp Phe Pro Gly Phe Val Gln
 85 90 95
 Thr Ser Leu Ala Thr Leu Arg Phe Cys Tyr Ile Val Gly Leu Ser Leu
 100 105 110
 Leu Ala Ala Val Ser Val Glu Gln Cys Leu Ala Ala Leu Phe Pro Ala
 115 120 125
 Trp Tyr Ser Cys Arg Arg Pro Arg His Leu Thr Thr Cys Val Cys Ala
 130 135 140

Leu Thr Trp Ala Leu Cys Leu Leu Leu His Leu Leu Leu Ser Gly Ala
 145 150 155 160
 Cys Thr Gln Phe Phe Gly Glu Pro Ser Arg His Leu Cys Arg Thr Leu
 165 170 175
 Trp Leu Val Ala Ala Val Leu Leu Ala Leu Leu Cys Cys Thr Met Cys
 180 185 190
 Gly Ala Ser Leu Met Leu Leu Leu Arg Val Glu Arg Gly Pro Gln Arg
 195 200 205
 Pro Pro Pro Arg Gly Phe Pro Gly Leu Ile Leu Leu Thr Val Leu Leu
 210 215 220
 Phe Leu Phe Cys Gly Leu Pro Phe Gly Ile Tyr Trp Leu Ser Arg Asn
 225 230 235 240
 Leu Leu Trp Tyr Ile Pro His Tyr Phe Tyr His Phe Ser Phe Leu Met
 245 250 255
 Ala Ala Val His Cys Ala Ala Lys Pro Val Val Tyr Phe Cys Leu Gly
 260 265 270
 Ser Ala Gln Gly Arg Arg Leu Pro Leu Arg Leu Val Leu Gln Arg Ala
 275 280 285
 Leu Gly Asp Glu Ala Glu Leu Gly Ala Val Arg Glu Thr Ser Arg Arg
 290 295 300
 Gly Leu Val Asp Ile Ala Ala
 305 310

<210> 112
 <211> 508
 <212> PRT
 <213> Homo sapiens

<400> 112

Met Thr Ser Thr Cys Thr Asn Ser Thr Arg Glu Ser Asn Ser Ser His
 1 5 10 15
 Thr Cys Met Pro Leu Ser Lys Met Pro Ile Ser Leu Ala His Gly Ile
 20 25 30
 Ile Arg Ser Thr Val Leu Val Ile Phe Leu Ala Ala Ser Phe Val Gly
 35 40 45
 Asn Ile Val Leu Ala Leu Val Leu Gln Arg Lys Pro Gln Leu Leu Gln
 50 55 60
 Val Thr Asn Arg Phe Ile Phe Asn Leu Leu Val Thr Asp Leu Leu Gln
 65 70 75 80
 Ile Ser Leu Val Ala Pro Trp Val Val Ala Thr Ser Val Pro Leu Phe
 85 90 95
 Trp Pro Leu Asn Ser His Phe Cys Thr Ala Leu Val Ser Leu Thr His

100					105					110						
Leu	Phe	Ala	Phe	Ala	Ser	Val	Asn	Thr	Ile	Val	Val	Val	Ser	Val	Asp	
115					120					125						
Arg	Tyr	Leu	Ser	Ile	Ile	His	Pro	Leu	Ser	Tyr	Pro	Ser	Lys	Met	Thr	
130					135					140						
Gln	Arg	Arg	Gly	Tyr	Leu	Leu	Leu	Tyr	Gly	Thr	Trp	Ile	Val	Ala	Ile	
145					150					155					160	
Leu	Gln	Ser	Thr	Pro	Pro	Leu	Tyr	Gly	Trp	Gly	Gln	Ala	Ala	Phe	Asp	
165					170					175						
Glu	Arg	Asn	Ala	Leu	Cys	Ser	Met	Ile	Trp	Gly	Ala	Ser	Pro	Ser	Tyr	
180					185					190						
Thr	Ile	Leu	Ser	Val	Val	Ser	Phe	Ile	Val	Ile	Pro	Leu	Ile	Val	Met	
195					200					205						
Ile	Ala	Cys	Tyr	Ser	Val	Val	Phe	Cys	Ala	Ala	Arg	Arg	Gln	His	Ala	
210					215					220						
Leu	Leu	Tyr	Asn	Val	Lys	Arg	His	Ser	Leu	Glu	Val	Arg	Val	Lys	Asp	
225					230					235					240	
Cys	Val	Glu	Asn	Glu	Asp	Glu	Glu	Gly	Ala	Glu	Lys	Lys	Glu	Glu	Phe	
245					250					255						
Gln	Asp	Glu	Ser	Glu	Phe	Arg	Arg	Gln	His	Glu	Gly	Glu	Val	Lys	Ala	
260					265					270						
Lys	Glu	Gly	Arg	Met	Glu	Ala	Lys	Asp	Gly	Ser	Leu	Lys	Ala	Lys	Glu	
275					280					285						
Gly	Ser	Thr	Gly	Thr	Ser	Glu	Ser	Ser	Val	Glu	Ala	Arg	Gly	Ser	Glu	
290					295					300						
Glu	Val	Arg	Glu	Ser	Ser	Thr	Val	Ala	Ser	Asp	Gly	Ser	Met	Glu	Gly	
305					310					315					320	
Lys	Glu	Gly	Ser	Thr	Lys	Val	Glu	Glu	Asn	Ser	Met	Lys	Ala	Asp	Lys	
325					330					335						
Gly	Arg	Thr	Glu	Val	Asn	Gln	Cys	Ser	Ile	Asp	Leu	Gly	Glu	Asp	Asp	
340					345					350						
Met	Glu	Phe	Gly	Glu	Asp	Asp	Ile	Asn	Phe	Ser	Glu	Asp	Asp	Val	Glu	
355					360					365						
Ala	Val	Asn	Ile	Pro	Glu	Ser	Leu	Pro	Pro	Ser	Arg	Arg	Asn	Ser	Asn	
370					375					380						
Ser	Asn	Pro	Pro	Leu	Pro	Arg	Cys	Tyr	Gln	Cys	Lys	Ala	Ala	Lys	Val	
385					390					395					400	
Ile	Phe	Ile	Ile	Ile	Phe	Ser	Tyr	Val	Leu	Ser	Leu	Gly	Pro	Tyr	Cys	
405					410					415						

Phe Leu Ala Val Leu Ala Val Trp Val Asp Val Glu Thr Gln Val Pro
 420 425 430
 Gln Trp Val Ile Thr Ile Ile Ile Trp Leu Phe Phe Leu Gln Cys Cys
 435 440 445
 Ile His Pro Tyr Val Tyr Gly Tyr Met His Lys Thr Ile Lys Lys Glu
 450 455 460
 Ile Gln Asp Met Leu Lys Lys Phe Phe Cys Lys Glu Lys Pro Pro Lys
 465 470 475 480
 Glu Asp Ser His Pro Asp Leu Pro Gly Thr Glu Gly Gly Thr Glu Gly
 485 490 495
 Lys Ile Val Pro Ser Tyr Asp Ser Ala Thr Phe Pro
 500 505

<210> 113
 <211> 311
 <212> PRT
 <213> Homo sapiens

<400> 113

Met Met Glu Pro Arg Glu Ala Gly Gln His Val Gly Ala Ala Asn Ser
 1 5 10 15
 Ala Gln Glu Asp Val Ala Phe Asn Leu Ile Ile Leu Ser Leu Thr Glu
 20 25 30
 Gly Leu Gly Leu Gly Gly Leu Leu Gly Asn Gly Ala Val Leu Trp Leu
 35 40 45
 Leu Ser Ser Asn Val Tyr Arg Asn Pro Phe Ala Ile Tyr Leu Leu Asp
 50 55 60
 Val Ala Cys Ala Asp Leu Ile Phe Leu Gly Cys His Met Val Ala Ile
 65 70 75 80
 Val Pro Asp Leu Leu Gln Gly Arg Leu Asp Phe Pro Gly Phe Val Gln
 85 90 95
 Thr Ser Leu Ala Thr Leu Arg Phe Cys Tyr Ile Val Gly Leu Ser Leu
 100 105 110
 Leu Ala Ala Val Ser Val Glu Gln Cys Leu Ala Ala Leu Phe Pro Ala
 115 120 125
 Trp Tyr Ser Cys Arg Arg Pro Arg His Leu Thr Thr Cys Val Cys Ala
 130 135 140
 Leu Thr Trp Ala Leu Cys Leu Leu Leu His Leu Leu Leu Ser Gly Ala
 145 150 155 160
 Cys Thr Gln Phe Phe Gly Glu Pro Ser Arg His Leu Cys Arg Thr Leu
 165 170 175
 Trp Leu Val Ala Ala Val Leu Leu Ala Leu Leu Cys Cys Thr Met Cys

[illegible]

```
<210> 114
<211> 333
<212> PRT
<213> Homo sapiens
```

<400> 114

Met 1	Trp	Ser	Cys 5	Ser	Trp	Phe	Asn	Gly	Thr 10	Gly	Leu	Val	Glu	Glu 15	Leu
Pro	Ala	Cys	Gln 20	Asp	Leu	Gln	Leu	Gly 25	Leu	Ser	Leu	Leu	Ser 30	Leu	Leu
Gly	Leu	Val 35	Val	Gly	Val	Pro	Val 40	Gly	Leu	Cys	Tyr	Asn 45	Ala	Leu	Leu
Val 50	Leu	Ala	Asn	Leu	His	Ser 55	Lys	Ala	Ser	Met	Thr 60	Met	Pro	Asp	Val
Tyr 65	Phe	Val	Asn	Met	Ala 70	Val	Ala	Gly	Leu	Val 75	Leu	Ser	Ala	Leu	Ala 80
Pro	Val	His	Leu 85	Leu	Gly	Pro	Pro	Ser	Ser 90	Arg	Trp	Ala	Leu	Trp 95	Ser
Val	Gly	Gly	Glu 100	Val	His	Val	Ala	Leu 105	Gln	Ile	Pro	Phe	Asn 110	Val	Ser
Ser	Leu	Val 115	Ala	Met	Tyr	Ser	Thr 120	Ala	Leu	Leu	Ser	Leu 125	Asp	His	Tyr
Ile 130	Glu	Arg	Ala	Leu	Pro	Arg 135	Thr	Tyr	Met	Ala	Ser 140	Val	Tyr	Asn	Thr

Arg His Val Cys Gly Phe Val Trp Gly Gly Ala Leu Leu Thr Ser Phe
 145 150 155 160
 Ser Ser Leu Leu Phe Tyr Ile Cys Ser His Val Ser Thr Arg Ala Leu
 165 170 175
 Glu Cys Ala Lys Met Gln Asn Ala Glu Ala Ala Asp Ala Thr Leu Val
 180 185 190
 Phe Ile Gly Tyr Val Val Pro Ala Leu Ala Thr Leu Tyr Ala Leu Val
 195 200 205
 Leu Leu Ser Arg Val Arg Arg Glu Asp Thr Pro Leu Asp Arg Asp Thr
 210 215 220
 Gly Arg Leu Glu Pro Ser Ala His Arg Leu Leu Val Ala Thr Val Cys
 225 230 235 240
 Thr Gln Phe Gly Leu Trp Thr Pro His Tyr Leu Ile Leu Leu Gly His
 245 250 255
 Thr Val Ile Ile Ser Arg Gly Lys Pro Val Asp Ala His Tyr Leu Gly
 260 265 270
 Leu Leu His Phe Val Lys Asp Phe Ser Lys Leu Leu Ala Phe Ser Ser
 275 280 285
 Ser Phe Val Thr Pro Leu Leu Tyr Arg Tyr Met Asn Gln Ser Phe Pro
 290 295 300
 Ser Lys Leu Gln Arg Leu Met Lys Lys Leu Pro Cys Gly Asp Arg His
 305 310 315 320
 Cys Ser Pro Asp His Met Gly Val Gln Gln Val Leu Ala
 325 330

<210> 115
 <211> 337
 <212> PRT
 <213> Homo sapiens

<400> 115

Met Gly Asn Asp Ser Val Ser Tyr Glu Tyr Gly Asp Tyr Ser Asp Leu
 1 5 10 15
 Ser Asp Arg Pro Val Asp Cys Leu Asp Gly Ala Cys Leu Ala Ile Asp
 20 25 30
 Pro Leu Arg Val Ala Pro Leu Pro Leu Tyr Ala Ala Ile Phe Leu Val
 35 40 45
 Gly Val Pro Gly Asn Ala Met Val Ala Trp Val Ala Gly Lys Val Ala
 50 55 60
 Arg Arg Arg Val Gly Ala Thr Trp Leu Leu His Leu Ala Val Ala Asp
 65 70 75 80

Val

<400> 116

Met Ala Pro Ser His Arg Ala Ser Gln Val Gly Phe Cys Pro Thr Pro
85

1	5	10	15
Glu Arg Pro	Leu Trp Arg	Leu Pro Pro Thr Cys Arg	Pro Arg Arg Met
	20	25	30
Ser Val Cys	Tyr Arg Pro Pro	Gly Asn Glu Thr	Leu Leu Ser Trp Lys
	35	40	45
Thr Ser Arg	Ala Thr Gly Thr	Ala Phe Leu Leu	Leu Ala Ala Leu Leu
	50	55	60
Gly Leu Pro	Gly Asn Gly Phe	Val Val Trp Ser	Leu Ala Gly Trp Arg
	65	70	75
Pro Ala Arg	Gly Arg Pro Leu	Ala Ala Thr Leu	Val Leu His Leu Ala
	85	90	95
Leu Ala Asp	Gly Ala Val Leu	Leu Leu Thr Pro	Leu Phe Val Ala Phe
	100	105	110
Leu Thr Arg	Gln Ala Trp Pro	Leu Gly Gln Ala	Gly Cys Lys Ala Val
	115	120	125
Tyr Tyr Val	Cys Ala Leu Ser	Met Tyr Ala Ser	Val Leu Leu Thr Gly
	130	135	140
Leu Leu Ser	Leu Gln Arg Cys	Leu Ala Val Thr	Arg Pro Phe Leu Ala
	145	150	155
Pro Arg Leu	Arg Ser Pro Ala	Leu Ala Arg Arg	Leu Leu Leu Ala Val
	165	170	175
Trp Leu Ala	Ala Leu Leu Leu	Ala Val Pro Ala	Ala Val Tyr Arg His
	180	185	190
Leu Trp Arg	Asp Arg Val Cys	Gln Leu Cys His	Pro Ser Pro Val His
	195	200	205
Ala Ala Ala	His Leu Ser Leu	Glu Thr Leu Thr	Ala Phe Val Leu Pro
	210	215	220
Phe Gly Leu	Met Leu Gly Cys	Tyr Ser Val Thr	Leu Ala Arg Leu Arg
	225	230	235
Gly Ala Arg	Trp Gly Ser Gly	Arg His Gly Ala	Arg Val Gly Arg Leu
	245	250	255
Val Ser Ala	Ile Val Leu Ala	Phe Gly Leu Leu	Trp Ala Pro Tyr His
	260	265	270
Ala Val Asn	Leu Leu Gln Ala	Val Ala Ala Leu	Ala Pro Pro Glu Gly
	275	280	285
Ala Leu Ala	Lys Leu Gly Gly	Ala Gly Gln Ala	Ala Arg Ala Gly Thr
	290	295	300
Thr Ala Leu	Ala Phe Phe Ser	Ser Ser Val Asn	Pro Val Leu Tyr Val
	305	310	315
			320

Phe Thr Ala Gly Asp Leu Leu Pro Arg Ala Gly Pro Arg Phe Leu Thr
 325 330 335
 Arg Leu Phe Glu Gly Ser Gly Glu Ala Arg Gly Gly Gly Arg Ser Arg
 340 345 350
 Glu Gly Thr Met Glu Leu Arg Thr Thr Pro Gln Leu Lys Val Val Gly
 355 360 365
 Gln Gly Arg Gly Asn Gly Asp Pro Gly Gly Gly Met Glu Lys Asp Gly
 370 375 380
 Pro Glu Trp Asp Leu
 385

<210> 117
 <211> 340
 <212> PRT
 <213> Homo sapiens

<400> 117

Met Asn Pro Phe His Ala Ser Cys Trp Asn Thr Ser Ala Glu Leu Leu
 1 5 10 15
 Asn Lys Ser Trp Asn Lys Glu Phe Ala Tyr Gln Thr Ala Ser Val Val
 20 25 30
 Asp Thr Val Ile Leu Pro Ser Met Ile Gly Ile Ile Cys Ser Thr Gly
 35 40 45
 Leu Val Gly Asn Ile Leu Ile Val Phe Thr Ile Ile Arg Ser Arg Lys
 50 55 60
 Lys Thr Val Pro Asp Ile Tyr Ile Cys Asn Leu Ala Val Ala Asp Leu
 65 70 75 80
 Val His Ile Val Gly Met Pro Phe Leu Ile His Gln Trp Ala Arg Gly
 85 90 95
 Gly Glu Trp Val Phe Gly Gly Pro Leu Cys Thr Ile Ile Thr Ser Leu
 100 105 110
 Asp Thr Cys Asn Gln Phe Ala Cys Ser Ala Ile Met Thr Val Met Ser
 115 120 125
 Val Asp Arg Tyr Phe Ala Leu Val Gln Pro Phe Arg Leu Thr Arg Trp
 130 135 140
 Arg Thr Arg Tyr Lys Thr Ile Arg Ile Asn Leu Gly Leu Trp Ala Ala
 145 150 155 160
 Ser Phe Ile Leu Ala Leu Pro Val Trp Val Tyr Ser Lys Val Ile Lys
 165 170 175
 Phe Lys Asp Gly Val Glu Ser Cys Ala Phe Asp Leu Thr Ser Pro Asp
 180 185 190
 Asp Val Leu Trp Tyr Thr Leu Tyr Leu Thr Ile Thr Thr Phe Phe Phe

195 200 205
 Pro Leu Pro Leu Ile Leu Val Cys Tyr Ile Leu Ile Leu Cys Tyr Thr
 210 215 220
 Trp Glu Met Tyr Gln Gln Asn Lys Asp Ala Arg Cys Cys Asn Pro Ser
 225 230 235 240
 Val Pro Lys Gln Arg Val Met Lys Leu Thr Lys Met Val Leu Val Leu
 245 250 255
 Val Val Val Phe Ile Leu Ser Ala Ala Pro Tyr His Val Ile Gln Leu
 260 265 270
 Val Asn Leu Gln Met Glu Gln Pro Thr Leu Ala Phe Tyr Val Gly Tyr
 275 280 285
 Tyr Leu Ser Ile Cys Leu Ser Tyr Ala Ser Ser Ser Ile Asn Pro Phe
 290 295 300
 Leu Tyr Ile Leu Leu Ser Gly Asn Phe Gln Lys Arg Leu Pro Gln Ile
 305 310 315 320
 Gln Arg Arg Ala Thr Glu Lys Glu Ile Asn Asn Met Gly Asn Thr Leu
 325 330 335
 Lys Ser His Phe
 340

<210> 118
 <211> 342
 <212> PRT
 <213> Homo sapiens

<400> 118

Met Thr Ser Asn Phe Ser Gln Pro Val Val Gln Leu Cys Tyr Glu Asp
 1 5 10 15
 Val Asn Gly Ser Cys Ile Glu Thr Pro Tyr Ser Pro Gly Ser Arg Val
 20 25 30
 Ile Leu Tyr Thr Ala Phe Ser Phe Gly Ser Leu Leu Ala Val Phe Gly
 35 40 45
 Asn Leu Leu Val Met Thr Ser Val Leu His Phe Lys Gln Leu His Ser
 50 55 60
 Pro Thr Asn Phe Leu Ile Ala Ser Leu Ala Cys Ala Asp Phe Leu Val
 65 70 75 80
 Gly Val Thr Val Met Leu Phe Ser Met Val Arg Thr Val Glu Ser Cys
 85 90 95
 Trp Tyr Phe Gly Ala Lys Phe Cys Thr Leu His Ser Cys Cys Asp Val
 100 105 110
 Ala Phe Cys Tyr Ser Ser Val Leu His Leu Cys Phe Ile Cys Ile Asp
 115 120 125

Arg Tyr Ile Val Val Thr Asp Pro Leu Val Tyr Ala Thr Lys Phe Thr
 130 135 140
 Val Ser Val Ser Gly Ile Cys Ile Ser Val Ser Trp Ile Leu Pro Leu
 145 150 155 160
 Thr Tyr Ser Gly Ala Val Phe Tyr Thr Gly Val Asn Asp Asp Gly Leu
 165 170 175
 Glu Glu Leu Val Ser Ala Leu Asn Cys Val Gly Gly Cys Gln Ile Ile
 180 185 190
 Val Ser Gln Gly Trp Val Leu Ile Asp Phe Leu Leu Phe Phe Ile Pro
 195 200 205
 Thr Leu Val Met Ile Ile Leu Tyr Ser Lys Ile Phe Leu Ile Ala Lys
 210 215 220
 Gln Gln Ala Ile Lys Ile Glu Thr Thr Ser Ser Lys Val Glu Ser Ser
 225 230 235 240
 Ser Glu Ser Tyr Lys Ile Arg Val Ala Lys Arg Glu Arg Lys Ala Ala
 245 250 255
 Lys Thr Leu Gly Val Thr Val Leu Ala Phe Val Ile Ser Trp Leu Pro
 260 265 270
 Tyr Thr Val Asp Ile Leu Ile Asp Ala Phe Met Gly Phe Leu Thr Pro
 275 280 285
 Ala Tyr Ile Tyr Glu Ile Cys Cys Trp Ser Ala Tyr Tyr Asn Ser Ala
 290 295 300
 Met Asn Pro Leu Ile Tyr Ala Leu Phe Tyr Pro Trp Phe Arg Lys Ala
 305 310 315 320
 Ile Lys Leu Ile Leu Ser Gly Asp Val Leu Lys Ala Ser Ser Ser Thr
 325 330 335
 Ile Ser Leu Phe Leu Glu
 340

<210> 119
 <211> 323
 <212> PRT
 <213> Homo sapiens

<400> 119

Met Pro Leu Pro Val Pro Pro Ala Gly Ala Gln Lys Thr Pro Glu Asp
 1 5 10 15
 His Val Cys Leu His Leu Ala Gly Pro Ser Pro Ala Pro Ser Glu Pro
 20 25 30
 Ala Arg Met Phe Gly Leu Phe Gly Leu Trp Arg Thr Phe Asp Ser Val
 35 40 45

Val Phe Tyr Leu Thr Leu Ile Val Gly Leu Gly Gly Pro Val Gly Asn
 50 55 60
 Gly Leu Val Leu Trp Asn Leu Gly Phe Arg Ile Lys Lys Gly Pro Phe
 65 70 75 80
 Ser Ile Tyr Leu Leu His Leu Ala Ala Ala Asp Phe Leu Phe Leu Ser
 85 90 95
 Cys Arg Val Gly Phe Ser Val Ala Gln Ala Ala Leu Gly Ala Gln Asp
 100 105 110
 Thr Leu Tyr Phe Val Leu Thr Phe Leu Trp Phe Ala Val Gly Leu Trp
 115 120 125
 Leu Leu Ala Ala Phe Ser Val Glu Arg Cys Leu Ser Asp Leu Phe Pro
 130 135 140
 Ala Cys Tyr Gln Gly Cys Arg Pro Arg His Ala Ser Ala Val Leu Cys
 145 150 155 160
 Ala Leu Val Trp Thr Pro Thr Leu Pro Ala Val Pro Leu Pro Ala Asn
 165 170 175
 Ala Cys Gly Leu Leu Arg Asn Ser Ala Cys Pro Leu Val Cys Pro Arg
 180 185 190
 Tyr His Val Ala Ser Val Thr Trp Phe Leu Val Leu Ala Arg Val Ala
 195 200 205
 Trp Thr Ala Gly Val Val Leu Phe Val Trp Val Thr Cys Cys Ser Thr
 210 215 220
 Arg Pro Arg Pro Arg Leu Tyr Gly Ile Val Leu Gly Ala Leu Leu Leu
 225 230 235 240
 Leu Phe Phe Cys Gly Leu Pro Ser Val Phe Tyr Trp Ser Leu Gln Pro
 245 250 255
 Leu Leu Asn Phe Leu Leu Pro Val Phe Ser Pro Leu Ala Thr Leu Leu
 260 265 270
 Ala Cys Val Asn Ser Ser Ser Lys Pro Leu Ile Tyr Ser Gly Leu Gly
 275 280 285
 Arg Gln Pro Gly Lys Arg Glu Pro Leu Arg Ser Val Leu Arg Arg Ala
 290 295 300
 Leu Gly Glu Gly Ala Glu Leu Gly Ala Arg Gly Gln Ser Leu Pro Met
 305 310 315 320
 Gly Leu Leu

<210> 120
 <211> 336
 <212> PRT
 <213> Homo sapiens

<400> 120

```

Met Asn Asn Asn Thr Thr Cys Ile Gln Pro Ser Met Ile Ser Ser Met
1      5      10      15

Ala Leu Pro Ile Ile Tyr Ile Leu Leu Cys Ile Val Gly Val Phe Gly
20      25      30

Asn Thr Leu Ser Gln Trp Ile Phe Leu Thr Lys Ile Gly Lys Lys Thr
35      40      45

Ser Thr His Ile Tyr Leu Ser His Leu Val Thr Ala Asn Leu Leu Val
50      55      60

Cys Ser Ala Met Pro Phe Met Ser Ile Tyr Phe Leu Lys Gly Phe Gln
65      70      75      80

Trp Glu Tyr Gln Ser Ala Gln Cys Arg Val Val Asn Phe Leu Gly Thr
85      90      95

Leu Ser Met His Ala Ser Met Phe Val Ser Leu Leu Ile Leu Ser Trp
100     105     110

Ile Ala Ile Ser Arg Tyr Ala Thr Leu Met Gln Lys Asp Ser Ser Gln
115     120     125

Glu Thr Thr Ser Cys Tyr Glu Lys Ile Phe Tyr Gly His Leu Leu Lys
130     135     140

Lys Phe Arg Gln Pro Asn Phe Ala Arg Lys Leu Cys Ile Tyr Ile Trp
145     150     155     160

Gly Val Val Leu Gly Ile Ile Ile Pro Val Thr Val Tyr Tyr Ser Val
165     170     175

Ile Glu Ala Thr Glu Gly Glu Glu Ser Leu Cys Tyr Asn Arg Gln Met
180     185     190

Glu Leu Gly Ala Met Ile Ser Gln Ile Ala Gly Leu Ile Gly Thr Thr
195     200     205

Phe Ile Gly Phe Ser Phe Leu Val Val Leu Thr Ser Tyr Tyr Ser Phe
210     215     220

Val Ser His Leu Arg Lys Ile Arg Thr Cys Thr Ser Ile Met Glu Lys
225     230     235     240

Asp Leu Thr Tyr Ser Ser Val Lys Arg His Leu Leu Val Ile Gln Ile
245     250     255

Leu Leu Ile Val Cys Phe Leu Pro Tyr Ser Ile Phe Lys Pro Ile Phe
260     265     270

Tyr Val Leu His Gln Arg Asp Asn Cys Gln Gln Leu Asn Tyr Leu Ile
275     280     285

Glu Thr Lys Asn Ile Leu Thr Cys Leu Ala Ser Ala Arg Ser Ser Thr
290     295     300

```

Asp Pro Ile Ile Phe Leu Leu Leu Asp Lys Thr Phe Lys Lys Thr Leu
305 310 315 320

Tyr Asn Leu Phe Thr Lys Ser Asn Ser Ala His Met Gln Ser Tyr Gly
325 330 335

<210> 121
<211> 28
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 121
ttcaaagctt atgacgtcca cctgcacc

28

<210> 122
<211> 35
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 122
ttcactcgag tcaaggaaaa gtagcagaat cgtag

35

<210> 123
<211> 35
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 123
gatcgaattc atgatggagc ccagagaagc tggac

35

<210> 124
<211> 28
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 124
cgagtcaggc tgctatgtcc accaggcc

28

<210> 125
<211> 37
<212> DNA
<213> Artificial

<220>

<223> Primer

<400> 125

gcataagctt ccatgtggag ctgcagctgg ttcaacg

37

<210> 126

<211> 33

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 126

gcatctcgag cctacgccag cacctgctgc acc

33

<210> 127

<211> 33

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 127

gcataagctt ccatggggaa cgattctgtc agc

33

<210> 128

<211> 33

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 128

gcatctcgag cctacacctc catctcogag acc

33

<210> 129

<211> 31

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 129

gatcaagctt gcatggcacc ttctcatcgg g

31

<210> 130

<211> 31

<212> DNA

<213> Artificial

<220>
<223> Primer

<400> 130
gatcctcgag tcaaagggtcc cattccggac c

31

<210> 131
<211> 13
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 131
tccctgtgcc ccc

13

<210> 132
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 132
ttataggaga cccatgggca ggg

23

<210> 133
<211> 40
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 133
ggtgctctgg aacctcggct tccgcatcaa gaagggtccc

40

<210> 134
<211> 40
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 134
ggggcccttc ttgatgcgga agccgaggtt ccagagcacc

40

<210> 135
<211> 38
<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 135

ttcaaagctt atgaacaaca atacaacatg tattcaac

38

<210> 136

<211> 23

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 136

tcaaacatat gattgcatat gtg

23

<210> 137

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 137

gcacatatgc aatcatatgg ttgactcgag tgaaaaggg

39

<210> 138

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 138

cccttttcac tcgagtcaac catatgattg catatgtgc

39

<210> 139

<211> 30

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 139

ctccatctgt ctcagctatg ccagcagcag

30

<210> 140

<211> 13

<212> DNA
<213> Artificial

<220> .
<223> Primer

<400> 140
tctcagctat gcc

13

<210> 141
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 141
tccttctcag tcgctcttc

19

<210> 142
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 142
cctccacttg tgcttcac

19

<210> 143
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 143
aaaatctatc aacacccagc c

21

<210> 144
<211> 32
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 144
gatcaagctt accatgacca gcaatttttc cc

32

<210> 145

<211> 34
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 145
gatcctcgag cttattctaa aaataaacta atgg

34

<210> 146
<211> 25
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 146
catgatctgg ggggccagcc ccagc

25

<210> 147
<211> 25
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 147
gctggggctg gccccccaga tcatg

25

<210> 148
<211> 34
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 148
gacatcaatt tcagtgagga tgacgtcgag gcag

34

<210> 149
<211> 33
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 149
tgccctcgacg tcatcctcac tgaaattgat gtc

33

<210> 150
<211> 34
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 150
cgaactccgc actcctggcc agggccctgc gggc

34

<210> 151
<211> 33
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 151
gcccgaggc ccctggccag gaggccctgc ggc

33

<210> 152
<211> 48
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 152
gcgtaatacg actcactata gggagacctg ccagtgtggt agatacag

48

<210> 153
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 153
ggatgtgatg atggtgcag

19

<210> 154
<211> 47
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 154
gcgtaatacg actcactata gggagaccgg atgtgatgat ggtgcag

47

<210> 155
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 155
tgccagtgtg gtagatacag

20

<210> 156
<211> 48
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 156
gcgtaatacg actcactata gggagaccac cagcaatttt tcccaacc

48

<210> 157
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 157
aataccagca gctctccac

19

<210> 158
<211> 47
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 158
gcgtaatacg actcactata gggagaccaa taccagcagc tctccac

47

<210> 159
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 159
accagcaatt tttcccaacc

20

<210> 160
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 160
gtgactaact ctgcctgcg

19

<210> 161
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 161
ttgcgctgca acactagcg

19

<210> 162
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 162
acagcccaa agccaaacac

20

<210> 163
<211> 22
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 163
ccgcaggagc aatgaaaatc ag

22

<210> 164
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 164

tctccaaact cctggccttc

20

<210> 165
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 165
gcagggcagc tttttcatcc

20

<210> 166
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 166
acgcccgcgtg aaccgtatac

20

<210> 167
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 167
gggtgccacc tggttgctc

19

<210> 168
<211> 18
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 168
atggcacctt ctcacg

18

<210> 169
<211> 18
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 169
acgtagtaca ccgccttg

18

<210> 170
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 170
agcaggtaga tggagaagg

19

<210> 171
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 171
gactcctgag gaccatgtc

19

<210> 172
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 172
cattggaacc acattttattg g

21

<210> 173
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 173
aagcaagaca ggtgagaatg

20

<210> 174
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 174
ccatctgtct cagctatgcc

20

<210> 175
<211> 19
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 175
tcctttctcag tcgctcttc

19

<210> 176
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 176
caaacaacaa acagcagaac c

21

<210> 177
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 177
tcacagtcac acctaccaag

20

<210> 178
<211> 20
<212> DNA
<213> Artificial

<220>
<223> Primer

<400> 178
ccatctgtct cagctatgcc

20

<210> 179
<211> 19
<212> DNA
<213> Artificial

<220>

<223> Primer

<400> 179

tcctttctcag tcgctcttc

19

<210> 180

<211> 21

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 180

gtctatgcta ccaagttcac c

21

<210> 181

<211> 19

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 181

attcctccag cccatcatc

19

<210> 182

<211> 9

<212> PRT

<213> Artificial

<220>

<223> Primer

<400> 182

Ala Pro Arg Thr Pro Gly Gly Arg Arg
1 5

<210> 183

<211> 19

<212> PRT

<213> Homo sapiens

<400> 183

Asp Phe Asp Met Leu Arg Cys Met Leu Gly Arg Val Tyr Arg Pro Cys
1 5 10 15

Trp Gln Val

<210> 184

<211> 17

<212> PRT

<213> Salmon

<400> 184

Asp	Thr	Met	Arg	Cys	Met	Val	Gly	Arg	Val	Tyr	Arg	Pro	Cys	Trp	Glu
1				5					10					15	

Val

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number
WO 01/062797 A3

(51) International Patent Classification⁷: C07K 14/72,
C12N 15/63, 15/11, C07K 1/14, C12Q 1/68, G01N 33/53,
C07K 16/28, A61K 38/17, 39/395

[US/US]; 2576 9th Avenue, Seattle, WA 98119 (US).
WOOD, Linda, S. [US/US]; 10193 Fox Hollow,
Portage, MI 49024 (US). **PARODI, Luis, A.** [SE/SE];
Grevgafan-24, S-115 43 Stockholm (SE). **LIND, Peter**
[SE/SE]; Borjegtatan 31 C, S-751 29 Uppsala (SE).

(21) International Application Number: PCT/US01/05676

(22) International Filing Date: 23 February 2001 (23.02.2001)

(74) Agents: **DELUCA, Mark** et al.; Woodcock Washburn
Kurtz Mackiewicz & Norris LLP, 46th floor, One Liberty
Place, Philadelphia, PA 19103 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/184,305	23 February 2000 (23.02.2000)	US
60/184,304	23 February 2000 (23.02.2000)	US
60/184,303	23 February 2000 (23.02.2000)	US
60/184,397	23 February 2000 (23.02.2000)	US
60/184,247	23 February 2000 (23.02.2000)	US
60/186,457	2 March 2000 (02.03.2000)	US
60/186,810	3 March 2000 (03.03.2000)	US
60/188,064	9 March 2000 (09.03.2000)	US
60/188,880	13 March 2000 (13.03.2000)	US
60/194,344	3 April 2000 (03.04.2000)	US
60/213,861	23 June 2000 (23.06.2000)	US
60/217,370	11 July 2000 (11.07.2000)	US
60/217,369	11 July 2000 (11.07.2000)	US
60/218,337	14 July 2000 (14.07.2000)	US
60/218,492	20 July 2000 (20.07.2000)	US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(71) Applicant (*for all designated States except US*): **PHAR-
MACIA & UPJOHN COMPANY** [US/US]; 301 Henri-
etta Street, Kalamazoo, MI 49001 (US).

(88) Date of publication of the international search report:
24 October 2002

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **VOGELI, Gabriel**

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: G PROTEIN-COUPLED RECEPTORS

(57) Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-x; constructs and re-combinant host cells incorporating the genes; the nGPCR-x polypeptides encoded by the gene; antibodies to the nGPCR-x polypep-tides; and methods of making and using all of the foregoing.

WO 01/062797 A3

INTERNATIONAL SEARCH REPORT

International Application No

PO/US 01/05676

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/72 C12N15/63 C12N15/11 C07K1/14 C12Q1/68
G01N33/53 C07K16/28 A61K38/17 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N C12Q G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, SEQUENCE SEARCH, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 892 051 A (SMITHKLINE BEECHAM CORP) 20 January 1999 (1999-01-20) page 12, line 1 - line 55 page 13, line 15 -page 15, line 10 ---	1-48,50, 51, 53-56, 58-62, 64-74, 82-89, 138
E	WO 01 36471 A (ARENA PHARMACEUTICALS INC) 25 May 2001 (2001-05-25) SEQ ID NO:25; SEQ ID NO:26 ----- -/-	1-48,50, 51,53, 54,61,62



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 November 2001

Date of mailing of the international search report

15. 5. 02

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schönwasser, D

INTERNATIONAL SEARCH REPORT

International Application No

P US 01/05676

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE EMBL [Online] Accession no. AL161458, 16 March 2000 (2000-03-16) BURTON J.: "Human DNA sequence *** SEQUENCE IN PROGRESS *** FROM CLONE RP11-163L4" XP002184439 abstract</p>	1-30
A	<p>WO 94 12635 A (ICOS CORP) 9 June 1994 (1994-06-09)</p> <p>SEQ ID NO:44</p>	1-48,50, 51, 53-56, 58-62, 64-74, 82-89, 138
A	<p>ALTSCHUL S F ET AL: "Iterated profile searches with PSI-BLAST-a tool for discovery in protein databases" TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 23, no. 11, 1 November 1998 (1998-11-01), pages 444-447, XP004143492 ISSN: 0968-0004 the whole document</p>	1-28, 35-39
A	<p>STADEL ET AL: "Orphan G protein-coupled receptors:" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, no. 18, 1 November 1997 (1997-11-01), pages 430-437, XP002073279 ISSN: 0165-6147 the whole document</p>	1-28, 35-39

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/05676

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

SIEHE PCT/ISA 210

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 49,52,57,75-81 no search; 1,45,47,48,50,51,53-56,58
incompl. search

Present claims 45, 50 and 53 relate to an extremely large number of methods involving possible nGPCR-x or nucleic acids encoding nGPCR-x. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the nGPCR-x or nucleic acids encoding nGPCR-x of SEQ ID NO:61-120 or SEQ ID NO:1-60, respectively.

Further, claims 49,52 and 57 refer to compounds identified in a certain screening process without giving a true technical characterization of said compounds. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

Furthermore, claims 75 and 76 refer to an allelic variant of certain claimed G-prtoein coupled receptors (GPCR) and claims 77-81 refer to polynucleotides encoding polypeptides which are related to mental disorder and which differ in at least one residue from the claimed GPCR polypeptides. No true technical characterization of said compounds is given and no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-48,50,51,53-56,58-62,64-74,82-89,
138 (all partially)

Invention 1:

An isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:61; an isolated nucleic acid sequence comprising the sequence SEQ ID NO:1; vector comprising said SEQ ID NO:1 and host cell comprising said vector; compositions comprising said nucleic acid molecule or said vector, methods of producing above polypeptide; said isolated polypeptide; an isolated antibody which binds to an epitope of above polypeptide; compositions comprising said polypeptide or antibody; a method for inducing an immune response in a mammal by using said polypeptide; methods for identifying compounds that bind above polypeptide or above nucleic acid molecule or which modulate the activity of above polypeptide, a method of identifying an animal homologue of said polypeptide; methods of screening a human subject involving said polypeptide, a kit for screening a human subject involving an oligonucleotide of above nucleic acid molecule; methods for identifying an allelic variant of above nucleic acid molecule; methods to identify compounds useful for the treatment of mental disorder or as modulators of binding between above polypeptide and its binding partner; a method of purifying a G-protein by use of above polypeptide; a method of identifying an allelic variant of above nucleic acid molecule.

2. Claims: 1-48,50,51,53-56,58-62,64-74,82-89,
138 (all partially)

Inventions 2-15:

The inventions 2-15 relate to subject-matter as defined above for "invention 1", whereby each invention refers to one of the polypeptide sequences of SEQ ID NO:62,86,91,94, 96,97,111-116,119 and 120 (and the respective nucleic acid sequences of SEQ ID NO:2,8,31,43,36,37,51-56, 59,60).

3. Claims: 1-5,7-10,12-27,29-38,40-45,47,48,50,51,53,55,56,
58-60,86-88,138 (all partially)

Invention 16:

An isolated nucleic acid molecule encoding a polypeptide

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

comprising the amino acid sequence of SEQ ID NO:63; an isolated nucleic acid sequence comprising the sequence SEQ ID NO:3; vector comprising said SEQ ID NO:3 and host cell comprising said vector; compositions comprising said nucleic acid molecule or said vector, methods of producing above polypeptide; said isolated polypeptide; an isolated antibody which binds to an epitope of above polypeptide; compositions comprising said polypeptide or antibody; a method for inducing an immune response in a mammal by using said polypeptide; methods for identifying compounds that bind above polypeptide or above nucleic acid molecule or which modulate the activity of above polypeptide, a method of identifying an animal homologue of said polypeptide; a method of purifying a G-protein by use of above polypeptide; a method of identifying an allelic variant of above nucleic acid molecule.

4. Claims: 1-5,7-10,12-27,29-38,40-45,47,48,50,51,53,55,56, 58-60,86-88,138 (all partially)

Inventions 17-56:

The inventions 17-56 relate to subject-matter as defined above for "invention 15", whereby each invention refers to one of the polypeptide sequences of SEQ ID NO:64-67,69-90, 92,93,95,98,111-120 (and the respective nucleic acid sequences of SEQ ID NO:4-7,9-30,32,33,35,38,41-50).

5. Claims: 1-48,50,51,53-56,58-74,82-89,95-113,115-117, 138 (all partially)

Invention 57:

An isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:99; an isolated nucleic acid sequence comprising the sequence SEQ ID NO:39; vector comprising said SEQ ID NO:39 and host cell comprising said vector; compositions comprising said nucleic acid molecule or said vector, methods of producing above polypeptide; said isolated polypeptide; an isolated antibody which binds to an epitope of above polypeptide; compositions comprising said polypeptide or antibody; a method for inducing an immune response in a mammal by using said polypeptide; methods for identifying compounds that bind above polypeptide or above nucleic acid molecule or which modulate the activity of above polypeptide, a method of identifying an animal homologue of said polypeptide; methods of screening a human subject involving said polypeptide, a kit for screening a human subject involving an oligonucleotide of above nucleic acid molecule; methods for identifying an allelic variant of above nucleic acid

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

molecule; methods to identify compounds useful for the treatment of mental disorder or as modulators of binding between above polypeptide and its binding partner; a method of purifying a G-protein by use of above polypeptide; methods for identifying a compound that binds to or modulates the activity of above polypeptide; a method of screening a human subject to diagnose a disorder affecting the brain, a kit for screening a human subject to diagnose a mental disorder; methods for identifying a compound useful for the treatment of a mental disorder or as a modulator of binding between above polypeptide and its binding partner; a method of identifying an allelic variant of above nucleic acid molecule.

6. Claims: 1-48,50,51,53-56,58-74,82-89,123-137,
139-141 (all partially)

Invention 58:

An isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:100; an isolated nucleic acid sequence comprising the sequence SEQ ID NO:40; vector comprising said SEQ ID NO:40 and host cell comprising said vector; compositions comprising said nucleic acid molecule or said vector, methods of producing above polypeptide; said isolated polypeptide; an isolated antibody which binds to an epitope of above polypeptide; compositions comprising said polypeptide or antibody; a method for inducing an immune response in a mammal by using said polypeptide; methods for identifying compounds that bind above polypeptide or above nucleic acid molecule or which modulate the activity of above polypeptide, a method of identifying an animal homologue of said polypeptide; methods of screening a human subject involving said polypeptide, a kit for screening a human subject involving an oligonucleotide of above nucleic acid molecule; methods to identify compounds useful for the treatment of mental disorder or as modulators of binding between above polypeptide and its binding partner; a method of purifying a G-protein by use of above polypeptide; methods of identifying a compound that binds to above polypeptide or modulated its activity; a method of screening a human subject to diagnose a disorder affecting the brain involving above nucleic acid molecule, a kit for screening a human subject to diagnose a mental disorder involving above nucleic acid molecule; a method of identifying an allelic variant of above nucleic acid molecule, methods of identifying compounds that modulate the biological activity of above polypeptide or which are useful for the treatment of a mental disorder or as modulators of binding between above polypeptide and its binding partner.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

7. Claims: 1-48,50,51,53-56,58-74,82-117,138 (all partially)

Invention 59:

An isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:117; an isolated nucleic acid sequence comprising the sequence SEQ ID NO:57; vector comprising said SEQ ID NO:57 and host cell comprising said vector; compositions comprising said nucleic acid molecule or said vector, methods of producing above polypeptide; said isolated polypeptide; an isolated antibody which binds to an epitope of above polypeptide; compositions comprising said polypeptide or antibody; a method for inducing an immune response in a mammal by using said polypeptide; methods for identifying compounds that bind above polypeptide or above nucleic acid molecule or which modulate the activity of above polypeptide, a method of identifying an animal homologue of said polypeptide; methods of screening a human subject involving said polypeptide, a kit for screening a human subject involving an oligonucleotide of above nucleic acid molecule; methods for identifying an allelic variant of above nucleic acid molecule; methods to identify compounds useful for the treatment of mental disorder or as modulators of binding between above polypeptide and a binding partner; a method of purifying above polypeptide; a nucleic acid encoding a polypeptide comprising SEQ ID NO:117; a nucleic acid molecule comprising SEQ ID NO:57; a polypeptide comprising SEQ ID NO:117; methods for identifying a compound that binds to or modulates the activity of above polypeptide; a method of screening a human subject to diagnose a disorder affecting the brain, a kit for screening a human subject to diagnose a mental disorder; methods for identifying a compound useful for the treatment of a mental disorder or as a modulator of binding between above polypeptide and a binding partner; methods of identifying an allelic variant of above nucleic acid molecule or above amino acid.

8. Claims: 1-48,50,51,53-56,58-74,82-89,
118-141 (all partially)

Invention 60:

An isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:118; an isolated nucleic acid sequence comprising the sequence SEQ ID NO:58; vector comprising said SEQ ID NO:58 and host cell comprising said vector; compositions comprising said nucleic acid molecule or said vector, methods of producing above polypeptide; said isolated polypeptide; an isolated antibody which binds to an epitope of above polypeptide; compositions comprising said polypeptide or antibody; a method for

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

inducing an immune response in a mammal by using said polypeptide; methods for identifying compounds that bind above polypeptide or above nucleic acid molecule or which modulate the activity of above polypeptide, a method of identifying an animal homologue of said polypeptide; methods of screening a human subject involving said polypeptide, a kit for screening a human subject involving an oligonucleotide of above nucleic acid molecule; methods for identifying an allelic variant of above nucleic acid molecule; methods to identify compounds useful for the treatment of mental disorder or as modulators of binding between above polypeptide and a binding partner; a method of purifying above polypeptide; a nucleic acid molecule comprising a sequence that encodes SEQ ID NO:118; a polypeptide comprising an amino acid sequence homologous to SEQ ID NO:118; methods of identifying a compound that binds to above polypeptide or modulated its activity; a method of screening a human subject to diagnose a disorder affecting the brain involving above nucleic acid molecule, a kit for screening a human subject to diagnose a mental disorder involving above nucleic acid molecule; a method of identifying an allelic variant of above nucleic acid molecule, methods of identifying compounds that modulate the biological activity of above polypeptide or which are useful for the treatment of a mental disorder or as modulators of binding between above polypeptide and its binding partner.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/05676

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0892051	A	20-01-1999	US 5955308 A	21-09-1999
			EP 0892051 A2	20-01-1999
			JP 11098988 A	13-04-1999

WO 0136471	A	25-05-2001	AU 1769601 A	30-05-2001
			WO 0136471 A2	25-05-2001

WO 9412635	A	09-06-1994	AT 164884 T	15-04-1998
			CA 2128208 A1	09-06-1994
			DE 69317883 D1	14-05-1998
			DE 69317883 T2	12-11-1998
			DK 630405 T3	04-01-1999
			EP 0630405 A1	28-12-1994
			EP 0846762 A2	10-06-1998
			ES 2118372 T3	16-09-1998
			JP 7503145 T	06-04-1995
			JP 2000350582 A	19-12-2000
			US 6348574 B1	19-02-2002
			WO 9412635 A2	09-06-1994
			US 5759804 A	02-06-1998
			US 6107475 A	22-08-2000

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)